| 1096790 | (+)-Catechin (25 mg) | Reference Standard | 154-23-4 | 25 | mg | VIAL | |
| 1236620 | (-)-Epicatechin (50 mg) | Reference Standard | 490-46-0 | 50 | mg | VIAL | |
| 1236700 | (-)-Epigallocatechin-3-O-gallate (20 mg) | Reference Standard | 989-51-5 | 20 | mg | VIAL | |
| 1666006 | (E)-Thiothixene (100 mg) | Reference Standard | 3313-27-7 | 100 | mg | VIAL | |
| 1A00550 | (R)-Clopidogrel Carboxylic Acid (10 mg) ((R)-2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetic acid) | Pharmaceutical Analytical Impurity | 324757-50-8 | 10 | mg | VIAL | |
| 1379456 | (Z)-N'-Methylmeloxicam (30 mg) ((Z)-N-(3,5-dimethylthiazol-2(3H)-ylidene)-4-hydroxy-2-methyl-2H-benzo[e][1,2]thiazine-3-carboxamide 1,1-dioxide) | Reference Standard | 1145656-36-5 | 30 | mg | VIAL | |
| 1213148 | 1,2-Dinitroglycerin (2 ampules x 1 mL) | Reference Standard | 621-65-8 | 2 | mL | AMPULE | |
| 1213159 | 1,3-Dinitroglycerin (2 ampules x 1 mL) | Reference Standard | 623-87-0 | 2 | mL | AMPULE | |
| 1570483 | 1,3-Propanediol (1 mL) | Reference Standard | 504-63-2 | 1 | mL | AMPULE | |
| 1056504 | 1,4-Benzoquinone (200 mg) | Reference Standard | 106-51-4 | 200 | mg | VIAL | |
| 1081750 | 1,4-Butanedisulfonic Acid (120 mg) | Reference Standard | 27665-39-0 | 120 | mg | VIAL | |
| 1616008 | 1,4-Sorbitan (300 mg) | Reference Standard | 27299-12-3 | 300 | mg | VIAL | |
| 1035300 | 1,6-anhydro-D-glucose (50 mg) | Reference Standard | 498-07-7 | 50 | mg | VIAL | |
| 1081807 | 1-Butanol (1.2 mL/ampule; 3 ampules) | Reference Standard | 71-36-3 | 3.6 | mL | AMPULE | |
| 1265739 | 1-Ethoxy-2-Methylpropane (3 x 0.2 mL) | Reference Standard | 627-02-1 | 0.6 | mL | AMPULE | |
| 1445571 | 1-Mononitroglycerin (2 ampules x 1 mL) | Reference Standard | 624-43-1 | 2 | mL | AMPULE | |
| 1504955 | 1-Pentanol (1.2 mL/ampule; 3 ampules) | Reference Standard | 71-41-0 | 3.6 | mL | AMPULE | |
| 1570406 | 1-Propanol (1.2 mL/ampule; 3 ampules) | Reference Standard | 71-23-8 | 3.6 | mL | AMPULE | |
| 1286300 | 10-Formylfolic Acid (25 mg) (L-Glutamic acid, N-[4-[[(2-amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl]formylamino-]benzoyl]-) | Reference Standard | 134-05-4 | 25 | mg | VIAL | |
| 1331008 | 12-Hydroxystearic Acid (200 mg) | Reference Standard | 106-14-9 | 200 | mg | VIAL | |
| 1A00470 | 17-Oxo Dexamethasone (10 mg) ((8S,9R,10S,11S,13S,14S,16R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione) | Pharmaceutical Analytical Impurity | 1880-61-1 | 10 | mg | VIAL | |
| 1201002 | 17alpha-Dihydroequilin (50 mg) (Estra-1,3,5(10),7-tetraene-3,17alpha-diol) | Reference Standard | 651-55-8 | 50 | mg | VIAL | |
| 1651654 | 2,3,5,4'-Tetrahydroxystilbene-2-O-Beta-D-Glucoside (50 mg) ((E)-2,4-dihydroxy-6-(4-hydroxystyryl)phenyl beta-D-glucopyranoside) | Reference Standard | 82373-94-2 | 50 | mg | VIAL | |
| 1081842 | 2,3-Butanedithiol (3 x 1 g) | Reference Standard | 4532-64-3 | 3 | g | AMPULE | |
| 1211254 | 2,3-Dimethylaniline (50 mg) | Reference Standard | 87-59-2 | 50 | mg | AMPULE | |
| 1696164 | 2,4,6-Tritertbutylphenol (25 mg) (2,4,6-Tri-tert-butylphenol) | Reference Standard | 732-26-3 | 25 | mg | VIAL | |
| 1187954 | 2,4-Dichlorophenol (100 mg) | Reference Standard | 120-83-2 | 100 | mg | VIAL | |
| 1223005 | 2,4-Disulfamyl-5-Trifluoromethylaniline (50 mg) | Reference Standard | 654-62-6 | 50 | mg | VIAL | |
| 1009479 | 2-Acetylpyridine (1 g) | Reference Standard | 1122-62-9 | 1 | g | AMPULE | |
| 1022808 | 2-Amino-5-chlorobenzophenone (25 mg) | Reference Standard | 719-59-5 | 25 | mg | VIAL | |
| 1081829 | 2-Butanol (1.2 mL/ampule; 3 ampules) | Reference Standard | 78-92-2 | 3.6 | mL | AMPULE | |
| 1265526 | 2-Ethylhexan-1-ol (1.5 mL) | Reference Standard | 104-76-7 | 1.5 | mL | AMPULE | |
| 1437053 | 2-Methyl-1-propanol (1.2 mL/ampule; 3 ampules) | Reference Standard | 78-83-1 | 3.6 | mL | AMPULE | |
| 1445584 | 2-Mononitroglycerin (2 ampules x 1 mL) | Reference Standard | 620-12-2 | 2 | mL | AMPULE | |
| 1A00560 | 2-Oxo Clopidogrel (Mixture of Diastereomers) (10 mg) (methyl 2-(2-chlorophenyl)-2-(2-oxo-2,6,7,7a-tetrahydrothieno[3,2-c]pyridin-5(4H)-yl)acetate) | Pharmaceutical Analytical Impurity | 109904-27-0 | 10 | mg | VIAL | |
| 1A00570 | 2-Oxo R-Clopidogrel (10 mg) (methyl (2R)-2-(2-chlorophenyl)-2-(2-oxo-2,6,7,7a-tetrahydrothieno[3,2-c]pyridin-5(4H)-yl)acetate) | Pharmaceutical Analytical Impurity | 1360923-54-1 | 10 | mg | VIAL | |
| 1570428 | 2-Propanol (1.2 mL/ampule; 3 ampules) | Reference Standard | 67-63-0 | 3.6 | mL | AMPULE | |
| 1570439 | 2-Propanol System Suitability (3 x 1 mL) | Reference Standard | N/A | 3 | mL | AMPULE | |
| 1685500 | 2-[N-(2,2,2-Trifluoroethyl)amino-5]-chlorobenzophenone (25 mg) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1083008 | 2-tert-Butyl-4-hydroxyanisole (200 mg) | Reference Standard | 88-32-4 | 200 | mg | VIAL | |
| 1171207 | 23-EPI-26-Deoxyactein (20 mg) | Reference Standard | 501938-01-8 | 20 | mg | VIAL | |
| 1305507 | 2E, 4E-Hexadienoic Acid Isobutylamide (25 mg) | Reference Standard | 65937-49-7 | 25 | mg | VIAL | |
| 1A00210 | 3'-(N,N-Didemethyl)-3'-N-formylazithromycin (25 mg) | Pharmaceutical Analytical Impurity | 765927-71-7 | 25 | mg | VIAL | |
| 1A00070 | 3'-(N,N-Didemethyl)azithromycin; (Aminoazithromycin) (25 mg) | Pharmaceutical Analytical Impurity | 612069-27-9 | 25 | mg | VIAL | |
| 1A00080 | 3'-De(dimethylamino)-3'-oxoazithromycin (25 mg) | Pharmaceutical Analytical Impurity | 612069-25-7 | 25 | mg | VIAL | |
| 1076261 | 3-Acetyl-11-Keto-Beta-Boswellic Acid (20 mg) | Reference Standard | 67416-61-9 | 20 | mg | VIAL | |
| 1026605 | 3-Amino-2,4,6-triiodobenzoic Acid (50 mg) | Reference Standard | 3119-15-1 | 50 | mg | VIAL | |
| 1064058 | 3-Benzyl-4-Heptanone (5 x 0.5 mL) | Reference Standard | 7492-37-7 | 2.5 | mL | AMPULE | |
| 1112299 | 3-Chlorobenzoic Acid (25 mg) | Reference Standard | 535-80-8 | 25 | mg | VIAL | |
| 1391000 | 3-Mercapto-2-methylpropanoic Acid 1,2-Diphenylethylamine Salt (75 mg) | Reference Standard | N/A | 75 | mg | VIAL | |
| 1424153 | 3-Methyl-1-butanol (1.2 mL/ampule; 3 ampules) | Reference Standard | 123-51-3 | 3.6 | mL | AMPULE | |
| 1430509 | 3-O-Methylmethyldopa (50 mg) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1083100 | 3-tert-Butyl-4-hydroxyanisole (200 mg) | Reference Standard | 121-00-6 | 200 | mg | VIAL | |
| 1019870 | 4-Aminobenzoylglutamic Acid (50 mg) | Reference Standard | 4271-30-1 | 50 | mg | VIAL | |
| 1021204 | 4-Aminophenol (100 mg) | Reference Standard | 123-30-8 | 100 | mg | VIAL | |
| 1112467 | 4-Chlorobenzophenone (30 mg) (4-Chlorobenzophenone) | Reference Standard | 134-85-0 | 30 | mg | VIAL | |
| 1236506 | 4-Epianhydrotetracycline Hydrochloride (50 mg) | Reference Standard | 4465-65-0 | 50 | mg | VIAL | |
| 1A00580 | 4-Fluoro Risperidone (COLD SHIPMENT REQUIRED) (10 mg) (3-(2-(4-(4-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one) | Pharmaceutical Analytical Impurity | N/A | 10 | mg | VIAL | |
| 1313254 | 4-Hydrazinylbenzenesulfonamide Hydrochloride (25 mg) | Reference Standard | 17852-52-7 | 25 | mg | VIAL | |
| 1327157 | 4-Hydroxyindole (25 mg) (1H-Indol-4-ol) | Reference Standard | 2380-94-1 | 25 | mg | VIAL | |
| 1327319 | 4-Hydroxyisoleucine (35 mg) | Reference Standard | 781658-23-9 | 35 | mg | VIAL | |
| 1379445 | 4-Methoxymeloxicam (30 mg) (4-methoxy-2-methyl-N-(5-methyl-1,3-thiazol-2-yl)-2H-1,2-benzothiazine-3-carboxamide 1,1-dioxide) | Reference Standard | 1391051-96-9 | 30 | mg | VIAL | |
| 1466572 | 4-Nitrobenzoic Acid (50 mg) | Reference Standard | 62-23-7 | 50 | mg | VIAL | |
| 1012178 | 5'-Adenylic Acid (500 mg) | Reference Standard | 61-19-8 | 500 | mg | VIAL | |
| 1162126 | 5'-Cytidylic Acid (500 mg) | Reference Standard | 63-37-6 | 500 | mg | VIAL | |
| 1027007 | 5-Amino-2,4,6-triiodo-N-methylisophthalamic Acid (50 mg) | Reference Standard | 2280-89-9 | 50 | mg | | |
| 1A00520 | 5-Fluoro Risperidone (25 mg) (3-(2-(4-(5-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one) | Pharmaceutical Analytical Impurity | 1199589-74-6 | 25 | mg | VIAL | |
| 1329913 | 5-Hydroxy-L-tryptophan (100 mg) | Reference Standard | 4350-09-8 | 100 | mg | VIAL | |
| 1327328 | 5-Hydroxymethylfurfural (50 mg) (5-(Hydroxymethyl)-2-furaldehyde) | Reference Standard | 67-47-0 | 50 | mg | VIAL | |
| 1533308 | 5-Phenylhydantoin (100 mg) | Reference Standard | 89-24-7 | 100 | mg | VIAL | |
| 1211287 | 6,6'-Dinicotinic Acid (50 mg) | Reference Standard | 1802-30-8 | 50 | mg | VIAL | |
| 1166535 | 6,7-Dehydronorethindrone Acetate (20 mg) (3-oxo-19-nor-17alpha-pregn-4,6-dien-20-yn-17-yl acetate) | Reference Standard | 106765-04-2 | 20 | mg | VIAL | |
| 1238578 | 6-D-Cys Eptifibatide (10 mg) (N6-Amidino-N2-(3-mercaptopropionyl)-L-lysylglycyl-L-alpha-aspartyl-L-tryptophyl-L-prolyl-D-cysteinamide, cyclic(1-6)-disulfide) | Reference Standard | NA | 10 | mg | VIAL | |
| 1327408 | 6-Hydroxynicotinic Acid (50 mg) | Reference Standard | 5006-66-6 | 50 | mg | VIAL | |
| 1356213 | 6-Ketonorethindrone Acetate (20 mg) (3,6-Dioxo-19-nor-17alpha pregn-4-en-20-yn-17-yl acetate) | Reference Standard | 438244-27-0 | 20 | mg | VIAL | |
| 1430815 | 6-Methylnicotinic Acid (50 mg) | Reference Standard | 3222-47-7 | 50 | mg | VIAL | |
| 1A00110 | 6Beta-Hydroxy Ethinyl Estradiol (25 mg) ((6R,8R,9S,13S,14S,17R)-17-ethynyl-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,6,17-triol) | Pharmaceutical Analytical Impurity | 56324-28-8 | 25 | mg | VIAL | |
| 1A00100 | 6alpha-HYDROXY ETHINYL ESTRADIOL (COLD SHIPMENT REQUIRED) (25 mg) (19-Nor-17alpha-pregna-1,3,5(10)-trien-20-yne-3,6alpha,17-triol) | Pharmaceutical Analytical Impurity | 27521-34-2 | 25 | mg | VIAL | |
| 1A00590 | 7-Fluoro Risperidone (COLD SHIPMENT REQUIRED) (10 mg) (3-(2-(4-(7-fluorobenzo[d]isoxazol-3-yl)piperidin-1-yl)ethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one) | Pharmaceutical Analytical Impurity | N/A | 10 | mg | VIAL | |
| 1077708 | 8-Bromotheophylline (400 mg) | Reference Standard | 10381-75-6 | 400 | mg | VIAL | |
| 1121038 | 8-Chlorotheophylline (200 mg) | Reference Standard | 85-18-7 | 200 | mg | VIAL | |
| 1424084 | 9-Methylacridine (25 mg) | Reference Standard | 611-64-3 | 25 | mg | VIAL | |
| 1000420 | Abacavir Related Compound A (20 mg) ([4-(2,6-diamino-9H-purin-9-yl)cyclopent-2-enyl]methanol) | Reference Standard | 906626-51-5 | 20 | mg | VIAL | |
| 1000441 | Abacavir Related Compound B (20 mg) ([4-(2,5-diamino-6-chloropyrimidin-4-ylamino)cyclopent-2-enyl]methanol) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1000452 | Abacavir Related Compound C (20 mg) ([(1S,4R)-4-(2-amino-6-chloro-9H-purin-9-yl)cyclopent-2-enyl]methanol hydrochloride) | Reference Standard | 172015-79-1 | 20 | mg | VIAL | |
| 1000437 | Abacavir Related Compound D (20 mg) (N6-Cyclopropyl-9-{(1R,4S)-4-[(2,5-diamino-6-chloropyrimidin-4-yloxy)methyl]cyclopent-2-enyl}-9H-purine-2,6-diamine) | Reference Standard | 1443421-69-9 | 20 | mg | VIAL | |
| 1000485 | Abacavir Related Compounds Mixture (15 mg) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1000496 | Abacavir Stereoisomers Mixture (15 mg) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1000408 | Abacavir Sulfate (200 mg) | Reference Standard | 188062-50-2 | 200 | mg | VIAL | |
| 1000419 | Abacavir Sulfate Racemic (20 mg) (4-[2-amino-6-(cyclopropylamino)-9H-purin-9yl]-2-cyclopentene-1-methanol sulfate (2:1)) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1000500 | Abacavir System Suitability Mixture (15 mg) (A mixture containing abacavir sulfate and trans-abacavir) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1000818 | Abiraterone Acetate (200 mg) | Reference Standard | 154229-18-2 | 200 | mg | VIAL | |
| 1000829 | Abiraterone System Suitability Mixture (20 mg) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1000554 | Acamprosate Calcium (200 mg) | Reference Standard | 77337-73-6 | 200 | mg | VIAL | |
| 1000565 | Acamprosate Related Compound A (15 mg) (3-aminopropane-1-sulfonic acid) | Reference Standard | 3687-18-1 | 15 | mg | VIAL | |
| 1000576 | Acamprosate Related Compound B (20 mg) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1000521 | Acarbose (200 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 56180-94-0 | 200 | mg | VIAL | |
| 1000532 | Acarbose System Suitability Mixture (2 mg) (COLD SHIPMENT REQUIRED) (A mixture containing acarbose and impurities A, B, C, D, E, F and G) | Reference Standard | N/A | 2 | mg | VIAL | |
| 1000601 | Acebutolol Hydrochloride (125 mg) | Reference Standard | 34381-68-5 | 125 | mg | VIAL | |
| 1000612 | Acebutolol Related Compound A (20 mg) (N-(3-Acetyl-4-hydroxyphenyl)butyramide) | Reference Standard | 40188-45-2 | 20 | mg | VIAL | |
| 1000623 | Acebutolol Related Compound B (20 mg) (N-{3-Acetyl-4-[2-hydroxy-3-(isopropylamino)propoxy]phenyl}acetamide) | Reference Standard | 22568-64-5 | 20 | mg | VIAL | |
| 1000699 | Acebutolol Related Compound I (20 mg) (N-{3-Acetyl-4-[3-(ethylamino)-2-hydroxypropoxy]phenyl}butyramide) | Reference Standard | 441019-91-6 | 20 | mg | VIAL | |
| 1001502 | Acepromazine Maleate (250 mg) | Reference Standard | 3598-37-6 | 250 | mg | VIAL | |
| 1002505 | Acesulfame Potassium (200 mg) | Reference Standard | 55589-62-3 | 200 | mg | VIAL | |
| 1002811 | Acetaldehyde (3 x 1.1 mL) | Reference Standard | 75-07-0 | 3.3 | mL | AMPULE | |
| 1003009 | Acetaminophen (400 mg) | Reference Standard | 103-90-2 | 400 | mg | VIAL | |
| 1003010 | Acetaminophen Related Compound A (15 mg) (4-(acetylamino)phenyl acetate) | Reference Standard | 2623-33-8 | 15 | mg | VIAL | |
| 1003027 | Acetaminophen Related Compound B (30 mg) (N-(4-hydroxyphenyl)propanamide) | Reference Standard | 1693-37-4 | 30 | mg | VIAL | |
| 1003031 | Acetaminophen Related Compound C (50 mg) (N-(2-hydroxyphenyl)acetamide) | Reference Standard | 614-80-2 | 50 | mg | VIAL | |
| 1003042 | Acetaminophen Related Compound D (50 mg) (N-phenylacetamide) | Reference Standard | 103-84-4 | 50 | mg | VIAL | |
| 1003064 | Acetaminophen Related Compound F (50 mg) (p-nitrophenol) | Reference Standard | 100-02-7 | 50 | mg | VIAL | |
| 1003100 | Acetaminophen Related Compound J (50 mg) (N-(4-chlorophenyl)acetamide) | Reference Standard | 539-03-7 | 50 | mg | VIAL | |
| 1004001 | Acetanilide Melting Point Standard (1g) (Approximately 114 degrees) | Reference Standard | 103-84-4 | 1 | g | VIAL | |
| 1005004 | Acetazolamide (2 g) | Reference Standard | 59-66-5 | 2 | g | VIAL | |
| 1005048 | Acetazolamide Related Compound D (25 mg) (5-Amino-1,3,4-thiadiazole-2-sulfonamide) | Reference Standard | 14949-00-9 | 25 | mg | VIAL | |
| 1005059 | Acetazolamide Related Compound E (25 mg) (5-Acetamido-1,3,4-thiadiazole-2-sulfonic acid potassium salt) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1006506 | Acetohydroxamic Acid (200 mg) | Reference Standard | 546-88-3 | 200 | mg | | |
| 1006801 | Acetone (1.5 mL/ampule; 3 ampules) | Reference Standard | 67-64-1 | 4.5 | mL | AMPULE | |
| 1010208 | Acetyl Simvastatin (30 mg) ((1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-(acetoxy)-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate) | Reference Standard | 145576-25-6 | 30 | mg | VIAL | |
| 1008501 | Acetylcholine Chloride (200 mg) | Reference Standard | 60-31-1 | 200 | mg | VIAL | |
| 1009005 | Acetylcysteine (200 mg) | Reference Standard | 616-91-1 | 200 | mg | VIAL | |
| 1009901 | Acetyltributyl Citrate (3 x 200 mg) | Reference Standard | 77-90-7 | 600 | mg | AMPULE | |
| 1009923 | Acetyltriethyl Citrate (500 mg) | Reference Standard | 77-89-4 | 500 | mg | AMPULE | |
| 1011007 | Acitretin (200 mg) | Reference Standard | 55079-83-9 | 200 | mg | VIAL | |
| 1011018 | Acitretin Related Compound A (20 mg) ((2Z,4E,6E,8E)-9-(4-Methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoic acid) | Reference Standard | 69427-46-9 | 20 | mg | VIAL | |
| 1011029 | Acitretin Related Compound B (20 mg) (ethyl (all-E)-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenoate) | Reference Standard | 54350-48-0 | 20 | mg | VIAL | |
| 1012032 | Actein (20 mg) | Reference Standard | 18642-44-9 | 20 | mg | VIAL | |
| 1012065 | Acyclovir (300 mg) | Reference Standard | 59277-89-3 | 300 | mg | VIAL | |
| 1012076 | Acyclovir Related Compound A (50 mg) (2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]ethyl acetate) | Reference Standard | 102728-64-3 | 50 | mg | VIAL | |
| 1012054 | Acyclovir Related Compound F (50 mg) (N-[9-[(2-Hydroxyethoxy)methyl]-6-oxo-6,9-dihydro-1H-purin-2-yl]acetamide) | Reference Standard | 110104-37-5 | 50 | mg | VIAL | |
| 1012087 | Acyclovir Related Compound G (50 mg) (2-{[2-(Acetylamino)-6-oxo-1,6-dihydro-9H-purin-9-yl]methoxy}ethyl acetate) | Reference Standard | 75128-73-3 | 50 | mg | VIAL | |
| 1011709 | Adapalene (200 mg) | Reference Standard | 106685-40-9 | 200 | mg | VIAL | |
| 1011710 | Adapalene Related Compound A (50 mg) (Methyl 6-bromo-2-naphthoate) | Reference Standard | 33626-98-1 | 50 | mg | VIAL | |
| 1011721 | Adapalene Related Compound B (50 mg) (Methyl 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoate) | Reference Standard | 106685-41-0 | 50 | mg | VIAL | |
| 1011732 | Adapalene Related Compound C (25 mg) (2-(adamant-1-yl)methoxybenzene) | Reference Standard | 43109-77-9 | 25 | mg | VIAL | |
| 1011743 | Adapalene Related Compound D (25 mg) (4,4'-dimethoxy-3,3'-di(adamant-1-yl)biphenyl) | Reference Standard | 932033-57-3 | 25 | mg | VIAL | |
| 1011754 | Adapalene Related Compound E (25 mg) (2,2'-binaphthyl-6,6'-dicarboxylic acid) | Reference Standard | 932033-58-4 | 25 | mg | VIAL | |
| 1012134 | Ademetionine Disulfate Tosylate (500 mg) (S-Adenosyl-L-Methionine Disulfate Tosylate) | Reference Standard | 97540-22-2 | 500 | mg | VIAL | |
| 1012101 | Adenine (200 mg) | Reference Standard | 73-24-5 | 200 | mg | VIAL | |
| 1012123 | Adenosine (200 mg) | Reference Standard | 58-61-7 | 200 | mg | VIAL | |
| 1012190 | Adipic Acid (100 mg) | Reference Standard | 124-04-9 | 100 | mg | VIAL | |
| 1011878 | Adrenalone Hydrochloride (25 mg) | Reference Standard | 62-13-5 | 25 | mg | VIAL | |
| 1011889 | Advantame (200 mg) | Reference Standard | 714229-20-6 | 200 | mg | VIAL | |
| 1011890 | Advantame Acid (20 mg) (N-[N-[3-(3-hydroxy-4-methoxyphenyl)propyl]aspartyl]phenylalanine) | Reference Standard | 713524-95-9 | 20 | mg | VIAL | |
| 1012214 | Agar (500 mg) | Reference Standard | 9002-18-0 | 500 | mg | | |
| 1012145 | Agigenin (25 mg) | Reference Standard | 55332-76-8 | 25 | mg | VIAL | |
| 1012203 | Agnuside (25 mg) | Reference Standard | 11027-63-7 | 25 | mg | VIAL | |
| 1012553 | Albendazole (200 mg) | Reference Standard | 54965-21-8 | 200 | mg | VIAL | |
| 1012600 | Albuterol (200 mg) | Reference Standard | 18559-94-9 | 200 | mg | VIAL | |
| 1012644 | Albuterol Related Compound A (25 mg) (4-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-2-methylphenol sulfate) | Reference Standard | 2044704-57-4 | 25 | mg | VIAL | |
| 1012655 | Albuterol Related Compound B (10 mg) (2-(tert-butylamino)-1-[4-hydroxy-3-(hydroxymethyl)phenyl]ethanone) | Reference Standard | 156547-62-5 | 10 | mg | VIAL | |
| 1012689 | Albuterol Related Compound E (10 mg) (2,2'-oxybis(methylene)bis{4-[2-(tert-butylamino)-1-hydroxyethyl]phenol} diacetate) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1012611 | Albuterol Related Compound F (15 mg) (4-[2-(tert-Butylamino)-1-ethoxyethyl]-2-(hydroxymethyl)phenol) | Reference Standard | 1221742-55-7 | 15 | mg | VIAL | |
| 1012564 | Albuterol Related Compound I (20 mg) (4-[2-(tert-Butylamino)-1-hydroxyethyl]phenol) | Reference Standard | 96948-64-0 | 20 | mg | VIAL | |
| 1012633 | Albuterol Sulfate (200 mg) | Reference Standard | 51022-70-9 | 200 | mg | VIAL | |
| 1012757 | Alclometasone Dipropionate (300 mg) | Reference Standard | 66734-13-2 | 300 | mg | VIAL | |
| 1012746 | Alclometasone Dipropionate Related Compound A (20 mg) (11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1012768 | Alcohol (1.2 mL/ampule; 5 ampules) | Reference Standard | 64-17-5 | 6 | mL | AMPULE | |
| 1012688 | Alcohol Determination - Alcohol (5 mL/ampule; 5 ampules) | Reference Standard | 64-17-5 | 25 | mL | AMPULE | |
| 1012699 | Alcohol Determination--Acetonitrile (5 x 5 mL) | Reference Standard | N/A | 25 | mL | AMPULE | |
| 1012780 | Alendronate Sodium (200 mg) | Reference Standard | 121268-17-5 | 200 | mg | VIAL | |
| 1012799 | Aleuritic Acid (50 mg) | Reference Standard | 533-87-9 | 50 | mg | VIAL | |
| 1012906 | Alfentanil Hydrochloride CII (500 mg) | Reference Standard | 70879-28-6 | 500 | mg | VIAL | |
| 1012917 | Alfuzosin Hydrochloride (150 mg) | Reference Standard | 81403-68-1 | 150 | mg | VIAL | |
| 1012928 | Alfuzosin System Suitability Mixture (15 mg) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1012871 | Alfuzosin System Suitability Mixture A (25 mg) (Alfuzosin Hydrochloride containing Impurity A, Impurity D, and Impurity E) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1012892 | Alginate-Konjac-Xanthan Polysaccharide Complex for Viscosity Identification | Reference Standard | N/A | | | | |
| 1012941 | Alginic Acid (100 mg) | Reference Standard | 9005-32-7 | 100 | mg | VIAL | |
| 1012848 | Alitame (250 mg) | Reference Standard | 99016-42-9 (hydrate); 80863-62 | 250 | mg | | |
| 1012859 | Alitame - Alanine Amide Impurity (25 mg) (N-(2,2,4,4-tetramethyl-3-thietanyl)-D-alanimamide) | Reference Standard | 80875-07-6 | 25 | mg | VIAL | |
| 1012939 | Allantoin (200 mg) | Reference Standard | 97-59-6 | 200 | mg | VIAL | |
| 1012950 | Alliin (25 mg) | Reference Standard | 556-27-4 | 25 | mg | VIAL | |
| 1013002 | Allopurinol (250 mg) | Reference Standard | 315-30-0 | 250 | mg | VIAL | |
| 1013024 | Allopurinol Related Compound A (25 mg) (3-Amino-4-carboxamidopyrazole Hemisulfate) | Reference Standard | 27511-79-1 | 25 | mg | VIAL | |
| 1013013 | Allopurinol Related Compound B (25 mg) (5-(formylamino)-1H-pyrazole-4-carboxamide) | Reference Standard | 22407-20-1 | 25 | mg | VIAL | |
| 1013035 | Allopurinol Related Compound C (25 mg) (5-(4H-1,2,4-triazol-4-yl)-1H-pyrazole-4-carboxamide) | Reference Standard | 1346604-13-4 | 25 | mg | VIAL | |
| 1013046 | Allopurinol Related Compound D (35 mg) (Ethyl 5-amino-1H-pyrazole-4-carboxylate) | Reference Standard | 6994-25-8 | 35 | mg | VIAL | |
| 1013068 | Allopurinol Related Compound E (25 mg) (ethyl 5-(formylamino)-1H-pyrazole-4-carboxylate) | Reference Standard | 31055-19-3 | 25 | mg | VIAL | |
| 1013079 | Allopurinol Related Compound F (25 mg) (ethyl-(E/Z)-3-(2-carbethoxy-2-cyanoethenyl)amino-1H-pyrazole-4-carboxylate) | Reference Standard | 321571-07-7 | 25 | mg | VIAL | |
| 1013115 | Allulose (200 mg) | Reference Standard | 551-68-8 | 200 | mg | VIAL | |
| 1039152 | Allyl Anthranilate (0.5 mL/ampule; 5 ampules) | Reference Standard | 7493-63-2 | 2.5 | mL | AMPULE | |
| 1084215 | Allyl Butyrate (5 x 0.5 mL) | Reference Standard | 2051-78-7 | 2.5 | mL | AMPULE | |
| 1154650 | Allyl Cyclohexane Valerate (3 x 0.5 mL) | Reference Standard | 7493-68-7 | 1.5 | mL | AMPULE | |
| 1223209 | Allyl Disulfide (5 x 0.5 mL) | Reference Standard | 2179-57-9 | 2.5 | mL | AMPULE | |
| 1636800 | Allyl Sulfide (5 x 0.5 mL) | Reference Standard | 592-88-1 | 2.5 | mL | AMPULE | |
| 1013206 | Almond Oil (1 g) | Reference Standard | 8007-69-0 | 1 | g | AMPULE | |
| 1013512 | Almotriptan Malate (200 mg) | Reference Standard | 181183-52-8 | 200 | mg | VIAL | |
| 1013523 | Almotriptan Related Compound A (20 mg) ({3-[2-(Dimethylamino)ethyl]-5-[(pyrrolidine-1-yl)sulfonylmethyl]-1H-indol-1-yl}methanol) | Reference Standard | 1018676-02-2 | 20 | mg | VIAL | |
| 1013545 | Almotriptan Related Compound B (15 mg) (2-{5-[(pyrrolidin-1-ylsulfonyl)methyl]-1H-indol-3-yl}ethanamine hemifumarate) | Reference Standard | 1246860-65-0 | 15 | mg | VIAL | |
| 1013556 | Almotriptan Related Compound C (15 mg) (N-methyl-2-{5-[(pyrrolidin-1-ylsulfonyl)methyl]-1H-indol-3-yl}ethanamine) | Reference Standard | 334981-12-3 | 15 | mg | VIAL | |
| 1013567 | Almotriptan Related Compound D (15 mg) (1-[({3-[2-(dimethylamino)ethyl]indol-5-yl}methyl)sulfonyl]pyrrolidine N-oxide hydrochloride) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1013534 | Almotriptan System Suitability (20 mg) (Mixture of Almotriptan Malate and Almotriptan Monomethyl Analog) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1013727 | Aloin (25 mg) (Aloin A; (S)-10-Beta-D-Glucopyranosyl-1,8-dihydroxy-3-hydroxymethylanthracen-9(10H)-one) | Reference Standard | 1415-73-2 | 25 | mg | VIAL | |
| 1013807 | Alosetron Hydrochloride (200 mg) (2,3,4,5-Tetrahydro-5-methyl-2-[(5-methylimidazol-4-yl)methyl]-1H-pyrido[4,3-b]indol-1-one hydrochloride) | Reference Standard | 122852-69-1 | 200 | mg | VIAL | |
| 1013818 | Alosetron Related Compound A (25 mg) (5-Methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indol-1-one) | Reference Standard | 122852-75-9 | 25 | mg | VIAL | |
| 1154558 | Alpha Cyclodextrin (500 mg) | Reference Standard | 10016-20-3 | 500 | mg | VIAL | |
| 1368201 | Alpha Lipoic Acid (500 mg) | Reference Standard | 1077-28-7 | 500 | mg | VIAL | |
| 1667600 | Alpha Tocopherol (250 mg) | Reference Standard | 10191-41-0 | 250 | mg | AMPULE | |
| 1667701 | Alpha Tocopheryl Acetate (250 mg) (Vitamin E Acetate) (COLD SHIPMENT REQUIRED) | Reference Standard | 7695-91-2 | 250 | mg | AMPULE | |
| 1667803 | Alpha Tocopheryl Acid Succinate (250 mg) | Reference Standard | 4345-03-3 | 250 | mg | VIAL | |
| 1162626 | Alpha-Damascone (3 x 0.5 mL) | Reference Standard | 43052-87-5 | 1.5 | mL | AMPULE | |
| 1013909 | Alpha-Lactalbumin (400 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 9051-29-0 | 400 | mg | | |
| 1015008 | Alprazolam CIV (200 mg) | Reference Standard | 28981-97-7 | 200 | mg | VIAL | |
| 1015019 | Alprazolam Related Compound A (30 mg) (2-(2-acetylhydrazino)-7-chloro-5-phenyl-3H-1,4-benzodiazepine) | Reference Standard | 28910-89-6 | 30 | mg | VIAL | |
| 1016000 | Alprostadil (25 mg) | Reference Standard | 745-65-3 | 25 | mg | VIAL | |
| 1017105 | Altretamine (500 mg) | Reference Standard | 645-05-6 | 500 | mg | VIAL | |
| 1017364 | Aluminum Sulfate (2 g) (AS) | Reference Standard | 17927-65-0 | 2 | g | | |
| 1018505 | Amantadine Hydrochloride (200 mg) | Reference Standard | 665-66-7 | 200 | mg | VIAL | |
| 1018516 | Amantadine Related Compound A (25 mg) (1-Chloroadamantane) | Reference Standard | 935-56-8 | 25 | mg | VIAL | |
| 1018527 | Amantadine Related Compound B (25 mg) (N-(Adamantan-1-yl)acetamide) | Reference Standard | 880-52-4 | 25 | mg | VIAL | |
| 1018607 | Amaranth (50 mg) | Reference Standard | 915-67-3 | 50 | mg | VIAL | |
| 1019202 | Amcinonide (200 mg) | Reference Standard | 51022-69-6 | 200 | mg | VIAL | |
| 1019406 | Amifostine (150 mg) | Reference Standard | 112901-68-5 | 150 | mg | VIAL | |
| 1019417 | Amifostine Disulfide (100 mg) (1,3-Propanediamine, N,N-(dithiodi-2,1-ethanediyl)bis, tetrahydrochloride) | Reference Standard | 10027-65-3 | 100 | mg | VIAL | |
| 1019428 | Amifostine Thiol (50 mg) (2-[(3-aminopropyl)amino]ethanethiol, dihydrochloride) | Reference Standard | 14653-77-1 | 50 | mg | VIAL | |
| 1019508 | Amikacin (300 mg) | Reference Standard | 37517-28-5 | 300 | mg | VIAL | |
| 1019494 | Amikacin Sulfate (100 mg) | Reference Standard | 39831-55-5 | 100 | mg | VIAL | |
| 1019701 | Amiloride Hydrochloride (500 mg) | Reference Standard | 17440-83-4 | 500 | mg | VIAL | |
| 1019712 | Amiloride Related Compound A (30 mg) (Methyl 3,5-diamino-6-chloropyrazine-2-carboxylate) | Reference Standard | 1458-01-1 | 30 | mg | VIAL | |
| 1347755 | Amiloxate (Isoamyl Methoxycinnamate) (750 mg/ampule) | Reference Standard | 71617-10-2 | 750 | mg | AMPULE | |
| 1025602 | Amino Methacrylate Copolymer (1.5 g) | Reference Standard | 24938-16-7 | 1.5 | g | VIAL | |
| 1019756 | Aminobenzoate Potassium (200 mg) | Reference Standard | 138-84-1 | 200 | mg | VIAL | |
| 1019767 | Aminobenzoate Sodium (200 mg) | Reference Standard | 555-06-6 | 200 | mg | VIAL | |
| 1019803 | Aminobenzoic Acid (200 mg) (p-aminobenzoic acid) | Reference Standard | 150-13-0 | 200 | mg | VIAL | |
| 1020008 | Aminobutanol (500 mg) (1-Butanol, 2-amino-, (+/-)-) | Reference Standard | 96-20-8 | 500 | mg | AMPULE | |
| 1021000 | Aminocaproic Acid (200 mg) | Reference Standard | 60-32-2 | 200 | mg | VIAL | |
| 1025351 | Aminohippuric Acid (200 mg) | Reference Standard | 61-78-9 | 200 | mg | VIAL | |
| 1025715 | Aminolevulinic Acid Hydrochloride (200 mg) | Reference Standard | 5451-09-2 | 200 | mg | VIAL | |
| 1025726 | Aminolevulinic Acid Related Compound A (25 mg) (3,3'-(Pyrazine-2,5-diyl)dipropionic acid) | Reference Standard | 77479-02-8 | 25 | mg | VIAL | |
| 1025737 | Aminolevulinic Acid Related Compound B (25 mg) (Methyl 5-(1,3-dioxoisoindolin-2-yl)-4-oxopentanoate) | Reference Standard | 109258-71-1 | 25 | mg | VIAL | |
| 1025908 | Aminopentamide Sulfate (200 mg) | Reference Standard | 20701-77-3 | 200 | mg | VIAL | |
| 1026401 | Aminosalicylic Acid (125 mg) | Reference Standard | 65-49-6 | 125 | mg | VIAL | |
| 1021292 | Aminotriazinone (300 mg) (3-Amino-1,2,4-triazin-5(2H)-one) | Reference Standard | 1121-90-0 | 300 | mg | VIAL | |
| 1027302 | Amiodarone Hydrochloride (200 mg) | Reference Standard | 19774-82-4 | 200 | mg | VIAL | |
| 1027346 | Amiodarone Related Compound D (20 mg) ((2-Butylbenzofuran-3-yl)(4-hydroxy-3,5-diiodophenyl)methanone) | Reference Standard | 1951-26-4 | 20 | mg | VIAL | |
| 1027357 | Amiodarone Related Compound E (25 mg) ((2-butylbenzofuran-3-yl)(4-hydroxyphenyl)methanone) | Reference Standard | 52490-15-0 | 25 | mg | VIAL | |
| 1027380 | Amiodarone Related Compound H (20 mg) (2-chloro-N,N-diethylethanamine hydrochloride) | Reference Standard | 869-24-9 | 20 | mg | VIAL | |
| 1028000 | Amitraz (200 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 33089-61-1 | 200 | mg | VIAL | |
| 1028019 | Amitraz Related Compound A (40 mg) (N-(2,4-Dimethylphenyl)formamide) | Reference Standard | 60397-77-5 | 40 | mg | VIAL | |
| 1028028 | Amitraz Related Compound B (40 mg) (N'-(2,4-Dimethylphenyl)-N-methylformimidamide) (COLD SHIPMENT REQUIRED) | Reference Standard | 33089-74-6 | 40 | mg | VIAL | |
| 1028032 | Amitraz Related Compound C (40 mg) (N,N'-Bis(2,4-dimethylphenyl)formimidamide) (COLD SHIPMENT REQUIRED) | Reference Standard | 16596-04-6 | 40 | mg | VIAL | |
| 1029002 | Amitriptyline Hydrochloride (200 mg) | Reference Standard | 549-18-8 | 200 | mg | VIAL | |
| 1029013 | Amitriptyline Related Compound A (25 mg) (dibenzosuberone) | Reference Standard | 1210-35-1 | 25 | mg | AMPULE | |
| 1029024 | Amitriptyline Related Compound B (25 mg) (5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenzo[a,d]-cyclohepten-5-ol) | Reference Standard | 1159-03-1 | 25 | mg | VIAL | |
| 1029501 | Amlodipine Besylate (350 mg) | Reference Standard | 111470-99-6 | 350 | mg | VIAL | |
| 1A00200 | Amlodipine Ethyl Analog (25 mg) (diethyl 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate, maleate) | Pharmaceutical Analytical Impurity | 400024-12-6 | 25 | mg | VIAL | |
| 1A00030 | Amlodipine Methyl Analog (25 mg) (dimethyl 2-((2-aminoethoxy)methyl)-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate, maleate) | Pharmaceutical Analytical Impurity | 400024-11-5 | 25 | mg | VIAL | |
| 1029512 | Amlodipine Related Compound A (25 mg) (3-Ethyl 5-methyl [2-(2-aminoethoxymethyl)-4-(2-chlorophenyl)-6-methyl-3,5-pyridinedicarboxylate] fumarate) | Reference Standard | 2138811-33-1 | 25 | mg | VIAL | |
| 1029534 | Amlodipine Related Compound C (25 mg) (Dimethyl 4-(2-chlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate) | Reference Standard | 43067-01-2 | 25 | mg | VIAL | |
| 1029545 | Amlodipine Related Compound D (25 mg) (3-Ethyl 5-methyl 4-(2-chlorophenyl)-2-{[2-(1,3-dioxoisoindolin-2-yl)ethoxy]methyl}-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate) | Reference Standard | 88150-62-3 | 25 | mg | VIAL | |
| 1029614 | Amlodipine Related Compound K (25 mg) (Ethyl 6-(2-chlorophenyl)-8-methyl-3,4,6,7-tetrahydro-2H-benzo[b][1,4]oxazine-5-carboxylate) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1029909 | Ammonio Methacrylate Copolymer Type A (500 mg) | Reference Standard | 33434-24-1 | 500 | mg | VIAL | |
| 1029910 | Ammonio Methacrylate Copolymer Type B (500 mg) | Reference Standard | 33434-24-1 | 500 | mg | VIAL | |
| 1029942 | Ammonium Carbonate (2 g) (AS) | Reference Standard | 8000-73-5 | 2 | g | VIAL | |
| 1029953 | Ammonium Chloride (200 mg) | Reference Standard | 12125-02-9 | 200 | mg | VIAL | |
| 1029929 | Ammonium Glycyrrhizate (100 mg) | Reference Standard | 53956-04-0 | 100 | mg | VIAL | |
| 1029986 | Ammonium Phosphate Dibasic (1 g) (AS) | Reference Standard | 7783-28-0 | 1 | g | VIAL | |
| 1030001 | Amobarbital CII (200 mg) | Reference Standard | 57-43-2 | 200 | mg | | |
| 1031004 | Amodiaquine Hydrochloride (500 mg) | Reference Standard | 6398-98-7 | 500 | mg | VIAL | |
| 1031401 | Amoxapine (200 mg) | Reference Standard | 14028-44-5 | 200 | mg | VIAL | |
| 1031445 | Amoxapine Related Compound D (50 mg) (2-Chlorodibenzo[b,f]-[1,4]-oxazepin-11-one) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1031478 | Amoxapine Related Compound G (50 mg) (3-Chloro-11-(piperazin-1-yl)dibenzo[b,f][1,4]oxazepine) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1031503 | Amoxicillin (200 mg) | Reference Standard | 61336-70-7 | 200 | mg | VIAL | |
| 1031514 | Amoxicillin Related Compound A (15 mg) ((2S,5R,6R)-6-Amino-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid) | Reference Standard | 551-16-6 | 15 | mg | VIAL | |
| 1031525 | Amoxicillin Related Compound B (15 mg) (L-amoxicillin) | Reference Standard | 26889-93-0 | 15 | mg | VIAL | |
| 1031536 | Amoxicillin Related Compound C (15 mg) ((4S)-2-[5-(4-hydroxyphenyl)-3,6-dioxopiperazin-2-yl]-5,5-dimethylthiazolidine-4-carboxylic acid) | Reference Standard | 94659-47-9 | 15 | mg | VIAL | |
| 1031547 | Amoxicillin Related Compound D (50 mg) ((4S)-2-{[(R)-2-amino-2-(4-hydroxyphenyl)acetamido](carboxy)methyl}-5,5-dimethylthiazolidine-4-carboxylic acid, monosodium salt) | Reference Standard | 1642559-71-4 | 50 | mg | VIAL | |
| 1031569 | Amoxicillin Related Compound F (15 mg) (3-(4-Hydroxyphenyl)pyrazin-2-ol; phenylpyrazinediol) | Reference Standard | 126247-63-0 | 15 | mg | VIAL | |
| 1031570 | Amoxicillin Related Compound G (15 mg) ((2S,5R,6R)-6-{(R)-2-[(R)-2-Amino-2-(4-hydroxyphenyl)acetamido]-2-(4-hydroxyphenyl)acetamido}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid) | Reference Standard | 188112-75-6 | 15 | mg | VIAL | |
| 1031616 | Amoxicillin Related Compound H (15 mg) ((R)-2-(4-hydroxyphenyl)-2-pivalamidoacetic acid) | Reference Standard | 205826-86-4 | 15 | mg | VIAL | |
| 1031591 | Amoxicillin Related Compound I (25 mg) ((R)-2-Amino-2-(4-hydroxyphenyl)acetic acid) | Reference Standard | 22818-40-2 | 25 | mg | VIAL | |
| 1031605 | Amoxicillin Related Compound J (15 mg) (Mixture of amoxicillin and amoxicillin related compound J (open ring dimer)) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1031558 | Amoxicillin Related Compounds D and E Mixture (15 mg) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1032007 | Amphotericin B (125 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 1397-89-3 | 125 | mg | VIAL | |
| 1033000 | Ampicillin (200 mg) | Reference Standard | 69-53-4 | 200 | mg | VIAL | |
| 1033203 | Ampicillin Sodium (125 mg) | Reference Standard | 69-52-3 | 125 | mg | VIAL | |
| 1033247 | Ampicillin System Suitability Mixture (10 mg) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1033407 | Ampicillin Trihydrate (200 mg) | Reference Standard | 7177-48-2 | 200 | mg | VIAL | |
| 1034002 | Amprolium (200 mg) | Reference Standard | 137-88-2 | 200 | mg | VIAL | |
| 1034308 | Amrinone (500 mg) (Inamrinone) | Reference Standard | 60719-84-8 | 500 | mg | VIAL | |
| 1034320 | Amrinone Related Compound A (100 mg) (5-carboxamide[3,4'-bipyridin]-6(1H)-one) (Inamrinone Related Compound A) | Reference Standard | 62749-46-6 | 100 | mg | VIAL | |
| 1034363 | Amrinone Related Compound C (50 mg) (1,6-dihydro-6-oxo-(3,4'-bipyridine)-5-carbonitrile) (Inamrinone Related Compound C) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1034738 | Anagrelide Hydrochloride (100 mg) | Reference Standard | 823178-43-4 | 100 | mg | VIAL | |
| 1034749 | Anagrelide Related Compound A (25 mg) (ethyl 2-(6-amino-2,3-dichlorobenzylamino)acetate) | Reference Standard | 85325-12-8 | 25 | mg | VIAL | |
| 1034750 | Anagrelide Related Compound B (25 mg) ((2-amino-5,6-dichloroquinazolin-3(4H)-yl)acetic acid) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1034771 | Anagrelide Related Compound C (25 mg) (Ethyl 2-(5,6-dichloro-2-imino-1,2-dihydroquinazolin-3(4H)-yl)acetate) | Reference Standard | 70381-75-8 | 25 | mg | VIAL | |
| 1034807 | Anastrozole (200 mg) | Reference Standard | 120511-73-1 | 200 | mg | VIAL | |
| 1034818 | Anastrozole Related Compound A (20 mg) (2,2'-(5-methyl-1,3-phenylene)bis(2-methylpropanenitrile)) | Reference Standard | 120511-72-0 | 20 | mg | VIAL | |
| 1034862 | Andrographolide (50 mg) | Reference Standard | 5508-58-7 | 50 | mg | VIAL | |
| 1035005 | Anethole (4 x 0.5 mL) | Reference Standard | 4180-23-8 | 2 | mL | AMPULE | |
| 1035402 | Anhydro Simvastatin (30 mg) ((1S,3R,7S,8S,8aR)-3,7-Dimethyl-8-[2-[(2R)-6-oxo-3,6-dihydro-2H-pyran-2-yl]ethyl]-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate) (COLD SHIPMENT REQUIRED) | Reference Standard | 210980-68-0 | 30 | mg | VIAL | |
| 1035708 | Anhydrotetracycline Hydrochloride (25 mg) ((4S ,4aS ,12aS )-4-(Dimethylamino)-3,10,11,12a-tetrahydroxy-6-methyl-1,12-dioxo-1,4,4a,5,12,12a-hexahydrotetracene-2-carboxamide monohydrochloride) | Reference Standard | 13803-65-1 | 25 | mg | VIAL | |
| 1356676 | Anhydrous Lactose (100 mg) (Mixture of alpha and beta anomers) | Reference Standard | 63-42-3 | 100 | mg | VIAL | |
| 1614716 | Anhydrous Sodium Succinate (250 mg) | Reference Standard | 150-90-3 | 250 | mg | VIAL | |
| 1036110 | Aniline (250 mg) | Reference Standard | 62-53-3 | 250 | mg | AMPULE | |
| 1036959 | Anise Oil (2 x 0.5 mL) | Reference Standard | 8007-70-3 | 1 | mL | AMPULE | |
| 1037011 | Anisole (1.2 mL/ampule; 3 ampules) | Reference Standard | 100-66-3 | 3.6 | mL | AMPULE | |
| 1037022 | Anisyl Butyrate (5 x 0.5 mL) | Reference Standard | 6963-56-0 | 2.5 | mL | AMPULE | |
| 1037044 | Anisyl Phenylacetate (5 x 0.5 mL) | Reference Standard | 102-17-0 | 2.5 | mL | AMPULE | |
| 1037033 | Anisyl Propionate (5 x 0.5 mL) | Reference Standard | 7549-33-9 | 2.5 | mL | AMPULE | |
| 1667870 | Annatto Seed Tocotrienols Extract (4 x 150 mg) | Reference Standard | N/A | 600 | mg | AMPULE | |
| 1038003 | Antazoline Phosphate (200 mg) | Reference Standard | 154-68-7 | 200 | mg | VIAL | |
| 1038025 | Antazoline Related Compound A (15 mg) (N-(2-Aminoethyl)-2-[benzyl(phenyl)amino]acetamide) | Reference Standard | 26953-37-7 | 15 | mg | VIAL | |
| 1039006 | Anthralin (200 mg) | Reference Standard | 1143-38-0 | 200 | mg | | |
| 1040005 | Antipyrine (200 mg) | Reference Standard | 60-80-0 | 200 | mg | VIAL | |
| 1040016 | Antipyrine Related Compound A (25 mg) (3-Methyl-1-phenyl-1H-pyrazol-5(4H)-one) | Reference Standard | 89-25-8 | 25 | mg | | |
| 1040504 | Antithrombin III Human (4.38 IU) | Reference Standard | 9000-94-6 | 1 | ea | AMPULE | |
| 1040683 | Apigenin (30 mg) (5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone) | Reference Standard | 520-36-5 | 30 | mg | VIAL | |
| 1040708 | Apigenin-7-glucoside (30 mg) | Reference Standard | 578-74-5 | 30 | mg | VIAL | |
| 1040854 | Apocarotenal (3 x 50 mg) (8'-apo-beta-caroten-8'-al) | Reference Standard | 1107-26-2 | 150 | mg | AMPULE | |
| 1041008 | Apomorphine Hydrochloride (250 mg) | Reference Standard | 41372-20-7 | 250 | mg | VIAL | |
| 1041609 | Apraclonidine Hydrochloride (100 mg) | Reference Standard | 73218-79-8 | 100 | mg | VIAL | |
| 1041904 | Aprepitant (150 mg) | Reference Standard | 170729-80-3 | 150 | mg | VIAL | |
| 1041915 | Aprepitant Related Compound A (10 mg) (3-[[(2R,3R)-2-[(R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholino]methyl]-1H-1,2,4-triazol-5(4H)-one) | Reference Standard | 1148113-53-4 | 10 | mg | VIAL | |
| 1041926 | Aprepitant Related Compound B (10 mg) (3-[[(2S,3R)-2-[(S)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholino]methyl]-1H-1,2,4-triazol-5(4H)-one) | Reference Standard | 172822-29-6 | 10 | mg | VIAL | |
| 1042055 | Arabinose (50 mg) | Reference Standard | 87-72-9 | 50 | mg | VIAL | |
| 1042270 | Arachidyl Alcohol (125 mg) | Reference Standard | 629-96-9 | 125 | mg | VIAL | |
| 1042408 | Argatroban (350 mg) | Reference Standard | 141396-28-3 | 350 | mg | VIAL | |
| 1042419 | Argatroban Related Compound A (15 mg) ((2R,4R)-1-[N8-nitro- N2-(3-methylquinoline-8-sulfonyl)-L-arginyl]-4-methylpiperidine-2-carboxylic acid) | Reference Standard | 74874-10-5 | 15 | mg | VIAL | |
| 1042420 | Argatroban Related Compound B (20 mg) (Ethyl (4R)-1-[N^8-nitro-L-arginyl]-4-methylpiperidine-2-carboxylate dihydrochloride) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1042437 | Argatroban Related Compound C (20 mg) ((2R,4R)-1-[N^8-amino- N^2-(3-methyl-1,2,3,4-tetrahydroquinoline-8-sulfonyl)-L-arginyl]-4-methylpiperidine-2-carboxylic acid) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1042554 | Arginine Ethyl Ester Dihydrochloride (250 mg) | Reference Standard | 36589-29-4 | 250 | mg | VIAL | |
| 1042601 | Arginine Hydrochloride (125 mg) | Reference Standard | 1119-34-2 | 125 | mg | VIAL | |
| 1042634 | Aripiprazole (200 mg) | Reference Standard | 129722-12-9 | 200 | mg | VIAL | |
| 1042645 | Aripiprazole Related Compound B (25 mg) (7-(4-hydroxy-butoxy)-3,4-dihydroquinolin-2(1H)-one) | Reference Standard | 889443-20-3 | 25 | mg | VIAL | |
| 1042656 | Aripiprazole Related Compound C (25 mg) (1-(2,3-dichlorophenyl)piperazine hydrochloride) | Reference Standard | 119532-26-2 | 25 | mg | VIAL | |
| 1042689 | Aripiprazole Related Compound F (25 mg) (4-(2,3-dichlorophenyl)-1-[4-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yloxy)butyl]piperazin 1-oxide) | Reference Standard | 573691-09-5 | 25 | mg | VIAL | |
| 1042690 | Aripiprazole Related Compound G (25 mg) (7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}quinolin-2(1H)-one) | Reference Standard | 129722-25-4 | 25 | mg | VIAL | |
| 1042714 | Aripiprazole Related Compound H (25 mg) (7-(4-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}butoxy)-3,4-dihydroquinolin-2(1H)-one) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1042758 | Armodafinil CIV (500 mg) | Reference Standard | 112111-43-0 | 500 | mg | VIAL | |
| 1042703 | Arsanilic Acid (25 mg) | Reference Standard | 98-50-0 | 25 | mg | VIAL | |
| 1042780 | Artemether (100 mg) | Reference Standard | 71963-77-4 | 100 | mg | VIAL | |
| 1042805 | Artemether Related Compound B (15 mg) ((3R,5aS,6R,8aS,9R,10R,12R,12aR)-Decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin) | Reference Standard | 71939-51-0 | 15 | mg | VIAL | |
| 1042747 | Artemisinin (50 mg) ((3R,5aS,6R,8aS,9R,12S,12aR)-Octahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10(3H)-one) | Reference Standard | 63968-64-9 | 50 | mg | VIAL | |
| 1042850 | Artesunate (200 mg) | Reference Standard | 88495-63-0 | 200 | mg | VIAL | |
| 1042907 | Articaine (40 mg) | Reference Standard | 23964-58-1 | 40 | mg | VIAL | |
| 1042918 | Articaine Hydrochloride (125 mg) | Reference Standard | 23964-57-0 | 125 | mg | VIAL | |
| 1042929 | Articaine Related Compound A (40 mg) (Methyl 4-methyl-3-[2-(propylamino)acetamido]thiophene-2-carboxylate) | Reference Standard | N/A | 40 | mg | VIAL | |
| 1042930 | Articaine Related Compound B (25 mg) (4-methyl-3-{[2-(propylamino)propanoyl]amino}thiophene-2-carboxylic acid) | Reference Standard | 114176-52-2 | 25 | mg | VIAL | |
| 1042962 | Articaine Related Compound E (40 mg) (Methyl 3-[2-(isopropylamino)propanamido]-4-methylthiophene-2-carboxylate) | Reference Standard | 1796888-45-3 | 40 | mg | VIAL | |
| 1043003 | Ascorbic Acid (1 g) (Vitamin C) | Reference Standard | 50-81-7 | 1 | g | VIAL | |
| 1043105 | Ascorbyl Palmitate (500 mg) | Reference Standard | 137-66-6 | 500 | mg | VIAL | |
| 1043149 | Ascorbyl Stearate (500 mg) | Reference Standard | 10605-09-1 | 500 | mg | VIAL | |
| 1354965 | Ashwagandha Aerial Parts Dry Extract (250 mg) | Reference Standard | N/A | 250 | mg | VIAL | |
| 1043331 | Asiaticoside (30 mg) | Reference Standard | 16830-15-2 | 30 | mg | VIAL | |
| 1076024 | Asp9-Bivalirudin (1 mg) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | 1182140-65-3 | 1 | mg | VIAL | |
| 1043502 | Asparagine Anhydrous (200 mg) | Reference Standard | 70-47-3 | 200 | mg | VIAL | |
| 1043513 | Asparagine Monohydrate (200 mg) | Reference Standard | 5794-13-8 | 200 | mg | VIAL | |
| 1043524 | Asparagine Related Compound A (10 mg) (2,2'-(3,6-dioxopiperazine-2,5-diyl)diacetamide) | Reference Standard | 98490-54-1 | 10 | mg | VIAL | |
| 1043706 | Aspartame (200 mg) | Reference Standard | 22839-47-0 | 200 | mg | VIAL | |
| 1043750 | Aspartame Acesulfame (200 mg) | Reference Standard | 106372-55-8 | 200 | mg | VIAL | |
| 1043728 | Aspartame Related Compound A (25 mg) (5-Benzyl-3,6-dioxo-2-piperazineacetic acid) | Reference Standard | 55102-13-1 | 25 | mg | VIAL | |
| 1043819 | Aspartic Acid (100 mg) | Reference Standard | 56-84-8 | 100 | mg | VIAL | |
| 1044006 | Aspirin (500 mg) | Reference Standard | 50-78-2 | 500 | mg | VIAL | |
| 1044200 | Astaxanthin (Synthetic) (3 x 30 mg) (3,3'-dihydroxy-Beta,Beta-Carotene-4,4'-dione) | Reference Standard | 7542-45-2 | 90 | mg | AMPULE | |
| 1044210 | Astaxanthin Esters from Haematococcus pluvialis (5 x 100 mg) | Reference Standard | 7542-45-2 (Free Astaxanthin) | 500 | mg | AMPULE | |
| 1044108 | Astragaloside IV (100 mg) ((3beta,6alpha,9beta,16beta,20R,24S)-16,25-Dihydroxy-3-(beta-D-xylopyranosyloxy)-20,24-epoxy-9,19-cyclolanostan-6-yl beta-D-glucopyranoside) | Reference Standard | 84687-43-4 | 100 | mg | VIAL | |
| 1044119 | Astragalus Root Dry Extract (1 g) | Reference Standard | N/A | 1 | g | VIAL | |
| 1044356 | Atazanavir Related Compound A (25 mg) ((S)-2-[(Methoxycarbonyl)amino]-3,3-dimethylbutanoic acid) | Reference Standard | 162537-11-3 | 25 | mg | VIAL | |
| 1044334 | Atazanavir Sulfate (200 mg) | Reference Standard | 229975-97-7 | 200 | mg | VIAL | |
| 1044345 | Atazanavir System Suitability Mixture (25 mg) (A mixture of atazanavir sulfate, atazanavir R, S, S, S,-diastereomer and atazanavir S,R,S,S diastereomer) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1044403 | Atenolol (200 mg) | Reference Standard | 29122-68-7 | 200 | mg | VIAL | |
| 1044254 | Atenolol Related Compound A (50 mg) (2-(4-Hydroxyphenyl)acetamide) | Reference Standard | 17194-82-0 | 50 | mg | VIAL | |
| 1044265 | Atenolol Related Compound B (25 mg) (2-[4-(2,3-Dihydroxypropoxy)phenyl]acetamide) | Reference Standard | 61698-76-8 | 25 | mg | VIAL | |
| 1044276 | Atenolol Related Compound C (25 mg) (2-[4-(Oxiran-2-ylmethoxy)phenyl]acetamide) | Reference Standard | 29122-69-8 | 25 | mg | VIAL | |
| 1044287 | Atenolol Related Compound D (25 mg) (2-[4-(3-Chloro-2-hydroxypropoxy)phenyl]acetamide) | Reference Standard | 115538-83-5 | 25 | mg | VIAL | |
| 1044298 | Atenolol Related Compound E (25 mg) (2,2'-{[(2-Hydroxypropane-1,3-diyl)bis(oxy)]bis(4,1-phenylene)}diacetamide) | Reference Standard | 141650-31-9 | 25 | mg | VIAL | |
| 1044367 | Atenolol Related Compound F (25 mg) (2,2'-[{[(Isopropylazanediyl)bis(2-hydroxypropane-3,1-diyl)]bis(oxy)}bis(4,1-phenylene)]diacetamide) | Reference Standard | 87619-83-8 | 25 | mg | VIAL | |
| 1044469 | Atomoxetine Hydrochloride (200 mg) | Reference Standard | 82248-59-7 | 200 | mg | VIAL | |
| 1044470 | Atomoxetine Related Compound A (10 mg) (3-(Methylamino)-1-phenylpropan-1-ol) | Reference Standard | 42142-52-9 | 10 | mg | VIAL | |
| 1044488 | Atomoxetine Related Compound B (10 mg) (N-Methyl-3-phenyl-3-(m-tolyloxy)propan-1-amine hydrochloride) | Reference Standard | 1643684-05-2 | 10 | mg | VIAL | |
| 1044491 | Atomoxetine Related Compound C (10 mg) (N-methyl-3-phenyl-3-(p-tolyloxy)propan-1-amine hydrochloride) | Reference Standard | 873310-31-7 | 10 | mg | VIAL | |
| 1044913 | Atomoxetine S-Isomer (10 mg) ((S)-N-Methyl-3-phenyl-3-(o-tolyloxy)propan-1-amine hydrochloride) | Reference Standard | 82857-39-4 | 10 | mg | VIAL | |
| 1044516 | Atorvastatin Calcium (100 mg) | Reference Standard | 344423-98-9 | 100 | mg | VIAL | |
| 1A00010 | Atorvastatin Ethyl Ester (25 mg) (ethyl (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate) | Pharmaceutical Analytical Impurity | 1146977-93-6 | 25 | mg | VIAL | |
| 1A00020 | Atorvastatin Methyl Ester (25 mg) (methyl (3R,5R)-7-(2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoate) | Pharmaceutical Analytical Impurity | 345891-62-5 | 25 | mg | VIAL | |
| 1044527 | Atorvastatin Related Compound A (20 mg) (Desfluoro impurity, or (3R,5R)-7-[3-(phenylcarbamoyl)-2-isopropyl-4,5-diphenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid calcium salt) | Reference Standard | 433289-83-9 | 20 | mg | VIAL | |
| 1044538 | Atorvastatin Related Compound B (20 mg) (Calcium (3S,5R)-7-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate (1:2)) | Reference Standard | 887196-25-0 | 20 | mg | VIAL | |
| 1044549 | Atorvastatin Related Compound C (20 mg) (Calcium (3R,5R)-7-[2,3-Bis(4-fluorophenyl)-5-isopropyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate (1:2)) | Reference Standard | 693793-53-2 | 20 | mg | VIAL | |
| 1044550 | Atorvastatin Related Compound D (10 mg) (Epoxide Impurity, 3-(4-Fluorobenzoyl)-2-isobutyryl-N,3-diphenyloxirane-2-carboxamide) | Reference Standard | 148146-51-4 | 10 | mg | VIAL | |
| 1044571 | Atorvastatin Related Compound E (10 mg) (Calcium(3S,5S)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoate (1:2)) | Reference Standard | 1105067-88-6 | 10 | mg | VIAL | |
| 1044582 | Atorvastatin Related Compound H (20 mg) (Lactone Impurity, 5-(4-Fluorophenyl)-1-{2-[(2R, 4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-2-isopropyl-N,4-diphenyl-1H-pyrrole-3-carboxamide) | Reference Standard | 125995-03-1 | 20 | mg | VIAL | |
| 1044593 | Atorvastatin Related Compound I (20 mg) (tert-Butyl 2-((4R,6R)-6-{2-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl]ethyl}-2,2-dimethyl-1,3-dioxan-4-yl)acetate) | Reference Standard | 125971-95-1 | 20 | mg | VIAL | |
| 1044651 | Atovaquone (200 mg) | Reference Standard | 95233-18-4 | 200 | mg | VIAL | |
| 1044662 | Atovaquone Related Compound A (25 mg) (cis-2-[4-(4-Chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone) | Reference Standard | 137732-39-9 | 25 | mg | VIAL | |
| 1044800 | Atracurium Besylate (100 mg) | Reference Standard | 64228-81-5 | 100 | mg | VIAL | |
| 1044990 | Atropine (50 mg) (1alphaH,5alphaH-Tropan-3alpha-ol (+/-)-tropate (ester)) | Reference Standard | 51-55-8 | 50 | mg | VIAL | |
| 1045009 | Atropine Sulfate (500 mg) | Reference Standard | 5908-99-6 | 500 | mg | VIAL | |
| 1045508 | Aurothioglucose (100 mg) | Reference Standard | 12192-57-3 | 100 | mg | | |
| 1045337 | Avobenzone (500 mg) | Reference Standard | 70356-09-1 | 500 | mg | VIAL | |
| 1045520 | Azacitidine (150 mg) | Reference Standard | 320-67-2 | 150 | mg | VIAL | |
| 1A00260 | Azacitidine Formyl Amidine Analog (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) (25 mg) (N-(Formyl amidino)-N'-Beta-D-ribofuranosylurea) | Pharmaceutical Analytical Impurity | 65126-88-7 | 25 | mg | VIAL | |
| 1A00270 | Azacitidine Isomer -3 (25 mg) (1-Beta-D-Ribofuranosyl-3-aminocarbonyl guanidine acetate) | Pharmaceutical Analytical Impurity | n/a | 25 | mg | VIAL | |
| 1045539 | Azacitidine Related Compound A (25 mg) (4-Amino-1,3,5-triazin-2(1H)-one) | Reference Standard | 931-86-2 | 25 | mg | VIAL | |
| 1045541 | Azacitidine Related Compound B (15 mg) (1-O-Acetyl-2,3,5-tri-O-benzoyl-Beta-D-ribofuranose) | Reference Standard | 6974-32-9 | 15 | mg | VIAL | |
| 1045574 | Azacitidine Related Compound C (15 mg) (1-beta-D-Ribofuranosyl-3-guanylurea picrate) | Reference Standard | 4336-46-3 | 15 | mg | VIAL | |
| 1045600 | Azaerythromycin A (100 mg) (9-Deoxo-9a-aza-9a-homoerythromycin A) | Reference Standard | 76801-85-9 | 100 | mg | VIAL | |
| 1045756 | Azaperone (200 mg) | Reference Standard | 1649-18-9 | 200 | mg | VIAL | |
| 1046001 | Azathioprine (200 mg) | Reference Standard | 446-86-6 | 200 | mg | VIAL | |
| 1045993 | Azathioprine Related Compound A (15 mg) (1-methyl-4-nitro-1H-imidazol-5-amine) | Reference Standard | 4531-54-8 | 15 | mg | VIAL | |
| 1045938 | Azathioprine Related Compound G (15 mg) (6-[(1-methyl-4-nitro-1H-imidazol-5-yl)thio]-9H-purin-2-amine) | Reference Standard | 5581-52-2 | 15 | mg | VIAL | |
| 1046158 | Azelastine Hydrochloride (300 mg) | Reference Standard | 79307-93-0 | 300 | mg | VIAL | |
| 1046170 | Azelastine Related Compound B (20 mg) (N'-(1-methylazepan-4-yl)benzohydrazide hydrochloride) | Reference Standard | 117078-69-0 | 20 | mg | VIAL | |
| 1046191 | Azelastine Related Compound D (20 mg) (4-(4-chlorobenzyl)phthalazin-1(2H)-one) | Reference Standard | 53242-88-9 | 20 | mg | VIAL | |
| 1046202 | Azelastine Related Compound E (20 mg) (3-(4-chlorobenzylidene)isobenzofuran-1(3H)-one) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1046213 | Azelastine Related Compound F (20 mg) (4-[4-(4-Chlorobenzyl)-1-oxophthalazin-2(1H)-yl]-1-methylazepane 1-oxide) | Reference Standard | 640279-88-5 | 20 | mg | VIAL | |
| 1046056 | Azithromycin (200 mg) | Reference Standard | 117772-70-0 | 200 | mg | VIAL | |
| 1046067 | Azithromycin Identity (75 mg) | Reference Standard | N/A | 75 | mg | VIAL | |
| 1046090 | Azithromycin N-Oxide (15 mg) | Reference Standard | 90503-06-3 | 15 | mg | VIAL | |
| 1046045 | Azithromycin Related Compound F (25 mg) (3'-N-demethyl-3'-N-formylazithromycin) | Reference Standard | 612069-28-0 | 25 | mg | VIAL | |
| 1046023 | Azithromycin Related Compound H (15 mg) (3'-N-{[4-(Acetylamino)phenyl]sulfonyl}-3'-N-demethylazithromycin) | Reference Standard | 612069-30-4 | 15 | mg | VIAL | |
| 1046125 | Azorubine (50 mg) | Reference Standard | 3567-69-9 | 50 | mg | VIAL | |
| 1733122 | Aztec Marigold Zeaxanthin Extract (4 x 50 mg) | Reference Standard | 148-68-3 | 200 | mg | AMPULE | |
| 1046205 | Aztreonam (200 mg) | Reference Standard | 78110-38-0 | 200 | mg | VIAL | |
| 1046307 | Aztreonam E-Isomer (15 mg) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1046351 | Azure B (50 mg) (3-(Dimethylamino)-7-(methylamino)phenothiazin-5-ium chloride) | Reference Standard | 531-55-5 | 50 | mg | VIAL | |
| 1076192 | BSA for Protein Quantitation (5 x 1 mL) | Reference Standard | 9048-46-8 | 5 | mL | AMPULE | |
| 1048007 | Bacitracin Zinc (200 mg) | Reference Standard | 1405-89-6 | 200 | mg | VIAL | |
| 1048200 | Baclofen (350 mg) | Reference Standard | 1134-47-0 | 350 | mg | VIAL | |
| 1048222 | Baclofen Related Compound A (50 mg) (4-(4-Chlorophenyl)-2-pyrrolidinone) | Reference Standard | 22518-27-0 | 50 | mg | VIAL | |
| 1048233 | Bacoside A3 (15 mg) | Reference Standard | 157408-08-7 | 15 | mg | VIAL | |
| 1048357 | Baicalein (50 mg) | Reference Standard | 491-67-8 | 50 | mg | VIAL | |
| 1048368 | Baicalein 7-O-Glucuronide (50 mg) | Reference Standard | 21967-41-9 | 50 | mg | VIAL | |
| 1048255 | Balsalazide Disodium (200 mg) | Reference Standard | 150399-21-6 | 200 | mg | VIAL | |
| 1048266 | Balsalazide Related Compound A (100 mg) ((E)-5-[(p-carboxyphenyl)azo]-2-salicylic acid, disodium salt) | Reference Standard | N/A | 100 | mg | VIAL | |
| 1048277 | Balsalazide Related Compound B (25 mg) ((E)-5-((m-[(2-carboxyethyl)carbamoyl]phenyl)azo)-2-salicylic acid) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1048506 | Beclomethasone Dipropionate (200 mg) | Reference Standard | 5534-09-8 | 200 | mg | VIAL | |
| 1048517 | Beclomethasone Dipropionate Related Compound A (25 mg) (9-Chloro-11Beta,17-dihydroxy-16Beta-methyl-3,20-dioxopregna-1,4-diene-21-yl propionate) | Reference Standard | 69224-79-9 | 25 | mg | VIAL | |
| 1048543 | Beclomethasone Dipropionate Related Compound H (25 mg) (9-Chloro-11Beta,17-dihydroxy-16Beta-methyl-3,20-dioxopregna-1,4-diene-17-yl propionate) | Reference Standard | 5534-18-9 | 25 | mg | VIAL | |
| 1048550 | Behenoyl Polyoxylglycerides (500 mg) | Reference Standard | N/A | 500 | mg | VIAL | |
| 1048572 | Bemotrizinol (200 mg) | Reference Standard | 187393-00-6 | 200 | mg | VIAL | |
| 1048583 | Bemotrizinol Impurity Mixture (100 mg) | Reference Standard | N/A | 100 | mg | VIAL | |
| 1048619 | Benazepril Hydrochloride (125 mg) | Reference Standard | 86541-74-4 | 125 | mg | VIAL | |
| 1048620 | Benazepril Related Compound A (25 mg) ((3R)-3-[[(1R)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid, monohydrochloride) | Reference Standard | 215447-89-5 | 25 | mg | VIAL | |
| 1048630 | Benazepril Related Compound B (15 mg) (2-[(S)-3-{[(R)-1-Ethoxy-1-oxo-4-phenylbutan-2-yl]amino}-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl]acetic acid hydrochloride) | Reference Standard | 86541-77-7 | 15 | mg | VIAL | |
| 1048641 | Benazepril Related Compound C (50 mg) ((3S)-3-[[(1S)-1-carboxy-3-phenylpropyl]amino-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine]-1-acetic acid) | Reference Standard | 86541-78-8 | 50 | mg | VIAL | |
| 1048652 | Benazepril Related Compound D (15 mg) (3-(1-Ethoxycarbonyl-3-cyclohexyl-(1S)-propyl)amino-2,3,4,5-tetrahydro-2-oxo-1H-1-(3S)-benzazepine-1-acetic acid monohydrochloride) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1048663 | Benazepril Related Compound E (25 mg) (3-amino-2,3,4,5-tetrahydro-2-oxo-1H-1-(3S)-benzazepine-1-acetic acid, monohydrochloride) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1048674 | Benazepril Related Compound F (15 mg) (tert-Butyl-3-amino-2,3,4,5-tetrahydro-2-oxo-1H-1-(3S)-benzazepine-1-acetic acid) | Reference Standard | 109010-60-8 | 15 | mg | VIAL | |
| 1048685 | Benazepril Related Compound G (15 mg) (COLD SHIPMENT REQUIRED) ((3-(1-Ethoxycarbonyl-3-phenyl-(1S)-propyl)amino-2,3,4,5-tetrahydro-2-oxo-1H-1-(3S)-benzazepine)-1-acetic acid, ethyl ester) | Reference Standard | 103129-58-4 | 15 | mg | VIAL | |
| 1065221 | Bendamustine Hydrochloride (200 mg) | Reference Standard | 3543-75-7 | 200 | mg | VIAL | |
| 1065232 | Bendamustine Related Compound A (25 mg) (4-{5-[Bis(2-hydroxyethyl)amino]-1-methyl-1H-benzimidazol-2-yl}butanoic acid hydrochloride) | Reference Standard | 109882-29-3 | 25 | mg | VIAL | |
| 1065243 | Bendamustine Related Compound B (20 mg) (4-(1-Methyl-5-morpholino-1H-benzimidazol-2-yl)butanoic acid hydrochloride) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1065254 | Bendamustine Related Compound C (20 mg) (Ethyl 4-{5-[bis(2-hydroxyethyl)amino]-1-methyl-1H -benzimidazol-2-yl}butanoate) | Reference Standard | 3543-74-6 | 20 | mg | VIAL | |
| 1065265 | Bendamustine Related Compound D (20 mg) (4-{5-[(2-Chloroethyl)amino]-1-methyl-1H -benzimidazol-2-yl}butanoic acid hydrochloride) | Reference Standard | 1797881-48-1 | 20 | mg | VIAL | |
| 1065276 | Bendamustine Related Compound E (20 mg) (4-{5-[(2-Chloroethyl)(2-hydroxyethyl)amino]-1-methyl-1H-benzimidazol-2-yl}butanoic acid) | Reference Standard | 109882-27-1 | 20 | mg | VIAL | |
| 1065287 | Bendamustine Related Compound F (20 mg) (Mannitol-1-yl 4-{5-[bis(2-chloroethyl)amino]-1-methyl-1H -benzimidazol-2-yl}butanoate) | Reference Standard | 1869075-89-7 | 20 | mg | VIAL | |
| 1065298 | Bendamustine Related Compound G (20 mg) (4-[6-(2-Chloroethyl)-3,6,7,8-tetrahydro-3-methylimidazo[4,5-h][1,4]benzothiazin-2-yl]butanoic acid hydrochloride) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1065301 | Bendamustine Related Compound H (25 mg) (4-[5-({2-[(4-{5-[Bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazol-2-yl}butanoyl)oxy]ethyl}(2-chloroethyl)amino)-1-methyl-1H-benzimidazol-2-yl]butanoic acid) | Reference Standard | 1228551-91-4 | 25 | mg | VIAL | |
| 1065312 | Bendamustine Related Compound I (25 mg) (Ethyl 4-{5-[bis(2-chloroethyl)amino]-1-methyl-1H-benzimidazol-2-yl}butanoate) | Reference Standard | 87475-54-5 | 25 | mg | VIAL | |
| 1049000 | Bendroflumethiazide (200 mg) | Reference Standard | 73-48-3 | 200 | mg | VIAL | |
| 1050009 | Benoxinate Hydrochloride (200 mg) | Reference Standard | 5987-82-6 | 200 | mg | VIAL | |
| 1050905 | Benzaldehyde (3 X 1 mL) (List Chemical) | Reference Standard | 100-52-7 | 3 | mL | AMPULE | |
| 1050949 | Benzaldehyde Propylene Glycol Acetal (5 x 0.5 mL) | Reference Standard | 2568-25-4 | 2.5 | mL | AMPULE | |
| 1050982 | Benzalkonium Bromide (C12) (150 mg) (Benzyldodecyldimethylammonium bromide) (COLD SHIPMENT REQUIRED) | Reference Standard | 7281-04-1 | 150 | mg | VIAL | |
| 1050993 | Benzalkonium Chloride (5 mL of approx. 4% aqueous solution) | Reference Standard | 8001-54-5 | 5 | mL | AMPULE | |
| 1051500 | Benzethonium Chloride (500 mg) | Reference Standard | 121-54-0 | 500 | mg | VIAL | |
| 1051602 | Benzhydrol (50 mg) | Reference Standard | 91-01-0 | 50 | mg | VIAL | |
| 1054000 | Benzocaine (500 mg) | Reference Standard | 94-09-7 | 500 | mg | VIAL | |
| 1055002 | Benzoic Acid (300 mg) | Reference Standard | 65-85-0 | 300 | mg | VIAL | |
| 1056005 | Benzonatate (1 g) | Reference Standard | 104-31-4 | 1 | g | AMPULE | |
| 1056130 | Benzophenone (25 mg) (Diphenylmethanone) | Reference Standard | 119-61-9 | 25 | mg | VIAL | |
| 1057507 | Benzothiadiazine Related Compound A (100 mg) (4-Amino-6-chloro-1,3-benzenedisulfonamide) | Reference Standard | 121-30-2 | 100 | mg | VIAL | |
| 1059003 | Benzphetamine Hydrochloride CIII (200 mg) | Reference Standard | 5411-22-3 | 200 | mg | VIAL | |
| 1059014 | Benzphetamine Related Compound A CIII (30 mg) ((R)-N-Benzyl-N-methyl-1-phenylpropan-2-amine hydrochloride) | Reference Standard | 28646-36-8 | 30 | mg | VIAL | |
| 1059058 | Benzphetamine Related Compound E (30 mg) ((1S,2S)-2-[Benzyl(methyl)amino]-1-phenylpropan-1-ol hydrochloride) | Reference Standard | 1591807-86-1 | 30 | mg | VIAL | |
| 1059069 | Benzphetamine Related Compound F (25 mg) ((1S,2S)-2-[Benzyl(methyl)amino]-1-cyclohexylpropan-1-ol hydrochloride) | Reference Standard | 1591761-34-0 | 25 | mg | VIAL | |
| 1061005 | Benztropine Mesylate (200 mg) | Reference Standard | 132-17-2 | 200 | mg | | |
| 1061027 | Benztropine Related Compound A (50 mg) ((1R,3r,5S)-3-(Benzhydryloxy)-8-azabicyclo[3.2.1]octane hydrochloride) | Reference Standard | 25471-67-4 | 50 | mg | VIAL | |
| 1061901 | Benzyl Alcohol (500 mg/ampule) | Reference Standard | 100-51-6 | 500 | mg | AMPULE | |
| 1062008 | Benzyl Benzoate (5 g) | Reference Standard | 120-51-4 | 5 | g | AMPULE | |
| 1062019 | Benzyl Chloride (3 x 200 mg) ((Chloromethyl)benzene) | Reference Standard | 100-44-7 | 600 | mg | AMPULE | |
| 1062020 | Benzyl Disulfide (200 mg) | Reference Standard | 150-60-7 | 200 | mg | VIAL | |
| 1062074 | Benzyl Mercaptan (5 x 0.5 mL) | Reference Standard | 100-53-8 | 2.5 | mL | AMPULE | |
| 1062085 | Benzyl Methyl Sulfide (5 x 0.5 mL) | Reference Standard | 766-92-7 | 2.5 | mL | AMPULE | |
| 1065210 | Berberine Chloride (50 mg) | Reference Standard | 141433-60-5 | 50 | mg | VIAL | |
| 1065209 | Berberis aristata Stem Dry Extract (100 mg) | Reference Standard | NA | 100 | mg | VIAL | |
| 1012495 | Beta Alanine (100 mg) | Reference Standard | 107-95-9 | 100 | mg | VIAL | |
| 1065480 | Beta Carotene (7 x 100 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 7235-40-7 | 700 | mg | AMPULE | |
| 1065491 | Beta Carotene System Suitability (200 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | N/A | 200 | mg | VIAL | |
| 1154569 | Beta Cyclodextrin (500 mg) | Reference Standard | 7585-39-9 | 500 | mg | VIAL | |
| 1048288 | Beta Glucan (1 g) (Beta Glucan from Baker's Yeast (Saccharomyces cerevisiae) | Reference Standard | 9012-72-0 | 1 | g | VIAL | |
| 1238512 | Beta-3-Asp Eptifibatide (10 mg) (N6-Amidino-N2-(3-mercaptopropionyl)-L-lysylglycyl-L-Beta-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide) | Reference Standard | NA | 10 | mg | VIAL | |
| 1073718 | Beta-Bisabolol (2 x 100 mg) | Reference Standard | 15352-77-9 | 200 | mg | AMPULE | |
| 1162648 | Beta-Damascone (3 x 0.5 mL) | Reference Standard | N/A | 1.5 | mL | AMPULE | |
| 1424511 | Beta-Methylcholine Chloride (2 X 25 mg) (2-Hydroxy-N,N,N-trimethylpropan-1-aminium chloride) | Reference Standard | 2382-43-6 | 50 | mg | VIAL | |
| 1612947 | Beta-Sitosterol (100 mg) | Reference Standard | 83-46-5 | 100 | mg | VIAL | |
| 1065550 | Betadex Sulfobutyl Ether Sodium (500 mg) | Reference Standard | 182410-00-0 | 500 | mg | VIAL | |
| 1065618 | Betahistine Hydrochloride (200 mg) | Reference Standard | 5579-84-0 | 200 | mg | VIAL | |
| 1065695 | Betaine (1 g) | Reference Standard | 107-43-7 | 1 | g | VIAL | |
| 1065709 | Betaine Hydrochloride (200 mg) | Reference Standard | 590-46-5 | 200 | mg | VIAL | |
| 1066009 | Betamethasone (200 mg) | Reference Standard | 378-44-9 | 200 | mg | VIAL | |
| 1067001 | Betamethasone Acetate (500 mg) | Reference Standard | 987-24-6 | 500 | mg | VIAL | |
| 1067034 | Betamethasone Acetate Related Compound C (20 mg) (9-Fluoro-11Beta,17,21-trihydroxy-16Beta-methylpregna-1,4-diene-3,20-dione 11,21-diacetate) | Reference Standard | 330157-05-6 | 20 | mg | VIAL | |
| 1067045 | Betamethasone Acetate Related Compound D (20 mg) (9,11Beta-Epoxy-17,21-dihydroxy-16Beta-methylpregna-1,4-diene-3,20-dione 21-acetate) | Reference Standard | 912-38-9 | 20 | mg | VIAL | |
| 1067307 | Betamethasone Benzoate (200 mg) | Reference Standard | 22298-29-9 | 200 | mg | VIAL | |
| 1067704 | Betamethasone Dipropionate (125 mg) | Reference Standard | 5593-20-4 | 125 | mg | VIAL | |
| 1067726 | Betamethasone Dipropionate Related Compound B (25 mg) (9-Fluoro-11Beta,21-dihydroxy-16Beta-methyl-3,20-dioxopregna-1,4-diene-17-yl propionate) | Reference Standard | 5534-13-4 | 25 | mg | VIAL | |
| 1067737 | Betamethasone Dipropionate Related Compound C (25 mg) (9-Fluoro-11Beta,17-dihydroxy-16Beta-methyl-3,20-dioxopregna-1,4-diene-21-yl propionate) | Reference Standard | 75883-07-7 | 25 | mg | VIAL | |
| 1067760 | Betamethasone Dipropionate Related Compound F (30 mg) (9,11Beta-Epoxy-16Beta-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl dipropionate) | Reference Standard | 66917-44-0 | 30 | mg | VIAL | |
| 1067781 | Betamethasone Dipropionate Related Compound H (30 mg) (6alpha-Bromo-9-fluoro-11Beta-hydroxy-16Beta-methyl-3,20-dioxopregna-1,4-diene-17,21-diyl dipropionate) | Reference Standard | 1186048-34-9 | 30 | mg | VIAL | |
| 1068004 | Betamethasone Sodium Phosphate (500 mg) | Reference Standard | 151-73-5 | 500 | mg | VIAL | |
| 1069007 | Betamethasone Valerate (200 mg) | Reference Standard | 2152-44-5 | 200 | mg | VIAL | |
| 1069018 | Betamethasone Valerate Related Compound A (50 mg) (9-Fluoro-11beta,17-dihydroxy-16beta-methyl-3,20-dioxopregna-1,4-diene-21-yl valerate) | Reference Standard | 2240-28-0 | 50 | mg | VIAL | |
| 1069049 | Betamethasone Valerate Related Compound D | Reference Standard | N/A | | | | |
| 1069903 | Betaxolol Hydrochloride (200 mg) | Reference Standard | 63659-19-8 | 200 | mg | | |
| 1069914 | Betaxolol Related Compound A (20 mg) (1-(4-Ethylphenoxy)-3-(isopropylamino)propan-2-ol) | Reference Standard | 67193-95-7 | 20 | mg | VIAL | |
| 1071009 | Bethanechol Chloride (200 mg) | Reference Standard | 590-63-6 | 200 | mg | VIAL | |
| 1071202 | Bicalutamide (200 mg) | Reference Standard | 90357-06-5 | 200 | mg | VIAL | |
| 1071213 | Bicalutamide Related Compound A (25 mg) (N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluoro-phenyl)sulfinyl]-2-hydroxy-2-methyl-propanamide) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1071224 | Bicalutamide Related Compound B (10 mg) ((RS)-N-(4-Cyano-3-(trifluoromethyl)phenyl)-3-(3-fluorophenylsulfonyl)-2-hydroxy-2-methylpropanamide) | Reference Standard | 1166228-30-3 | 10 | mg | VIAL | |
| 1071304 | Bile Salts (10 g) | Reference Standard | NA | 10 | g | BOTTLE | |
| 1071381 | Biochanin A (20 mg) | Reference Standard | 491-80-5 | 20 | mg | VIAL | |
| 1071508 | Biotin (200 mg) | Reference Standard | 58-85-5 | 200 | mg | VIAL | |
| 1073423 | Biphenyl (500 mg) | Reference Standard | 92-52-4 | 500 | mg | VIAL | |
| 1A00540 | Bis((R)-butyramide) (10 mg) ((R)-2-amino-N-((R)-1-amino-1-oxobutan-2-yl)butanamide) | Pharmaceutical Analytical Impurity | 1867585-44-1 | 10 | mg | VIAL | |
| 1075203 | Bis(2-ethylhexyl)maleate (2 g) (Maleic acid, bis(2-ethylhexyl)ester) | Reference Standard | 142-16-5 | 2 | g | AMPULE | |
| 1A00150 | Bis(dibenzothiazepinyl) Piperazine (25 mg) (1,4-Bis(dibenzo[b,f][1,4]thiazepin-11-yl)piperazine) | Pharmaceutical Analytical Impurity | 945668-94-0 | 25 | mg | VIAL | |
| 1074007 | Bisacodyl (125 mg) | Reference Standard | 603-50-9 | 125 | mg | VIAL | |
| 1074030 | Bisacodyl Related Compound A (20 mg) (4,4'-(Pyridin-2-ylmethylene)diphenol) | Reference Standard | 603-41-8 | 20 | mg | VIAL | |
| 1074042 | Bisacodyl Related Compound B (20 mg) (2,4'-(Pyridin-2-ylmethylene)diphenol) | Reference Standard | 16985-05-0 | 20 | mg | VIAL | |
| 1074051 | Bisacodyl Related Compound C (20 mg) (4-[(4-Hydroxyphenyl)(pyridin-2-yl)methyl]phenyl acetate) | Reference Standard | 72901-16-7 | 20 | mg | VIAL | |
| 1074073 | Bisacodyl Related Compound E (20 mg) (2-[(4-Acetoxyphenyl)(pyridin-2-yl)methyl]phenyl acetate) | Reference Standard | 111664-35-8 | 20 | mg | VIAL | |
| 1075305 | Bisdesmethoxycurcumin (30 mg) | Reference Standard | 33171-05-0 | 30 | mg | VIAL | |
| 1075531 | Bismuth Citrate (100 mg) | Reference Standard | 813-93-4 | 100 | mg | | |
| 1075600 | Bismuth Subcarbonate (1 g) (AS) | Reference Standard | 5892-10-4 | 1 | g | VIAL | |
| 1075553 | Bismuth Subsalicylate (100 mg) | Reference Standard | 14882-18-9 | 100 | mg | VIAL | |
| 1075677 | Bisoctrizole (200 mg) | Reference Standard | 103597-45-1 | 200 | mg | VIAL | |
| 1075688 | Bisoctrizole Related Compound A (25 mg) (2-(2H-Benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl) phenol) | Reference Standard | 3147-75-9 | 25 | mg | VIAL | |
| 1075699 | Bisoctrizole Resolution Mixture (50 mg) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1075757 | Bisoprolol Fumarate (200 mg) | Reference Standard | 104344-23-2 | 200 | mg | VIAL | |
| 1075768 | Bisoprolol Related Compound A (50 mg) (1-[4-(Hydroxymethyl)phenoxy]-3-(isopropylamino)propan-2-ol) | Reference Standard | 62572-93-4 | 50 | mg | VIAL | |
| 1075780 | Bisoprolol Related Compound C (50 mg) (1-(Isopropylamino)-3-(4-methylphenoxy)propan-2-ol) | Reference Standard | 5790-46-5 | 50 | mg | VIAL | |
| 1075799 | Bisoprolol Related Compound D (50 mg) (1-(4-{[(2-Isopropoxyethoxy)methoxy]methyl}phenoxy)-3-(isopropylamino)propan-2-ol fumarate (2:1) salt) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1075804 | Bisoprolol Related Compound E (25 mg) (3,3'-(Isopropylazanediyl)bis(1-(4-((2-isopropoxyethoxy)methyl)phenoxy)propan-2-ol)) | Reference Standard | N/A | 25 | mg | AMPULE | |
| 1075815 | Bisoprolol Related Compound F (50 mg) (2-Isopropoxyethyl 4-[2-hydroxy-3-(isopropylamino)propoxy]benzoate) | Reference Standard | 864544-37-6 | 50 | mg | VIAL | |
| 1075892 | Bisphenol A (200 mg) | Reference Standard | 80-05-7 | 200 | mg | VIAL | |
| 1075870 | Bitter Orange Fruit Flavonoids Dry Extract (1 g) | Reference Standard | N/A | 1 | g | VIAL | |
| 1076013 | Bivalirudin (5 mg) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | 128270-60-0 | 5 | mg | VIAL | |
| 1076308 | Bleomycin Sulfate (15 mg) | Reference Standard | 9041-93-4 | 15 | mg | VIAL | |
| 1076057 | Borage Seed Oil (1 g) | Reference Standard | 84012-16-8 | 1 | g | AMPULE | |
| 1076341 | Boric Acid (1 g) | Reference Standard | 10043-35-3 | 1 | g | VIAL | |
| 1076115 | Bosentan (200 mg) | Reference Standard | 157212-55-0 | 200 | mg | VIAL | |
| 1076126 | Bosentan Related Compound A (15 mg) (4-(tert-butyl)-N-[6-chloro-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl] benzenesulfonamide) | Reference Standard | 150727-06-3 | 15 | mg | VIAL | |
| 1076137 | Bosentan Related Compound B (15 mg) (4-(tert-butyl)-N-[6-hydroxy-5-(2-methoxyphenoxy)-(2,2'-bipyrimidin)-4-yl]benzenesulfonamide) | Reference Standard | 174227-14-6 | 15 | mg | VIAL | |
| 1076148 | Bosentan Related Compound C (15 mg) (1,2-bis({6-[4-(tert-butyl)phenylsulfonamido]-5-(2-methoxyphenoxy)-[2,2'-bipyrimidin]-4-yl}oxy)ethane) | Reference Standard | 1097263-60-9 | 15 | mg | VIAL | |
| 1076159 | Bosentan Related Compound D (15 mg) (4,6-dichloro-5-(2-methoxyphenoxy)-2,2'-bipyrimidine) | Reference Standard | 150728-13-5 | 15 | mg | VIAL | |
| 1076160 | Bosentan Related Compound E (15 mg) (4-(tert-butyl)benzenesulfonamide) | Reference Standard | 6292-59-7 | 15 | mg | VIAL | |
| 1076250 | Boswellia Serrata Extract (1 g) | Reference Standard | N/A | 1 | g | VIAL | |
| 1535824 | Bovine Acellular Dermal Matrix Reference Photomicrographs (CD) | Reference Standard | N/A | 1 | ea | OTHER | |
| 1076352 | Bretylium Tosylate (200 mg) | Reference Standard | 61-75-6 | 200 | mg | VIAL | |
| 1076329 | Brilliant Black PN (50 mg) | Reference Standard | 2519-30-4 | 50 | mg | VIAL | |
| 1076419 | Brimonidine Related Compound A (50 mg) (5-Bromoquinoxalin-6-amine) | Reference Standard | 50358-63-9 | 50 | mg | VIAL | |
| 1076421 | Brimonidine Related Compound B (50 mg) (1-(5-Bromoquinoxalin-6-yl)thiourea) | Reference Standard | 842138-74-3 | 50 | mg | VIAL | |
| 1076454 | Brimonidine Related Compound E (15 mg) (2-(5-Bromoquinoxalin-6-yl)guanidine dihydrochloride) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1076400 | Brimonidine Tartrate (250 mg) | Reference Standard | 70359-46-5 | 250 | mg | VIAL | |
| 1076363 | Brinzolamide (200 mg) | Reference Standard | 138890-62-7 | 200 | mg | VIAL | |
| 1076374 | Brinzolamide Related Compound A (50 mg) ((S)-4-(Ethylamino)-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e] [1,2]thiazine-6-sulfonamide 1,1-dioxide), (Brinzolamide (S)-Isomer)) | Reference Standard | 154127-19-2 | 50 | mg | VIAL | |
| 1076385 | Brinzolamide Related Compound B (50 mg) ((R)-4-Amino-2-(3-methoxypropyl)-3,4-dihydro-2H-thieno[3,2-e][1,2]thiazine-6-sulfonamide 1,1-dioxide oxalate) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1077774 | Broccoli Seed Dry Extract (350 mg) | Reference Standard | N/A | 350 | mg | VIAL | |
| 1076465 | Bromazepam CIV (100 mg) (AS) | Reference Standard | 1812-30-2 | 100 | mg | VIAL | |
| 1076501 | Bromocriptine Mesylate (150 mg) | Reference Standard | 22260-51-1 | 150 | mg | VIAL | |
| 1077005 | Bromodiphenhydramine Hydrochloride (200 mg) | Reference Standard | 1808-12-4 | 200 | mg | VIAL | |
| 1077887 | Bromperidol Decanoate (15 mg) | Reference Standard | 75067-66-2 | 15 | mg | VIAL | |
| 1078008 | Brompheniramine Maleate (125 mg) | Reference Standard | 980-71-2 | 125 | mg | VIAL | |
| 1078201 | Budesonide (200 mg) | Reference Standard | 51333-22-3 | 200 | mg | VIAL | |
| 1A00680 | Budesonide 9(11)-ene (25 mg) ((6aS,8aS,8bS,11aR,12aS,12bS)-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-10-propyl-1,2,6a,8,8a,8b,11a,12,12a,12b-decahydro-4H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one) | Pharmaceutical Analytical Impurity | 313474-58-7 | 25 | mg | VIAL | |
| 1A00510 | Budesonide Acetaldehyde Acetal (25 mg) (16alpha,17-[(1RS)-ethylidenebis(oxy)]-11beta,21-dihydroxypregna-1,4-diene-3,20-dione) | Pharmaceutical Analytical Impurity | 1040085-98-0 | 25 | mg | VIAL | |
| 1A00500 | Budesonide D-homo Analog (10 mg) ((4aR,4bS,5S,6aS,7aR,10aR,11aS,11bS)-5-hydroxy-7a-(hydroxymethyl)-4a,6a-dimethyl-9-propyl-4b,6,6a,7a,10a,11,11a,11b,12,13-decahydrochryseno[2,3-d][1,3]dioxole-2,7(4aH,5H)-dione) | Pharmaceutical Analytical Impurity | 1040085-99-1 | 10 | mg | VIAL | |
| 1078245 | Budesonide Related Compound E (25 mg) (16alpha,17-[butylidenebis(oxy)]-11Beta,21-dihydroxypregna-1,4,14-triene-3,20-dione) | Reference Standard | 131918-64-4 | 25 | mg | VIAL | |
| 1078267 | Budesonide Related Compound G (25 mg) (16alpha,17-[butylidenebis(oxy)]-11beta, 21-dihydroxypregna-4-ene-3,20-dione) | Reference Standard | 137174-25-5 | 25 | mg | VIAL | |
| 1078289 | Budesonide Related Compound L (25 mg) (16alpha,17-[butylidenebis(oxy)]-21-hydroxypregna-1,4-diene-3,11,20-trione) | Reference Standard | 216453-74-6 | 25 | mg | VIAL | |
| 1A00410 | Budesonide Sulfate Triethylamine Salt (10 mg) | Pharmaceutical Analytical Impurity | 1436872-65-9 | 10 | mg | VIAL | |
| 1078303 | Bumetanide (125 mg) | Reference Standard | 28395-03-1 | 125 | mg | VIAL | |
| 1078325 | Bumetanide Related Compound A (10 mg) (3-Amino-4-phenoxy-5-sulfamoylbenzoic Acid) | Reference Standard | 28328-54-3 | 10 | mg | VIAL | |
| 1078336 | Bumetanide Related Compound B (25 mg) (3-Nitro-4-phenoxy-5-sulfamoylbenzoic Acid) | Reference Standard | 28328-53-2 | 25 | mg | VIAL | |
| 1078507 | Bupivacaine Hydrochloride (300 mg) | Reference Standard | 73360-54-0 | 300 | mg | VIAL | |
| 1078518 | Bupivacaine Related Compound A (50 mg) (6-(butylamino)-N-(2,6-dimethylphenyl)hexanamide) (AS) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1078529 | Bupivacaine Related Compound B (50 mg) N-(2,6-Dimethylphenyl)piperidine-2-carboxamide Hydrochloride | Reference Standard | 65797-42-4 | 50 | mg | VIAL | |
| 1078700 | Buprenorphine Hydrochloride CIII (50 mg) | Reference Standard | 53152-21-9 | 50 | mg | VIAL | |
| 1078711 | Buprenorphine Related Compound A CII (25 mg) ((S)-2-[17-(But-3-en-1-yl)-4,5alpha-epoxy-3-hydroxy-6-methoxy-6alpha,14-ethanomorphinan-7alpha-yl]- 3,3-dimethylbutan-2-ol) | Reference Standard | 457071-73-7 | 25 | mg | VIAL | |
| 1078722 | Buprenorphine System Suitability Mixture CII (50 mg) (Mixture of Buprenorphine and about 0.5% of Ethenobuprenorphine) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1078846 | Bupropion Hydrobromide (200 mg) | Reference Standard | 905818-69-1 | 200 | mg | VIAL | |
| 1078733 | Bupropion Hydrochloride (200 mg) | Reference Standard | 31677-93-7 | 200 | mg | VIAL | |
| 1078744 | Bupropion Hydrochloride Related Compound A (15 mg) (2-(tert-butylamino)-4'-chloropropiophenone hydrochloride) | Reference Standard | 1049718-72-0 | 15 | mg | VIAL | |
| 1078755 | Bupropion Hydrochloride Related Compound B (10 mg) (2-(tert-butylamino)-3'-bromopropiophenone hydrochloride) | Reference Standard | 1049718-43-5 | 10 | mg | VIAL | |
| 1078766 | Bupropion Hydrochloride Related Compound C (40 mg) (1-(3-chlorophenyl)-2-hydroxypropan-1-one) (COLD SHIPMENT REQUIRED) | Reference Standard | N/A | 40 | mg | AMPULE | |
| 1078799 | Bupropion Hydrochloride Related Compound F (40 mg) (1-(3-chlorophenyl)-1-hydroxypropan-2-one) (COLD SHIPMENT REQUIRED) | Reference Standard | 857233-13-7 | 40 | mg | AMPULE | |
| 1078857 | Bupropion Related Compound G (50 mg) (2-Bromo-1-(3-chlorophenyl)propan-1-one) | Reference Standard | 34911-51-8 | 50 | mg | AMPULE | |
| 1078802 | Buspirone Hydrochloride (200 mg) | Reference Standard | 33386-08-2 | 200 | mg | VIAL | |
| 1078573 | Buspirone Related Compound A (2 x 75 mg) (2-(Piperazin-1-yl)pyrimidine) | Reference Standard | 20980-22-7 | 150 | mg | AMPULE | |
| 1078813 | Buspirone Related Compound G (50 mg) (1,4-Di(pyrimidin-2-yl)piperazine) | Reference Standard | 84746-24-7 | 50 | mg | VIAL | |
| 1078642 | Buspirone Related Compound K (50 mg) (8-azaspiro[4.5]decane-7,9-dione) | Reference Standard | 1075-89-4 | 50 | mg | VIAL | |
| 1078824 | Buspirone Related Compound L (75 mg x 2) (8-(4-Chlorobutyl)-8-azaspiro[4.5]decane-7,9-dione) | Reference Standard | 21098-11-3 | 150 | mg | AMPULE | |
| 1078835 | Buspirone Related Compound N (50 mg) (8,8'-(Butane-1,4-diyl)bis(8-azaspiro[4.5]decane-7,9-dione) | Reference Standard | 257877-44-4 | 50 | mg | VIAL | |
| 1079000 | Butabarbital CIII (200 mg) | Reference Standard | 125-40-6 | 200 | mg | VIAL | |
| 1081002 | Butalbital CIII (200 mg) | Reference Standard | 77-26-9 | 200 | mg | VIAL | |
| 1081501 | Butamben (200 mg) | Reference Standard | 94-25-7 | 200 | mg | VIAL | |
| 1082956 | Butane-1,3-diol (1 mL) | Reference Standard | 107-88-0 | 1 | mL | AMPULE | |
| 1082300 | Butoconazole Nitrate (200 mg) | Reference Standard | 64872-77-1 | 200 | mg | VIAL | |
| 1082504 | Butorphanol Tartrate CIV (350 mg) | Reference Standard | 58786-99-5 | 350 | mg | VIAL | |
| 1082901 | Butyl 3-(butylamino)-4-phenoxy-5-sulfamoylbenzoate (25 mg) | Reference Standard | 32643-00-8 | 25 | mg | VIAL | |
| 1082606 | Butyl Acetate (1.2 mL/ampule; 3 ampules) | Reference Standard | 123-86-4 | 3.6 | mL | AMPULE | |
| 1082592 | Butyl Anthranilate (1 mL) (List Chemical) | Reference Standard | 7756-96-9 | 1 | mL | AMPULE | |
| 1082617 | Butyl Cinnamate (500 mg) | Reference Standard | 538-65-8 | 500 | mg | AMPULE | |
| 1082628 | Butyl Heptanoate (5 x 0.5 mL) | Reference Standard | 5454-28-4 | 2.5 | mL | AMPULE | |
| 1082967 | Butyl Hexanoate (3 x 500 mg) | Reference Standard | 626-82-4 | 1500 | mg | AMPULE | |
| 1082640 | Butyl Isothiocyanate (1 mL) | Reference Standard | 592-82-5 | 1 | mL | AMPULE | |
| 1083529 | Butyl Palmitate (500 mg) | Reference Standard | 111-06-8 | 500 | mg | AMPULE | |
| 1082639 | Butyl Stearate (500 mg) | Reference Standard | 123-95-5 | 500 | mg | VIAL | |
| 1082672 | Butyl Valerate (1 ml) | Reference Standard | 591-68-4 | 1 | mL | AMPULE | |
| 1082708 | Butylated Hydroxytoluene (500 mg) | Reference Standard | 128-37-0 | 500 | mg | VIAL | |
| 1084000 | Butylparaben (200 mg) | Reference Standard | 94-26-8 | 200 | mg | VIAL | |
| 1084259 | Butyraldehyde (3 x 1.2 mL) | Reference Standard | 123-72-8 | 3.6 | mL | AMPULE | |
| 1084292 | CD34+ Cell Enumeration System Suitability (1.24 x 10^4 CD34+ Cells) (COLD SHIPMENT REQUIRED) | Reference Standard | N/A | 1 | ea | VIAL | |
| 1130710 | CHO Genomic DNA (40 uL per vial) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | NA | 0.04 | mL | VIAL | |
| 1084306 | Cabergoline (125 mg) | Reference Standard | 81409-90-7 | 125 | mg | VIAL | |
| 1085003 | Caffeine (200 mg) | Reference Standard | 58-08-2 | 200 | mg | VIAL | |
| 1086006 | Caffeine Melting Point Standard (1 g) (Approximately 236 degrees) | Reference Standard | 58-08-2 | 1 | g | VIAL | |
| 1086039 | Caftaric Acid (20 mg) | Reference Standard | 67879-58-7 | 20 | mg | VIAL | |
| 1086108 | Calcifediol (75 mg) | Reference Standard | 63283-36-3 | 75 | mg | VIAL | |
| 1086141 | Calcipotriene (200 mg) | Reference Standard | 112965-21-6 | 200 | mg | VIAL | |
| 1086152 | Calcipotriene Related Compound C (15 mg) ((5E,7E,22E,24S)-24-Cyclopropyl-9,10-secochola-5,7,10(19),22-tetraene-1alpha,3beta,24-triol) | Reference Standard | 113082-99-8 | 15 | mg | VIAL | |
| 1086200 | Calcitonin Salmon (40 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 47931-85-1 | 40 | mg | VIAL | |
| 1086210 | Calcitonin Salmon Related Compound A (20 mg) (N-acetyl-Cys(1)-calcitonin salmon) (COLD SHIPMENT REQUIRED) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1086221 | Calcitonin Salmon Related Compound B (0.34 mg) (calcitonin salmon-glycine) (COLD SHIPMENT REQUIRED) | Reference Standard | N/A | 0.34 | mg | | |
| 1086301 | Calcitriol (10 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 32222-06-3 | 10 | mg | VIAL | |
| 1086312 | Calcitriol Solution (5 mL) (COLD SHIPMENT REQUIRED) | Reference Standard | N/A | 5 | mL | AMPULE | |
| 1086866 | Calcium (-)-Hydroxycitrate (150 mg) | Reference Standard | NA | 150 | mg | VIAL | |
| 1086334 | Calcium Acetate (500 mg) | Reference Standard | 62-54-4 | 500 | mg | VIAL | |
| 1086356 | Calcium Ascorbate (200 mg) | Reference Standard | 5743-28-2 | 200 | mg | VIAL | |
| 1086378 | Calcium Benzoate (200 mg) | Reference Standard | 5743-30-6 | 200 | mg | VIAL | |
| 1086403 | Calcium Carbonate (1 g) | Reference Standard | 471-34-1 | 1 | g | VIAL | |
| 1086436 | Calcium Chloride (1 g) | Reference Standard | 10035-04-8 | 1 | g | VIAL | |
| 1086414 | Calcium Citrate (500 mg) | Reference Standard | 5785-44-4 | 500 | mg | VIAL | |
| 1086425 | Calcium Citrate Malate (200 mg) | Reference Standard | 142606-53-9 | 200 | mg | VIAL | |
| 1086447 | Calcium Cyclamate (200 mg) | Reference Standard | 5897-16-5 (dihydrate); 139-06- | 200 | mg | VIAL | |
| 1379081 | Calcium D,L-5-Methyltetrahydrofolate (300 mg) | Reference Standard | 26560-38-3 | 300 | mg | VIAL | |
| 1086800 | Calcium Gluceptate (200 mg) | Reference Standard | 29039-00-7 | 200 | mg | VIAL | |
| 1086822 | Calcium Gluconate Anhydrous (200 mg) | Reference Standard | 299-28-5 | 200 | mg | VIAL | |
| 1086833 | Calcium Gluconate Monohydrate (200 mg) (Calcium D-Gluconate Monohydrate) | Reference Standard | 66905-23-5 | 200 | mg | VIAL | |
| 1086877 | Calcium L-Threonate (500 mg) (Calcium (2R,3S)-2,3,4-trihydroxybutanoate) | Reference Standard | 70753-61-6 | 500 | mg | VIAL | |
| 1086888 | Calcium Lactate (1 g) | Reference Standard | 63690-56-2 | 1 | g | VIAL | |
| 1086902 | Calcium Lactobionate (200 mg) | Reference Standard | 110638-68-1 | 200 | mg | VIAL | |
| 1086935 | Calcium Levulinate (1 g) (AS) | Reference Standard | 5743-49-7 | 1 | g | VIAL | |
| 1086957 | Calcium Lignosulfonate (40-65) (2 g) | Reference Standard | 8061-52-7 | 2 | g | VIAL | |
| 1086979 | Calcium Magnesium Citrate (200 mg) | Reference Standard | 1370511-52-6 | 200 | mg | VIAL | |
| 1087009 | Calcium Pantothenate (300 mg) (Vitamin B5) | Reference Standard | 137-08-6 | 300 | mg | VIAL | |
| 1087202 | Calcium Saccharate (200 mg) | Reference Standard | 5793-89-5 | 200 | mg | VIAL | |
| 1087360 | Calcium Succinate (200 mg) | Reference Standard | 159389-75-0 | 200 | mg | VIAL | |
| 1087450 | Calcium Undecylenate (200 mg) | Reference Standard | 1322-14-1 | 200 | mg | VIAL | |
| 1087472 | Calycosin (50 mg) (7-Hydroxy-3-(3-hydroxy-4-methoxyphenyl)-4H-chromen-4-one) | Reference Standard | 20575-57-9 | 50 | mg | VIAL | |
| 1087483 | Calycosin 7-O-beta-D-Glucopyranoside (50 mg) (3-(3-Hydroxy-4-methoxyphenyl)-4-oxo-4H-chromen7-yl beta-D-glucopyranoside) | Reference Standard | 20633-67-4 | 50 | mg | VIAL | |
| 1087494 | Camellia Seed Oil (500 mg) | Reference Standard | 225233-97-6 | 500 | mg | AMPULE | |
| 1087508 | Camphor (1 g) | Reference Standard | 464-49-3 | 1 | g | VIAL | |
| 1087701 | Candelilla Wax (250 mg) | Reference Standard | 8006-44-8 | 250 | mg | VIAL | |
| 1087803 | Candesartan Cilexetil (100 mg) | Reference Standard | 145040-37-5 | 100 | mg | VIAL | |
| 1087814 | Candesartan Cilexetil Related Compound A (10 mg) (Ethyl 1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-2-ethoxybenzimidazole-7-carboxylate) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1087825 | Candesartan Cilexetil Related Compound B (10 mg) (1-{[(Cyclohexyloxy)carbonyl]oxy}ethyl 3-({2'-(1H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl}methyl)-2-oxo-2,3-dihydro-1H-benzo[d]imidazole-4-carboxylate) | Reference Standard | 869631-11-8 | 10 | mg | VIAL | |
| 1087847 | Candesartan Cilexetil Related Compound D (10 mg) (1-{[(Cyclohexyloxy)carbonyl]oxy}ethyl 3-({2'-(2-ethyl-2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl}methyl)-2-oxo-2,3-dihydro-1H-benzimidazole-4-carboxylate) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1087869 | Candesartan Cilexetil Related Compound F (10 mg) (1-(Cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-{[2'-(2-ethyl-2H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-benzimidazole-7-carboxylate) | Reference Standard | 914613-36-8 | 10 | mg | VIAL | |
| 1087870 | Candesartan Cilexetil Related Compound G (10 mg) (1-{[2'-(1H-Tetrazol-5-yl)biphenyl-4-yl]methyl}-2-ethoxybenzimidazole-7-carboxylic acid) | Reference Standard | 139481-59-7 | 10 | mg | VIAL | |
| 1089149 | Cannabidiol (30 mg) | Reference Standard | 13956-29-1 | 30 | mg | VIAL | |
| 1089161 | Cannabidiol Solution (1 mL (1mg/mL)) | Reference Standard | 13956-29-1 | 1 | mL | AMPULE | |
| 1089172 | Cannabinoid Acids Mixture (1 mL) | Reference Standard | NA | 1 | mL | AMPULE | |
| 1089183 | Cannabinoids Mixture (1 mL) | Reference Standard | NA | 1 | mL | AMPULE | |
| 1090150 | Canola Oil (1 g) | Reference Standard | 120962-03-0 | 1 | g | AMPULE | |
| 1090706 | Capecitabine (200 mg) | Reference Standard | 154361-50-9 | 200 | mg | VIAL | |
| 1090717 | Capecitabine Related Compound A (15 mg) (5'-deoxy-5-fluorocytidine) | Reference Standard | 66335-38-4 | 15 | mg | VIAL | |
| 1090728 | Capecitabine Related Compound B (20 mg) (5'-deoxy-5-fluorouridine) | Reference Standard | 3094-09-5 | 20 | mg | VIAL | |
| 1090739 | Capecitabine Related Compound C (10 mg) (2',3'-O-carbonyl-5'-deoxy-5-fluoro-N4-(pentyloxycarbonyl)cytidine) (COLD SHIPMENT REQUIRED) | Reference Standard | 921769-65-5 | 10 | mg | VIAL | |
| 1091006 | Capreomycin Sulfate (250 mg) | Reference Standard | 1405-37-4 | 250 | mg | VIAL | |
| 1091028 | Capric Alcohol (5 x 30 mg) | Reference Standard | 112-30-1 | 150 | mg | AMPULE | |
| 1091039 | Caprolactam (1 g) | Reference Standard | 105-60-2 | 1 | g | VIAL | |
| 1091040 | Caprylic Acid (300 mg) | Reference Standard | 124-07-2 | 300 | mg | VIAL | |
| 1091505 | Caprylocaproyl Polyoxylglycerides (200 mg) | Reference Standard | N/A | 200 | mg | AMPULE | |
| 1091108 | Capsaicin (100 mg) | Reference Standard | 404-86-4 | 100 | mg | VIAL | |
| 1091200 | Captopril (200 mg) | Reference Standard | 62571-86-2 | 200 | mg | VIAL | |
| 1091221 | Captopril Disulfide (100 mg) | Reference Standard | 64806-05-9 | 100 | mg | VIAL | |
| 1092009 | Carbachol (200 mg) | Reference Standard | 51-83-2 | 200 | mg | VIAL | |
| 1093001 | Carbamazepine (100 mg) | Reference Standard | 298-46-4 | 100 | mg | VIAL | |
| 1093012 | Carbamazepine Related Compound A (30 mg) (10,11-dihydrocarbamazepine) | Reference Standard | 3564-73-6 | 30 | mg | VIAL | |
| 1093023 | Carbamazepine Related Compound B (50 mg) (5H-Dibenz[b,f]azepine) | Reference Standard | 256-96-2 | 50 | mg | VIAL | |
| 1095506 | Carbidopa (400 mg) | Reference Standard | 38821-49-7 | 400 | mg | VIAL | |
| 1095517 | Carbidopa Related Compound A (25 mg) (3-O-Methylcarbidopa) | Reference Standard | 85933-19-3 | 25 | mg | VIAL | |
| 1096000 | Carbinoxamine Maleate (200 mg) | Reference Standard | 3505-38-2 | 200 | mg | VIAL | |
| 1096019 | Carbinoxamine Related Compound A (25 mg) ((4-Chlorophenyl)(pyridin-2-yl)methanone) | Reference Standard | 6318-51-0 | 25 | mg | VIAL | |
| 1096021 | Carbinoxamine Related Compound B (25 mg) ((4-Chlorophenyl)(pyridin-2-yl)methanol) | Reference Standard | 27652-89-7 | 25 | mg | VIAL | |
| 1096032 | Carbinoxamine Related Compound C (25 mg) (N,N-Dimethyl-2-[phenyl(pyridin-2-yl)methoxy]ethan-1-amine oxalate) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1096270 | Carbomer Copolymer (100 mg) | Reference Standard | 138789-85-2 | 100 | mg | VIAL | |
| 1096281 | Carbomer Homopolymer (100 mg) | Reference Standard | 151687-96-6 | 100 | mg | VIAL | |
| 1096407 | Carboplatin (100 mg) | Reference Standard | 41575-94-4 | 100 | mg | VIAL | |
| 1096509 | Carboprost Tromethamine (30 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 58551-69-2 | 30 | mg | | |
| 1096531 | Carboxymethylcellulose Calcium (1.5 g) (AS) | Reference Standard | 9050-04-8 | 1.5 | g | VIAL | |
| 1096553 | Carboxymethylcellulose Sodium (1.5 g) | Reference Standard | 9004-32-4 | 1.5 | g | VIAL | |
| 1096586 | Carglumic Acid (200 mg) | Reference Standard | 1188-38-1 | 200 | mg | VIAL | |
| 1096510 | Carglumic Acid Related Compound A (30 mg) ((S)-3-(2,5-dioxoimidazolidin-4-yl)propanoic acid) | Reference Standard | 17027-50-8 | 30 | mg | VIAL | |
| 1096542 | Carglumic Acid Related Compound C | Reference Standard | N/A | | | | |
| 1096600 | Carisoprodol CIV (1 g) | Reference Standard | 78-44-4 | 1 | g | | |
| 1096597 | Carisoprodol Related Compound A (10 mg) (2-hydroxymethyl-2-methylpentyl carbamate) | Reference Standard | 1471-56-3 | 10 | mg | VIAL | |
| 1096611 | Carmellose (500 mg) | Reference Standard | 9000-11-7 | 500 | mg | VIAL | |
| 1096724 | Carmustine (75 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 154-93-8 | 75 | mg | VIAL | |
| 1096735 | Carmustine Related Compound A (25 mg) (1,3-bis(2-chloroethyl)urea) | Reference Standard | 2214-72-4 | 25 | mg | VIAL | |
| 1096860 | Carnauba Wax (200 mg) | Reference Standard | 8015-86-9 | 200 | mg | VIAL | |
| 1096746 | Carnosic acid (20 mg) | Reference Standard | 3650-09-7 | 20 | mg | VIAL | |
| 1012288 | Carotenes (3 x 100 mg) | Reference Standard | N/A | 300 | mg | VIAL | |
| 1096699 | Carprofen (200 mg) | Reference Standard | 53716-49-7 | 200 | mg | VIAL | |
| 1096702 | Carprofen Related Compound A (50 mg) (carbazole) | Reference Standard | 86-74-8 | 50 | mg | VIAL | |
| 1096757 | Carteolol Hydrochloride (200 mg) | Reference Standard | 51781-21-6 | 200 | mg | VIAL | |
| 1096859 | Carteolol Related Compound F (25 mg) (5-(2-Hydroxy-3-methoxypropoxy)-3,4-dihydroquinolin-2(1H)-one) | Reference Standard | NA | 25 | mg | VIAL | |
| 1096622 | Carvedilol (200 mg) | Reference Standard | 72956-09-3 | 200 | mg | VIAL | |
| 1096633 | Carvedilol Related Compound A (15 mg) (1-(4-(2-hydroxy-3-(2-(2-methoxyphenoxy)ethylamino)propoxy)-9H-carbazol-9-yl)-3-(2-(2-methoxyphenoxy)ethylamino)propan-2-ol) | Reference Standard | 1198090-73-1 | 15 | mg | VIAL | |
| 1096644 | Carvedilol Related Compound B (15 mg) (3,3'-(2-(2-methoxyphenoxy)ethylazanediyl)bis(1-(9H-carbazol-4-yloxy)propan-2-ol)) | Reference Standard | 918903-20-5 | 15 | mg | VIAL | |
| 1096655 | Carvedilol Related Compound C (20 mg) (1-(9H-Carbazol-4-yloxy)-3-(benzyl(2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol) | Reference Standard | 72955-94-3 | 20 | mg | VIAL | |
| 1096666 | Carvedilol Related Compound D (15 mg) (4-(Oxiran-2-ylmethoxy)-9H-carbazole) | Reference Standard | 51997-51-4 | 15 | mg | VIAL | |
| 1096677 | Carvedilol Related Compound E (15 mg) (2-(2-Methoxyphenoxy)ethyl amine hydrochloride monohydrate) | Reference Standard | 2057412-43-6 | 15 | mg | VIAL | |
| 1096688 | Carvedilol System Suitability Mixture (25 mg) (carvedilol spiked with carvedilol related compound F) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1096779 | Casticin (25 mg) | Reference Standard | 479-91-4 | 25 | mg | VIAL | |
| 1096826 | Castor Oil (3 x 100 mg) (Mixture containing about 92% of Triricinolein) | Reference Standard | 8001-79-4 | 300 | mg | AMPULE | |
| 1096804 | Cathinone Hydrochloride CI (50 mg) (alpha-Aminopropiophenone Hydrochloride) | Reference Standard | 16735-19-6 | 50 | mg | VIAL | |
| 1096906 | Cefaclor (400 mg) | Reference Standard | 70356-03-5 | 400 | mg | VIAL | |
| 1096917 | Cefaclor Delta-3 Isomer (15 mg) | Reference Standard | 152575-13-8 | 15 | mg | VIAL | |
| 1097104 | Cefadroxil (200 mg) | Reference Standard | 66592-87-8 | 200 | mg | VIAL | |
| 1097126 | Cefadroxil Related Compound B (25 mg) ((6R,7R)-7-amino-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid) | Reference Standard | 22252-43-3 | 25 | mg | VIAL | |
| 1097148 | Cefadroxil Related Compound D (25 mg) ((6R,7R)-7-[(S)-2-Amino-2-(4-hydroxyphenyl)acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid) | Reference Standard | 144790-28-3 | 25 | mg | VIAL | |
| 1097192 | Cefadroxil Related Compound I (25 mg) ((6R,7R)-7-[(R)-2-amino-2-(4-hydroxyphenyl)acetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid) | Reference Standard | 147103-94-4 | 25 | mg | VIAL | |
| 1096994 | Cefadroxil System Suitability Mixture (25 mg) (Mixture of cefadroxil and O-ethoxycarbonyl cefadroxil) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1097400 | Cefamandole Nafate (250 mg) | Reference Standard | 42540-40-9 | 250 | mg | AMPULE | |
| 1097603 | Cefazolin (200 mg) | Reference Standard | 25953-19-9 | 200 | mg | VIAL | |
| 1097614 | Cefdinir (300 mg) | Reference Standard | 91832-40-5 | 300 | mg | VIAL | |
| 1097625 | Cefdinir Related Compound A (10 mg) (2(R)-2-[(Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetamido]-2-[(2RS,5RS)-5-methyl-7-oxo-2,4,5,7-tetrahydro-1H-furo[3,4-d][1,3]thiazin-2-yl]acetic acid) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1097589 | Cefdinir Related Compound B (10 mg) ((6R,7R)-7-[2-(2-amino-4-thiazolyl)acetamido]-8-oxo-3-vinyl-5-thia-1-azabicyclo[4,2,0]oct-2-ene-2-carboxylic acid) | Reference Standard | 79350-10-0 | 10 | mg | VIAL | |
| 1097636 | Cefepime Hydrochloride (500 mg) | Reference Standard | 123171-59-5 | 500 | mg | VIAL | |
| 1097680 | Cefepime Related Compound D (20 mg) ((Z)-2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetic acid) | Reference Standard | 65872-41-5 | 20 | mg | VIAL | |
| 1097691 | Cefepime Related Compound E (20 mg) (1-{[(6R,7R)-7-Amino-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl}-1-methylpyrrolidin-1-ium chloride) | Reference Standard | 103121-85-3 | 20 | mg | VIAL | |
| 1097727 | Cefetamet (15 mg) | Reference Standard | 65052-63-3 | 15 | mg | VIAL | |
| 1097658 | Cefixime (500 mg) | Reference Standard | 125110-14-7 | 500 | mg | VIAL | |
| 1097782 | Cefmetazole (200 mg) | Reference Standard | 56796-20-4 | 200 | mg | VIAL | |
| 1097750 | Cefonicid Sodium (1 g) (COLD SHIPMENT REQUIRED) | Reference Standard | 61270-78-8 | 1 | g | VIAL | |
| 1097705 | Cefoperazone Dihydrate (200 mg) | Reference Standard | 113826-44-1 | 200 | mg | VIAL | |
| 1097807 | Ceforanide (200 mg) | Reference Standard | 60925-61-3 | 200 | mg | VIAL | |
| 1097953 | Cefotaxime Related Compound E (15 mg) ((Z)-2-(2-aminothiazol-4-yl)-N-{(5aR,6R)-1,7-dioxo-1,3,4,5a,6,7-hexahydroazeto[2,1-b]furo[3,4-d][1,3]thiazin-6-yl}-2-(methoxyimino)acetamide) | Reference Standard | 66340-33-8 | 15 | mg | VIAL | |
| 1097909 | Cefotaxime Sodium (500 mg) | Reference Standard | 64485-93-4 | 500 | mg | VIAL | |
| 1097975 | Cefotetan (500 mg) | Reference Standard | 69712-56-7 | 500 | mg | VIAL | |
| 1098107 | Cefoxitin (500 mg) | Reference Standard | 35607-66-0 | 500 | mg | VIAL | |
| 1098118 | Cefpiramide (300 mg) | Reference Standard | 70797-11-4 | 300 | mg | VIAL | |
| 1098027 | Cefpodoxime Proxetil (350 mg) | Reference Standard | 87239-81-4 | 350 | mg | VIAL | |
| 1098062 | Cefprozil (200 mg) | Reference Standard | 121123-17-9 | 200 | mg | VIAL | |
| 1098049 | Cefprozil (E)-Isomer (50 mg) | Reference Standard | 111900-24-4 | 50 | mg | VIAL | |
| 1098050 | Cefprozil (Z)-Isomer (200 mg) | Reference Standard | 114876-72-1 | 200 | mg | VIAL | |
| 1097997 | Cefprozil L-Epimer (30 mg) ((6R,7R)-7-[(S)-2-amino-2-(4-hydroxyphenyl)acetamido]-8-oxo-3-[(Z)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid) | Reference Standard | 110764-35-7 | 30 | mg | VIAL | |
| 1097986 | Cefprozil Related Compound D (30 mg) ((6R,7R)-7-amino-8-oxo-3-[(Z)-prop-1-enyl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid) | Reference Standard | 106447-44-3 | 30 | mg | VIAL | |
| 1098129 | Ceftazidime Delta-3-Isomer (15 mg) | Reference Standard | 1000980-60-8 | 15 | mg | VIAL | |
| 1098130 | Ceftazidime Pentahydrate (300 mg) | Reference Standard | 78439-06-2 | 300 | mg | VIAL | |
| 1098071 | Ceftiofur Hydrochloride (100 mg) | Reference Standard | 103980-44-5 | 100 | mg | | |
| 1098165 | Ceftiofur Sodium Trihydrate (100 mg) | Reference Standard | N/A | 100 | mg | | |
| 1098093 | Ceftiofur System Suitability Mixture (50 mg) (Mixture of about 93% of ceftiofur and total of about 2% of ceftiofur delta-3 isomer and ceftiofur E-isomer) | Reference Standard | N/A | 50 | mg | | |
| 1098173 | Ceftizoxime (350 mg) | Reference Standard | 68401-81-0 | 350 | mg | VIAL | |
| 1098184 | Ceftriaxone Sodium (350 mg) | Reference Standard | 104376-79-6 | 350 | mg | VIAL | |
| 1098195 | Ceftriaxone Sodium E-Isomer (25 mg) | Reference Standard | 97164-54-0 | 25 | mg | VIAL | |
| 1098220 | Cefuroxime Axetil (350 mg) | Reference Standard | 64544-07-6 | 350 | mg | VIAL | |
| 1098231 | Cefuroxime Axetil Delta-3-Isomers (10 mg) ((1RS,6R,7R)-1-Acetoxyethyl 3-[(carbamoyloxy)methyl]-7-[(Z)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylate) | Reference Standard | 123458-61-7 | 10 | mg | VIAL | |
| 1098253 | Cefuroxime Axetil E-isomers (15 mg) ((1RS,6R,7R)-1-Acetoxyethyl 3-[(carbamoyloxy)methyl]-7-[(E)-2-(furan-2-yl)-2-(methoxyimino)acetamido]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate) | Reference Standard | 97232-96-7 | 15 | mg | VIAL | |
| 1098209 | Cefuroxime Sodium (200 mg) | Reference Standard | 56238-63-2 | 200 | mg | VIAL | |
| 1098504 | Celecoxib (200 mg) | Reference Standard | 169590-42-5 | 200 | mg | VIAL | |
| 1098515 | Celecoxib Related Compound A (10 mg) (4-[5-(3-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide) | Reference Standard | 170570-01-1 | 10 | mg | VIAL | |
| 1098526 | Celecoxib Related Compound B (10 mg) (4-[3-(4-methylphenyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide) | Reference Standard | 331943-04-5 | 10 | mg | VIAL | |
| 1098537 | Celecoxib Related Compound C (25 mg) (4-[5-(2,4-Dimethylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide) | Reference Standard | 170570-09-9 | 25 | mg | VIAL | |
| 1098570 | Celecoxib Related Compound D (25 mg) ((E)-4-{2-[1-(p-Tolyl)ethylidene]hydrazineyl}benzenesulfonamide) | Reference Standard | 1061214-06-9 | 25 | mg | VIAL | |
| 1098322 | Cellaburate (350 mg) (Cellulose Acetate Butyrate) | Reference Standard | 9004-36-8 | 350 | mg | VIAL | |
| 1098355 | Cellacefate (125 mg) (Cellulose Acetate Phthalate) | Reference Standard | 9004-38-0 | 125 | mg | VIAL | |
| 1098300 | Cellulose Acetate (125 mg) | Reference Standard | 9004-35-7 | 125 | mg | VIAL | |
| 1099008 | Cephalexin (400 mg) | Reference Standard | 23325-78-2 | 400 | mg | VIAL | |
| 1099041 | Cephalexin Related Compound D (25 mg) (3-Hydroxy-4-methylthiophen-2(5H)-one) | Reference Standard | 34876-35-2 | 25 | mg | VIAL | |
| 1099063 | Cephalexin Related Compound F (25 mg) ((6R,7R)-7-[(R)-2-Amino-2-phenylacetamido]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-3-ene-2-carboxylic acid) | Reference Standard | 79750-46-2 | 25 | mg | VIAL | |
| 1102000 | Cephalothin Sodium (200 mg) | Reference Standard | 58-71-9 | 200 | mg | AMPULE | |
| 1102408 | Cephapirin Benzathine (100 mg) | Reference Standard | 97468-37-6 | 100 | mg | VIAL | |
| 1102500 | Cephapirin Sodium (500 mg) | Reference Standard | 24356-60-3 | 500 | mg | VIAL | |
| 1102805 | Cephradine (300 mg) | Reference Standard | 75975-70-1 | 300 | mg | VIAL | |
| 1102929 | Cetirizine Hydrochloride (250 mg) | Reference Standard | 83881-52-1 | 250 | mg | VIAL | |
| 1102930 | Cetirizine Related Compound A (20 mg) ((RS)-2-[2-[4-[(4-Chlorophenyl)phenylmethyl]piperazin-1-yl]ethoxy]acetic acid ethyl ester oxalate) | Reference Standard | 246870-46-2 | 20 | mg | VIAL | |
| 1102941 | Cetirizine Related Compound B (25 mg) (2-(4-Benzhydrylpiperazin-1-yl)ethan-1-ol dihydrochloride) | Reference Standard | 108983-83-1 | 25 | mg | VIAL | |
| 1102952 | Cetirizine Related Compound C (25 mg) (2-(2-{4-[(4-Chlorophenyl)phenylmethyl]piperazin-1-yl}ethoxy)acetamide) | Reference Standard | 83881-37-2 | 25 | mg | VIAL | |
| 1102963 | Cetirizine Related Compound G (50 mg) (2-{4-[(4-Chlorophenyl)phenylmethyl]piperazin-1-yl}ethanol dihydrochloride) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1102974 | Cetrimonium Bromide (1 g) | Reference Standard | 57-09-0 | 1 | g | VIAL | |
| 1103003 | Cetyl Alcohol (100 mg) | Reference Standard | 36653-82-4 | 100 | mg | VIAL | |
| 1719135 | Cetyl Esters Wax (125 mg) | Reference Standard | N/A | 125 | mg | VIAL | |
| 1103105 | Cetyl Palmitate (50 mg) | Reference Standard | 540-10-3 | 50 | mg | VIAL | |
| 1104006 | Cetylpyridinium Chloride (500 mg) | Reference Standard | 6004-24-6 | 500 | mg | VIAL | |
| 1104210 | Cevimeline Hydrochloride | Reference Standard | 153504-70-2 | | | | |
| 1104265 | Cevimeline trans-Isomer (15 mg) ((2RS,2'SR)-2'-Methyl-4-azaspiro{bicyclo[2.2.2]octane-2,5'-[1,3]oxathiolane} hydrochloride hemihydrate) | Reference Standard | 1462862-74-3 | 15 | mg | VIAL | |
| 1105155 | Chebulagic Acid (25 mg) | Reference Standard | 23094-71-5 | 25 | mg | VIAL | |
| 1105280 | Chia Seed Oil (3 x 1 g) | Reference Standard | 93384-40-8 | 3 | g | AMPULE | |
| 1105315 | Chicoric Acid (20 mg) | Reference Standard | 70831-56-0 | 20 | mg | VIAL | |
| 1105508 | Chitosan (500 mg) | Reference Standard | 9012-76-4 | 500 | mg | VIAL | |
| 1106001 | Chlorambucil (125 mg) | Reference Standard | 305-03-3 | 125 | mg | VIAL | |
| 1106078 | Chlorambucil System Suitability Mixture (25 mg) (A mixture containing 4-[p-[Bis(2-chloroethyl)amino]phenyl]butyric acid and a small amount of 4-[m-[Bis(2-chloroethyl)amino]phenyl]butyric acid) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1107004 | Chloramphenicol (200 mg) | Reference Standard | 56-75-7 | 200 | mg | VIAL | |
| 1107300 | Chloramphenicol Palmitate (200 mg) | Reference Standard | 530-43-8 | 200 | mg | VIAL | |
| 1107401 | Chloramphenicol Palmitate Nonpolymorph A (200 mg) | Reference Standard | 530-43-8 | 200 | mg | VIAL | |
| 1107503 | Chloramphenicol Palmitate Polymorph A (100 mg) | Reference Standard | 530-43-8 | 100 | mg | VIAL | |
| 1109000 | Chlordiazepoxide CIV (200 mg) | Reference Standard | 58-25-3 | 200 | mg | VIAL | |
| 1110009 | Chlordiazepoxide Hydrochloride CIV (200 mg) | Reference Standard | 438-41-5 | 200 | mg | VIAL | |
| 1110020 | Chlordiazepoxide Related Compound A (25 mg) (7-Chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one 4-Oxide) | Reference Standard | 963-39-3 | 25 | mg | | |
| 1111001 | Chlorhexidine (200 mg) | Reference Standard | 55-56-1 | 200 | mg | VIAL | |
| 1111103 | Chlorhexidine Acetate (200 mg) | Reference Standard | 56-95-1 | 200 | mg | VIAL | |
| 1111012 | Chlorhexidine System Suitability Mixture (50 mg) | Reference Standard | NA | 50 | mg | VIAL | |
| 1112311 | Chlorobenzhydryl Piperazine (75 mg) | Reference Standard | 300543-56-0 | 75 | mg | VIAL | |
| 1112503 | Chlorobutanol (200 mg) | Reference Standard | 6001-64-5 | 200 | mg | VIAL | |
| 1115545 | Chlorogenic Acid (50 mg) | Reference Standard | 327-97-9 | 50 | mg | VIAL | |
| 1115705 | Chloromethyl Isopropyl Carbonate (100 mg) | Reference Standard | 35180-01-9 | 100 | mg | AMPULE | |
| 1116774 | Chlorophyll A (15 mg) | Reference Standard | 479-61-8 | 15 | mg | VIAL | |
| 1117008 | Chloroprocaine Hydrochloride (200 mg) | Reference Standard | 3858-89-7 | 200 | mg | VIAL | |
| 1117020 | Chloropropiophenone (10 mg) (1-(3-Chlorophenyl)propan-1-one) (COLD SHIPMENT REQUIRED) | Reference Standard | 34841-35-5 | 10 | mg | VIAL | |
| 1117110 | Chloropropyl Vanillin (25 mg) (4-(3-Chloropropoxy)-3-methoxybenzaldehyde) | Reference Standard | 151719-92-5 | 25 | mg | VIAL | |
| 1118000 | Chloroquine Phosphate (500 mg) | Reference Standard | 50-63-5 | 500 | mg | VIAL | |
| 1118328 | Chloroquine Related Compound A (15 mg) (4,7-dichloroquinoline) | Reference Standard | 86-98-6 | 15 | mg | VIAL | |
| 1118350 | Chloroquine Related Compound D (15 mg) (7-Chloro-4-{[4-(ethylamino)-1-methylbutyl] amino} quinoline) | Reference Standard | 1476-52-4 | 15 | mg | VIAL | |
| 1118361 | Chloroquine Related Compound E (10 mg) (N4-(5-chloroquinolin-4-yl)-N1,N1-diethylpentane-1,4-diamine oxalate) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1118394 | Chloroquine Related Compound G (15 mg) (4-((7-chloroquinolin-4-yl)amino)-N,N-diethylpentan-1-amine oxide sulfate) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1121005 | Chlorothiazide (200 mg) | Reference Standard | 58-94-6 | 200 | mg | VIAL | |
| 1122700 | Chloroxylenol (125 mg) | Reference Standard | 88-04-0 | 125 | mg | VIAL | |
| 1122722 | Chloroxylenol Related Compound A (25 mg) (2-chloro-3,5-dimethylphenol) | Reference Standard | 5538-41-0 | 25 | mg | VIAL | |
| 1123000 | Chlorpheniramine Maleate (125 mg) | Reference Standard | 113-92-8 | 125 | mg | VIAL | |
| 1123135 | Chlorpheniramine Related Compound B (25 mg) (di(pyridin-2-yl)amine) | Reference Standard | 1202-34-2 | 25 | mg | VIAL | |
| 1123146 | Chlorpheniramine Related Compound C (10 mg) (3-(4-chlorophenyl)-N-methyl-3-(pyridin-2-yl)propan-1-amine maleate) | Reference Standard | 22630-25-7 | 10 | mg | VIAL | |
| 1125006 | Chlorpromazine Hydrochloride (200 mg) | Reference Standard | 69-09-0 | 200 | mg | VIAL | |
| 1126009 | Chlorpropamide (200 mg) | Reference Standard | 94-20-2 | 200 | mg | VIAL | |
| 1129007 | Chlortetracycline Hydrochloride (200 mg) | Reference Standard | 64-72-2 | 200 | mg | VIAL | |
| 1130006 | Chlorthalidone (200 mg) | Reference Standard | 77-36-1 | 200 | mg | VIAL | |
| 1119309 | Chlorthalidone Related Compound A (10 mg) (4'-Chloro-3'-sulfamoyl-2-benzophenone Carboxylic Acid) | Reference Standard | 5270-74-6 | 10 | mg | VIAL | |
| 1130505 | Chlorzoxazone (350 mg) | Reference Standard | 95-25-0 | 350 | mg | VIAL | |
| 1130527 | Chlorzoxazone Related Compound A (50 mg) (2-Amino-4-chlorophenol) | Reference Standard | 95-85-2 | 50 | mg | VIAL | |
| 1131009 | Cholecalciferol (30 mg/ampule; 5 ampules) (Vitamin D3) | Reference Standard | 67-97-0 | 150 | mg | AMPULE | |
| 1131858 | Cholestanol (200 mg) | Reference Standard | 80-97-7 | 200 | mg | VIAL | |
| 1131960 | Cholesterol (125 mg) | Reference Standard | 57-88-5 | 125 | mg | VIAL | |
| 1132001 | Cholesteryl Caprylate (200 mg) | Reference Standard | 1182-42-9 | 200 | mg | VIAL | |
| 1133004 | Cholestyramine Resin (500 mg) | Reference Standard | 11041-12-6 | 500 | mg | VIAL | |
| 1133503 | Cholic Acid (2 g) | Reference Standard | 81-25-4 | 2 | g | VIAL | |
| 1133536 | Choline Bitartrate (200 mg) | Reference Standard | 87-67-2 | 200 | mg | VIAL | |
| 1133547 | Choline Chloride (500 mg) | Reference Standard | 67-48-1 | 500 | mg | VIAL | |
| 1133591 | Choline Citrate (500 mg) | Reference Standard | 77-91-8 | 500 | mg | VIAL | |
| 1133558 | Choline Fenofibrate (50 mg)(2-Hydroxy-N,N,N-trimethylethanaminium 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate) | Reference Standard | 856676-23-8 | 50 | mg | VIAL | |
| 1133616 | Choline Related Compound A (200 mg) ([2-(Hydroxyethoxy)ethyl]trimethylammonium iodide) | Reference Standard | 41830-55-1 | 200 | mg | VIAL | |
| 1133570 | Chondroitin Sulfate Sodium (300 mg) | Reference Standard | 9082-07-9 | 300 | mg | VIAL | |
| 1133569 | Chondroitin Sulfate Sodium, Shark (300 mg) | Reference Standard | 9082-07-9 | 300 | mg | | |
| 1133638 | Chromium Picolinate (100 mg) | Reference Standard | 14639-25-9 | 100 | mg | VIAL | |
| 1133740 | Chrysanthemum Indicum Flower Dry Extract (500 mg) | Reference Standard | N/A | 500 | mg | VIAL | |
| 1133751 | Chrysanthemum X Morifolium Flower Dry Extract (500 mg) | Reference Standard | N/A | 500 | mg | VIAL | |
| 1134007 | Chymotrypsin (300 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 9004-07-3 | 300 | mg | VIAL | |
| 1134018 | Ciclopirox (50 mg) | Reference Standard | 29342-05-0 | 50 | mg | VIAL | |
| 1134030 | Ciclopirox Olamine (125 mg) | Reference Standard | 41621-49-2 | 125 | mg | VIAL | |
| 1134029 | Ciclopirox Related Compound A (25 mg) (3-Cyclohexyl-4,5-dihydro-5-methyl-5-isoxazolyl acetic acid) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1134040 | Ciclopirox Related Compound B (25 mg) (6-Cyclohexyl-4-methyl-2-pyrone) | Reference Standard | 14818-35-0 | 25 | mg | VIAL | |
| 1134084 | Ciclopirox Related Compound C (10 mg) (6-Cyclohexyl-4-methylpyridin-2(1H)-one) | Reference Standard | 67587-24-0 | 10 | mg | VIAL | |
| 1133853 | Cidofovir (100 mg) | Reference Standard | 149394-66-1 | 100 | mg | VIAL | |
| 1133864 | Cidofovir Enantiomer (15 mg) (1-[(R)-3-Hydroxy-2-(phosphonomethoxy)propyl]cytosine dihydrate) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1133875 | Cidofovir Related Compound A (15 mg) (1-[(S)-3-Hydroxy-2-(O-ethylphosphonomethoxy)propyl]cytosine) | Reference Standard | 1312776-50-3 | 15 | mg | VIAL | |
| 1133886 | Cidofovir Related Compound B (15 mg) (1-[(S)-3-Hydroxy-2-(O,O-diethylphosphonomethoxy)propyl]cytosine hydrochloride) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1134051 | Cilastatin Ammonium Salt (100 mg) | Reference Standard | 877674-82-3 | 100 | mg | VIAL | |
| 1134153 | Cilostazol (200 mg) | Reference Standard | 73963-72-1 | 200 | mg | VIAL | |
| 1134164 | Cilostazol Related Compound A (50 mg) (6-hydroxy-3,4-dihydro-1H-quinolin-2-one) | Reference Standard | 54197-66-9 | 50 | mg | VIAL | |
| 1134175 | Cilostazol Related Compound B (50 mg) (6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)-butoxy]-1H-quinolin-2-one) | Reference Standard | 73963-62-9 | 50 | mg | VIAL | |
| 1134186 | Cilostazol Related Compound C (50 mg) (1-(4-(1-Cyclohexyl-1H-tetrazol-5-yl)butyl)-6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydroquinolin-2(1H)-one) | Reference Standard | 865792-18-3 | 50 | mg | VIAL | |
| 1134062 | Cimetidine (200 mg) | Reference Standard | 51481-61-9 | 200 | mg | VIAL | |
| 1134073 | Cimetidine Hydrochloride (200 mg) | Reference Standard | 70059-30-2 | 200 | mg | VIAL | |
| 1133977 | Cinacalcet Hydrochloride (250 mg) | Reference Standard | 364782-34-3 | 250 | mg | VIAL | |
| 1133911 | Cinacalcet Related Compound B | Reference Standard | N/A | | | | |
| 1133922 | Cinacalcet Related Compound C (50 mg) ((R)-N-[1-(Naphthalen-1-yl)ethyl]-3-[4-(trifluoromethyl)phenyl]propan-1-amine hydrochloride) | Reference Standard | 1428118-39-1 | 50 | mg | VIAL | |
| 1133966 | Cinacalcet Related Compound D (50 mg) ((S)-N-[1-(Naphthalen-1-yl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine hydrochloride) | Reference Standard | 1217809-88-5 | 50 | mg | VIAL | |
| 1133831 | Cinacalcet Related Compound E | Reference Standard | N/A | | | | |
| 1133897 | Cinnamaldehyde (3 x 100 mg) | Reference Standard | 14371-10-9 | 300 | mg | AMPULE | |
| 1133933 | Cinnamic Acid (100 mg) | Reference Standard | 140-10-3 | 100 | mg | VIAL | |
| 1133900 | Cinnamomum Cassia Twig Powder (5 g) | Reference Standard | 84961-46-6 | 5 | g | BOTTLE | |
| 1134313 | Ciprofloxacin (200 mg) | Reference Standard | 85721-33-1 | 200 | mg | VIAL | |
| 1134324 | Ciprofloxacin Ethylenediamine Analog (25 mg) (1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-[(2-aminoethyl)amino]-3-quinolinecarboxylic acid hydrochloride) | Reference Standard | 528851-31-2 | 25 | mg | VIAL | |
| 1134459 | Ciprofloxacin Formamide (125 mg) | Reference Standard | 93594-39-9 | 125 | mg | VIAL | |
| 1134335 | Ciprofloxacin Hydrochloride (400 mg) | Reference Standard | 86393-32-0 | 400 | mg | VIAL | |
| 1134346 | Ciprofloxacin Related Compound A (25 mg) (7-Chloro-1-cyclopropyl-4-oxo-6-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid hydrochloride salt) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1134120 | Cisapride (200 mg) | Reference Standard | 260779-88-2 | 200 | mg | | |
| 1134118 | Cisatracurium Besylate (350 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 96946-42-8 | 350 | mg | VIAL | |
| 1134131 | Cisatracurium Besylate System Suitability Mixture (20 mg) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1134357 | Cisplatin (100 mg) | Reference Standard | 15663-27-1 | 100 | mg | VIAL | |
| 1134233 | Citalopram Hydrobromide (200 mg) | Reference Standard | 59729-32-7 | 200 | mg | VIAL | |
| 1134244 | Citalopram Related Compound A (25 mg) (1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carboxamide) | Reference Standard | 64372-56-1 | 25 | mg | VIAL | |
| 1134255 | Citalopram Related Compound B (25 mg) (1-(3-Dimethylaminopropyl)-1-(4-fluorophenyl)-3-hydroxy-1,3-dihydroisobenzofuran-5-carbonitrile oxalate) | Reference Standard | 1332724-03-4 | 25 | mg | VIAL | |
| 1134266 | Citalopram Related Compound C (25 mg) (3-(3-Dimethylaminopropyl)-3-(4-fluorophenyl)-6-cyano-1(3H)-isobenzofuranone oxalate) | Reference Standard | 1440961-11-4 | 25 | mg | VIAL | |
| 1134277 | Citalopram Related Compound D (15 mg) (1-(4-Fluorophenyl)-1-(3-methylaminopropyl)-1,3-dihydroisobenzofuran-5-carbonitrile hydrochloride) | Reference Standard | 97743-99-2 | 15 | mg | VIAL | |
| 1134288 | Citalopram Related Compound E (25 mg) (1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile-N-oxide hydrochloride) | Reference Standard | 62498-71-9 | 25 | mg | VIAL | |
| 1134299 | Citalopram Related Compound F (200 mg) (dimethyl-(1-methyl-3,3-diphenyl-allyl)-amine hydrochloride) | Reference Standard | 55011-89-7 | 200 | mg | VIAL | |
| 1134197 | Citalopram Related Compound G (25 mg) (1-(4'-fluorophenyl)-1-(3-dimethylaminopropyl)-5-chlorophthalane hydrobromide) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1134222 | Citalopram Related Compound H (25 mg) (1-(4'-fluorophenyl)-1-(3-dimethylaminopropyl)-5-bromophthalane hydrobromide) | Reference Standard | 479065-02-6 | 25 | mg | VIAL | |
| 1135123 | Citicoline (30 mg) | Reference Standard | 987-78-0 | 30 | mg | VIAL | |
| 1134305 | Citicoline Sodium (2 x 350 mg) | Reference Standard | 33818-15-4 | 700 | mg | VIAL | |
| 1134368 | Citric Acid (200 mg) | Reference Standard | 77-92-9 | 200 | mg | VIAL | |
| 1135190 | Citrus Maxima Peel Flavonoids Dry Extract (500 mg) | Reference Standard | N/A | 500 | mg | VIAL | |
| 1643317 | Citrus reticulata Pericarp Dry Extract (1 g) | Reference Standard | 8016-85-1 | 1 | g | VIAL | |
| 1134200 | Cladribine (200 mg) | Reference Standard | 4291-63-8 | 200 | mg | VIAL | |
| 1134211 | Cladribine Related Compound A (20 mg) (2-methoxy-2'-deoxyadenosine) | Reference Standard | 24757-70-8 | 20 | mg | VIAL | |
| 1134379 | Clarithromycin (100 mg) | Reference Standard | 81103-11-9 | 100 | mg | VIAL | |
| 1134390 | Clarithromycin Identity (10 mg) | Reference Standard | 81103-11-9 | 10 | mg | VIAL | |
| 1134619 | Clarithromycin Impurity D (10 mg) (N-desmethyl clarithromycin) | Reference Standard | 101666-68-6 | 10 | mg | VIAL | |
| 1134620 | Clarithromycin Impurity H (10 mg) (3"-N-Demethyl-3"-N-formyl-6-O-methylerythromycin A) | Reference Standard | 127140-69-6 | 10 | mg | VIAL | |
| 1134631 | Clarithromycin Impurity Q (10 mg) (Clarithromycin N-oxide) | Reference Standard | 118074-07-0 | 10 | mg | VIAL | |
| 1134642 | Clarithromycin Impurity R (10 mg) (3"-N-Demethylerythromycin A) | Reference Standard | 992-62-1 | 10 | mg | VIAL | |
| 1134380 | Clarithromycin Related Compound A (25 mg) (6,11-di-O-methylerythromycin A) | Reference Standard | 81103-14-2 | 25 | mg | VIAL | |
| 1134404 | Clavam-2-carboxylate Potassium (2 mg) | Reference Standard | 2196185-67-6 | 2 | mg | VIAL | |
| 1134426 | Clavulanate Lithium (200 mg) | Reference Standard | N/A | 200 | mg | VIAL | |
| 1134506 | Clemastine Fumarate (250 mg) | Reference Standard | 14976-57-9 | 250 | mg | VIAL | |
| 1134674 | Clenbuterol Hydrochloride (100 mg) | Reference Standard | 21898-19-1 | 100 | mg | VIAL | |
| 1134696 | Clenbuterol Related Compound B (10 mg) (1-(4-amino-3,5-dichlorophenyl)-2-tert-butylaminoethanone hydrochloride) | Reference Standard | 37148-49-5 | 10 | mg | VIAL | |
| 1135000 | Clidinium Bromide (500 mg) | Reference Standard | 3485-62-9 | 500 | mg | VIAL | |
| 1135021 | Clidinium Bromide Related Compound A (250 mg) (3-Hydroxy-1-methylquinuclindinium Bromide) | Reference Standard | 2096336-00-2 | 250 | mg | VIAL | |
| 1135600 | Climbazole (400 mg) | Reference Standard | 38083-17-9 | 400 | mg | VIAL | |
| 1135892 | Clindamycin 2,3-Dipalmitate (25 mg) (Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-alpha-D-galacto-octopyranoside 2,3-dipalmitate monohydrochloride) | Reference Standard | NA | 25 | mg | VIAL | |
| 1136002 | Clindamycin Hydrochloride (200 mg) | Reference Standard | 58207-19-5 | 200 | mg | VIAL | |
| 1137005 | Clindamycin Palmitate Hydrochloride (500 mg) | Reference Standard | 25507-04-4 | 500 | mg | VIAL | |
| 1138008 | Clindamycin Phosphate (250 mg) | Reference Standard | 24729-96-2 | 250 | mg | VIAL | |
| 1138019 | Clindamycin Phosphate System Suitability (30 mg) | Reference Standard | 24729-96-2 | 30 | mg | VIAL | |
| 1138201 | Clioquinol (500 mg) | Reference Standard | 130-26-7 | 500 | mg | VIAL | |
| 1138405 | Clobetasol Propionate (200 mg) | Reference Standard | 25122-46-7 | 200 | mg | VIAL | |
| 1138427 | Clobetasol Propionate Related Compound A (50 mg) (9-alpha-fluoro-11-beta-hydroxy-16-beta-methyl-3-oxoandrosta-1,4-diene-17(R)-spiro-2'-[4'-chloro-5'-ethylfuran-3'(2'H)-one]) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1138493 | Clocortolone (25 mg) (9-Chloro-6alpha-fluoro-11beta,21-dihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione) | Reference Standard | 4828-27-7 | 25 | mg | VIAL | |
| 1138507 | Clocortolone Pivalate (200 mg) | Reference Standard | 34097-16-0 | 200 | mg | VIAL | |
| 1138904 | Clofazimine (200 mg) | Reference Standard | 2030-63-9 | 200 | mg | VIAL | |
| 1138926 | Clofazimine Related Compound B (25 mg) (5-(4-Chlorophenyl)-3-(isopropylimino)-N-phenyl-3,5-dihydrophenazin-2-amine) | Reference Standard | 2158184-11-1 | 25 | mg | VIAL | |
| 1140000 | Clomiphene Citrate (500 mg) | Reference Standard | 50-41-9 | 500 | mg | VIAL | |
| 1140101 | Clomiphene Related Compound A (100 mg) ((E,Z)-2-[4-(1,2-Diphenylethenyl)phenoxy]-N,N-diethylethanamine hydrochloride (1:1)) | Reference Standard | N/A | 100 | mg | VIAL | |
| 1140247 | Clomipramine Hydrochloride (200 mg) | Reference Standard | 17321-77-6 | 200 | mg | VIAL | |
| 1140258 | Clomipramine Related Compound A (25 mg) (N1-[3-(3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)propyl]-N1,N3,N3-trimethylpropane-1,3-diamine dihydrochloride) | Reference Standard | 2305824-51-3 | 25 | mg | VIAL | |
| 1140269 | Clomipramine Related Compound C (15 mg) (3-(3-Chloro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine hydrochloride, monohydrate) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1140270 | Clomipramine Related Compound D (15 mg) (3-(3,7-Dichloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine hydrochloride) | Reference Standard | 115189-28-1 | 15 | mg | VIAL | |
| 1140292 | Clomipramine Related Compound F (15 mg) (3-Chloro-10,11-dihydro-5H-dibenzo[b,f]azepine) | Reference Standard | 32943-25-2 | 15 | mg | VIAL | |
| 1140305 | Clonazepam CIV (200 mg) | Reference Standard | 1622-61-3 | 200 | mg | VIAL | |
| 1140327 | Clonazepam Related Compound A (25 mg) (3-Amino-4-(2-chlorophenyl)-6-nitrocarbostyril) | Reference Standard | 55198-89-5 | 25 | mg | VIAL | |
| 1140338 | Clonazepam Related Compound B (25 mg) (2-Amino-2'-chloro-5-nitrobenzophenone) | Reference Standard | 2011-66-7 | 25 | mg | VIAL | |
| 1140349 | Clonazepam Related Compound C (25 mg) (2-bromo-2'-(2-chlorobenzoyl)-4'-nitroacetanilide) | Reference Standard | 52130-87-7 | 25 | mg | VIAL | |
| 1140393 | Clonidine (200 mg) | Reference Standard | 4205-90-7 | 200 | mg | VIAL | |
| 1140407 | Clonidine Hydrochloride (200 mg) | Reference Standard | 4205-91-8 | 200 | mg | VIAL | |
| 1140418 | Clonidine Related Compound A (25 mg) (1-Acetyl-2-(2,6-dichlorophenylimino)-imidazolidine) | Reference Standard | 54707-71-0 | 25 | mg | VIAL | |
| 1140429 | Clonidine Related Compound B (25 mg) (2-[(E)-2,6-dichlorophenylimino]-1-(1-{2-[(E)-2,6-dichlorophenylimino]-imidazolidin-1-yl}-ethyl)-imidazolidine) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1140445 | Clonidine Related Compound C (15 mg) (Methyl N'-(2,6-dichlorophenyl)carbamimidothioate) | Reference Standard | 27806-81-1 | 15 | mg | | |
| 1140430 | Clopidogrel Bisulfate (125 mg) | Reference Standard | 120202-66-6 | 125 | mg | VIAL | |
| 1A00420 | Clopidogrel Diester Analog (10 mg) (R)-1-(2-chlorophenyl)-2-methoxy-2-oxoethyl (S)-2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate, sulfate | Pharmaceutical Analytical Impurity | 1421283-60-4 (free base) | 10 | mg | VIAL | |
| 1A00430 | Clopidogrel Open Ring Methyl Ester Hydrochloride (10 mg) (methyl 2-(2-chlorophenyl)-2-((2-(thiophen-2-yl)ethyl)amino)acetate, hydrochloride) | Pharmaceutical Analytical Impurity | 141109-18-4 | 10 | mg | VIAL | |
| 1140586 | Clopidogrel Related Compound A (20 mg) ((+)-(S)-(o-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetic acid, hydrochloride) | Reference Standard | 144750-42-5 | 20 | mg | VIAL | |
| 1140597 | Clopidogrel Related Compound B (20 mg) (Methyl(+/-)-(o-chlorophenyl)-4,5-dihydrothieno[2,3-c]pyridine-6(7H)-acetate, hydrochloride) | Reference Standard | 144750-52-7 | 20 | mg | VIAL | |
| 1140600 | Clopidogrel Related Compound C (20 mg) (methyl (-)-(R)-(o-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate, hydrogen sulfate) | Reference Standard | 120202-71-3 | 20 | mg | VIAL | |
| 1140666 | Cloprostenol Sodium (400 mg) | Reference Standard | 55028-72-3 | 400 | mg | VIAL | |
| 1140509 | Clorazepate Dipotassium CIV (125 mg) | Reference Standard | 57109-90-7 | 125 | mg | VIAL | |
| 1140702 | Clorsulon (200 mg) | Reference Standard | 60200-06-8 | 200 | mg | VIAL | |
| 1141002 | Clotrimazole (200 mg) | Reference Standard | 23593-75-1 | 200 | mg | VIAL | |
| 1141024 | Clotrimazole Related Compound A (25 mg) ((o-chlorophenyl)diphenylmethanol) | Reference Standard | 66774-02-5 | 25 | mg | VIAL | |
| 1141909 | Cloxacillin Benzathine (200 mg) | Reference Standard | 23736-58-5 | 200 | mg | VIAL | |
| 1144951 | Cloxacillin Related Compound D (15 mg) (3-(2-Chlorophenyl)-5-methylisoxazole-4-carboxylic acid) | Reference Standard | 23598-72-3 | 15 | mg | VIAL | |
| 1142005 | Cloxacillin Sodium (200 mg) | Reference Standard | 7081-44-9 | 200 | mg | VIAL | |
| 1142107 | Clozapine (100 mg) | Reference Standard | 5786-21-0 | 100 | mg | VIAL | |
| 1142108 | Clozapine Resolution Mixture (30 mg) | Reference Standard | N/A | 30 | mg | VIAL | |
| 1311500 | Coagulation Factor VIIa (2 x 1.15 mg) (Eptacog Alfa (Activated)) | Reference Standard | 102786-61-8 | 2.3 | mg | VIAL | |
| 1142195 | Cobamamide (3 x 100 mg) (5,6-Dimethylbenzimidazolyl-Co-5'-deoxyadenosylcobamide) | Reference Standard | 13870-90-1 | 300 | mg | AMPULE | |
| 1143008 | Cocaine Hydrochloride CII (250 mg) | Reference Standard | 53-21-4 | 250 | mg | VIAL | |
| 1145207 | Cod Liver Oil (1 g) | Reference Standard | 8001-69-2 | 1 | g | AMPULE | |
| 1143802 | Codeine N-Oxide CI (30 mg) | Reference Standard | 3688-65-1 | 30 | mg | VIAL | |
| 1144000 | Codeine Phosphate CII (100 mg) | Reference Standard | 41444-62-6 | 100 | mg | VIAL | |
| 1145003 | Codeine Sulfate CII (250 mg) | Reference Standard | 6854-40-6 | 250 | mg | VIAL | |
| 1145025 | Codeine System Suitability Mixture CI (25 mg) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1145411 | Coffee Fruit Dry Extract (1 g) | Reference Standard | N/A | 1 | g | VIAL | |
| 1145477 | Coix Seed Oil Extract (2 x 1 g) | Reference Standard | 537-40-6 | 2 | g | AMPULE | |
| 1146006 | Colchicine (350 mg) | Reference Standard | 64-86-8 | 350 | mg | VIAL | |
| 1146505 | Colestipol Hydrochloride (200 mg) | Reference Standard | 37296-80-3 | 200 | mg | VIAL | |
| 1147009 | Colistimethate Sodium (200 mg) | Reference Standard | 8068-28-8 | 200 | mg | VIAL | |
| 1148001 | Colistin Sulfate (200 mg) | Reference Standard | 1264-72-8 | 200 | mg | VIAL | |
| 1148089 | Collagenase I (2 x 0.5 mL) (COLD SHIPMENT REQUIRED) | Reference Standard | 9001-12-1 | 1 | mL | VIAL | |
| 1148090 | Collagenase II (2 x 0.5 mL) (COLD SHIPMENT REQUIRED) | Reference Standard | 9001-12-1 | 1 | mL | VIAL | |
| 1148238 | Color Related Compound 005 (20 mg) (3-hydroxy-2-naphthalenecarboxylic acid) | Reference Standard | 92-70-6 | 20 | mg | VIAL | |
| 1148249 | Color Related Compound 006 (20 mg) (3-hydroxy-4-[(4-methylphenyl)azo]-2-naphthalenecarboxylic acid) | Reference Standard | 82896-77-3 | 20 | mg | VIAL | |
| 1148250 | Color Related Compound 007 (20 mg) (1-[(4-methylphenyl)azo]-2-naphthalenol) | Reference Standard | 6756-41-8 | 20 | mg | VIAL | |
| 1623386 | Compressible Sugar (200 mg) | Reference Standard | N/A | 200 | mg | VIAL | |
| 1367676 | Conjugated Linoleic Acids - Free Fatty Acid (3 x 100 mg) | Reference Standard | N/A | 300 | mg | AMPULE | |
| 1357090 | Conjugated Linoleic Acids - Triglycerides (100 mg) | Reference Standard | N/A | 100 | mg | AMPULE | |
| 1148500 | Copovidone (100 mg) | Reference Standard | 2586-89-9 | 100 | mg | VIAL | |
| 1148555 | Coptis Chinensis Rhizome Dry Extract (150 mg) | Reference Standard | N/A | 150 | mg | VIAL | |
| 1148566 | Coptisine Chloride (15 mg) | Reference Standard | 6020-18-4 | 15 | mg | VIAL | |
| 1148806 | Corn Oil (5 x 200 mg) | Reference Standard | 8001-30-7 | 1 | g | AMPULE | |
| 1148737 | Corosolic Acid (50 mg) | Reference Standard | 4547-24-4 | 50 | mg | VIAL | |
| 1149004 | Corticotropin (5.8 Units/vial; 2 vials) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | 9002-60-2 | 2 | EA | VIAL | |
| 1149999 | Cortisone (20 mg) (17, 21-Dihydroxypregna-4-ene-3,11,20-trione) | Reference Standard | 53-06-5 | 20 | mg | VIAL | |
| 1150003 | Cortisone Acetate (150 mg) | Reference Standard | 50-04-4 | 150 | mg | VIAL | |
| 1150115 | Cosyntropin Acetate (1.72 mg) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | 32489-98-8 | 1.72 | mg | VIAL | |
| 1150207 | Cottonseed Oil (1 g) | Reference Standard | 8001-29-4 | 1 | g | AMPULE | |
| 1150320 | Creatine (200 mg) | Reference Standard | 6020-87-7 | 200 | mg | VIAL | |
| 1150353 | Creatinine (100 mg) (2-Imino-1-methylimidazolidin-4-one) | Reference Standard | 60-27-5 | 100 | mg | VIAL | |
| 1150513 | Cromolyn Related Compound A (25 mg) (1,3-bis(2-acetyl-3-hydroxyphenoxy) propan-2-ol) | Reference Standard | 16150-44-0 | 25 | mg | VIAL | |
| 1150524 | Cromolyn Related Compound B (25 mg) (diethyl 5,5'-[(2-hydroxypropane-1,3-diyl)bis(oxy)]bis(4-oxo-4H-chromene-2-carboxylate)) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1150502 | Cromolyn Sodium (500 mg) | Reference Standard | 15826-37-6 | 500 | mg | VIAL | |
| 1150659 | Croscarmellose Sodium (20 mg) | Reference Standard | 74811-65-7 | 20 | mg | VIAL | |
| 1150706 | Crospovidone (100 mg) | Reference Standard | 9003-39-8 | 100 | mg | VIAL | |
| 1151006 | Crotamiton (200 mg) | Reference Standard | 483-63-6 | 200 | mg | VIAL | |
| 1535868 | Cryopreserved Human Fibroblast-Derived Dermal Substitute Reference Photomicrographs (CD) | Reference Standard | N/A | 1 | ea | OTHER | |
| 1151651 | Cullen Corylifolium Fruit Dry Extract (1 g) | Reference Standard | N/A | 1 | g | VIAL | |
| 1535835 | Cultured Rat Pheochromocytoma Reference Photomicrographs (CD) | Reference Standard | N/A | 1 | ea | OTHER | |
| 1151709 | Cumene (1.2 mL/ampule; 3 ampules) | Reference Standard | 98-82-8 | 3.6 | mL | AMPULE | |
| 1151855 | Curcumin (30 mg) | Reference Standard | 458-37-7 | 30 | mg | VIAL | |
| 1151866 | Curcuminoids (300 mg) | Reference Standard | N/A | 300 | mg | VIAL | |
| 1151924 | Cyanidin Chloride (25 mg) | Reference Standard | 528-58-5 | 25 | mg | VIAL | |
| 1151935 | Cyanidin-3-O-glucoside Chloride (15 mg) | Reference Standard | 7084-24-4 | 15 | mg | VIAL | |
| 1152011 | Cyanocobalamin (Crystalline) (2 x 150 mg) | Reference Standard | 68-19-9 | 300 | mg | VIAL | |
| 1152600 | Cyclamic Acid (100 mg) | Reference Standard | 100-88-9 | 100 | mg | VIAL | |
| 1152701 | Cyclandelate (200 mg) | Reference Standard | 456-59-7 | 200 | mg | VIAL | |
| 1152825 | Cyclic Olefin Copolymer (3 strips, 2'' x 2'' x 1 mm each) | Reference Standard | 26007-43-2 | 3 | ea | OTHER | |
| 1152814 | Cyclic Olefin Polymer (1 g) | Reference Standard | N/A | 1 | g | VIAL | |
| 1154004 | Cyclizine Hydrochloride (200 mg) | Reference Standard | 303-25-3 | 200 | mg | VIAL | |
| 1154015 | Cyclizine Related Compound A (50 mg) (1-methylpiperazine) | Reference Standard | 109-01-3 | 50 | mg | AMPULE | |
| 1154503 | Cyclobenzaprine Hydrochloride (200 mg) | Reference Standard | 6202-23-9 | 200 | mg | VIAL | |
| 1154514 | Cyclobenzaprine Related Compound A (10 mg) (5-[3-(dimethylamino)propyl]-5H-dibenzo[a,d]-cyclohepten-5-ol) | Reference Standard | 18029-54-4 | 10 | mg | VIAL | |
| 1154525 | Cyclobenzaprine Related Compound B (10 mg) (3-(5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine, hydrochloride) | Reference Standard | 438-59-5 | 10 | mg | VIAL | |
| 1154649 | Cyclohexanecarboxylic Acid (500 mg) | Reference Standard | 98-89-5 | 500 | mg | VIAL | |
| 1154605 | Cyclohexylmethanol (1 mL/ampule; 2 ampules) | Reference Standard | 100-49-2 | 2 | mL | AMPULE | |
| 1154707 | Cyclomethicone 4 (200 mg) | Reference Standard | 556-67-2 | 200 | mg | AMPULE | |
| 1154809 | Cyclomethicone 5 (200 mg) | Reference Standard | 541-02-6 | 200 | mg | AMPULE | |
| 1154900 | Cyclomethicone 6 (200 mg) | Reference Standard | 540-97-6 | 200 | mg | AMPULE | |
| 1156000 | Cyclopentolate Hydrochloride (300 mg) | Reference Standard | 5870-29-1 | 300 | mg | VIAL | |
| 1156167 | Cyclopentylpropanoic Acid (25 mg) (3-Cyclopentylpropanoic acid) | Reference Standard | 140-77-2 | 25 | mg | AMPULE | |
| 1157002 | Cyclophosphamide (500 mg) | Reference Standard | 6055-19-2 | 500 | mg | VIAL | |
| 1157013 | Cyclophosphamide Related Compound A (25 mg) (bis(2-chloroethyl)amine hydrochloride) | Reference Standard | 821-48-7 | 25 | mg | VIAL | |
| 1157024 | Cyclophosphamide Related Compound B (25 mg) (3-(2-chloroethyl)-2-oxo-2-hydroxy-1,3,6,2-oxadiazaphosphonane) | Reference Standard | 158401-52-6 | 25 | mg | VIAL | |
| 1157035 | Cyclophosphamide Related Compound C (25 mg) (3-aminopropyl dihydrogen phosphate) | Reference Standard | 1071-28-9 | 25 | mg | VIAL | |
| 1157046 | Cyclophosphamide Related Compound D (25 mg) (3-[2-(2-chloroethylamino)ethylamino]propyl dihydrogen phosphate dihydrochloride) | Reference Standard | 158401-51-5 | 25 | mg | VIAL | |
| 1158005 | Cycloserine (250 mg) | Reference Standard | 68-41-7 | 250 | mg | VIAL | |
| 1158504 | Cyclosporine (50 mg) | Reference Standard | 59865-13-3 | 50 | mg | VIAL | |
| 1158650 | Cyclosporine Resolution Mixture (25 mg) (This material is an approximate 100:1 (w/w) mixture of cyclosporine and cyclosporine U) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1159008 | Cyclothiazide (200 mg) (AS) | Reference Standard | 2259-96-3 | 200 | mg | VIAL | |
| 1161000 | Cyproheptadine Hydrochloride (500 mg) | Reference Standard | 41354-29-4 | 500 | mg | VIAL | |
| 1161010 | Cyproheptadine Related Compound A (40 mg) (5H-dibenzo[a,d]cycloheptene) | Reference Standard | 256-81-5 | 40 | mg | VIAL | |
| 1161032 | Cyproheptadine Related Compound C (25 mg) (5-(1-methyl-piperidin-4-yl)-5H-dibenzo[a,d]cyclohepten-5-ol) | Reference Standard | 3967-32-6 | 25 | mg | VIAL | |
| 1161203 | Cyromazine (200 mg) | Reference Standard | 66215-27-8 | 200 | mg | VIAL | |
| 1161586 | Cystine (200 mg) | Reference Standard | 56-89-3 | 200 | mg | VIAL | |
| 1162002 | Cytarabine (250 mg) | Reference Standard | 147-94-4 | 250 | mg | VIAL | |
| 1162148 | Cytosine (100 mg) | Reference Standard | 71-30-7 | 100 | mg | VIAL | |
| 1096564 | D-Carglumic Acid (30 mg) (N-Carbamoyl-D-glutamic acid) | Reference Standard | 26117-15-7 | 30 | mg | VIAL | |
| 1294319 | D-Glucuronic Acid (50 mg) | Reference Standard | 6556-12-3 | 50 | mg | VIAL | |
| 1238523 | D-Har Eptifibatide (10 mg) (N6-Amidino-N2-(3-mercaptopropionyl)-D-lysylglycyl-D-alpha-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide, cyclic(1-6)-disulfide) | Reference Standard | NA | 10 | mg | VIAL | |
| 1607903 | D-Salicin (150 mg) | Reference Standard | 138-52-3 | 150 | mg | VIAL | |
| 1707817 | D-Valacyclovir (25 mg) (D-Valine, 2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)methoxy] ethyl ester) | Reference Standard | 142963-60-8 | 25 | mg | VIAL | |
| 1708015 | D-Valganciclovir (10 mg) (2-[(2-amino-1,6-dihydro-6-oxo-9H-purin-9-yl)-methoxy]-3-hydroxypropyl D-valine ester monohydrochloride) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1087520 | D-camphor sulfonic acid (100 mg) | Reference Standard | 3144-16-9 | 100 | mg | VIAL | |
| 1105450 | D-chiro-Inositol (150 mg) | Reference Standard | 643-12-9 | 150 | mg | VIAL | |
| 1162308 | Dacarbazine (125 mg) | Reference Standard | 4342-03-4 | 125 | mg | | |
| 1162320 | Dacarbazine Related Compound A (50 mg) (5-aminoimidazole-4-carboxamide hydrochloride) | Reference Standard | 72-40-2 | 50 | mg | VIAL | |
| 1162330 | Dacarbazine Related Compound B (50 mg) (2-Azahypoxanthine monohydrate) | Reference Standard | 7151-03-3 | 50 | mg | VIAL | |
| 1162400 | Dactinomycin (50 mg) | Reference Standard | 50-76-0 | 50 | mg | VIAL | |
| 1162421 | Daidzein (25 mg) | Reference Standard | 486-66-8 | 25 | mg | VIAL | |
| 1162432 | Daidzin (30 mg) | Reference Standard | 552-66-9 | 30 | mg | VIAL | |
| 1162454 | Dalfampridine (200 mg) | Reference Standard | 504-24-5 | 200 | mg | | |
| 1162545 | Dalfampridine Related Compound A (25 mg) (4-Aminopyridine 1-oxide) | Reference Standard | 3535-75-9 | 25 | mg | VIAL | |
| 1162556 | Dalfampridine Related Compound B (50 mg) (3,5-Dibromopyridin-4-amine) | Reference Standard | 84539-34-4 | 50 | mg | VIAL | |
| 1162567 | Dalfampridine Related Compound C (25 mg) (1,3-Di(pyridin-4-yl)urea) | Reference Standard | 39642-87-0 | 25 | mg | VIAL | |
| 1162443 | Dalfampridine Resolution Mixture (15 mg) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1162487 | Dalteparin Sodium (300 mg) | Reference Standard | 9041-08-1 | 300 | mg | VIAL | |
| 1162501 | Danazol (200 mg) | Reference Standard | 17230-88-5 | 200 | mg | VIAL | |
| 1163140 | Dantrolene (200 mg) | Reference Standard | 7261-97-4 | 200 | mg | VIAL | |
| 1163162 | Dantrolene Related Compound A (50 mg) (1,2-Bis{[5-(4-nitrophenyl)furan-2-yl]methylene}hydrazine) | Reference Standard | 301359-05-7 | 50 | mg | VIAL | |
| 1163173 | Dantrolene Related Compound B (50 mg) (5-(4-nitrophenyl)-2-furaldehyde-(2-carboxymethyl) semicarbazone) | Reference Standard | 57268-33-4 | 50 | mg | VIAL | |
| 1163184 | Dantrolene Related Compound C (50 mg) (5-(4-Nitrophenyl)furan-2-carbaldehyde) | Reference Standard | 7147-77-5 | 50 | mg | VIAL | |
| 1163151 | Dantrolene Sodium (100 mg) | Reference Standard | 24868-20-0 | 100 | mg | VIAL | |
| 1163253 | Dapagliflozin Propanediol (100 mg) | Reference Standard | 960404-48-2 | 100 | mg | VIAL | |
| 1163264 | Dapagliflozin Related Compound A (15 mg) ((2S,3R,4R,5S,6R)-2-[4-Bromo-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol) | Reference Standard | 1807632-95-6 | 15 | mg | VIAL | |
| 1164008 | Dapsone (200 mg) | Reference Standard | 80-08-0 | 200 | mg | | |
| 1164211 | Darifenacin Chiral Peak ID Mixture (25 mg) (See USP Certificate for full Chemical Name) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1164200 | Darifenacin Hydrobromide (150 mg) | Reference Standard | 133099-07-7 | 150 | mg | VIAL | |
| 1164222 | Darifenacin Peak ID Mixture (25 mg) (A mixture consisting of Darifenacin Hydrobromide (99%), Dealkyl darifenacin (0.3%), Ketodarifenacin (0.2%), and 7-Bromo darifenacin (0.3%)) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1164700 | Daunorubicin Hydrochloride (200 mg) | Reference Standard | 23541-50-6 | 200 | mg | VIAL | |
| 1164697 | Daunorubicinone (25 mg) ((8S,10S)-8-Acetyl-6,8,10,11-tetrahydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione) | Reference Standard | 21794-55-8 | 25 | mg | VIAL | |
| 1471958 | Deacetylnorgestimate (25 mg) ((E)- and (Z)-17-deacetyl norgestimate mixture) | Reference Standard | 53016-31-2 | 25 | mg | VIAL | |
| 1A00160 | Decarboxy Levofloxacin (25 mg) ((S)-9-fluoro-3-methyl-7-oxo-10-(4-methylpiperazine-1-yl)-2,3-dihydro-7H-pyrido [1,2,3-de] -1,4-benzoxazine) | Pharmaceutical Analytical Impurity | 178964-53-9 | 25 | mg | VIAL | |
| 1165204 | Decitabine (100 mg) | Reference Standard | 2353-33-5 | 100 | mg | VIAL | |
| 1165215 | Decitabine Related Compound A (25 mg) (1-O-Acetyl-3,5-di-O-(4-chlorobenzoyl)-2-deoxy-D-ribofuranose) | Reference Standard | 1207459-15-1 | 25 | mg | VIAL | |
| 1165248 | Decitabine Related Compound D (25 mg) (Methyl 4-chlorobenzoate) | Reference Standard | 1126-46-1 | 25 | mg | VIAL | |
| 1165259 | Decitabine Related Compound E (25 mg) (4-Amino-1-(2-deoxy-alpha-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one) | Reference Standard | 22432-95-7 | 25 | mg | VIAL | |
| 1165226 | Decitabine Related Compounds B and C Mixture (25 mg) (4-Amino-1-(3,5-di-O-(4-chlorobenzoyl)-2-deoxy-Beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one and 4-Amino-1-(3,5-di-O-(4-chlorobenzoyl)-2-deoxy-a-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1165408 | Decoquinate (200 mg) | Reference Standard | 18507-89-6 | 200 | mg | VIAL | |
| 1617474 | Defatted Powdered Soy (2.5 g) | Reference Standard | 68513-95-1 | 2.5 | g | VIAL | |
| 1165656 | Deferasirox (200 mg) | Reference Standard | 201530-41-8 | 200 | mg | | |
| 1165667 | Deferasirox System Suitability Mixture (20 mg) (A mixture containing Deferasirox, Benzoxazinone analog, Deferasirox ethyl ester, Deferasirox 1,2-isomer, Deferasirox 1,3-isomer and Salicylimide) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1166003 | Deferoxamine Mesylate (300 mg) | Reference Standard | 138-14-7 | 300 | mg | VIAL | |
| 1166116 | Deflazacort (100 mg) | Reference Standard | 14484-47-0 | 100 | mg | VIAL | |
| 1012772 | Dehydrated Alcohol (1.2 mL/ampule; 5 ampules) | Reference Standard | 64-17-5 | 6 | mL | AMPULE | |
| 1166309 | Dehydroacetic Acid (200 mg) | Reference Standard | 520-45-6 | 200 | mg | VIAL | |
| 1166400 | Dehydrocarteolol Hydrochloride (100 mg) (5-[3-(tert-Butylamino)-2-hydroxypropoxy]quinolin-2(1H)-one hydrochloride) | Reference Standard | 53371-79-2 | 100 | mg | VIAL | |
| 1166502 | Dehydrocholic Acid (200 mg) | Reference Standard | 81-23-2 | 200 | mg | VIAL | |
| 1651621 | Delta-9-Tetrahydrocannabinol 1 mL (1 mg/mL) | Reference Standard | N/A | 1 | mL | AMPULE | |
| 1162637 | Delta-Damascone (3 x 0.5 mL) | Reference Standard | 57378-68-4 | 1.5 | mL | AMPULE | |
| 1169001 | Demecarium Bromide (250 mg) | Reference Standard | 56-94-0 | 250 | mg | VIAL | |
| 1170000 | Demeclocycline Hydrochloride (200 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 64-73-3 | 200 | mg | VIAL | |
| 1171003 | Denatonium Benzoate (200 mg) | Reference Standard | 3734-33-6 | 200 | mg | VIAL | |
| 1171273 | Deoxycholic Acid (Desoxycholic Acid) (100 mg) | Reference Standard | 83-44-3 | 100 | mg | VIAL | |
| 1171397 | Depramine (20 mg) (3-(5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine hydrochloride) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1171455 | Dermatan Sulfate (25 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 54328-33-5 | 25 | mg | VIAL | |
| 1171706 | Desacetyl Diltiazem Hydrochloride (50 mg) | Reference Standard | 23515-45-9 | 50 | mg | VIAL | |
| 1171819 | Desbenzyl Donepezil Hydrochloride (20 mg) (5,6-dimethoxy-2-(piperidin-4-ylmethyl)indan-1-one hydrochloride) | Reference Standard | 120013-39-0 | 20 | mg | VIAL | |
| 1041992 | Desfluoro Aprepitant (15 mg) (5-{[(2R,3S)-2-{(R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-3-phenylmorpholino]methyl}-2H-1,2,4-triazol-3(4H)-one) | Reference Standard | 170729-76-7 | 15 | mg | VIAL | |
| 1171900 | Desflurane (0.5 mL) | Reference Standard | 57041-67-5 | 0.5 | mL | AMPULE | |
| 1171910 | Desflurane Related Compound A (0.1 mL) (Bis-(1,2,2,2-tetrafluoroethyl)ether) | Reference Standard | 67429-44-1 | 0.1 | mL | AMPULE | |
| 1613032 | Desiccant, Large (2 pouches (approximate weight 80 grams, each)) | Reference Standard | 1318-02-1 | 160 | g | | |
| 1613021 | Desiccant, Medium (2 pouches (approximate weight 80 grams, each)) | Reference Standard | 1318-02-1 | 160 | g | OTHER | |
| 1613010 | Desiccant, Small (2 pouches (approximate weight 44 grams, each)) | Reference Standard | 1318-02-1 | 88 | g | OTHER | |
| 1A00720 | Desiodoamiodarone (25 mg) ((2-butylbenzofuran-3-yl)(4-(2-(diethylamino)ethoxy)phenyl)methanone) | Pharmaceutical Analytical Impurity | 23551-25-9 | 25 | mg | VIAL | |
| 1172006 | Desipramine Hydrochloride (125 mg) | Reference Standard | 58-28-6 | 125 | mg | VIAL | |
| 1173009 | Deslanoside (200 mg) | Reference Standard | 17598-65-1 | 200 | mg | VIAL | |
| 1173042 | Desloratadine (200 mg) | Reference Standard | 100643-71-8 | 200 | mg | VIAL | |
| 1173053 | Desloratadine Related Compound A (20 mg) (8-Bromo-6,11-dihydro-11-(piperidin-4-ylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine) | Reference Standard | 117796-50-6 | 20 | mg | VIAL | |
| 1173086 | Desloratadine Related Compound B (20 mg) (8-chloro-11-(1,2,3,6-tetrahydropyridin-4-yl)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine hydrochloride) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1173064 | Desloratadine Related Compound F (50 mg) (8-Chloro-6,11-dihydro-11-(N-formyl-4-piperidinylidene) -5H-benzo[5,6]cyclohepta[1,2-b]pyridine) | Reference Standard | 117810-61-4 | 50 | mg | VIAL | |
| 1A00060 | Desmethoxy Omeprazole (25 mg) (2-(((3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-5-methoxy-1H-benzo[d]imidazole) | Pharmaceutical Analytical Impurity | 110374-16-8 | 25 | mg | VIAL | |
| 1173100 | Desmethoxycurcumin (30 mg) | Reference Standard | 22608-11-3 | 30 | mg | VIAL | |
| 1173202 | Desmopressin Acetate (1.75 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 62288-83-9 | 1.75 | mg | VIAL | |
| 1173235 | Desogestrel (100 mg) | Reference Standard | 54024-22-5 | 100 | mg | VIAL | |
| 1173246 | Desogestrel Related Compound A (15 mg) (13-Ethyl-11-methylene-18,19-dinor-5alpha,17alpha-pregn-3-en-20-yn-17-ol, Desogestrel delta-3-isomer) | Reference Standard | 201360-82-9 | 15 | mg | VIAL | |
| 1173257 | Desogestrel Related Compound B (25 mg) (13-Ethyl-3-hydroxy-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-17-ol) | Reference Standard | 869627-85-0 | 25 | mg | VIAL | |
| 1173268 | Desogestrel Related Compound C (25 mg) (13-Ethyl-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-17-ol-3-one) | Reference Standard | 54048-10-1 | 25 | mg | VIAL | |
| 1173279 | Desogestrel Related Compound D (25 mg) (13-Ethyl-11-methylenegon-4-en-17-one) | Reference Standard | 54024-21-4 | 25 | mg | VIAL | |
| 1173304 | Desonide (250 mg) | Reference Standard | 638-94-8 | 250 | mg | VIAL | |
| 1173315 | Desonide Impurities Mixture (25 mg) (See long description for full chemcial name) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1046078 | Desosaminylazithromycin (15 mg) | Reference Standard | 117693-41-1 | 15 | mg | VIAL | |
| 1173508 | Desoximetasone (200 mg) | Reference Standard | 382-67-2 | 200 | mg | VIAL | |
| 1A00220 | Desoximetasone Acid (25 mg) ((11Beta,16alpha,17Beta)-9-Fluoro-11-hydroxy-16-methyl-3-oxoandrosta-1,4- diene-17-carboxylic acid; 9-Fluoro-11Beta-hydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17Beta-carboxylic acid) | Pharmaceutical Analytical Impurity | 75262-69-0 | 25 | mg | VIAL | |
| 1173519 | Desoximetasone Related Compound A (25 mg) (9-Fluoro-11Beta,21-dihydroxy-16Alpha-methylpregna-4-ene-3,20-dione) | Reference Standard | 432-54-2 | 25 | mg | VIAL | |
| 1174001 | Desoxycorticosterone Acetate (200 mg) | Reference Standard | 56-47-3 | 200 | mg | VIAL | |
| 1175004 | Desoxycorticosterone Pivalate (125 mg) | Reference Standard | 808-48-0 | 125 | mg | VIAL | |
| 1175751 | Desvenlafaxine (200 mg) (1-[2-(Dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol hydrogen) | Reference Standard | 93413-62-8 | 200 | mg | VIAL | |
| 1175762 | Desvenlafaxine Fumarate (200 mg) (1-[2-(Dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol trans-butenedioate monohydrate) | Reference Standard | 313471-75-9 | 200 | mg | VIAL | |
| 1175784 | Desvenlafaxine Related Compound A (25 mg) (4-[1-(Cyclohex-1-en-1-yl)-2-(dimethylamino)ethyl]phenol) | Reference Standard | 1346600-38-1 | 25 | mg | VIAL | |
| 1175795 | Desvenlafaxine Related Compound B (25 mg) (4-[1-(1-Hydroxycyclohexyl)-2-(methylamino)ethyl]phenol) | Reference Standard | 135308-74-6 | 25 | mg | VIAL | |
| 1175773 | Desvenlafaxine Succinate (200 mg) (1-[2-(Dimethylamino)-1-(4-hydroxyphenyl)ethyl]cyclohexanol hydrogen butanedioate monohydrate) | Reference Standard | 386750-22-7 | 200 | mg | VIAL | |
| 1175800 | Deutero N-Nitrosodimethylamine (NDMA-d6) (1 mL (1 mg/mL)) (N-(Methyl-d3)-N-nitrosomethan-d3-amine) | Reference Standard | 17829-05-9 | 1 | mL | AMPULE | |
| 1176007 | Dexamethasone (125 mg) | Reference Standard | 50-02-2 | 125 | mg | VIAL | |
| 1176506 | Dexamethasone Acetate (200 mg) | Reference Standard | 1177-87-3 | 200 | mg | VIAL | |
| 1A00090 | Dexamethasone Enol-Pyruvaldehyde Analog (25 mg) ((Z)-2-((8S,9R,10S,11S,13S,14S,16R)-9-fluoro-11-hydroxy-10,13,16-trimethyl-3-oxo-3,6,7,8,9,10,11,12,13,14,15,16-dodecahydro-17H-cyclopenta[a]phenanthren-17-ylidene)-2-hydroxyacetaldehyde) | Pharmaceutical Analytical Impurity | 1174035-75-6 | 25 | mg | VIAL | |
| 1A00340 | Dexamethasone Ethyl Ester (25 mg) (COLD SHIPMENT REQUIRED) (Ethyl 11Beta,17alpha-dihydroxy-9-fluoro-16alpha-methylandrostane-1,4-diene-3-one-17-ylcarboxylate) | Pharmaceutical Analytical Impurity | 37926-77-5 | 25 | mg | VIAL | |
| 1A00300 | Dexamethasone Formate (25 mg) (COLD SHIPMENT REQUIRED) ((8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-17-(formyloxy)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-17-carboxylic acid) | Pharmaceutical Analytical Impurity | 473273-04-0 | 25 | mg | VIAL | |
| 1177000 | Dexamethasone Phosphate (500 mg) | Reference Standard | 312-93-6 | 500 | mg | VIAL | |
| 1177032 | Dexamethasone Sodium Phosphate (500 mg) | Reference Standard | 2392-39-4 | 500 | mg | VIAL | |
| 1178002 | Dexbrompheniramine Maleate (200 mg) | Reference Standard | 2391-03-9 | 200 | mg | VIAL | |
| 1179005 | Dexchlorpheniramine Maleate (300 mg) | Reference Standard | 2438-32-6 | 300 | mg | VIAL | |
| 1179118 | Dexketoprofen Tromethamine (200 mg) | Reference Standard | 156604-79-4 | 200 | mg | VIAL | |
| 1179333 | Dexmedetomidine Hydrochloride (200 mg) | Reference Standard | 145108-58-3 | 200 | mg | VIAL | |
| 1179504 | Dexpanthenol (500 mg) | Reference Standard | 81-13-0 | 500 | mg | VIAL | |
| 1179628 | Dextran 1 (50 mg) | Reference Standard | 9004-54-0 | 50 | mg | VIAL | |
| 1179865 | Dextran 10 Calibration (100 mg) | Reference Standard | 9004-54-0 | 100 | mg | VIAL | |
| 1179898 | Dextran 250 Calibration (100 mg) | Reference Standard | 9004-54-0 | 100 | mg | VIAL | |
| 1179854 | Dextran 4 Calibration (100 mg) | Reference Standard | 9004-54-0 | 100 | mg | VIAL | |
| 1179708 | Dextran 40 (50 mg) | Reference Standard | 9004-54-0 | 50 | mg | VIAL | |
| 1179876 | Dextran 40 Calibration (100 mg) | Reference Standard | 9004-54-0 | 100 | mg | VIAL | |
| 1179720 | Dextran 40 System Suitability (200 mg) | Reference Standard | 9004-54-0 | 200 | mg | VIAL | |
| 1179741 | Dextran 70 (50 mg) | Reference Standard | 9004-54-0 | 50 | mg | VIAL | |
| 1179887 | Dextran 70 Calibration (100 mg) | Reference Standard | 9004-54-0 | 100 | mg | VIAL | |
| 1179650 | Dextran T-10 (200 mg) | Reference Standard | 9004-54-0 | 200 | mg | VIAL | |
| 1179800 | Dextran V0 Marker (100 mg) | Reference Standard | 9004-54-0 | 100 | mg | VIAL | |
| 1179912 | Dextrates Monohydrate | Reference Standard | 68131-37-3 | | | | |
| 1180015 | Dextroamphetamine Related Compound A (25 mg) (1-Phenyl-2-propanol) | Reference Standard | 698-87-3 | 25 | mg | AMPULE | |
| 1180026 | Dextroamphetamine Related Compound B CII (25 mg) (Phenyl acetone) | Reference Standard | 103-79-7 | 25 | mg | AMPULE | |
| 1180004 | Dextroamphetamine Sulfate CII (500 mg) | Reference Standard | 51-63-8 | 500 | mg | VIAL | |
| 1180503 | Dextromethorphan (500 mg) | Reference Standard | 125-71-3 | 500 | mg | VIAL | |
| 1181007 | Dextromethorphan Hydrobromide (500 mg) | Reference Standard | 6700-34-1 | 500 | mg | VIAL | |
| 1181040 | Dextromethorphan Related Compound C (30 mg) (3-Methoxy-17-methyl-9 Alpha,13 Alpha,14 Alpha-morphinan-10-one) | Reference Standard | 57969-05-8 | 30 | mg | VIAL | |
| 1181302 | Dextrose (500 mg) | Reference Standard | 50-99-7 | 500 | mg | VIAL | |
| 1181506 | Diacetylated Monoglycerides (200 mg) | Reference Standard | 68990-54-5 | 200 | mg | AMPULE | |
| 1182000 | Diacetylfluorescein (200 mg) | Reference Standard | 596-09-8 | 200 | mg | VIAL | |
| 1184005 | Diatrizoic Acid (100 mg) | Reference Standard | 50978-11-5 | 100 | mg | VIAL | |
| 1184027 | Diatrizoic Acid Related Compound A (50 mg) (5-Acetamido-3-amino-2,4,6-triiodobenzoic Acid) | Reference Standard | 1713-07-1 | 50 | mg | VIAL | |
| 1184118 | Diaveridine (25 mg) (5-(3,4-Dimethoxybenzyl)pyrimidine-2,4-diamine) | Reference Standard | 5355-16-8 | 25 | mg | VIAL | |
| 1185008 | Diazepam CIV (100 mg) | Reference Standard | 439-14-5 | 100 | mg | VIAL | |
| 1185020 | Diazepam Related Compound A (25 mg) (2-methylamino-5-chlorobenzophenone) | Reference Standard | 1022-13-5 | 25 | mg | VIAL | |
| 1023403 | Diazepam Related Compound B (25 mg) (3-Amino-6-chloro-1-methyl-4-phenylcarbostyril) | Reference Standard | 5220-02-0 | 25 | mg | VIAL | |
| 1185063 | Diazepam Related Compound E (25 mg) (6-Chloro-1-methyl-4-phenylquinazolin-2(1H)-one) | Reference Standard | 20927-53-1 | 25 | mg | VIAL | |
| 1186000 | Diazoxide (200 mg) | Reference Standard | 364-98-7 | 200 | mg | | |
| 1551128 | Dibasic Potassium Phosphate (500 mg) | Reference Standard | 7758-11-4 | 500 | mg | VIAL | |
| 1187003 | Dibucaine Hydrochloride (500 mg) | Reference Standard | 61-12-1 | 500 | mg | VIAL | |
| 1187080 | Dibutyl Phthalate (200 mg) | Reference Standard | 84-74-2 | 200 | mg | AMPULE | |
| 1187091 | Dibutyl Sebacate (1 mL) | Reference Standard | 109-43-3 | 1 | mL | AMPULE | |
| 1188006 | Dichlorphenamide (200 mg) | Reference Standard | 120-97-8 | 200 | mg | VIAL | |
| 1188301 | Dichlorvos (150 mg) (2,2-dichlorovinyl dimethyl phosphate) (AS) | Reference Standard | 62-73-7 | 150 | mg | AMPULE | |
| 1188560 | Diclazuril (200 mg) | Reference Standard | 101831-37-2 | 200 | mg | VIAL | |
| 1188571 | Diclazuril System Suitability Mixture (50 mg) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1188709 | Diclofenac Potassium (200 mg) | Reference Standard | 15307-81-0 | 200 | mg | VIAL | |
| 1188811 | Diclofenac Related Compound A (25 mg) (N-(2,6-dichlorophenyl)indolin-2-one) | Reference Standard | 15362-40-0 | 25 | mg | VIAL | |
| 1188800 | Diclofenac Sodium (200 mg) | Reference Standard | 15307-79-6 | 200 | mg | VIAL | |
| 1189053 | Dicloxacillin Related Compound D (15 mg) (3-(2,6-Dichlorophenyl)-5-methylisoxazole-4-carboxylic acid) | Reference Standard | 3919-76-4 | 15 | mg | VIAL | |
| 1189009 | Dicloxacillin Sodium (300 mg) | Reference Standard | 13412-64-1 | 300 | mg | VIAL | |
| 1191000 | Dicyclomine Hydrochloride (125 mg) | Reference Standard | 67-92-5 | 125 | mg | VIAL | |
| 1191011 | Dicyclomine Related Compound A (40 mg) ([1,1'-Bi(cyclohexane)]-1-carboxylic acid) | Reference Standard | 60263-54-9 | 40 | mg | VIAL | |
| 1191204 | Didanosine (200 mg) | Reference Standard | 69655-05-6 | 200 | mg | VIAL | |
| 1191226 | Didanosine Related Compound A (25 mg) (Hypoxanthine) | Reference Standard | 68-94-0 | 25 | mg | VIAL | |
| 1191237 | Didanosine Related Compound B (25 mg) (2',3'-dideoxyadenosine) | Reference Standard | 4097-22-7 | 25 | mg | VIAL | |
| 1191215 | Didanosine System Suitability Mixture (10 mg) | Reference Standard | 69655-05-6 | 10 | mg | VIAL | |
| 1191554 | Didymin (30 mg) ((RS)-5-Hydroxy-2-(4-methoxyphenyl)-4-oxo-3,4-dihydro-2H-chromen-7-yl 6-O-(alpha-L-rhamnopyranosyl)-beta-D-glucopyranoside) | Reference Standard | 2418540-64-2 | 30 | mg | VIAL | |
| 1192808 | Diethanolamine (3 x 1 mL) | Reference Standard | 111-42-2 | 3 | mL | AMPULE | |
| 1193505 | Diethyl Phthalate (200 mg) | Reference Standard | 84-66-2 | 200 | mg | AMPULE | |
| 1194803 | Diethyl Sebacate (1 mL) | Reference Standard | 110-40-7 | 1 | mL | AMPULE | |
| 1193006 | Diethylcarbamazine Citrate (200 mg) | Reference Standard | 1642-54-2 | 200 | mg | VIAL | |
| 1193265 | Diethylene Glycol (5 x 0.2 mL) | Reference Standard | 111-46-6 | 1 | mL | AMPULE | |
| 1193301 | Diethylene Glycol Monoethyl Ether (4 x 0.25 mL/ampule) | Reference Standard | 111-90-0 | 1 | mL | AMPULE | |
| 1194009 | Diethylpropion Hydrochloride CIV (200 mg) | Reference Standard | 134-80-5 | 200 | mg | VIAL | |
| 1195001 | Diethylstilbestrol (200 mg) | Reference Standard | 56-53-1 | 200 | mg | VIAL | |
| 1197007 | Diethyltoluamide (3 g) | Reference Standard | 134-62-3 | 3 | g | AMPULE | |
| 1197018 | Diethyltoluamide Related Compound A (25 mg) (N,N-Diethyl-4-toluamide) | Reference Standard | 2728-05-4 | 25 | mg | VIAL | |
| 1197302 | Diflorasone Diacetate (200 mg) | Reference Standard | 33564-31-7 | 200 | mg | VIAL | |
| 1197506 | Diflunisal (200 mg) | Reference Standard | 22494-42-4 | 200 | mg | VIAL | |
| 1198000 | Digitalis (3 g) | Reference Standard | 8031-42-3 | 3 | g | | |
| 1199002 | Digitoxin (200 mg) | Reference Standard | 71-63-6 | 200 | mg | VIAL | |
| 1199308 | Diglycine (50 mg) (glycylglycine) | Reference Standard | 556-50-3 | 50 | mg | VIAL | |
| 1200000 | Digoxin (250 mg) | Reference Standard | 20830-75-5 | 250 | mg | VIAL | |
| 1200520 | Dihydroartemisinin (200 mg) | Reference Standard | 131175-87-6 | 200 | mg | VIAL | |
| 1200600 | Dihydrocapsaicin (25 mg) | Reference Standard | 19408-84-5 | 25 | mg | VIAL | |
| 1200804 | Dihydrocodeine Bitartrate CII (200 mg) | Reference Standard | 5965-13-9 | 200 | mg | VIAL | |
| 1200881 | Dihydrodaunorubicin Hydrochloride (20 mg) ((8S,10S)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-6,8,11-trihydroxy-8-(1-hydroxyethyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1200917 | Dihydrodutasteride (25 mg) (N-[2,5-Bis(trifluoromethyl)phenyl]-3-oxo-4-aza-5alpha-androst-1-ene-17Beta-carboxamide) | Reference Standard | 164656-22-8 | 25 | mg | VIAL | |
| 1202005 | Dihydroergotamine Mesylate (500 mg) | Reference Standard | 6190-39-2 | 500 | mg | VIAL | |
| 1203008 | Dihydrostreptomycin Sulfate (200 mg) | Reference Standard | 5490-27-7 | 200 | mg | VIAL | |
| 1204102 | Dihydroxyacetone (250 mg) | Reference Standard | 96-26-4 | 250 | mg | VIAL | |
| 1204805 | Diloxanide Furoate (200 mg) | Reference Standard | 3736-81-0 | 200 | mg | VIAL | |
| 1205003 | Diltiazem Hydrochloride (200 mg) | Reference Standard | 33286-22-5 | 200 | mg | VIAL | |
| 1205014 | Diltiazem Related Compound A (AS) (25 mg) (trans-diltiazem hydrochloride) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1353000 | Diluted Isosorbide Dinitrate (500 mg of 25% mixture with lactose) | Reference Standard | 87-33-2 | 500 | mg | VIAL | |
| 1353102 | Diluted Isosorbide Mononitrate (750 mg) | Reference Standard | 16051-77-7 | 750 | mg | VIAL | |
| 1353113 | Diluted Isosorbide Mononitrate Related Compound A (150 mg) (1,4:3,6-Dianhydro-D-glucitol 2-nitrate in lactose) | Reference Standard | 16106-20-0 | 150 | mg | VIAL | |
| 1466506 | Diluted Nitroglycerin (5 ampules, approx. 200 mg of a 0.974% solution in propylene glycol each) (COLD SHIPMENT REQUIRED) | Reference Standard | 55-63-0 | 1000 | mg | AMPULE | |
| 1206006 | Dimenhydrinate (200 mg) | Reference Standard | 523-87-5 | 200 | mg | VIAL | |
| 1206017 | Dimenhydrinate Related Compound E (15 mg) (8-chloro-3,7-dihydro-1,3,7-trimethyl-1H-purine-2,6-dione) | Reference Standard | 4921-49-7 | 15 | mg | VIAL | |
| 1211006 | Dimethyl Sulfoxide (3 g) | Reference Standard | 67-68-5 | 3 | g | AMPULE | |
| 1211200 | Dimethylamine Solution (6 x 3 mL) (International Restricted Sales Item) | Reference Standard | 124-40-3 (Dimethylamine) | 18 | mL | AMPULE | |
| 1213001 | Dinoprost Tromethamine (50 mg) | Reference Standard | 38562-01-5 | 50 | mg | VIAL | |
| 1213103 | Dinoprostone (125 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 363-24-6 | 125 | mg | VIAL | |
| 1213136 | Dinoprostone Related Compound C (20 mg) ((E)-7-{(1R,2R,3R)-3-Hydroxy-2-[(S,E)-3-hydroxyoct-1-en-1-yl]-5-oxocyclopentyl}hept-5-enoic acid) | Reference Standard | 36150-00-2 | 20 | mg | VIAL | |
| 1213318 | Diosmin (300 mg) | Reference Standard | 520-27-4 | 300 | mg | VIAL | |
| 1213329 | Diosmin for System Suitability (15 mg) (A Mixture of Acetoisovanillone, Hesperidin, Isorhoifolin, Diosmin, Linarin and Diosmetin) | Reference Standard | N/A | 15 | mg | | |
| 1214004 | Dioxybenzone (150 mg) | Reference Standard | 131-53-3 | 150 | mg | VIAL | |
| 1217909 | Diphenhydramine Citrate (200 mg) | Reference Standard | 88637-37-0 | 200 | mg | VIAL | |
| 1218005 | Diphenhydramine Hydrochloride (200 mg) | Reference Standard | 147-24-0 | 200 | mg | VIAL | |
| 1218050 | Diphenhydramine N-Oxide (25 mg) (2-(benzhydryloxy)-N,N-dimethylethan-1-amine oxide hydrochloride) | Reference Standard | 13168-00-8 | 25 | mg | VIAL | |
| 1218016 | Diphenhydramine Related Compound A (25 mg) (2-(Diphenylmethoxy)-N-methylethanamine hydrochloride) | Reference Standard | 53499-40-4 | 25 | mg | VIAL | |
| 1218027 | Diphenhydramine Related Compound B (20 mg) (3-(benzhydryloxy)propane-1,2-diol) | Reference Standard | 19574-66-4 | 20 | mg | VIAL | |
| 1219008 | Diphenoxylate Hydrochloride CII (200 mg) | Reference Standard | 3810-80-8 | 200 | mg | VIAL | |
| 1219019 | Diphenoxylate Related Compound A CI (25 mg) (1-(3-Cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylic acid) | Reference Standard | 28782-42-5 | 25 | mg | VIAL | |
| 1220357 | Dipivefrin Related Compound E (25 mg) (4-[(Methylamino)acetyl]-1,2-phenylene dipivalate hydrochloride) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1220506 | Dipyridamole (200 mg) | Reference Standard | 58-32-2 | 200 | mg | VIAL | |
| 1220517 | Dipyridamole Related Compound A (25 mg) (2,2'-{[4,6,8-Tri(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-2-yl]azanediyl}diethanol) | Reference Standard | 16982-40-4 | 25 | mg | VIAL | |
| 1220528 | Dipyridamole Related Compound B (25 mg) (2,2',2'',2''',2'''',2'''''-{[8-(Piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,4,6-triyl]tris(azanetriyl)}hexaethanol) | Reference Standard | 16908-47-7 | 25 | mg | VIAL | |
| 1220539 | Dipyridamole Related Compound C (25 mg) (2,2'-{[6-chloro-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-2-yl]azanediyl}diethanol) | Reference Standard | 54093-92-4 | 25 | mg | VIAL | |
| 1220540 | Dipyridamole Related Compound D (25 mg) (2,2'-({6-[(2-Hydroxyethyl)amino]-4,8-di(piperidin-1-yl)pyrimido[5,4-d]pyrimidin-2-yl}azanediyl)diethanol) | Reference Standard | 1176886-12-6 | 25 | mg | VIAL | |
| 1220559 | Dipyridamole Related Compound E (25 mg) (2,2',2'',2'''-{[6,8-Di(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,4-diyl]bis(azanetriyl)}tetraethanol) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1220561 | Dipyridamole Related Compound F (25 mg) (2,2',2'',2'''-({4-[(2-Hydroxyethyl)amino]-8-(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl}bis(azanetriyl))tetraethanol) | Reference Standard | 60286-30-8 | 25 | mg | VIAL | |
| 1222400 | Disodium 5'-Uridylate (500 mg) | Reference Standard | 3387-36-8 | 500 | mg | VIAL | |
| 1221000 | Disodium Guanylate (350 mg) | Reference Standard | 5550-12-9 | 350 | mg | VIAL | |
| 1222002 | Disodium Inosinate (500 mg) | Reference Standard | 352195-40-5 | 500 | mg | VIAL | |
| 1222501 | Disopyramide Phosphate (200 mg) | Reference Standard | 22059-60-5 | 200 | mg | VIAL | |
| 1224008 | Disulfiram (200 mg) | Reference Standard | 97-77-8 | 200 | mg | VIAL | |
| 1224201 | Divalproex Sodium (200 mg) | Reference Standard | 76584-70-8 | 200 | mg | VIAL | |
| 1224507 | Dobutamine Hydrochloride (400 mg) | Reference Standard | 49745-95-1 | 400 | mg | VIAL | |
| 1224530 | Dobutamine Related Compound C (50 mg) (N-(3,4-Dimethoxyphenethyl)-4-(4-methoxyphenyl)butan-2-amine hydrochloride) | Reference Standard | 51062-14-7 | 50 | mg | VIAL | |
| 1224551 | Docetaxel (200 mg) ((2R,3S)-N-Carboxy-3-phenylisoserine, N-tert-butyl ester, 13-ester with 5Beta,20-epoxy-1,2alpha,4,7Beta,10Beta,13alpha-hexahydroxytax-11-en-9-one 4-acetate 2-benzoate trihydrate) | Reference Standard | 148408-66-6 | 200 | mg | VIAL | |
| 1224562 | Docetaxel Identification (50 mg) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1224573 | Docetaxel System Suitability Mixture (15 mg) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1224609 | Docosahexaenoic Acid (250 mg) ((4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid) | Reference Standard | 6217-54-5 | 250 | mg | AMPULE | |
| 1224620 | Docosahexaenoic Acid Ethyl Ester (500 mg) | Reference Standard | 81926-94-5 | 500 | mg | AMPULE | |
| 1224664 | Docosyl Ferulate (50 mg) | Reference Standard | 101927-24-6 | 50 | mg | VIAL | |
| 1224700 | Docusate Calcium (500 mg) | Reference Standard | 128-49-4 | 500 | mg | VIAL | |
| 1224904 | Docusate Potassium (100 mg) | Reference Standard | 7491-09-0 | 100 | mg | VIAL | |
| 1224802 | Docusate Sodium (1 g) | Reference Standard | 577-11-7 | 1 | g | VIAL | |
| 1224824 | Docusate Sodium Related Compound B (40 mg) (disodium mono (2-ethylhexyl) sulfosuccinate) | Reference Standard | N/A | 40 | mg | VIAL | |
| 1224937 | Dofetilide (200 mg) | Reference Standard | 115256-11-6 | 200 | mg | VIAL | |
| 1224948 | Dofetilide Related Compound A (25 mg) (N-[4-(2-{2-[4-(Methanesulfonamido)phenoxy]ethylamino}ethyl)phenyl]methanesulfonamide) | Reference Standard | 176447-94-2 | 25 | mg | VIAL | |
| 1224959 | Dolasetron Mesylate (125 mg) | Reference Standard | 878143-33-0 | 125 | mg | | |
| 1224960 | Dolasetron Mesylate Related Compound A (25 mg) (Hexahydro-8-hydroxy-2,6-methano-2H-quinolizin-3 (4H)-one, hydrochloride) | Reference Standard | 148091-18-3 | 25 | mg | VIAL | |
| 1224981 | Donepezil Hydrochloride (200 mg) | Reference Standard | 884740-09-4 | 200 | mg | VIAL | |
| 1224992 | Donepezil Related Compound A (25 mg) ((E)-2-[(1-benzylpiperidin-4-yl)methylene]-5,6-dimethoxyindan-1-one) | Reference Standard | 145546-80-1 | 25 | mg | VIAL | |
| 1A00250 | Donepezil quaternary salt (donepezilbenzyl Bromide) (25 mg) (1,1-dibenzyl-4-((5,6-dimethoxy-1-oxo-2,3-dihydro-1H-inden-2-yl)methyl)piperidin-1-ium, bromide) | Pharmaceutical Analytical Impurity | 844694-85-5 | 25 | mg | VIAL | |
| 1224970 | Donepezil-N-Oxide (20 mg) | Reference Standard | 120013-84-5 | 20 | mg | VIAL | |
| 1225204 | Dopamine Hydrochloride (200 mg) | Reference Standard | 62-31-7 | 200 | mg | VIAL | |
| 1225215 | Dopamine Related Compound A (30 mg) (5-(2-Aminoethyl)-2-methoxyphenol) | Reference Standard | 3213-30-7 | 30 | mg | VIAL | |
| 1225226 | Dopamine Related Compound B (30 mg) (4-(2-Aminoethyl)-2-methoxyphenol hydrochloride) | Reference Standard | 1477-68-5 | 30 | mg | VIAL | |
| 1225237 | Dopamine Related Compound C (100 mg) (2-(3,4-Dimethoxyphenyl)ethan-1-amine) | Reference Standard | 120-20-7 | 100 | mg | AMPULE | |
| 1225281 | Dorzolamide Hydrochloride (200 mg) | Reference Standard | 130693-82-2 | 200 | mg | VIAL | |
| 1225292 | Dorzolamide Hydrochloride Related Compound A (20 mg) ((4R,6R)-4-(ethylamino)-5,6-dihydro-6-methyl-4H-thieno[2,3-b]thiopyran-2-sulfonamide-7,7-dioxide, monohydrochloride) | Reference Standard | 122028-36-8 | 20 | mg | VIAL | |
| 1225317 | Dorzolamide Related Compound B (15 mg) ((4RS,6SR)-4-(Ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide hydrochloride) | Reference Standard | 120279-37-0 | 15 | mg | VIAL | |
| 1225306 | Dorzolamide Related Compound D (30 mg) ((4S,6S)-4-Amino-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide hydrochloride) | Reference Standard | 164455-27-0 | 30 | mg | VIAL | |
| 1225000 | Doxapram Hydrochloride (200 mg) | Reference Standard | 7081-53-0 | 200 | mg | VIAL | |
| 1225022 | Doxapram Related Compound B (25 mg) (1-Ethyl-4-{2-[(2-hydroxyethyl)amino]ethyl}-3,3-diphenylpyrrolidin-2-one, hydrochloride) | Reference Standard | 100106-91-0 | 25 | mg | VIAL | |
| 1225419 | Doxazosin Mesylate (200 mg) | Reference Standard | 77883-43-3 | 200 | mg | VIAL | |
| 1225420 | Doxazosin Related Compound A (20 mg) (N-(1,4-benzodioxane-2-carbonyl)piperazine hydrochloride) | Reference Standard | 70918-74-0 | 20 | mg | VIAL | |
| 1225441 | Doxazosin Related Compound B (20 mg) (6,7-dimethoxyquinazoline-2,4-dione) | Reference Standard | 28888-44-0 | 20 | mg | VIAL | |
| 1225452 | Doxazosin Related Compound C (20 mg) (2-chloro-4-amino-6,7-dimethoxyquinazoline) | Reference Standard | 23680-84-4 | 20 | mg | VIAL | |
| 1225463 | Doxazosin Related Compound D (20 mg) (1,4-benzodioxane-2-carboxylic acid) | Reference Standard | 3663-80-7 | 20 | mg | VIAL | |
| 1225474 | Doxazosin Related Compound E (20 mg) (2,4-dichloro-6,7-dimethoxyquinazoline) | Reference Standard | 27631-29-4 | 20 | mg | VIAL | |
| 1225485 | Doxazosin Related Compound F (15 mg) (N,N'-bis(1,4-benzodioxane-2-carbonyl)piperazine) | Reference Standard | 617677-53-9 | 15 | mg | VIAL | |
| 1225496 | Doxazosin Related Compound G (15 mg) (4-Amino-6,7-dimethoxyquinazolin-2(1H)-one hydrochloride) (COLD SHIPMENT REQUIRED) | Reference Standard | 134749-43-2 | 15 | mg | VIAL | |
| 1225500 | Doxepin Hydrochloride (500 mg) | Reference Standard | 1229-29-4 | 500 | mg | VIAL | |
| 1225511 | Doxepin Related Compound A (50 mg) (dibenzo[b,e]oxepin-11(6H)-one) | Reference Standard | 4504-87-4 | 50 | mg | VIAL | |
| 1225522 | Doxepin Related Compound B (50 mg) ((11RS)-11-[3-(dimethylamino)propyl]-6,11-dihydrodibenzo[b,e]oxepin-11-ol) | Reference Standard | 4504-88-5 | 50 | mg | VIAL | |
| 1225533 | Doxepin Related Compound C (25 mg) ((E,Z)-3-(Dibenzo[b,e]oxepin-11(6H)-ylidene)-N-methylpropan-1-amine hydrochloride) | Reference Standard | 2887-91-4 | 25 | mg | VIAL | |
| 1225601 | Doxercalciferol (2 x 20 mg) | Reference Standard | 54573-75-0 | 40 | mg | VIAL | |
| 1225703 | Doxorubicin Hydrochloride (50 mg) | Reference Standard | 25316-40-9 | 50 | mg | VIAL | |
| 1225758 | Doxorubicinone (25 mg) ((8S,10S)-6,8,10,11-Tetrahydroxy-8-(hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione) | Reference Standard | 24385-10-2 | 25 | mg | VIAL | |
| 1226003 | Doxycycline Hyclate (200 mg) | Reference Standard | 24390-14-5 | 200 | mg | VIAL | |
| 1225984 | Doxycycline Monohydrate (100 mg) | Reference Standard | 17086-28-1 | 100 | mg | VIAL | |
| 1226014 | Doxycycline Related Compound A (10 mg) ((4S,4aR,5S,5aR,6S,12aS)-4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-2-naphthacenecarboxamide) | Reference Standard | 3219-99-6 | 10 | mg | VIAL | |
| 1227006 | Doxylamine Succinate (300 mg) | Reference Standard | 562-10-7 | 300 | mg | VIAL | |
| 1017502 | Dried Aluminum Hydroxide Gel (200 mg) | Reference Standard | 21645-51-2 | 200 | mg | VIAL | |
| 1228009 | Drometrizole (25 mg) (2-(2H-Benzotriazol-2-yl)-p-cresol) | Reference Standard | 2440-22-4 | 25 | mg | VIAL | |
| 1228010 | Drometrizole Trisiloxane (200 mg) | Reference Standard | 155633-54-8 | 200 | mg | VIAL | |
| 1228029 | Drometrizole Trisiloxane Related Compound A (25 mg) (2-(2H-Benzotriazol-2-yl)-6-(isobuten-1-yl)-p-cresol) | Reference Standard | 2170-37-8 | 25 | mg | VIAL | |
| 1228031 | Drometrizole Trisiloxane Related Compound B (25 mg) (2-(2H-Benzotriazol-2-yl)-6-(isobuten-3-yl)-p-cresol) | Reference Standard | 98809-58-6 | 25 | mg | VIAL | |
| 1228042 | Drometrizole Trisiloxane Related Compound C (150 mg) (2-(2H-Benzotriazol-2-yl)-6-(isobuten-1-yl)-O1-[bis(trimethylsiloxy)methylsilyl]-p-cresol) | Reference Standard | N/A | 150 | mg | AMPULE | |
| 1228053 | Drometrizole Trisiloxane Related Compound D (25 mg) (2-(2H-Benzotriazol-2-yl)-6-isobutyl-p-cresol) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1228064 | Drometrizole Trisiloxane Related Compound E (150 mg) (2-(2H-Benzotriazol-2-yl)-6-{3-[bis(trimethylsiloxy)methylsilyl]isobutyl}-O1-[bis(trimethylsiloxy)methylsilyl]-p-cresol) | Reference Standard | N/A | 150 | mg | AMPULE | |
| 1228530 | Dronedarone Hydrochloride (125 mg) | Reference Standard | 141625-93-6 | 125 | mg | VIAL | |
| 1228541 | Dronedarone Related Compound A (25 mg) (N-{2-Butyl-3-[4-(3-butylaminopropoxy)benzoyl]benzofuran-5-yl}methanesulfonamide, hydrochloride) | Reference Standard | 197431-02-0 | 25 | mg | VIAL | |
| 1228552 | Dronedarone Related Compound B (20 mg) ((5-Amino-2-butylbenzofuran-3-yl){4-[3-(dibutylamino)propoxy]phenyl}methanone, dihydrochloride) | Reference Standard | 1309476-91-2 | 20 | mg | VIAL | |
| 1228563 | Dronedarone Related Compound C (20 mg) ((5-Amino-2-butylbenzofuran-3-yl)(4-hydroxyphenyl)methanone) | Reference Standard | 1278585-68-4 | 20 | mg | VIAL | |
| 1228574 | Dronedarone Related Compound D (20 mg) ((2-Butyl-5-nitrobenzofuran-3-yl)(4-hydroxyphenyl)methanone) | Reference Standard | 141645-16-1 | 20 | mg | VIAL | |
| 1229001 | Droperidol (250 mg) | Reference Standard | 548-73-2 | 250 | mg | VIAL | |
| 1229409 | Drospirenone (200 mg) | Reference Standard | 67392-87-4 | 200 | mg | VIAL | |
| 1229410 | Drospirenone Related Compound A (15 mg) (17-Hydroxy-6beta,7beta:15beta,16beta-dimethylene-3-oxo-17beta-pregn-4-ene-21-carboxylic acid, gamma-lactone) | Reference Standard | 90457-65-1 | 15 | mg | VIAL | |
| 1229817 | Duloxetine Hydrochloride (100 mg) | Reference Standard | 136434-34-9 | 100 | mg | VIAL | |
| 1229828 | Duloxetine Related Compound A (10 mg) ((R)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1-amine hydrochloride) | Reference Standard | 910138-96-4 | 10 | mg | VIAL | |
| 1229872 | Duloxetine Related Compound F (10 mg) ((S)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-3-yl)propan-1-amine hydrochloride) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1229883 | Duloxetine Related Compound H (30 mg) ((S)-4-(Methyl[3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propyl]amino)-4-oxobutanoic acid) (COLD SHIPMENT REQUIRED) | Reference Standard | 199191-66-7 | 30 | mg | VIAL | |
| 1229922 | Dutasteride (200 mg) | Reference Standard | 164656-23-9 | 200 | mg | VIAL | |
| 1229931 | Dutasteride Resolution Mixture (20 mg) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1230000 | Dyclonine Hydrochloride (200 mg) | Reference Standard | 536-43-6 | 200 | mg | VIAL | |
| 1231003 | Dydrogesterone (200 mg) | Reference Standard | 152-62-5 | 200 | mg | VIAL | |
| 1231502 | Dyphylline (200 mg) | Reference Standard | 479-18-5 | 200 | mg | VIAL | |
| 1231557 | E. Coli Genomic DNA (30 uL) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | N/A | 0.03 | mL | VIAL | |
| 1231615 | Ecamsule Related Compound A (50 mg) (1,4-Phenylenedimethanol) | Reference Standard | 589-29-7 | 50 | mg | VIAL | |
| 1231626 | Ecamsule Related Compound B (50 mg) (4-(Hydroxymethyl)benzoic acid) | Reference Standard | 3006-96-0 | 50 | mg | VIAL | |
| 1231637 | Ecamsule Related Compound C (50 mg) (terephthalic acid) | Reference Standard | 100-21-0 | 50 | mg | VIAL | |
| 1231648 | Ecamsule Related Compound D (50 mg) (((1SR,4RS)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonic acid) | Reference Standard | 5872-08-2 | 50 | mg | VIAL | |
| 1231659 | Ecamsule Related Compound E (25 mg) (sodium ((1SR,4SR,E)-3-(4-(hydroxymethyl)benzylidene)-7,7-dimethyl-2-oxobicyclo[2.2.1]heptan-1-yl)methanesulfonate) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1231660 | Ecamsule Related Compound F (25 mg) (4-((E)-((1SR,4SR)-7,7-dimethyl-3-oxo-4-(sulfomethyl)bicyclo[2.2.1]heptan-2-ylidene)methyl)benzoic acid) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1231681 | Ecamsule Related Compound G (25 mg) (4-((E)-((1SR,4SR)-7,7-dimethyl-3-oxo-4-(sulfomethyl)bicyclo[2.2.1]heptan-2-ylidene)methyl)benzaldehyde, sodium salt) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1231580 | Ecamsule Solution (0.5 mL) | Reference Standard | 92761-26-7 | 0.5 | mL | AMPULE | |
| 1231604 | Ecamsule Triethanolamine (200 mg) | Reference Standard | 92841-53-7 | 200 | mg | VIAL | |
| 1231750 | Echinacoside (15 mg) | Reference Standard | 82854-37-3 | 15 | mg | VIAL | |
| 1231808 | Econazole Nitrate (250 mg) | Reference Standard | 24169-02-6 | 250 | mg | VIAL | |
| 1231830 | Econazole Related Compound A (15 mg) (1-(2,4-Dichlorophenyl)-2-(1H-imidazole-1-yl)ethanol) | Reference Standard | 24155-42-8 | 15 | mg | VIAL | |
| 1231841 | Econazole Related Compound B (15 mg) (2-[(4-Chlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethanamine nitrate) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1231852 | Econazole Related Compound C (15 mg) (1-(4-Chlorobenzyl)-3-[(2RS)-2-[(4-chlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl]imidazolium chloride) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1232006 | Edetate Calcium Disodium (200 mg) | Reference Standard | 6766-87-6 | 200 | mg | VIAL | |
| 1233009 | Edetate Disodium (200 mg) | Reference Standard | 6381-92-6 | 200 | mg | VIAL | |
| 1233508 | Edetic Acid (200 mg) | Reference Standard | 60-00-4 | 200 | mg | VIAL | |
| 1234001 | Edrophonium Chloride (200 mg) | Reference Standard | 116-38-1 | 200 | mg | VIAL | |
| 1234103 | Efavirenz (200 mg) | Reference Standard | 154598-52-4 | 200 | mg | VIAL | |
| 1234114 | Efavirenz Racemic (20 mg) (6-Chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one) | Reference Standard | 177530-93-7 | 20 | mg | VIAL | |
| 1234125 | Efavirenz Related Compound A (20 mg) ((S)-2-(2-amino-5-chlorophenyl)-4-cyclopropyl-1,1,1-trifluorobut-3-yn-2-ol) | Reference Standard | 209414-27-7 | 20 | mg | VIAL | |
| 1234147 | Efavirenz Related Compound B (10 mg) ((S,E)-6-Chloro-4-(2-Cyclopropylvinyl)-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one) | Reference Standard | 440124-96-9 | 10 | mg | VIAL | |
| 1234136 | Efavirenz Related Compound C (20 mg) (6-chloro-2-cyclopropyl-4-(trifluoromethyl)quinoline) | Reference Standard | 391860-73-4 | 20 | mg | VIAL | |
| 1234249 | Eflornithine Hydrochloride (150 mg) | Reference Standard | 96020-91-6 | 150 | mg | | |
| 1234260 | Egeline (10 mg) | Reference Standard | 456-12-2 | 10 | mg | VIAL | |
| 1234293 | Eicosapentaenoic Acid (300 mg) ((5Z,8Z,11Z,14Z,17Z)-Icosa-5,8,11,14,17-pentaenoic acid) | Reference Standard | 10417-94-4 | 300 | mg | AMPULE | |
| 1234307 | Eicosapentaenoic Acid Ethyl Ester (500 mg) (All-cis-5,8,11,14,17-Eicosapentaenoic acid ethyl ester) | Reference Standard | 86227-47-6 | 500 | mg | AMPULE | |
| 1234410 | Elemental Impurities Class 1 and 2A Mixture (120 mL) | Reference Standard | N/A | 120 | mL | BOTTLE | |
| 1234427 | Elemental Impurities Class 2B Mixture (120 mL) | Reference Standard | N/A | 120 | mL | BOTTLE | |
| 1234431 | Elemental Impurities Class 3 Mixture (120 mL) | Reference Standard | N/A | 120 | mL | BOTTLE | |
| 1234453 | Eletriptan Hydrobromide (200 mg) (3-[[(R)-1-Methyl-2-pyrrolidinyl]methyl]-5-[2-(phenylsulfonyl)ethyl]indole monohydrobromide monohydrate) | Reference Standard | 273211-28-2 | 200 | mg | VIAL | |
| 1234475 | Eletriptan Related Compound B (20 mg) ((R)-5-Bromo-3-[(1-methylpyrrolidin-2-yl)methyl]-1H-indole) | Reference Standard | 143322-57-0 | 20 | mg | VIAL | |
| 1234522 | Eletriptan S-Enantiomer (20 mg) ((S)-3-[(1-methylpyrrolidin-2-yl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-indole, monohydrobromide) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1234668 | Eleutheroside B (15 mg) (Syringin) | Reference Standard | 118-34-3 | 15 | mg | VIAL | |
| 1234680 | Eleutheroside E (15 mg) (syringaresinol diglucoside) | Reference Standard | 39432-56-9 | 15 | mg | | |
| 1234806 | Emedastine Difumarate (100 mg) | Reference Standard | 87233-62-3 | 100 | mg | VIAL | |
| 1235004 | Emetine Hydrochloride (300 mg) | Reference Standard | 7083-71-8 | 300 | mg | VIAL | |
| 1235059 | Emodin (30 mg) (1,3,8-trihydroxy-6-methylanthracene-9,10-dione) | Reference Standard | 518-82-1 | 30 | mg | VIAL | |
| 1235106 | Emtricitabine (200 mg) | Reference Standard | 143491-57-0 | 200 | mg | VIAL | |
| 1235128 | Emtricitabine System Suitability Mixture A (15 mg) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1235139 | Emtricitabine System Suitability Mixture B (15 mg) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1235300 | Enalapril Maleate (200 mg) | Reference Standard | 76095-16-4 | 200 | mg | VIAL | |
| 1235332 | Enalapril Related Compound D (25 mg) ((S)-Ethyl 2-[(3S,8aS)-3-methyl-1,4-dioxohexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl]-4-phenylbutanoate) | Reference Standard | 115729-52-7 | 25 | mg | VIAL | |
| 1235365 | Enalapril Related Compound H (25 mg) (1-{N-[(S)-1-Ethoxycarbonyl-3-cyclohexylpropyl]-L-alanyl}-L-proline, maleate (1:1)) | Reference Standard | n/a | 25 | mg | VIAL | |
| 1235274 | Enalaprilat (300 mg) | Reference Standard | 84680-54-6 | 300 | mg | VIAL | |
| 1235398 | Enanthic Acid (100 mg) (Heptanoic Acid) | Reference Standard | 111-14-8 | 100 | mg | AMPULE | |
| 1235503 | Endotoxin (10,000 USP Endotoxin Units) (COLD SHIPMENT REQUIRED) | Reference Standard | N/A | 1 | EA | VIAL | |
| 1235809 | Enflurane (1 mL) | Reference Standard | 13838-16-9 | 1 | mL | AMPULE | |
| 1235820 | Enoxaparin Sodium (300 mg) | Reference Standard | 679809-58-6 | 300 | mg | VIAL | |
| 1235853 | Enoxaparin Sodium Molecular Weight Calibrant A (8.0 mg) | Reference Standard | N/A | 8 | mg | VIAL | |
| 1235864 | Enoxaparin Sodium Molecular Weight Calibrant B (6.0 mg) | Reference Standard | 9041-08-1 | 6 | mg | VIAL | |
| 1235831 | Enoxaparin Sodium for Bioassays (COLD SHIPMENT REQUIRED) | Reference Standard | 9041-08-1 | 1 | ea | AMPULE | |
| 1235900 | Enrofloxacin (200 mg) | Reference Standard | 93106-60-6 | 200 | mg | VIAL | |
| 1235911 | Enrofloxacin Related Compound Mixture (50 mg) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1530809 | Ensulizole (200 mg) (2-phenylbenzimidazole-5-sulfonic acid) | Reference Standard | 27503-81-7 | 200 | mg | VIAL | |
| 1235933 | Entacapone (200 mg) | Reference Standard | 130929-57-6 | 200 | mg | VIAL | |
| 1235944 | Entacapone Related Compound A (25 mg) ((Z)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylacrylamide) | Reference Standard | 145195-63-7 | 25 | mg | VIAL | |
| 1235966 | Entecavir Monohydrate (200 mg) | Reference Standard | 209216-23-9 | 200 | mg | VIAL | |
| 1235977 | Entecavir Related Compound A (15 mg) (9-[(1S,3R,4S)-4-Dimethylphenylsilyl-3-(benzyloxymethyl)-2-methylenecyclopentyl]guanine) | Reference Standard | 649761-24-0 | 15 | mg | VIAL | |
| 1235988 | Entecavir System Suitability Mixture (15 mg) (This is a mixture containing entecavir 1-epimer (0.2%), entecavir (99.6%), 8-hydroxy entecavir (0.1%), and 8-methoxy entecavir (0.1%)) | Reference Standard | 1367369-78-5 | 15 | mg | VIAL | |
| 1235999 | Ephedrine Hydrochloride (200 mg) (List Chemical) | Reference Standard | 50-98-6 | 200 | mg | VIAL | |
| 1236007 | Ephedrine Sulfate (200 mg) (List Chemical) | Reference Standard | 134-72-5 | 200 | mg | VIAL | |
| 1236663 | Epicoprostanol (200 mg) | Reference Standard | 516-92-7 | 200 | mg | VIAL | |
| 1236801 | Epilactose (200 mg) | Reference Standard | 50468-56-9 | 200 | mg | VIAL | |
| 1236889 | Epinastine Hydrochloride (250 mg) | Reference Standard | 108929-04-0 | 250 | mg | VIAL | |
| 1236890 | Epinastine Related Compound A (25 mg) ((6,11-Dihydro-5H-dibenzo[b,e]azepin-6-yl)methanamine fumarate) | Reference Standard | 127785-96-0 | 25 | mg | VIAL | |
| 1236970 | Epinephrine (200 mg) | Reference Standard | 51-43-4 | 200 | mg | VIAL | |
| 1237000 | Epinephrine Bitartrate (200 mg) | Reference Standard | 51-42-3 | 200 | mg | VIAL | |
| 1237382 | Epirubicin Hydrochloride (200 mg) | Reference Standard | 56390-09-1 | 200 | mg | VIAL | |
| 1237509 | Epitetracycline Hydrochloride (250 mg) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | 23313-80-6 | 250 | mg | VIAL | |
| 1237553 | Eplerenone (250 mg) | Reference Standard | 107724-20-9 | 250 | mg | VIAL | |
| 1237611 | Epoprostenol Related Compound A (15 mg) (7-{(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(S,E)-3-hydroxyoct-1-enyl]cyclopentyl}-6-oxoheptanoic acid) (COLD SHIPMENT REQUIRED) | Reference Standard | 58962-34-8 | 15 | mg | VIAL | |
| 1237622 | Epoprostenol Related Compound B (15 mg) (Sodium 5-(diphenylphosphinoyl)pentanoate) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1237600 | Epoprostenol Sodium (100 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 61849-14-7 | 100 | mg | VIAL | |
| 1237752 | Eprinomectin (300 mg) (A mixture of component B1a and component B1b) (COLD SHIPMENT REQUIRED) | Reference Standard | N/A | 300 | mg | VIAL | |
| 1238217 | Eprosartan Mesylate (50 mg) ((E)-2-Butyl-1-(p-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid, monomethanesulfonate) | Reference Standard | 144143-96-4 | 50 | mg | VIAL | |
| 1238228 | Eprosartan Related Compound A (20 mg) ((E)-3-(2-butyl-1H-imidazol-5-yl)-2-(thiophen-2-ylmethyl)acrylic acid hydrochloride) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1238239 | Eprosartan Related Compound B (15 mg) (3-(thiophen-2-yl)propanoic acid) | Reference Standard | 5928-51-8 | 15 | mg | VIAL | |
| 1238240 | Eprosartan Related Compound C (25 mg) (2-(thiophen-2-ylmethyl)malonic acid) | Reference Standard | 4475-24-5 | 25 | mg | VIAL | |
| 1238251 | Eprosartan Related Compound D (15 mg) (4-(bromomethyl)benzoic acid) | Reference Standard | 6232-88-8 | 15 | mg | VIAL | |
| 1238262 | Eprosartan Related Compound E (15 mg) (4-(hydroxymethyl)benzoic acid) | Reference Standard | 3006-96-0 | 15 | mg | VIAL | |
| 1238501 | Eptifibatide | Reference Standard | N/A | | | | |
| 1238002 | Equilin (25 mg) | Reference Standard | 474-86-2 | 25 | mg | VIAL | |
| 1239005 | Ergocalciferol (30 mg/ampule; 5 ampules) (Vitamin D2) | Reference Standard | 50-14-6 | 150 | mg | AMPULE | |
| 1239504 | Ergoloid Mesylates (300 mg) | Reference Standard | 8067-24-1 | 300 | mg | VIAL | |
| 1240004 | Ergonovine Maleate (150 mg) (List Chemical) | Reference Standard | 129-51-1 | 150 | mg | VIAL | |
| 1241007 | Ergosterol (50 mg) | Reference Standard | 57-87-4 | 50 | mg | VIAL | |
| 1241506 | Ergotamine Tartrate (150 mg) (List Chemical) | Reference Standard | 379-79-3 | 150 | mg | VIAL | |
| 1241550 | Ergotaminine (100 mg) | Reference Standard | 639-81-6 | 100 | mg | VIAL | |
| 1241608 | Erlotinib Hydrochloride (150 mg) | Reference Standard | 183319-69-9 | 150 | mg | VIAL | |
| 1241619 | Erlotinib Related Compound A (25 mg) (4-(3-{[6,7-Bis(2-methoxyethoxy) quinazolin-4-yl]amino}phenyl)-2-methyl-3-butyn-2-ol hydrochloride) | Reference Standard | 299912-59-7 | 25 | mg | VIAL | |
| 1241823 | Erythorbic Acid (50 mg) | Reference Standard | 89-65-6 | 50 | mg | VIAL | |
| 1241903 | Erythritol (200 mg) | Reference Standard | 149-32-6 | 200 | mg | VIAL | |
| 1242000 | Erythromycin (250 mg) | Reference Standard | 114-07-8 | 250 | mg | VIAL | |
| 1242010 | Erythromycin B (100 mg) | Reference Standard | 527-75-3 | 100 | mg | VIAL | |
| 1242021 | Erythromycin C (50 mg) | Reference Standard | 1675-02-1 | 50 | mg | VIAL | |
| 1243002 | Erythromycin Estolate (200 mg) | Reference Standard | 3521-62-8 | 200 | mg | VIAL | |
| 1245008 | Erythromycin Ethylsuccinate (200 mg) | Reference Standard | 1264-62-6 | 200 | mg | VIAL | |
| 1246000 | Erythromycin Gluceptate (200 mg) | Reference Standard | 23067-13-2 | 200 | mg | | |
| 1247003 | Erythromycin Lactobionate (200 mg) | Reference Standard | 3847-29-8 | 200 | mg | VIAL | |
| 1242032 | Erythromycin Related Compound N (50 mg) (N-Demethylerythromycin A) | Reference Standard | 992-62-1 | 50 | mg | VIAL | |
| 1248006 | Erythromycin Stearate (200 mg) | Reference Standard | 643-22-1 | 200 | mg | VIAL | |
| 1248218 | Erythropoietin (100 ug) | Reference Standard | 113427-24-0 | 100 | ug | VIAL | |
| 1248200 | Erythropoietin for Bioassays | Reference Standard | 113427-24-0 | 1 | ea | AMPULE | |
| 1249202 | Escin (350 mg) | Reference Standard | 11072-93-8 | 350 | mg | VIAL | |
| 1249406 | Escitalopram Oxalate (200 mg) | Reference Standard | 219861-08-2 | 200 | mg | VIAL | |
| 1249417 | Escitalopram Related Compound A (10 mg) ((S)-4-[4-dimethylamino-1-(4-fluoropheny)-1-hydroxy-1-butyl]-3-hydroxymethylbenzonitrile hemi(+)-di-toluoyltartrate) | Reference Standard | 128173-53-5 | 10 | mg | VIAL | |
| 1249701 | Esmolol Hydrochloride (100 mg) | Reference Standard | 81161-17-3 | 100 | mg | VIAL | |
| 1249789 | Esomeprazole Magnesium (100 mg) | Reference Standard | 217087-09-7 | 100 | mg | VIAL | |
| 1249790 | Esomeprazole Sodium | Reference Standard | 161796-78-7 | | | | |
| 1249803 | Esomeprazole Strontium (20 mg) | Reference Standard | 934714-36-0 | 20 | mg | VIAL | |
| 1249905 | Estazolam CIV (100 mg) | Reference Standard | 29975-16-4 | 100 | mg | VIAL | |
| 1249916 | Estazolam Related Compound A (10 mg) (5-Chloro-2-(3-chloromethyl-4H-1,2,4-triazol-4-yl)-benzophenone) | Reference Standard | 37945-06-5 | 10 | mg | VIAL | |
| 1250008 | Estradiol (500 mg) | Reference Standard | 35380-71-3 | 500 | mg | VIAL | |
| 1251000 | Estradiol Benzoate (250 mg) | Reference Standard | 50-50-0 | 250 | mg | VIAL | |
| 1252003 | Estradiol Cypionate (200 mg) | Reference Standard | 313-06-4 | 200 | mg | VIAL | |
| 1252193 | Estradiol Cypionate System Suitability Mixture (10 mg) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1250020 | Estradiol Related Compound B (10 mg) (1,3,5(10),6-estratetraen-3,17beta-diol) | Reference Standard | 7291-41-0 | 10 | mg | VIAL | |
| 1250041 | Estradiol Related Compound C (15 mg) (1,3,5(10)-estratrien-3,17beta-diol-6-one) | Reference Standard | 571-92-6 | 15 | mg | VIAL | |
| 1254009 | Estradiol Valerate (100 mg) | Reference Standard | 979-32-8 | 100 | mg | VIAL | |
| 1254031 | Estradiol Valerate Identification Mixture (15 mg) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1254508 | Estriol (100 mg) | Reference Standard | 50-27-1 | 100 | mg | VIAL | |
| 1254519 | Estriol Related Compound A (25 mg) (Estra-1,3,5(10),9(11)-tetraene-3,16alpha,17Beta-triol) | Reference Standard | 246021-20-5 | 25 | mg | VIAL | |
| 1255001 | Estrone (200 mg) | Reference Standard | 53-16-7 | 200 | mg | VIAL | |
| 1255500 | Estropipate (500 mg) | Reference Standard | 7280-37-7 | 500 | mg | VIAL | |
| 1255850 | Eszopiclone CIV (100 mg) | Reference Standard | 138729-47-2 | 100 | mg | VIAL | |
| 1255861 | Eszopiclone Related Compound A (10 mg) (6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo [3,4,b] pyrazin-5-yl 4-methylpiperazine-1-carboxylate 4-oxide) | Reference Standard | 43200-96-0 | 10 | mg | VIAL | |
| 1256004 | Ethacrynic Acid (200 mg) | Reference Standard | 58-54-8 | 200 | mg | VIAL | |
| 1256015 | Ethacrynic Acid Related Compound A (25 mg) ((4-Butyryl-2,3-dichlorophenoxy)acetic acid) | Reference Standard | 1217-67-0 | 25 | mg | VIAL | |
| 1257007 | Ethambutol Hydrochloride (200 mg) | Reference Standard | 1070-11-7 | 200 | mg | VIAL | |
| 1257018 | Ethambutol Related Compound A (15 mg) ((2R,2'S)-2,2'-[ethane-1,2-diylbis(azanediyl)]dibutan-1-ol)dihydrochloride) | Reference Standard | 32454-69-6 | 15 | mg | VIAL | |
| 1257029 | Ethambutol Related Compound B (15 mg) (((2R,2'R)-2,2'-[Ethane-1,2-diylbis(azanediyl)]dibutan-1-ol) dihydrochloride) | Reference Standard | 134566-79-3 | 15 | mg | VIAL | |
| 1258305 | Ethchlorvynol CIV (0.7 mL) | Reference Standard | 113-18-8 | 0.7 | mL | AMPULE | |
| 1260001 | Ethinyl Estradiol (150 mg) | Reference Standard | 57-63-6 | 150 | mg | VIAL | |
| 1260012 | Ethinyl Estradiol Related Compound A (20 mg) (19-Nor-17alpha-pregna-1,3,5(10)-trien-20-yne-3,17-diol-6-one) | Reference Standard | 38002-18-5 | 20 | mg | VIAL | |
| 1260023 | Ethinyl Estradiol Related Compound B (20 mg) (19-Nor-17alpha-pregna-1,3,5(10),9(11)-tetraen-20-yne-3,17-diol monohydrate) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1261004 | Ethionamide (200 mg) | Reference Standard | 536-33-4 | 200 | mg | VIAL | |
| 1261117 | Ethisterone (50 mg) | Reference Standard | 434-03-7 | 50 | mg | VIAL | |
| 1262801 | Ethopabate (125 mg) | Reference Standard | 59-06-3 | 125 | mg | VIAL | |
| 1262823 | Ethopabate Related Compound A (25 mg) (Methyl-4-acetamido-2-hydroxybenzoate) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1264002 | Ethosuximide (500 mg) | Reference Standard | 77-67-8 | 500 | mg | VIAL | |
| 1264013 | Ethosuximide Related Compound A (50 mg) (2-Ethyl-2-methylsuccinic acid) | Reference Standard | 631-31-2 | 50 | mg | VIAL | |
| 1264501 | Ethotoin (500 mg) | Reference Standard | 86-35-1 | 500 | mg | VIAL | |
| 1021077 | Ethyl 3-Aminocrotonate (2 x 200 mg) (Ethyl (Z)-3-aminobut-2-enoate) | Reference Standard | 626-34-6 | 400 | mg | AMPULE | |
| 1265300 | Ethyl 4-nitrobenzoate (40 mg) | Reference Standard | 99-77-4 | 40 | mg | VIAL | |
| 1265402 | Ethyl Acetate (1.2 mL/ampule; 3 ampules) | Reference Standard | 141-78-6 | 3.6 | mL | AMPULE | |
| 1265424 | Ethyl Acrylate and Methyl Methacrylate Copolymer Dispersion (1.5 g) (Poly(ethyl acrylate-co-methyl methacrylate)) | Reference Standard | N/A | 1.5 | g | AMPULE | |
| 1265606 | Ethyl Formate (1.2 mL/ampule; 3 ampules) | Reference Standard | 109-94-4 | 3.6 | mL | AMPULE | |
| 1265752 | Ethyl Laurate (500 mg) | Reference Standard | 106-33-2 | 500 | mg | AMPULE | |
| 1265800 | Ethyl Lauroyl Arginate (200 mg) | Reference Standard | 60372-77-2 | 200 | mg | VIAL | |
| 1265843 | Ethyl Linoleate (1 mL) | Reference Standard | 544-35-4 | 1 | mL | AMPULE | |
| 1266008 | Ethyl Maltol (1 g) | Reference Standard | 4940-11-8 | 1 | g | VIAL | |
| 1266609 | Ethyl Oleate (1 mL) | Reference Standard | 111-62-6 | 1 | mL | AMPULE | |
| 1266868 | Ethyl Palmitate (500 mg) | Reference Standard | 628-97-7 | 500 | mg | VIAL | |
| 1267102 | Ethyl Stearate (100 mg) | Reference Standard | 111-61-5 | 100 | mg | VIAL | |
| 1267500 | Ethyl Vanillin (200 mg) | Reference Standard | 121-32-4 | 200 | mg | VIAL | |
| 1265457 | Ethylbenzene (0.5 mL/ampule; 3 ampules) | Reference Standard | 100-41-4 | 1.5 | mL | AMPULE | |
| 1265504 | Ethylcellulose (1 g) | Reference Standard | 9004-57-3 | 1 | g | VIAL | |
| 1265515 | Ethylene Glycol (0.5 mL) | Reference Standard | 107-21-1 | 0.5 | mL | AMPULE | |
| 1265592 | Ethylene Glycol and Vinyl Alcohol Graft Copolymer (1 g) | Reference Standard | 121786-16-1 | 1 | g | VIAL | |
| 1265537 | Ethylhexyl Triazone (200 mg) | Reference Standard | 88122-99-0 | 200 | mg | VIAL | |
| 1265548 | Ethylhexyl Triazone Related Compound A (20 mg) (2-ethylhexyl 4-aminobenzoate) | Reference Standard | 26218-04-2 | 20 | mg | VIAL | |
| 1265559 | Ethylhexyl Triazone Related Compound B (20 mg) (4-[(4,6-Bis[(4-{[(2-ethylhexyl)oxy]carbonyl}phenyl)amino]-1,3,5-triazin-2-yl)amino]benzoic acid) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1265560 | Ethylhexyl Triazone Related Compound C (20 mg) (Bis(2-ethylhexyl) 4,4'-[(6-{[4-(ethoxycarbonyl)phenyl]amino}-1,3,5-triazine-2,4-diyl)bis(azanediyl)]dibenzoate) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1267000 | Ethylparaben (200 mg) | Reference Standard | 120-47-8 | 200 | mg | VIAL | |
| 1A00360 | Ethylpyrazinediethanol (10 mg) (2,2'-(3-ethylpyrazine-2,5-diyl)bis(ethan-1-ol)) | Pharmaceutical Analytical Impurity | 86917-74-0 | 10 | mg | VIAL | |
| 1268003 | Ethynodiol Diacetate (200 mg) | Reference Standard | 297-76-7 | 200 | mg | VIAL | |
| 1268502 | Etidronate Disodium (200 mg) | Reference Standard | 7414-83-7 | 200 | mg | VIAL | |
| 1268513 | Etidronate Disodium Related Compound A (300 mg) (Sodium phosphite dibasic pentahydrate) | Reference Standard | 13517-23-2 | 300 | mg | VIAL | |
| 1268604 | Etidronic Acid Monohydrate (1 g) | Reference Standard | 25211-86-3 | 1 | g | VIAL | |
| 1268706 | Etodolac (400 mg) | Reference Standard | 41340-25-4 | 400 | mg | VIAL | |
| 1268892 | Etodolac Peak Identification Mixture (15 mg) | Reference Standard | MIXTURE | 15 | mg | VIAL | |
| 1268728 | Etodolac Related Compound A (25 mg) ((+/-)-8-Ethyl-1-methyl-1,3,4,9-tetrahydropyrano [3,4-b]-indole-1-acetic acid) | Reference Standard | 109518-50-5 | 25 | mg | VIAL | |
| 1268750 | Etomidate (200 mg) | Reference Standard | 33125-97-2 | 200 | mg | VIAL | |
| 1268783 | Etonogestrel (100 mg) | Reference Standard | 54048-10-1 | 100 | mg | VIAL | |
| 1268794 | Etonogestrel Related Compound A (10 mg) (13Beta-Ethyl-11-methylenegon-4-ene-3,17-dione) | Reference Standard | 54024-17-8 | 10 | mg | VIAL | |
| 1268839 | Etonogestrel Related Compound B (10 mg) (13-Ethyl-6Beta,17Beta-dihydroxy-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one) | Reference Standard | 215252-94-1 | 10 | mg | VIAL | |
| 1268841 | Etonogestrel Related Compound C (10 mg) (13-Ethyl-17Beta-hydroxy-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-3,6-dione) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1268943 | Etonogestrel Related Compound D (10 mg) (17Beta-Hydroxy-11-methylene-19-nor-17alpha-pregn-4-en-20-yn-3-one) | Reference Standard | 54024-10-1 | 10 | mg | VIAL | |
| 1268954 | Etonogestrel Related Compound E | Reference Standard | N/A | | | | |
| 1268808 | Etoposide (300 mg) | Reference Standard | 33419-42-0 | 300 | mg | VIAL | |
| 1268819 | Etoposide Phosphate (200 mg) | Reference Standard | 117091-64-2 | 200 | mg | VIAL | |
| 1268852 | Etoposide Resolution Mixture (30 mg) | Reference Standard | 33419-42-0 | 30 | mg | VIAL | |
| 1266824 | Etravirine (100 mg) | Reference Standard | 269055-15-4 | 100 | mg | VIAL | |
| 1268900 | Eucalyptol (200 mg) | Reference Standard | 470-82-6 | 200 | mg | AMPULE | |
| 1268919 | Eucalyptus Oil (1 g) | Reference Standard | 8000-48-4 | 1 | g | AMPULE | |
| 1268965 | Eugenol (5 x 100 mg) | Reference Standard | 97-53-0 | 500 | mg | AMPULE | |
| 1234340 | European Elder Berry Dry Extract (1 g) | Reference Standard | N/A | 1 | g | VIAL | |
| 1269017 | Evening Primrose Oil (1 g) | Reference Standard | 308064-97-3 | 1 | g | AMPULE | |
| 1268976 | Everolimus (300 mg) | Reference Standard | 159351-69-6 | 300 | mg | VIAL | |
| 1268987 | Everolimus System Suitability Mixture (25 mg) | Reference Standard | N/A | 25 | mg | | |
| 1269050 | Exemestane (150 mg) | Reference Standard | 107868-30-4 | 150 | mg | VIAL | |
| 1269061 | Exemestane Related Compound A (15 mg) (6-Methyleneandrosta-4-ene-3,17-dione) | Reference Standard | 19457-55-7 | 15 | mg | VIAL | |
| 1269072 | Exemestane Related Compound B (15 mg) (6-hydroxymethylandrostra-1,4-diene-3,17-dione) | Reference Standard | 184972-09-6 | 15 | mg | VIAL | |
| 1269083 | Exemestane Related Compound C CIII (15 mg) (androsta-1,4-diene-3,17-dione) | Reference Standard | 897-06-3 | 15 | mg | VIAL | |
| 1269094 | Exemestane System Suitability Mixture (25 mg) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1269105 | Exenatide (2.73 mg) | Reference Standard | 141758-74-9 | 2.73 | mg | VIAL | |
| 1090014 | Exo-tetrahydrocannabinol (1 mL) | Reference Standard | N/A | 1 | mL | AMPULE | |
| 1269028 | Ezetimibe (250 mg) | Reference Standard | 163222-33-1 | 250 | mg | VIAL | |
| 1269039 | Ezetimibe System Suitability Mixture (20 mg) | Reference Standard | Mixture | 20 | mg | VIAL | |
| 1269119 | FAME Standard Mixture (100 mg) (A mixture of 25 Fatty Acid Methyl Esters) | Reference Standard | N/A | 100 | mg | AMPULE | |
| 1269152 | Famciclovir (200 mg) | Reference Standard | 104227-87-4 | 200 | mg | VIAL | |
| 1269174 | Famciclovir Related Compound A (20 mg) (2-[2-(2-Amino-9H-purin-9-yl)ethyl]propane-1,3-diol] hydrochloride) | Reference Standard | 246021-75-0; 104227-86-3 (base | 20 | mg | VIAL | |
| 1269185 | Famciclovir Related Compound B (20 mg) [4-(2-Amino-9H-purin-9-yl)-2-(hydroxymethyl)butyl acetate] | Reference Standard | 104227-88-5 | 20 | mg | VIAL | |
| 1269196 | Famciclovir Related Compound C (20 mg) (4-(2-amino-9H-purin-9-yl)-2-methylbutyl acetate) | Reference Standard | 174155-70-5 | 20 | mg | VIAL | |
| 1269130 | Famciclovir Related Compound E (25 mg) (2-aminopurine) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1269141 | Famciclovir Related Compound F (25 mg) (2-Amino-6-chloropurine) | Reference Standard | 10310-21-1 | 25 | mg | VIAL | |
| 1269163 | Famciclovir System Suitability Mixture (20 mg) (Mixture of Famciclovir, Propionyl famciclovir and 6-Chloro famciclovir) | Reference Standard | N/A | 20 | mg | | |
| 1269200 | Famotidine (125 mg) | Reference Standard | 76824-35-6 | 125 | mg | VIAL | |
| 1269221 | Famotidine Related Compound B (25 mg) (3,5-Bis[2-[[2-[(diaminomethylene)amino]thiazol-4-yl]methylthio]ethyl]-4H-1,2,4,6-thiatriazine 1,1-dioxide) | Reference Standard | 89268-62-2 | 25 | mg | VIAL | |
| 1269232 | Famotidine Related Compound C (25 mg) (3-[[2-(Diaminomethyleneamino)thiazol-4-yl]methylthio]-N-sulfamoylpropanamide hydrochloride) | Reference Standard | 76824-17-4 | 25 | mg | VIAL | |
| 1269243 | Famotidine Related Compound D (25 mg) (3-[[2-(diaminomethyleneamino)thiazol-4-yl]methylthio]propanamide) | Reference Standard | 76824-16-3 | 25 | mg | VIAL | |
| 1269254 | Famotidine Related Compound E (25 mg) (2,2'-[4,4'-disulfanediylbis(methylene)bis(thiazole-4,2-diyl)]diguanidine) | Reference Standard | 129083-44-9 | 25 | mg | VIAL | |
| 1269265 | Famotidine Related Compound F (25 mg) (3-[[2-(diaminomethyleneamino)thiazol-4-yl]methylthio]propanoic acid) | Reference Standard | 107880-74-0 | 25 | mg | VIAL | |
| 1269356 | Febantel (200 mg) | Reference Standard | 58306-30-2 | 200 | mg | VIAL | |
| 1269367 | Febantel Related Compound A (15 mg) (Methyl [[2-[(methoxyacetyl)amino]-4-(phenylthio)phenyl]carbamimidoyl]carbamate) | Reference Standard | 92088-58-9 | 15 | mg | VIAL | |
| 1269378 | Febantel Related Compound B (15 mg) (2-(Methoxymethyl)-5-(phenylthio)-1H-benzimidazole) | Reference Standard | 92114-71-1 | 15 | mg | VIAL | |
| 1269312 | Felbamate (250 mg) | Reference Standard | 25451-15-4 | 250 | mg | VIAL | |
| 1269323 | Felbamate Related Compound A (25 mg) (3-Hydroxy-2-phenylpropyl carbamate) | Reference Standard | 25451-53-0 | 25 | mg | VIAL | |
| 1269334 | Felbamate Related Compound B (25 mg) (Phenethyl carbamate) | Reference Standard | 6326-19-8 | 25 | mg | VIAL | |
| 1269389 | Felodipine (300 mg) | Reference Standard | 72509-76-3 | 300 | mg | VIAL | |
| 1269390 | Felodipine Related Compound A (15 mg) (3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethylpyridine-3,5-dicarboxylate) | Reference Standard | 96382-71-7 | 15 | mg | VIAL | |
| 1269403 | Fenbendazole (100 mg) | Reference Standard | 43210-67-9 | 100 | mg | VIAL | |
| 1269414 | Fenbendazole Related Compound A (30 mg) (Methyl (1H-benzimidazole-2-yl)carbamate) | Reference Standard | 10605-21-7 | 30 | mg | VIAL | |
| 1269425 | Fenbendazole Related Compound B (30 mg) (Methyl [5(6)-chlorobenzimidazole-2-yl]carbamate) | Reference Standard | 20367-38-8 | 30 | mg | VIAL | |
| 1269447 | Fenofibrate (200 mg) | Reference Standard | 49562-28-9 | 200 | mg | VIAL | |
| 1269607 | Fenofibrate Related Compound A (25 mg) ((4-Chlorophenyl)(4-hydroxyphenyl)methanone) | Reference Standard | 42019-78-3 | 25 | mg | VIAL | |
| 1269618 | Fenofibrate Related Compound B (25 mg) (2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoic acid) | Reference Standard | 42017-89-0 | 25 | mg | VIAL | |
| 1269629 | Fenofibrate Related Compound C (25 mg) (1-methylethyl 2-[[2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoyl]oxy]-2-methylpropanoate) | Reference Standard | 217636-48-1 | 25 | mg | VIAL | |
| 1269436 | Fenofibric Acid (250 mg) (2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid) | Reference Standard | 42017-89-0 | 250 | mg | VIAL | |
| 1269458 | Fenoldopam Mesylate (200 mg) | Reference Standard | 67227-57-0 | 200 | mg | VIAL | |
| 1269469 | Fenoldopam Related Compound A (20 mg) (N-Methyl-6-chloro-2,3,4,5-tetrahydro-1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol hydrochloride) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1269470 | Fenoldopam Related Compound B (20 mg) (1-(4-Hydroxyphenyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7,8-diol methanesulfonate) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1269505 | Fenoprofen Calcium (500 mg) | Reference Standard | 71720-56-4 | 500 | mg | VIAL | |
| 1269550 | Fenoprofen Sodium (500 mg) | Reference Standard | 66424-46-2 | 500 | mg | | |
| 1269902 | Fentanyl CII (100 mg) | Reference Standard | 437-38-7 | 100 | mg | VIAL | |
| 1270005 | Fentanyl Citrate CII (100 mg) | Reference Standard | 990-73-8 | 100 | mg | VIAL | |
| 1269913 | Fentanyl Related Compound A (100 mg) ((2-bromoethyl)benzene) | Reference Standard | 103-63-9 | 100 | mg | AMPULE | |
| 1269924 | Fentanyl Related Compound B (10 mg) (4-Anilinopiperidine) | Reference Standard | 23056-29-3 | 10 | mg | VIAL | |
| 1269946 | Fentanyl Related Compound D (10 mg) (N-Phenyl-1-(phenylmethyl)-4-piperidinamine) | Reference Standard | 1155-56-2 | 10 | mg | VIAL | |
| 1269957 | Fentanyl Related Compound E CII (10 mg) (N-Phenyl-1-(2-phenylethyl)-4-piperidinamine) | Reference Standard | 21409-26-7 | 10 | mg | VIAL | |
| 1269979 | Fentanyl Related Compound G CI (10 mg) (N-(1-Phenethylpiperidin-4-yl)-N-phenylacetamide) | Reference Standard | 3258-84-2 | 10 | mg | VIAL | |
| 1270355 | Ferrous Sulfate (2 x 1 g) | Reference Standard | 7782-63-0 | 2 | g | VIAL | |
| 1270311 | Ferulic Acid (25 mg) ((E)-3-(4-hydroxy-3-methoxyphenyl)acrylic acid) | Reference Standard | 537-98-4 | 25 | mg | VIAL | |
| 1270548 | Fetal Bovine Serum (10 mL) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | N/A | 10 | mL | VIAL | |
| 1270363 | Fexofenadine (200 mg) (2-(4-{1-Hydroxy-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl}phenyl)-2-methylpropanoic acid dihydrate) | Reference Standard | 885946-90-7 | 200 | mg | VIAL | |
| 1270377 | Fexofenadine Hydrochloride (200 mg) | Reference Standard | 153439-40-8 | 200 | mg | VIAL | |
| 1A00731 | Fexofenadine Olefin (25 mg) (2-(4-(4-(4-(diphenylmethylene)piperidin-1-yl)-1-hydroxybutyl)phenyl)-2-methylpropanoic acid) | Pharmaceutical Analytical Impurity | 1187954-57-9 | 25 | mg | VIAL | |
| 1270388 | Fexofenadine Related Compound A (25 mg) (2-(4-{4-[4-(Hydroxydiphenylmethyl)piperidin-1-yl]butanoyl}phenyl)-2-methylpropanoic acid) | Reference Standard | 76811-98-8 | 25 | mg | VIAL | |
| 1270399 | Fexofenadine Related Compound B (25 mg) (2-(3-{1-Hydroxy-4-[4-(hydroxydiphenylmethyl)piperidin-1-yl]butyl}phenyl)-2-methylpropanoic acid hydrochloride monohydrate) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1270446 | Fexofenadine Related Compound C (25 mg) ((+/-)-4-[1-hydroxy-4-[4-(hydroxydiphenylmethyl)-1-piperidinyl]-butyl]-isopropylbenzene hydrochloride) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1270537 | Filgrastim System Suitability (COLD SHIPMENT REQUIRED) (1 mg) | Reference Standard | 121181-53-1 | 1 | mg | AMPULE | |
| 1270468 | Filgrastim for Bioassay (96,815 IU) (COLD SHIPMENT REQUIRED) | Reference Standard | 121181-53-1 | 1 | ea | AMPULE | |
| 1270402 | Finasteride (200 mg) | Reference Standard | 98319-26-7 | 200 | mg | VIAL | |
| 1270480 | Fingolimod Hydrochloride (300 mg) | Reference Standard | 162359-56-0 | 300 | mg | VIAL | |
| 1270526 | Fingolimod System Suitability Mixture (40 mg) | Reference Standard | N/A | 40 | mg | VIAL | |
| 1270424 | Fish Oil (1 g) | Reference Standard | 8016-13-5 | 1 | g | AMPULE | |
| 1270708 | Flavoxate Hydrochloride (200 mg) | Reference Standard | 3717-88-2 | 200 | mg | VIAL | |
| 1270719 | Flavoxate Related Compound A (25 mg) (3-methylflavone-8-carboxylic acid) | Reference Standard | 3468-01-7 | 25 | mg | VIAL | |
| 1270720 | Flavoxate Related Compound B (20 mg) (3-Methylflavone-8-carboxylic acid methyl ester) | Reference Standard | 90101-87-4 | 20 | mg | VIAL | |
| 1270731 | Flavoxate Related Compound C (20 mg) (3-Methylflavone-8-carboxylic acid ethyl ester) | Reference Standard | 35888-94-9 | 20 | mg | VIAL | |
| 1270774 | Flax Seed Oil (1 g) | Reference Standard | 8001-26-1 | 1 | g | AMPULE | |
| 1270800 | Flecainide Acetate (200 mg) | Reference Standard | 54143-56-5 | 200 | mg | VIAL | |
| 1270821 | Flecainide Related Compound A (75 mg) (3-[2,5-Bis(2,2,2-trifluoroethoxy)phenyl]-1,5,6,7,8,8alpha-hexahydroimidazo-[1,5alpha]pyridine hydrochloride) | Reference Standard | N/A | 75 | mg | VIAL | |
| 1271008 | Floxuridine (250 mg) | Reference Standard | 50-91-9 | 250 | mg | VIAL | |
| 1271700 | Fluconazole (200 mg) | Reference Standard | 86386-73-4 | 200 | mg | VIAL | |
| 1271711 | Fluconazole Related Compound A (10 mg) (2-[2-fluoro-4-(1H-1,2,4-triazol-1-yl)phenyl]-1,3-bis(1H-1,2,4-triazol-1-yl)-propan-2-ol) | Reference Standard | 871550-15-1 | 10 | mg | VIAL | |
| 1271722 | Fluconazole Related Compound B (10 mg) (2-(4-fluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)-propan-2-ol) | Reference Standard | 81886-51-3 | 10 | mg | VIAL | |
| 1271733 | Fluconazole Related Compound C (10 mg) (1,1'-(1,3-phenylene)di(1H-1,2,4-triazole)) | Reference Standard | 514222-44-7 | 10 | mg | VIAL | |
| 1272000 | Flucytosine (200 mg) | Reference Standard | 2022-85-7 | 200 | mg | VIAL | |
| 1272204 | Fludarabine Phosphate (300 mg) | Reference Standard | 75607-67-9 | 300 | mg | VIAL | |
| 1272907 | Fludeoxyglucose (100 mg) | Reference Standard | 29702-43-0 | 100 | mg | VIAL | |
| 1272918 | Fludeoxyglucose Related Compound A (15 mg) (4,7,13,16,21,24-hexaoxa-1,10-diazabicyclo[8.8.8]hexacosane) | Reference Standard | 23978-09-8 | 15 | mg | | |
| 1272929 | Fludeoxyglucose Related Compound B (10 mg) (2-chloro-2-deoxy-D-glucose) | Reference Standard | 14685-79-1 | 10 | mg | | |
| 1273003 | Fludrocortisone Acetate (200 mg) | Reference Standard | 514-36-3 | 200 | mg | VIAL | |
| 1273808 | Flumazenil (200 mg) | Reference Standard | 78755-81-4 | 200 | mg | VIAL | |
| 1273819 | Flumazenil Related Compound A (20 mg) (8-Fluoro-5-methyl-6-oxo-5,6-dihydro-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylic acid) | Reference Standard | 84378-44-9 | 20 | mg | VIAL | |
| 1273820 | Flumazenil Related Compound B (20 mg) (Ethyl 8-hydroxy-5,6-dihydro-5-methyl-6-oxo-4H-imidazol-[1,5-a][1,4]benzodiazepine-3-carboxylate) | Reference Standard | 131666-45-0 | 20 | mg | VIAL | |
| 1273841 | Flumazenil Related Compound C (500 mg) (N,N-Dimethylformamide diethyl acetal) | Reference Standard | 1188-33-6 | 500 | mg | AMPULE | |
| 1274505 | Flunisolide (200 mg) | Reference Standard | 77326-96-6 | 200 | mg | | |
| 1274607 | Flunixin Meglumine (300 mg) | Reference Standard | 42461-84-7 | 300 | mg | VIAL | |
| 1274629 | Flunixin Related Compound A (15 mg) (2-Chloronicotinic acid) | Reference Standard | 2942-59-8 | 15 | mg | VIAL | |
| 1274630 | Flunixin Related Compound B (25 mg) (2-Methyl-3-(trifluoromethyl)aniline) | Reference Standard | 54396-44-0 | 25 | mg | VIAL | |
| 1274631 | Flunixin Related Compound C (50 mg) (Ethyl 2-chloronicotinate) | Reference Standard | 1452-94-4 | 50 | mg | AMPULE | |
| 1275009 | Fluocinolone Acetonide (200 mg) | Reference Standard | 67-73-2 | 200 | mg | VIAL | |
| 1276001 | Fluocinonide (200 mg) | Reference Standard | 356-12-7 | 200 | mg | VIAL | |
| 1277004 | Fluorescein (200 mg) | Reference Standard | 2321-07-5 | 200 | mg | VIAL | |
| 1277037 | Fluorescein Related Compound C (25 mg) (2-(2,4-Dihydroxybenzoyl)benzoic acid) | Reference Standard | 2513-33-9 | 25 | mg | VIAL | |
| 1277252 | Fluoride Dentifrice: Sodium Fluoride/Silica (4.6 oz) | Reference Standard | N/A | 4.6 | oz | OTHER | |
| 1277274 | Fluoride Dentifrice: Sodium Fluoride/Sodium Bicarbonate Powder (4 oz) | Reference Standard | N/A | 4 | oz | OTHER | |
| 1277401 | Fluoride Dentifrice: Sodium Monofluorophosphate (1000 ppm)/Silica (5.25 oz) | Reference Standard | N/A | 5.25 | oz | | |
| 1277423 | Fluoride Dentifrice: Sodium Monofluorophosphate (1500 ppm)/Silica (5.25 oz) | Reference Standard | N/A | 5.25 | oz | OTHER | |
| 1277300 | Fluoride Dentifrice: Sodium Monofluorophosphate-Calcium Carbonate (4.6 oz) | Reference Standard | N/A | 4.6 | oz | | |
| 1277354 | Fluoride Dentifrice: Sodium Monofluorophosphate/Dicalcium Phosphate (4.6 oz) | Reference Standard | N/A | 4.6 | oz | OTHER | |
| 1277456 | Fluoride Dentifrice: Stannous Fluoride-Silica (4 oz) | Reference Standard | N/A | 4 | oz | OTHER | |
| 1A00120 | Fluoroandrostadiene Carboxylic Acid (25 mg) ((8S,9R,10S,11S,13S,14S,16R,17R)-9-fluoro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-17-carboxylic acid) | Pharmaceutical Analytical Impurity | 37927-01-8 | 25 | mg | VIAL | |
| 1278007 | Fluorometholone (200 mg) | Reference Standard | 426-13-1 | 200 | mg | VIAL | |
| 1278109 | Fluorometholone Acetate (200 mg) | Reference Standard | 3801-06-7 | 200 | mg | VIAL | |
| 1278018 | Fluorometholone Related Compound A (15 mg) (11Beta,17alpha-Dihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione) | Reference Standard | 6870-94-6 | 15 | mg | VIAL | |
| 1278302 | Fluoroquinolonic Acid (150 mg) | Reference Standard | 86393-33-1 | 150 | mg | VIAL | |
| 1279000 | Fluorouracil (250 mg) | Reference Standard | 51-21-8 | 250 | mg | | |
| 1279019 | Fluorouracil Related Compound A (25 mg) (Pyrimidine-2,4,6(1H,3H,5H)-trione) | Reference Standard | 67-52-7 | 25 | mg | VIAL | |
| 1279021 | Fluorouracil Related Compound B (25 mg) (Dihydropyrimidine-2,4,5(3H)-trione) | Reference Standard | 496-76-4 | 25 | mg | VIAL | |
| 1279054 | Fluorouracil Related Compound E (25 mg) (5-Chloropyrimidine-2,4(1H,3H)-dione) | Reference Standard | 1820-81-1 | 25 | mg | VIAL | |
| 1279065 | Fluorouracil Related Compound F (25 mg) (2-Ethoxy-5-fluoropyrimidin-4(1H)-one) | Reference Standard | 56177-80-1 | 25 | mg | VIAL | |
| 1279804 | Fluoxetine Hydrochloride (200 mg) | Reference Standard | 56296-78-7 | 200 | mg | VIAL | |
| 1279815 | Fluoxetine Related Compound A (15 mg) (N-methyl-3-phenyl-3-[(alpha, alpha, alpha-trifluoro-m-tolyl)oxy]propylamine hydrochloride) | Reference Standard | 79088-29-2 | 15 | mg | VIAL | |
| 1279826 | Fluoxetine Related Compound B (5 mL of a 0.01N HCl Solution, approx. 2 mg/mL) (N-Methyl-3-phenylpropan-1-amine) | Reference Standard | 23580-89-4 | 5 | mL | AMPULE | |
| 1279837 | Fluoxetine Related Compound C (15 mg) (4-(methyl{3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl}amino)-4-oxobutanoic acid) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1280009 | Fluoxymesterone CIII (200 mg) | Reference Standard | 76-43-7 | 200 | mg | VIAL | |
| 1280803 | Fluphenazine Decanoate Dihydrochloride (300 mg) | Reference Standard | 2376-65-0 | 300 | mg | | |
| 1281001 | Fluphenazine Enanthate Dihydrochloride (125 mg) | Reference Standard | 3105-68-8 | 125 | mg | VIAL | |
| 1282004 | Fluphenazine Hydrochloride (125 mg) | Reference Standard | 146-56-5 | 125 | mg | VIAL | |
| 1282015 | Fluphenazine Related Compound A (50 mg) (10-{3-[4-(2-Hydroxyethyl)piperazin-1-yl]propyl}-2-(trifluoromethyl)-10H-phenothiazine 5-oxide) | Reference Standard | Free base: 1674-76-6 | 50 | mg | VIAL | |
| 1282026 | Fluphenazine Related Compound B (50 mg) (10-{3-[4-(2-Hydroxyethyl)piperazin-1-yl]propyl}-2-(trifluoromethyl)-10H-phenothiazine 5,5-dioxide) | Reference Standard | 1476-79-5 | 50 | mg | VIAL | |
| 1284000 | Flurandrenolide (100 mg) | Reference Standard | 1524-88-5 | 100 | mg | VIAL | |
| 1285002 | Flurazepam Hydrochloride CIV (200 mg) | Reference Standard | 1172-18-5 | 200 | mg | VIAL | |
| 1285308 | Flurazepam Related Compound C (50 mg) (5-chloro-2-(2-diethylaminoethylamino)-2'-fluorobenzophenone hydrochloride) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1285603 | Flurazepam Related Compound F (50 mg) (7-chloro-5-(2-fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepin-2-one) | Reference Standard | 2886-65-9 | 50 | mg | VIAL | |
| 1285750 | Flurbiprofen (200 mg) | Reference Standard | 5104-49-4 | 200 | mg | | |
| 1285760 | Flurbiprofen Related Compound A (100 mg) (2-(4-Biphenylyl)propionic Acid) | Reference Standard | 6341-72-6 | 100 | mg | VIAL | |
| 1285807 | Flurbiprofen Sodium (200 mg) | Reference Standard | 56767-76-1 | 200 | mg | VIAL | |
| 1285851 | Flutamide (200 mg) | Reference Standard | 13311-84-7 | 200 | mg | VIAL | |
| 1285997 | Flutamide Related Compound A (20 mg) (4-nitro-3-(trifluoromethyl)aniline) | Reference Standard | 393-11-3 | 20 | mg | VIAL | |
| 1285986 | Flutamide Related Compound B (20 mg) (N-[4-nitro-3-(trifluoromethyl)phenyl]acetamide) | Reference Standard | 393-12-4 | 20 | mg | VIAL | |
| 1285873 | Fluticasone Propionate (100 mg) | Reference Standard | 80474-14-2 | 100 | mg | VIAL | |
| 1285910 | Fluticasone Propionate Nasal Spray Resolution Mixture (25 mg) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1285829 | Fluticasone Propionate Related Compound D (15 mg) (S-methyl 6alpha, 9alpha-difluoro-11beta-hydroxy-16alpha-methyl-3-oxo-17alpha-propionyloxyandrosta-1,4-diene-17beta-carbothioate) | Reference Standard | 73205-13-7 | 15 | mg | VIAL | |
| 1285818 | Fluticasone Propionate Related Compound J (15 mg) (6alpha, 9alpha-difluoro-11beta,17alpha-dihydroxy-16alpha-methyl-3-oxoandrosta-1,4-diene-17beta-carboxylic acid) | Reference Standard | 28416-82-2 | 15 | mg | VIAL | |
| 1285840 | Fluticasone Propionate Related Compounds Mixture (25 mg) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1285884 | Fluticasone Propionate Resolution Mixture (25 mg) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1285895 | Fluticasone Propionate System Suitability Mixture (25 mg) (Fluticasone Propionate and Fluticasone Propionate Related Compounds B, C and D) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1285964 | Fluvastatin Related Compound B (15 mg) ([R*,S*-E]-(+/-)-7-[3-(4-fluorophenyl)-1-methylethyl-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid 1,1, dimethylethyl ester) | Reference Standard | 129332-29-2 | 15 | mg | VIAL | |
| 1285931 | Fluvastatin Sodium (2 x 350 mg) | Reference Standard | 93957-55-2 | 700 | mg | VIAL | |
| 1285942 | Fluvastatin for System Suitability (25 mg) (Fluvastatin sodium and fluvastatin sodium anti-isomer ([R*,R*-E]-(+/-)-7-[3-(4-Fluorophenyl)-1-(methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid monosodium salt)) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1285909 | Fluvoxamine Maleate (200 mg) | Reference Standard | 61718-82-9 | 200 | mg | VIAL | |
| 1282591 | Foeniculin (4 x 50 mg) | Reference Standard | 78259-41-3 | 200 | mg | AMPULE | |
| 1286005 | Folic Acid (500 mg) (Vitamin M or Vitamin Bc) | Reference Standard | 59-30-3 | 500 | mg | VIAL | |
| 1286027 | Folic Acid Related Compound A (50 mg) (Calcium Formyltetrahydrofolate) | Reference Standard | 1492-18-8 | 50 | mg | VIAL | |
| 1282718 | Fondaparinux Sodium Identification (30 mg) | Reference Standard | 114870-03-0 | 30 | mg | VIAL | |
| 1282729 | Fondaparinux Sodium System Suitability Mixture A (2.5 mg) | Reference Standard | N/A | 2.5 | mg | VIAL | |
| 1282730 | Fondaparinux Sodium System Suitability Mixture B (2.5 mg) (A mixture containing fondaparinux sodium and fondaparinux related compound A, B, C, D, E, F, and G) | Reference Standard | 114870-03-0 | 2.5 | mg | VIAL | |
| 1282707 | Fondaparinux Sodium for Assay (0.6 mL) (COLD SHIPMENT REQUIRED) | Reference Standard | 114870-03-0 | 0.6 | mL | AMPULE | |
| 1283200 | Formic Acid (1.2 mL/ampule; 3 ampules) | Reference Standard | 64-18-6 | 3.6 | mL | AMPULE | |
| 1286060 | Formononetin (50 mg) | Reference Standard | 485-72-3 | 50 | mg | VIAL | |
| 1286107 | Formoterol Fumarate (200 mg) | Reference Standard | 183814-30-4 | 200 | mg | VIAL | |
| 1286129 | Formoterol Fumarate Resolution Mixture (20 mg) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1042351 | Formoterol Related Compound A (30 mg) (2-Amino-4-(1-hydroxy-2-((1-(4-methoxyphenyl)propan-2-yl)amino)ethyl)phenol) | Reference Standard | 150513-24-9 | 30 | mg | VIAL | |
| 1042373 | Formoterol Related Compound C (30 mg) (N-(2-Hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl]amino}ethyl)phenyl)acetamide fumarate) | Reference Standard | N/A | 30 | mg | VIAL | |
| 1286141 | Formoterol Related Compound D (30 mg) (N-(2-Hydroxy-5-(1-hydroxy-2-{[1-(4-methoxyphenyl)propan-2-yl](methyl)amino}ethyl)phenyl)formamide fumarate) | Reference Standard | 1795133-97-9 | 30 | mg | VIAL | |
| 1286184 | Formoterol Related Compound I (25 mg) (N-(2-hydroxy-5-[(RS)-1-hydroxy-2-{[(SR)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]phenyl)formamide) | Reference Standard | 532414-36-1 | 25 | mg | VIAL | |
| 1286311 | Formyl Penicillamine (25 mg) (2-Formamido-3-mercapto-3-methylbutanoic acid) | Reference Standard | 158411-82-6 | 25 | mg | VIAL | |
| 1283244 | Forskolin (40 mg) (7Beta-acetoxy-8,13-epoxy-1alpha,6Beta,9alpha-trihydroxy-labd-14-en-11-one) | Reference Standard | 66575-29-9 | 40 | mg | VIAL | |
| 1283368 | Fosamprenavir Calcium (200 mg) | Reference Standard | 226700-81-8 | 200 | mg | VIAL | |
| 1283379 | Fosamprenavir Related Compound A (10 mg) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1283380 | Fosamprenavir System Suitability Mixture (15 mg) (A mixture of fosamprenavir calcium, fosamprenavir pyrophosphate, fosamprenavir n-propyl homolog and fosamprenavir n-butyl isomer. Other impurities may also be present) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1283313 | Foscarnet Related Compound B (10 mg) (disodium (ethoxyoxidophosphanyl)formate) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1283324 | Foscarnet Related Compound D (0.27 mL) (O,O-diethyl ethoxycarbonylphosphonate) | Reference Standard | 1474-78-8 | 0.27 | mL | AMPULE | |
| 1283302 | Foscarnet Sodium (50 mg) (Phosphonoformic acid, trisodium salt, hexahydrate) | Reference Standard | 34156-56-4 | 50 | mg | VIAL | |
| 1286322 | Fosfomycin Tromethamine (800 mg) | Reference Standard | 78964-85-9 | 800 | mg | VIAL | |
| 1283415 | Fosinopril Related Compound A (25 mg) ((4S)-4-cyclohexyl-[(4-phenylbutyl)phosphinyl]acetyl-L-proline) | Reference Standard | 95399-71-6 | 25 | mg | VIAL | |
| 1283426 | Fosinopril Related Compound B (25 mg) ((4S)-4-Cyclohexyl-1-[(R)-[(S)-1-hydroxy-2-methylpropoxy](4-phenylbutyl)phosphinyl]acetyl-D-proline propionate (ester), hemibarium salt, sesquihydrate) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1283437 | Fosinopril Related Compound C (15 mg) ((4S)-4-cyclohexyl-1-[(RS)-1-hydroxy-2-methylpropoxy](4-phenylbutyl)phosphinyl]-acetyl-L-proline propionate (ester), sodium salt) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1283448 | Fosinopril Related Compound D (15 mg) ((4R)-4-cyclohexyl-1-[(R)-[(S)-1-hydroxy-2-methylpropoxy](4-phenylbutyl)phosphinyl]acetyl-L-proline propionate (ester), sodium salt) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1283459 | Fosinopril Related Compound E (15 mg) ((4S)-4-phenyl-1-[(R)-[(S)-1-hydroxy-2-methyl-propoxy](4-phenylbutyl)phospinyl]acetyl-L-proline propionate (ester), sodium salt) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1283460 | Fosinopril Related Compound F (15 mg) ((4S)-4-cyclohexyl-1-[(R)-[(S)-1-hydroxypropoxy](4-phenylbutyl)phosphinyl]acetyl-L-proline propionate(ester), sodium salt) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1283470 | Fosinopril Related Compound G (15 mg) ((4-phenylbutyl)phosphinyl acetic acid, disodium salt) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1283481 | Fosinopril Related Compound H (25 mg) (4-phenylbutyl phosphonic acid) | Reference Standard | 46348-61-2 | 25 | mg | VIAL | |
| 1283404 | Fosinopril Sodium (200 mg) | Reference Standard | 88889-14-9 | 200 | mg | VIAL | |
| 1286366 | Fosphenytoin Sodium (350 mg) | Reference Standard | 2214317-48-1 | 350 | mg | VIAL | |
| 1286402 | Frovatriptan Racemate (15 mg) | Reference Standard | 147009-08-3 | 15 | mg | VIAL | |
| 1286424 | Frovatriptan Related Compound A (20 mg) ((R)-3-Amino-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamide) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1286413 | Frovatriptan Succinate (200 mg) | Reference Standard | 158930-17-7 | 200 | mg | VIAL | |
| 1286504 | Fructose (125 mg) | Reference Standard | 57-48-7 | 125 | mg | VIAL | |
| 1286650 | Fulvestrant (200 mg) | Reference Standard | 129453-61-8 | 200 | mg | VIAL | |
| 1286661 | Fulvestrant System Suitability Mixture (30 mg) | Reference Standard | N/A | 30 | mg | VIAL | |
| 1286708 | Fumaric Acid (200 mg) | Reference Standard | 110-17-8 | 200 | mg | VIAL | |
| 1286800 | Furazolidone (200 mg) | Reference Standard | 67-45-8 | 200 | mg | VIAL | |
| 1287008 | Furosemide (200 mg) | Reference Standard | 54-31-9 | 200 | mg | VIAL | |
| 1287020 | Furosemide Related Compound A (50 mg) (2-Chloro-4-N-furfurylamino-5-sulfamoylbenzoic Acid) | Reference Standard | 4818-59-1 | 50 | mg | VIAL | |
| 1287030 | Furosemide Related Compound B (100 mg) (4-Chloro-5-sulfamoylanthranilic Acid) | Reference Standard | 3086-91-7 | 100 | mg | VIAL | |
| 1287303 | Gabapentin (250 mg) | Reference Standard | 60142-96-3 | 250 | mg | VIAL | |
| 1287325 | Gabapentin Related Compound A (50 mg) (2-Azaspiro[4.5]decan-3-one) | Reference Standard | 64744-50-9 | 50 | mg | VIAL | |
| 1287347 | Gabapentin Related Compound B (30 mg) ((1-cyanocyclohexyl)acetic acid) (COLD SHIPMENT REQUIRED) | Reference Standard | 133481-09-1 | 30 | mg | VIAL | |
| 1287358 | Gabapentin Related Compound D (10 mg) ([1-(3-Oxo-2-aza-spiro[4.5]dec-2-ylmethyl)cyclohexyl]acetic acid) | Reference Standard | 1076198-17-8 | 10 | mg | VIAL | |
| 1287369 | Gabapentin Related Compound E (25 mg) (carboxymethyl-cyclohexanecarboxylic acid) | Reference Standard | 67950-95-2 | 25 | mg | VIAL | |
| 1287449 | Gadobutrol (200 mg) | Reference Standard | 198637-52-4 | 200 | mg | VIAL | |
| 1287450 | Gadobutrol System Suitability Mixture (30 mg) (A mixture containing Gadobutrol and Gadobutrol dealkyl analog) | Reference Standard | NA | 30 | mg | VIAL | |
| 1287507 | Gadodiamide (500 mg) | Reference Standard | 131410-48-5 | 500 | mg | | |
| 1287518 | Gadodiamide Related Compound A (25 mg) (Gadolinium sodium diethylenetriamine pentaacetic acid monomethylamide) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1287529 | Gadodiamide Related Compound B (50 mg) (gadolinium disodium diethylenetriamine pentaacetic acid) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1287609 | Gadopentetate Monomeglumine (500 mg) | Reference Standard | 92923-57-4 | 500 | mg | VIAL | |
| 1287620 | Gadoterate Meglumine (200 mg) | Reference Standard | 92943-93-6 | 200 | mg | VIAL | |
| 1287631 | Gadoteridol (500 mg) | Reference Standard | 120066-54-8 | 500 | mg | VIAL | |
| 1287642 | Gadoteridol Related Compound A (50 mg) (10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid) | Reference Standard | 120041-08-9 | 50 | mg | VIAL | |
| 1287653 | Gadoteridol Related Compound B (50 mg) (1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid gadolinium salt) | Reference Standard | 112188-16-6 | 50 | mg | VIAL | |
| 1287664 | Gadoteridol Related Compound C (50 mg) (1,4,7,10-Tetraaza-11-oxo-bicyclo[8.2.2]tetradecane-4,7-diacetic acid) | Reference Standard | 220182-19-4 | 50 | mg | VIAL | |
| 1287675 | Gadoversetamide (200 mg) | Reference Standard | 131069-91-5 | 200 | mg | VIAL | |
| 1287711 | Galactitol (500 mg) | Reference Standard | 608-66-2 | 500 | mg | VIAL | |
| 1287722 | Galactosamine Hydrochloride (50 mg) | Reference Standard | 1772-03-8 | 50 | mg | VIAL | |
| 1287700 | Galactose (200 mg) (D-Galactopyranose) | Reference Standard | 59-23-4 | 200 | mg | VIAL | |
| 1287755 | Galantamine Hydrobromide (200 mg) | Reference Standard | 1953-04-4; 69353-21-5 | 200 | mg | VIAL | |
| 1287766 | Galantamine Hydrobromide Racemic (15 mg) | Reference Standard | 193146-85-9 | 15 | mg | VIAL | |
| 1287777 | Galantamine Hydrobromide Related Compounds Mixture (25 mg) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1154591 | Gamma Cyclodextrin (200 mg) | Reference Standard | 17465-86-0 | 200 | mg | VIAL | |
| 1020023 | Gamma-Aminobutyric Acid (50 mg) | Reference Standard | 56-12-2 | 50 | mg | VIAL | |
| 1294848 | Gamma-Glutamyl-(S)-allyl-L-cysteine (30 mg) | Reference Standard | 91216-95-4 | 30 | mg | VIAL | |
| 1479202 | Gamma-Oryzanol (50 mg) | Reference Standard | 11042-64-1 | 50 | mg | VIAL | |
| 1288306 | Ganciclovir (200 mg) | Reference Standard | 82410-32-0 | 200 | mg | VIAL | |
| 1288339 | Ganciclovir Mono-N-methyl Valinate (10 mg) (2-(RS)-[(guanin-9-yl)methoxy]-3-hydroxypropyl N-methyl-L-valinate hydrochloride) | Reference Standard | 1401562-16-0 | 10 | mg | VIAL | |
| 1288317 | Ganciclovir Related Compound A (15 mg) ((RS)-2-Amino-9-(2,3-dihydroxy-propoxymethyl)-1,9-dihydro-purin-6-one) | Reference Standard | 86357-09-7 | 15 | mg | | |
| 1288383 | Ganoderic Acid A (50 mg) | Reference Standard | 81907-62-2 | 50 | mg | VIAL | |
| 1288372 | Ganoderma lucidum Fruiting Body Dry Extract (1 g) | Reference Standard | N/A | 1 | g | VIAL | |
| 1288408 | Gatifloxacin (300 mg) | Reference Standard | 112811-59-3 | 300 | mg | VIAL | |
| 1288419 | Gatifloxacin Related Compound A (15 mg) (1-Cyclopropyl-6-fluoro-8-hydroxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid) | Reference Standard | 616205-76-6 | 15 | mg | VIAL | |
| 1288441 | Gatifloxacin Related Compound D (15 mg) (1-Cyclopropyl-6-fluoro-8-methoxy-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid) | Reference Standard | 112811-57-1 | 15 | mg | VIAL | |
| 1288452 | Gatifloxacin Related Compound E (15 mg) (1-Cyclopropyl-6-fluoro-8-methoxy-7-(2-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid monohydrochloride) | Reference Standard | 1219097-41-2 | 15 | mg | VIAL | |
| 1288485 | Gelatin (500 mg) | Reference Standard | 9000-70-8 | 500 | mg | VIAL | |
| 1288463 | Gemcitabine Hydrochloride (200 mg) | Reference Standard | 122111-03-9 | 200 | mg | VIAL | |
| 1288500 | Gemfibrozil (200 mg) | Reference Standard | 25812-30-0 | 200 | mg | VIAL | |
| 1288510 | Gemfibrozil Related Compound A (20 mg) ((E,Z)-2,2-dimethyl-5-[2,5-dimethyl-4-(propene-1-yl)phenoxy]valeric acid) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1288667 | Gemifloxacin Mesylate (300 mg) | Reference Standard | 210353-53-0 | 300 | mg | VIAL | |
| 1288634 | Gemifloxacin Related Compound B (15 mg) (7-[3-(Aminomethyl)-4-hydroxypyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid monomethanesulfonate) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1288645 | Gemifloxacin Related Compound C (15 mg) (7-[3-(Aminomethyl)-4-oxopyrrolidin-1-yl]-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid monomethanesulfonate) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1288816 | Genistein (15 mg) | Reference Standard | 446-72-0 | 15 | mg | VIAL | |
| 1288805 | Genistin (30 mg) | Reference Standard | 529-59-9 | 30 | mg | VIAL | |
| 1289003 | Gentamicin Sulfate (200 mg) | Reference Standard | 1405-41-0 | 200 | mg | VIAL | |
| 1290002 | Gentian Violet (650 mg) | Reference Standard | 548-62-9 | 650 | mg | VIAL | |
| 1291446 | Ginger Constituent Mixture (0.6 mg) (A freeze-dried mixture of 6-Gingerol and 6-Shogaol) | Reference Standard | N/A | 0.6 | mg | VIAL | |
| 1291559 | Ginkgo Terpene Lactones (50 mg) | Reference Standard | NA | 50 | mg | VIAL | |
| 1291548 | Ginkgolic Acids (20 mg) (Mixture of ginkgolic acid C13:0, ginkgolic acid C15:1 and ginkgolic acid C17:1) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1291661 | Ginsenoside Rb1 (20 mg) | Reference Standard | 41753-43-9 | 20 | mg | VIAL | |
| 1291672 | Ginsenoside Rg1 (20 mg) | Reference Standard | 22427-39-0 | 20 | mg | VIAL | |
| 1005706 | Glacial Acetic Acid (3 x 1.5 mL ampules) | Reference Standard | 64-19-7 | 4.5 | mL | AMPULE | |
| 1292303 | Glimepiride (200 mg) | Reference Standard | 93479-97-1 | 200 | mg | VIAL | |
| 1292314 | Glimepiride Related Compound A (20 mg) (1-[[p-[2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl]phenyl]sulfonyl]-3-(cis-4-methylcyclohexyl)urea) | Reference Standard | 684286-46-2 | 20 | mg | VIAL | |
| 1292325 | Glimepiride Related Compound B (20 mg) (glimepiride sulfonamide, or 3-Ethyl-4-methyl-2-oxo-N-(4-sulfamoylphenethyl)-2,5-dihydro-1H-pyrrole-1-carboxamide) | Reference Standard | 119018-29-0 | 20 | mg | VIAL | |
| 1292336 | Glimepiride Related Compound C (20 mg) ((Methyl ({4-[2-(3-ethyl-4-methyl-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamido)ethyl]phenyl}sulfonyl)carbamate) | Reference Standard | 119018-30-3 | 20 | mg | VIAL | |
| 1292347 | Glimepiride Related Compound D (20 mg) (Glimepiride 3-isomer, or 1-[[m-[2-(3-Ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl]phenyl]sulfonyl]-3-(trans-4-methylcyclohexyl)urea) | Reference Standard | 791104-62-6 | 20 | mg | VIAL | |
| 1292507 | Glipizide (125 mg) | Reference Standard | 29094-61-9 | 125 | mg | VIAL | |
| 1292609 | Glipizide Related Compound A (25 mg) (N-{2-[(4-aminosulfonyl)phenyl]ethyl}-5-methyl-pyrazinecarboxamide) | Reference Standard | 33288-71-0 | 25 | mg | VIAL | |
| 1292610 | Glipizide Related Compound B (15 mg) (6-methyl-N-[2-(4-sulphamoylphenyl)ethyl]pyrazine-2-carboxamide) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1292631 | Glipizide Related Compound C (15 mg) (1-cyclohexyl-3-[[4-[2-[[(6-methylpyrazin-2-yl)carbonyl]amino]ethyl]phenyl]sulfonyl]urea) | Reference Standard | 66375-96-0 | 15 | mg | VIAL | |
| 1294150 | Gluconolactone (100 mg) | Reference Standard | 90-80-2 | 100 | mg | VIAL | |
| 1294207 | Glucosamine Hydrochloride (200 mg) | Reference Standard | 66-84-2 | 200 | mg | VIAL | |
| 1294976 | Glutamic Acid (200 mg) | Reference Standard | 56-86-0 | 200 | mg | VIAL | |
| 1294808 | Glutamine (100 mg) | Reference Standard | 56-85-9 | 100 | mg | VIAL | |
| 1294820 | Glutathione (300 mg) | Reference Standard | 70-18-8 | 300 | mg | VIAL | |
| 1294839 | Gluten in Oat Flour Method Development Materials (7 x 50 g) | Reference Standard | N/A | 350 | g | OTHER | |
| 1295505 | Glyburide (200 mg) | Reference Standard | 10238-21-8 | 200 | mg | VIAL | |
| 1295516 | Glyburide Related Compound A (25 mg) (4-[2-(5-chloro-2-methoxybenzamido)ethyl]benzenesulfonamide) | Reference Standard | 16673-34-0 | 25 | mg | VIAL | |
| 1295527 | Glyburide Related Compound B (25 mg) (methyl-[[4-[2-[(5-chloro-2-methoxybenzoyl)-amino]ethyl]phenyl]sulfonyl]carbamate) (AS) | Reference Standard | 21165-77-5 | 25 | mg | VIAL | |
| 1295607 | Glycerin (2 mL) | Reference Standard | 56-81-5 | 2 | mL | AMPULE | |
| 1295709 | Glyceryl Dibehenate (200 mg) (Glyceryl dibehenate) | Reference Standard | N/A | 200 | mg | VIAL | |
| 1295724 | Glyceryl Distearate (500 mg) | Reference Standard | 1323-83-7 | 500 | mg | VIAL | |
| 1295775 | Glyceryl Mono and Dicaprylocaprate (300 mg) | Reference Standard | 91744-32-0 | 300 | mg | VIAL | |
| 1295764 | Glyceryl Monocaprylate (300 mg) | Reference Standard | 26402-26-6 | 300 | mg | VIAL | |
| 1295731 | Glyceryl Monolinoleate (500 mg) | Reference Standard | 26545-74-4 | 500 | mg | AMPULE | |
| 1295753 | Glyceryl Monooleate 40% (500 mg) | Reference Standard | 25496-72-4 | 500 | mg | AMPULE | |
| 1295742 | Glyceryl Monooleate 90% (250 mg) | Reference Standard | 111-03-5 | 250 | mg | | |
| 1295797 | Glyceryl Tricaprylate (3 x 0.5 mL) | Reference Standard | 538-23-8 | 1.5 | mL | AMPULE | |
| 1295800 | Glycine (200 mg) | Reference Standard | 56-40-6 | 200 | mg | VIAL | |
| 1295844 | Glycitein (15 mg) | Reference Standard | 40957-83-3 | 15 | mg | VIAL | |
| 1295855 | Glycitin (15 mg) | Reference Standard | 40246-10-4 | 15 | mg | VIAL | |
| 1296009 | Glycopyrrolate (200 mg) | Reference Standard | 51186-83-5 | 200 | mg | VIAL | |
| 1296010 | Glycopyrrolate Erythro Isomer (25 mg) ((RS)-3-[(RS)-2-cyclopentyl-2-hydroxy-2-phenylacetoxy]-1,1-dimethylpyrrolidinium bromide) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1296029 | Glycopyrrolate Related Compound A (50 mg) (5-Nitrobenzene-1,3-dicarboxylic acid) | Reference Standard | 618-88-2 | 50 | mg | VIAL | |
| 1296031 | Glycopyrrolate Related Compound B (50 mg) (1-Methylpyrrolidin-3-yl 2-cyclopentyl-2-hydroxy-2-phenylacetate Hydrochloride) | Reference Standard | 13118-10-0 | 50 | mg | VIAL | |
| 1296042 | Glycopyrrolate Related Compound C (25 mg) (2-Cyclopentyl-2-hydroxy-2-phenylacetic acid) | Reference Standard | 427-49-6 | 25 | mg | VIAL | |
| 1296086 | Glycopyrrolate Related Compound I (15 mg) ((RS)-3-[(SR)-2-(4-Chlorophenyl)-2-cyclopentyl-2-hydroxyacetoxy]-1,1-dimethylpyrrolidin-1-ium bromide) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1296100 | Glycopyrrolate Related Compound L (50 mg) (Methyl 2-cyclopentyl-2-hydroxy-2-phenylacetate) | Reference Standard | 19833-96-6 | 50 | mg | AMPULE | |
| 1295866 | Glycyl-L-Glutamine (200 mg) | Reference Standard | 211446-46-7 | 200 | mg | VIAL | |
| 1295877 | Glycyl-L-Tyrosine (200 mg) | Reference Standard | 39630-46-1 | 200 | mg | VIAL | |
| 1295888 | Glycyrrhizic Acid (25 mg) | Reference Standard | 1405-86-3 | 25 | mg | VIAL | |
| 1296756 | Gonadorelin Acetate (2 mg) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | 78308-49-3 | 2 | mg | VIAL | |
| 1296767 | Gonadorelin Acetate Related Compound A (10 mg) (5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolylglycine) (COLD SHIPMENT REQUIRED) | Reference Standard | 35263-73-1 | 10 | mg | VIAL | |
| 1296803 | Gonadorelin Hydrochloride (6.53 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 51952-41-1 | 6.53 | mg | VIAL | |
| 1297205 | Goserelin Acetate (100 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 145781-92-6 | 100 | mg | VIAL | |
| 1297216 | Goserelin Related Compound A (10 mg) (4-D-Serine Goserelin, 1-(5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-D-seryl-L-tyrosyl-O-tert-butyl-D-seryl-L-leucyl-L-arginyl-L-prolyl) semicarbazide) (COLD SHIPMENT REQUIRED) | Reference Standard | 1926163-39-4 | 10 | mg | VIAL | |
| 1297250 | Goserelin System Suitability Mixture (1.075 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | N/A | 1.075 | mg | VIAL | |
| 1535846 | Graftskin Reference Photomicrographs (CD) | Reference Standard | N/A | 1 | ea | OTHER | |
| 1298004 | Gramicidin (200 mg) | Reference Standard | 1405-97-6 | 200 | mg | VIAL | |
| 1298092 | Granisetron (100 mg) | Reference Standard | 109889-09-0 | 100 | mg | VIAL | |
| 1298106 | Granisetron Hydrochloride (150 mg) | Reference Standard | 107007-99-8 | 150 | mg | VIAL | |
| 1298117 | Granisetron Related Compound A (15 mg) (2-methyl-N-[(1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-2H-indazole-3-carboxamide) | Reference Standard | 127472-42-8 | 15 | mg | VIAL | |
| 1298128 | Granisetron Related Compound B (15 mg) (N-[(1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]non-3-yl]-1H-indazole-3-carboxamide) | Reference Standard | 107007-95-4 | 15 | mg | VIAL | |
| 1298139 | Granisetron Related Compound C (15 mg) (N-[(1R,3r,5S)-9-azabicyclo[3.3.1]non-3-yl]-1-methyl-1H-indazole-3-carboxamide hydrochloride) | Reference Standard | 141136-01-8 | 15 | mg | VIAL | |
| 1298140 | Granisetron Related Compound D (15 mg) (1-Methyl-1H-indazole-3-carboxylic acid) | Reference Standard | 50890-83-0 | 15 | mg | VIAL | |
| 1298150 | Granisetron Related Compound E (15 mg) ((1R,3r,5S)-9-methyl-9-azabicyclo[3.3.1]nonan-3-amine acetate) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1298208 | Grape Seeds Oligomeric Proanthocyanidins (500 mg) | Reference Standard | NA | 500 | mg | VIAL | |
| 1299007 | Griseofulvin (200 mg) | Reference Standard | 126-07-8 | 200 | mg | VIAL | |
| 1299200 | Griseofulvin Permeability Diameter (2 g) | Reference Standard | 126-07-8 | 2 | g | VIAL | |
| 1300004 | Guaiacol (1 g) (2-Methoxyphenol) | Reference Standard | 90-05-1 | 1 | g | AMPULE | |
| 1301007 | Guaifenesin (200 mg) | Reference Standard | 93-14-1 | 200 | mg | VIAL | |
| 1301404 | Guanabenz Acetate (200 mg) | Reference Standard | 23256-50-0 | 200 | mg | | |
| 1301801 | Guanethidine Monosulfate (200 mg) | Reference Standard | 645-43-2 | 200 | mg | VIAL | |
| 1302101 | Guanfacine Hydrochloride (125 mg) | Reference Standard | 29110-48-3 | 125 | mg | VIAL | |
| 1302134 | Guanidine Hydrochloride (100 mg) | Reference Standard | 50-01-1 | 100 | mg | VIAL | |
| 1302156 | Guanine (100 mg) | Reference Standard | 73-40-5 | 100 | mg | VIAL | |
| 1302178 | Guarana Seed Dry Extract (1 g) | Reference Standard | NA | 1 | g | VIAL | |
| 1302214 | Guggulsterone Z (25 mg) | Reference Standard | 39025-23-5 | 25 | mg | VIAL | |
| 1302247 | Gymnemagenin (15 mg) | Reference Standard | 22467-07-8 | 15 | mg | | |
| 1302509 | Halcinonide (200 mg) | Reference Standard | 3093-35-4 | 200 | mg | VIAL | |
| 1302906 | Halobetasol Propionate (200 mg) | Reference Standard | 66852-54-8 | 200 | mg | VIAL | |
| 1303002 | Haloperidol (200 mg) | Reference Standard | 52-86-8 | 200 | mg | VIAL | |
| 1303057 | Haloperidol Decanoate (200 mg (COLD SHIPMENT REQUIRED) | Reference Standard | 74050-97-8 | 200 | mg | VIAL | |
| 1303013 | Haloperidol Related Compound A (10 mg) (4,4'-Bis[4-(p-chlorophenyl)-4-hydroxypiperidino]-butyrophenone) | Reference Standard | 67987-08-0 | 10 | mg | VIAL | |
| 1303024 | Haloperidol Related Compound B (10 mg) (4-[4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(2-fluorophenyl)butan-1-one) | Reference Standard | 1391052-53-1 | 10 | mg | VIAL | |
| 1303501 | Halothane (1 mL) ((+/-)-2-Bromo-2-chloro-1,1,1-trifluoroethane) | Reference Standard | 151-67-7 | 1 | mL | AMPULE | |
| 1303750 | Hemoglobin Protease Substrate (100 g) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | 9008-02-0 | 100 | g | BOTTLE | |
| 1304038 | Heparin Sodium Identification (50 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 9041-08-1 | 50 | mg | VIAL | |
| 1304107 | Heparin Sodium Molecular Weight Calibrant (10.3 mg) | Reference Standard | N/A | 10.3 | mg | AMPULE | |
| 1304049 | Heparin Sodium System Suitability (50 mg) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1304016 | Heparin Sodium for Assays (9.5 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 9041-08-1 | 9.5 | mg | AMPULE | |
| 1304050 | Heparin Sodium with Oversulfated Chondroitin Sulfate (8.8 mg) | Reference Standard | N/A | 8.8 | mg | AMPULE | |
| 1228075 | Heptamethyl Trisiloxane (150 mg) (1,1,1,3,5,5,5-Heptamethyltrisiloxane) | Reference Standard | 1873-88-7 | 150 | mg | AMPULE | |
| 1304209 | Heptane (1.2 mL/ampule; 3 ampules) | Reference Standard | 142-82-5 | 3.6 | mL | AMPULE | |
| 1304377 | Hesperidin (200 mg) | Reference Standard | 64726-90-5 | 200 | mg | VIAL | |
| 1305008 | Hexachlorophene (500 mg) | Reference Standard | 70-30-4 | 500 | mg | VIAL | |
| 1305303 | Hexacosanol (100 mg) | Reference Standard | 506-52-5 | 100 | mg | VIAL | |
| 1308200 | Hexylene Glycol (125 mg) | Reference Standard | 107-41-5 | 125 | mg | AMPULE | |
| 1308307 | Hexylresorcinol (200 mg) | Reference Standard | 136-77-6 | 200 | mg | VIAL | |
| 1270457 | High Molecular Weight Filgrastim (0.7 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | N/A | 0.7 | mg | VIAL | |
| 1342150 | High Molecular Weight Insulin Human (8.4 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 11061-68-0 | 8.4 | mg | AMPULE | |
| 1546707 | High-Density Polyethylene (3 strips (2'' x 2 1/2'' each)) | Reference Standard | 9002-88-4 | 1 | EA | OTHER | |
| 1309009 | Histamine Dihydrochloride (250 mg) | Reference Standard | 56-92-8 | 250 | mg | VIAL | |
| 1310008 | Homatropine Hydrobromide (200 mg) | Reference Standard | 51-56-9 | 200 | mg | | |
| 1311000 | Homatropine Methylbromide (250 mg) | Reference Standard | 80-49-9 | 250 | mg | VIAL | |
| 1311306 | Homopolymer Polypropylene (3 Strips, 2'' x 2 1/2'' each) | Reference Standard | 9003-07-0 | 1 | ea | OTHER | |
| 1311408 | Homosalate (500 mg) | Reference Standard | 118-56-9 | 500 | mg | AMPULE | |
| 1297001 | Human Chorionic Gonadotropin (1 vial, 5,760 USP Units per package) (COLD SHIPMENT REQUIRED) | Reference Standard | 9002-61-3 | 1 | EA | | |
| 1535857 | Human Fibroblast-Derived Skin Substitute Reference Photomicrographs (CD) | Reference Standard | N/A | 1 | ea | OTHER | |
| 1313006 | Hydralazine Hydrochloride (200 mg) | Reference Standard | 304-20-1 | 200 | mg | VIAL | |
| 1313210 | Hydrastine (10 mg) | Reference Standard | 118-08-1 | 10 | mg | VIAL | |
| 1314009 | Hydrochlorothiazide (200 mg) | Reference Standard | 58-93-5 | 200 | mg | VIAL | |
| 1315001 | Hydrocodone Bitartrate CII (100 mg) | Reference Standard | 34195-34-1 | 100 | mg | VIAL | |
| 1314960 | Hydrocodone CII (125 mg) | Reference Standard | 125-29-1 | 125 | mg | VIAL | |
| 1315012 | Hydrocodone Related Compound A CII (70 mg) (4-hydroxy-3-methoxy-17-methylmorphinan-6-one) | Reference Standard | 847-86-9 | 70 | mg | VIAL | |
| 1316004 | Hydrocortisone (200 mg) | Reference Standard | 50-23-7 | 200 | mg | VIAL | |
| 1317007 | Hydrocortisone Acetate (200 mg) | Reference Standard | 50-03-3 | 200 | mg | VIAL | |
| 1317302 | Hydrocortisone Butyrate (200 mg) | Reference Standard | 13609-67-1 | 200 | mg | | |
| 1319002 | Hydrocortisone Hemisuccinate (200 mg) | Reference Standard | 83784-20-7 | 200 | mg | VIAL | |
| 1320001 | Hydrocortisone Phosphate Triethylamine (200 mg) | Reference Standard | 122764-80-1 | 200 | mg | | |
| 1321004 | Hydrocortisone Valerate (200 mg) | Reference Standard | 57524-89-7 | 200 | mg | VIAL | |
| 1322007 | Hydroflumethiazide (200 mg) | Reference Standard | 135-09-1 | 200 | mg | VIAL | |
| 1096837 | Hydrogenated Castor Oil (250 mg) (Mixture containing about 83% triglyceride of 12-hydroxystearic acid) | Reference Standard | 8001-78-3 | 250 | mg | VIAL | |
| 1356871 | Hydrogenated Lanolin (200 mg) | Reference Standard | N/A | 200 | mg | VIAL | |
| 1323000 | Hydromorphone Hydrochloride CII (50 mg) | Reference Standard | 71-68-1 | 50 | mg | VIAL | |
| 1323019 | Hydromorphone N-Oxide Hydrochloride CII (15 mg) (4,5alpha-Epoxy-3-hydroxy-17-methylmorphinan-6-one N-oxide, hydrochloride) | Reference Standard | 109648-80-8 (base) | 15 | mg | VIAL | |
| 1323021 | Hydromorphone Related Compound A CII (10 mg) (7,8-didehydro-4,5alpha-epoxy-3-hydroxy-17-methylmorphinan-6-one perchlorate) | Reference Standard | 91265-67-7 | 10 | mg | VIAL | |
| 1324002 | Hydroquinone (500 mg) | Reference Standard | 123-31-9 | 500 | mg | VIAL | |
| 1324308 | Hydroxocobalamin Acetate (150 mg) | Reference Standard | 22465-48-1 | 150 | mg | VIAL | |
| 1324319 | Hydroxocobalamin Chloride (3 x 150 mg) | Reference Standard | 59461-30-2 | 450 | mg | AMPULE | |
| 1325005 | Hydroxyamphetamine Hydrobromide (200 mg) ((+/-)-p-(2-Aminopropyl)phenol hydrobromide) | Reference Standard | 306-21-8 | 200 | mg | VIAL | |
| 1327000 | Hydroxychloroquine Sulfate (200 mg) | Reference Standard | 747-36-4 | 200 | mg | VIAL | |
| 1327088 | Hydroxyethyl Cellulose (60 mg) | Reference Standard | 9004-62-0 | 60 | mg | VIAL | |
| 1A00310 | Hydroxyisobutyl Acetophenone (25 mg) (COLD SHIPMENT REQUIRED) (1-(4-(1-hydroxy-2-methylpropyl)phenyl)ethan-1-one) | Pharmaceutical Analytical Impurity | 1314907-71-5 | 25 | mg | VIAL | |
| 1329006 | Hydroxyprogesterone Caproate (200 mg) | Reference Standard | 630-56-8 | 200 | mg | VIAL | |
| 1329709 | Hydroxypropyl Betadex (200 mg) | Reference Standard | 128446-35-5 | 200 | mg | VIAL | |
| 1329800 | Hydroxypropyl Cellulose (500 mg) | Reference Standard | 9004-64-2 | 500 | mg | | |
| 1A00040 | Hydroxythiadiazol Sulfoxide Derivative (25 mg) (4-morpholino-1,2,5-thiadiazol-3(2H)-one 1-oxide) | Pharmaceutical Analytical Impurity | 75202-36-7 | 25 | mg | VIAL | |
| 1332000 | Hydroxyurea (200 mg) | Reference Standard | 127-07-1 | 200 | mg | VIAL | |
| 1333003 | Hydroxyzine Hydrochloride (500 mg) | Reference Standard | 2192-20-3 | 500 | mg | VIAL | |
| 1334006 | Hydroxyzine Pamoate (500 mg) | Reference Standard | 10246-75-0 | 500 | mg | VIAL | |
| 1333058 | Hydroxyzine Related Compound A (25 mg) (1-[(4-Chlorophenyl)phenylmethyl]piperazine) | Reference Standard | 303-26-4 | 25 | mg | VIAL | |
| 1335010 | Hyoscyamine Related Compound A (10 mg) (Norhyoscyamine Sulfate) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1335009 | Hyoscyamine Sulfate (125 mg) | Reference Standard | 6835-16-1 | 125 | mg | VIAL | |
| 1335202 | Hyperoside (50 mg) | Reference Standard | 482-36-0 | 50 | mg | VIAL | |
| 1330005 | Hypromellose (250 mg) | Reference Standard | 9004-65-3 | 250 | mg | VIAL | |
| 1335279 | Hypromellose Acetate Succinate (100 mg) | Reference Standard | 71138-97-1 | 100 | mg | VIAL | |
| 1335304 | Hypromellose Phthalate (100 mg) | Reference Standard | 9050-31-1 | 100 | mg | VIAL | |
| 1335428 | Ibandronate Related Compound A (25 mg) (3-[Methyl(pentyl)amino]propanoic acid hydrochloride) | Reference Standard | 625120-81-2 | 25 | mg | VIAL | |
| 1335417 | Ibandronate Sodium (200 mg) | Reference Standard | 138926-19-9 | 200 | mg | VIAL | |
| 1335508 | Ibuprofen (750 mg) | Reference Standard | 15687-27-1 | 750 | mg | VIAL | |
| 1335541 | Ibuprofen Related Compound C (0.2 mL/ampule; 3 ampules) (4-isobutylacetophenone) | Reference Standard | 38861-78-8 | 0.6 | mL | AMPULE | |
| 1335596 | Ibuprofen Related Compound J (25 mg) (2-(4-Isobutyrylphenyl)propanoic acid) | Reference Standard | 65813-55-0 | 25 | mg | VIAL | |
| 1A00480 | Ibuprofen Tetraethylene Glycol Diester (25 mg) (((oxybis(ethane-2,1-diyl))bis(oxy))bis(ethane-2,1-diyl) bis(2-(4-isobutylphenyl)propanoate))) | Pharmaceutical Analytical Impurity | 1161014-75-0 | 25 | mg | VIAL | |
| 1335610 | Ibutilide Fumarate (100 mg) | Reference Standard | 122647-32-9 | 100 | mg | VIAL | |
| 1335621 | Ibutilide Related Compound A (20 mg) (N-Ethyl-N-heptyl-4-[4-(methylsulfonamido)phenyl]-4-oxobutanamide) | Reference Standard | 100632-58-4 | 20 | mg | VIAL | |
| 1335632 | Ibutilide Related Compound B (20 mg) (N-Ethyl-N-heptyl-4-hydroxy-4-[4-(methylsulfonamido)phenyl]butanamide) | Reference Standard | 160087-98-9 | 20 | mg | VIAL | |
| 1335701 | Idarubicin Hydrochloride (50 mg) | Reference Standard | 57852-57-0 | 50 | mg | VIAL | |
| 1336001 | Idoxuridine (250 mg) | Reference Standard | 54-42-2 | 250 | mg | VIAL | |
| 1336205 | Ifosfamide (500 mg) | Reference Standard | 3778-73-2 | 500 | mg | VIAL | |
| 1336249 | Iloperidone (200 mg) | Reference Standard | 133454-47-4 | 200 | mg | VIAL | |
| 1336250 | Iloperidone Related Compound A (20 mg) ([4'-(3-Chloropropoxy)-3'-methoxy]acetophenone) | Reference Standard | 58113-30-7 | 20 | mg | VIAL | |
| 1336500 | Imidazole (200 mg) (1H-Imidazole) | Reference Standard | 288-32-4 | 200 | mg | VIAL | |
| 1336806 | Imidurea (200 mg) | Reference Standard | 39236-46-9 | 200 | mg | VIAL | |
| 1337004 | Iminodibenzyl (25 mg) (10,11-Dihydro-5H-dibenzo[b,f]azepine) | Reference Standard | 494-19-9 | 25 | mg | VIAL | |
| 1337809 | Imipenem Monohydrate (100 mg) | Reference Standard | 74431-23-5 | 100 | mg | VIAL | |
| 1338007 | Imipramine Hydrochloride (200 mg) | Reference Standard | 113-52-0 | 200 | mg | VIAL | |
| 1338481 | Imipramine Pamoate (300 mg) | Reference Standard | 10075-24-8 | 300 | mg | VIAL | |
| 1338313 | Imiquimod (200 mg) | Reference Standard | 99011-02-6 | 200 | mg | VIAL | |
| 1338324 | Imiquimod Related Compound A (25 mg) (1-Isobutyl-1H-imidazo[4,5-c]quinoline) | Reference Standard | 99010-24-9 | 25 | mg | VIAL | |
| 1338335 | Imiquimod Related Compound B (25 mg) (1-Isobutyl-1H-imidazo[4,5-c]quinoline 5-oxide) | Reference Standard | 99010-63-6 | 25 | mg | VIAL | |
| 1338346 | Imiquimod Related Compound C (25 mg) (4-Chloro-1-isobutyl-1H-imidazo[4,5-c]quinoline) | Reference Standard | 99010-64-7 | 25 | mg | VIAL | |
| 1338357 | Imiquimod Related Compound D (25 mg) (1-Propyl-1H-imidazo[4,5-c]quinolin-4-amine) | Reference Standard | 853792-81-1 | 25 | mg | VIAL | |
| 1034341 | Inamrinone Related Compound B (100 mg) (2-Hydroxy-N-(6-oxo-1,6-dihydro-[3,4'-bipyridin]-5-yl)propanamide) | Reference Standard | N/A | 100 | mg | VIAL | |
| 1338801 | Indapamide (500 mg) | Reference Standard | 26807-65-8 | 500 | mg | VIAL | |
| 1338812 | Indapamide Related Compound A (50 mg) (4-chloro-N-(2-methyl-1H-indol-1-yl)-3-sulfamoylbenzamide) | Reference Standard | 63968-75-2 | 50 | mg | VIAL | |
| 1339000 | Indigotindisulfonate Sodium (750 mg) | Reference Standard | 860-22-0 | 750 | mg | VIAL | |
| 1339178 | Indinavir (100 mg) | Reference Standard | 180683-37-8 | 100 | mg | VIAL | |
| 1339189 | Indinavir System Suitability (100 mg) | Reference Standard | 180683-37-8 | 100 | mg | VIAL | |
| 1340009 | Indocyanine Green (250 mg) | Reference Standard | 3599-32-4 | 250 | mg | VIAL | |
| 1340086 | Indole (25 mg) | Reference Standard | 120-72-9 | 25 | mg | VIAL | |
| 1341001 | Indomethacin (200 mg) | Reference Standard | 53-86-1 | 200 | mg | VIAL | |
| 1417113 | Indomethacin Related Compound A (25 mg) (2-(5-methoxy-2-methyl-1H-indol-3-yl)acetic acid) | Reference Standard | 2882-15-7 | 25 | mg | VIAL | |
| 1112423 | Indomethacin Related Compound B (25 mg) (4-chlorobenzoic acid) | Reference Standard | 74-11-3 | 25 | mg | VIAL | |
| 1340960 | Inositol (500 mg) | Reference Standard | 87-89-8 | 500 | mg | VIAL | |
| 1342037 | Insulin Aspart (7.62 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 116094-23-6 | 7.62 | mg | VIAL | |
| 1342059 | Insulin Glargine (15.27 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 160337-95-1 | 15.27 | mg | AMPULE | |
| 1342060 | Insulin Glargine for Peak Identification (3.2 mg) (Mixture of Insulin Glargine and 0A-Arg-Insulin Glargine) (COLD SHIPMENT REQUIRED) | Reference Standard | N/A | 3.2 | mg | AMPULE | |
| 1342106 | Insulin Human (100 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 11061-68-0 | 100 | mg | VIAL | |
| 1342321 | Insulin Lispro (5.73 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 133107-64-9 | 5.73 | mg | VIAL | |
| 1342300 | Insulin Pork (50 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 12584-58-6 | 50 | mg | VIAL | |
| 1342401 | Interferon Beta-1A (1.0 mL) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | 145258-61-3 | 1 | mL | AMPULE | |
| 1343007 | Iodipamide (200 mg) | Reference Standard | 606-17-7 | 200 | mg | VIAL | |
| 1343517 | Iodixanol (200 mg) | Reference Standard | 92339-11-2 | 200 | mg | VIAL | |
| 1343540 | Iodixanol Related Compound C (25 mg) (5-[Acetyl[3-[[3,5-bis[[(2,3-dihydroxypropyl)amino]carbonyl]-2,4,6-triiodophenyl]amino]-2-hydroxypropyl]amino]-N,N'-bis-(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide) | Reference Standard | 171897-74-8 | 25 | mg | VIAL | |
| 1343550 | Iodixanol Related Compound D (50 mg) (5-[Acetyl(2-hydroxy-3-methoxypropyl)amino]-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide) | Reference Standard | 89797-00-2 | 50 | mg | VIAL | |
| 1343561 | Iodixanol Related Compound E (25 mg) (5-{N-[3-(N-{3-carbamoyl-5-[(2,3-dihydroxypropyl)carbamoyl]-2,4,6-triiodophenyl}acetamido)-2-hydroxypropyl]acetamido}-N1,N3-bis(2,3-dihydroxypropyl)-2,4,6-triiodoisophthalamide) | Reference Standard | 255376-57-9 | 25 | mg | | |
| 1344509 | Iodoquinol (100 mg) | Reference Standard | 83-73-8 | 100 | mg | VIAL | |
| 1344600 | Iohexol (550 mg) | Reference Standard | 66108-95-0 | 550 | mg | VIAL | |
| 1344622 | Iohexol Related Compound A (100 mg) (5-(acetylamino)-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide) | Reference Standard | 31127-80-7 | 100 | mg | VIAL | |
| 1344644 | Iohexol Related Compound B (50 mg) (5-amino-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-1,3-benzenedicarboxamide) | Reference Standard | 76801-93-9 | 50 | mg | VIAL | |
| 1344666 | Iohexol Related Compound C (50 mg) (N,N'-bis(2,3-dihydroxypropyl)-5-nitro-1,3-benzenedicarboxamide) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1344702 | Iopamidol (200 mg) | Reference Standard | 60166-93-0 | 200 | mg | VIAL | |
| 1344724 | Iopamidol Related Compound A (50 mg) (N,N'-Bis-(1,3-dihydroxy-2-propyl)-5-amino-2,4,6-triiodoisophthalamide) | Reference Standard | 60166-98-5 | 50 | mg | VIAL | |
| 1344735 | Iopamidol Related Compound B (50 mg) (5-Glycolamido-N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-2,4,6-triiodoisophthalamide) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1344746 | Iopamidol Related Compound C (40 mg) (4-chloro-N1, N3-bis(1,3-dihydroxypropan-2-yl)-5-(S)-lactamido-2,6-diiodoisophthalamide) | Reference Standard | N/A | 40 | mg | | |
| 1344804 | Iopromide (400 mg) | Reference Standard | 73334-07-3 | 400 | mg | VIAL | |
| 1344826 | Iopromide Related Compound A (50 mg) (5-Amino-N1,N3-Bis-(2,3-dihydroxypropyl)-2,4,6-triiodo-N1-methylisophthalamide) | Reference Standard | 154361-51-0 | 50 | mg | VIAL | |
| 1344837 | Iopromide Related Compound B (50 mg) (5-(Acetylamino)-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-N-methyl-1,3-benzenedicarboxamide) | Reference Standard | 76350-28-2 | 50 | mg | VIAL | |
| 1345002 | Iothalamic Acid (200 mg) | Reference Standard | 2276-90-6 | 200 | mg | VIAL | |
| 1345104 | Ioversol (200 mg) | Reference Standard | 87771-40-2 | 200 | mg | VIAL | |
| 1345126 | Ioversol Related Compound B (50 mg) (N,N'-Bis(2,3-dihydroxypropyl)-5-{[N-(2-hydroxyethyl)amino]-2-oxoethoxy}-2,4,6-triiodoisophthalamide) | Reference Standard | 104517-96-6 | 50 | mg | VIAL | |
| 1345159 | Ioxaglic Acid (100 mg) | Reference Standard | 59017-64-0 | 100 | mg | VIAL | |
| 1345206 | Ioxilan (400 mg) | Reference Standard | 107793-72-6 | 400 | mg | VIAL | |
| 1345228 | Ioxilan Related Compound A (100 mg) (5-amino-2,4,6-triiodo-3 N-(2-hydroxyethyl)carbamoyl benzoic acid) | Reference Standard | 22871-58-5 | 100 | mg | | |
| 1347507 | Ipratropium Bromide (200 mg) | Reference Standard | 66985-17-9 | 200 | mg | VIAL | |
| 1347518 | Ipratropium Bromide Related Compound A (10 mg) ((1R,3r,5S,8r)-3-Hydroxy-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane, bromide) | Reference Standard | 58005-18-8 | 10 | mg | VIAL | |
| 1347529 | Ipratropium Bromide Related Compound B (10 mg) ((1R,3r,5S,8s)-3-[[(2RS)-3-hydroxy-2-phenylpropanoyl]oxy]-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane, bromide) | Reference Standard | 58073-59-9 | 10 | mg | VIAL | |
| 1347530 | Ipratropium Bromide Related Compound C (15 mg) ((2-RS)-3-hydroxy-2-phenylpropanoic acid) | Reference Standard | 552-63-6 | 15 | mg | VIAL | |
| 1347700 | Irbesartan (200 mg) | Reference Standard | 138402-11-6 | 200 | mg | VIAL | |
| 1347711 | Irbesartan Related Compound A (25 mg) (1-pentanoylamino-cyclopentanecarboxylic acid [2'-(1H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-amide) | Reference Standard | 748812-53-5 | 25 | mg | VIAL | |
| 1347609 | Irinotecan Hydrochloride (100 mg) | Reference Standard | 136572-09-3 | 100 | mg | VIAL | |
| 1347610 | Irinotecan Related Compound A (10 mg) ((S)-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione) | Reference Standard | 19685-09-7 | 10 | mg | VIAL | |
| 1347631 | Irinotecan Related Compound B (10 mg) ((S)-4,11-diethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione) | Reference Standard | 86639-52-3 | 10 | mg | VIAL | |
| 1347642 | Irinotecan Related Compound C (10 mg) (11-Ethyl-4-hydroxy-4-methyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl (1,4'-bipiperidine)- 1'-carboxylate hydrochloride) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1347653 | Irinotecan Related Compound D (15 mg) ((R)-9-[(1,4'-Bipiperidine)-1'-carbonyloxy]-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline hydrochloride, trihydrate) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1347664 | Irinotecan Related Compound E (15 mg) ((S)-4,11-Diethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione) | Reference Standard | 78287-27-1 | 15 | mg | VIAL | |
| 1193356 | Iscotrizinol (200 mg) | Reference Standard | 154702-15-5 | 200 | mg | VIAL | |
| 1193378 | Iscotrizinol Related Compound B (25 mg) (4-[(4-{[4-(tert-butylcarbamoyl)phenyl]amino}-6-[(4-{[(2-ethylhexyl)oxy]carbonyl}phenyl)amino]-1,3,5-triazin-2-yl)amino]benzoic acid) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1193389 | Iscotrizinol Related Compound C (25 mg) (2-Ethylhexyl 4-[(4-{[4-(tert-butylcarbamoyl)phenyl]amino}-6-chloro-1,3,5-triazin-2-yl)amino]benzoate) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1193390 | Iscotrizinol Related Compound D (25 mg) (2-Ethylhexyl 4-[(4,6-bis{[4-(tert-butylcarbamoyl)phenyl]amino}-1,3,5-triazin-2-yl)amino]benzoate) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1193414 | Iscotrizinol Related Compound F (25 mg) (Bis(2-ethylhexyl) 4,4'-({6-[(4-carbamoylphenyl)amino]-1,3,5-triazine-2,4-diyl}bis(azanediyl))dibenzoate) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1193425 | Iscotrizinol Related Compound G (25 mg) (2-Ethylhexyl 4-{4-[(4-{[4-(tert-butylcarbamoyl)phenyl]amino}-6-[(4-{[(2-ethylhexyl)oxy]carbonyl}phenyl)amino]-1,3,5-triazin-2-yl)amino]benzamido}benzoate) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1193447 | Iscotrizinol Related Compound I (25 mg) (Bis(2-ethylhexyl) 4,4'-{[6-({4-[(4-{[(2-ethylhexyl)oxy]carbonyl}phenyl)carbamoyl]phenyl}amino)-1,3,5-triazine-2,4-diyl]bis(azanediyl)}dibenzoate) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1350625 | Iso-propyl p-Toluenesulfonate (50 mg) (Isopropyl toluene-4-sulfonate) | Reference Standard | 2307-69-9 | 50 | mg | AMPULE | |
| 1347824 | Isobutyl Heptanoate (5 x 0.5 mL) | Reference Standard | 7779-80-8 | 2.5 | mL | AMPULE | |
| 1347835 | Isobutyl Isobutyrate (5 x 0.5 mL) | Reference Standard | 97-85-8 | 2.5 | mL | AMPULE | |
| 1347802 | Isobutyl acetate (1.2 mL/ampule; 3 ampules) | Reference Standard | 110-19-0 | 3.6 | mL | AMPULE | |
| 1347813 | Isobutylidene Diurea (300 mg) (1,1'-(2-Methylpropane-1,1-diyl)diurea) | Reference Standard | 6104-30-9 | 300 | mg | VIAL | |
| 1347880 | Isobutyraldehyde (3 x 1.2 mL) | Reference Standard | 78-84-2 | 3.6 | mL | AMPULE | |
| 1348033 | Isochlorogenic Acid A (50 mg) | Reference Standard | 89919-62-0 | 50 | mg | VIAL | |
| 1348532 | Isoeugenol (0.2 mL) | Reference Standard | 97-54-1 | 0.2 | mL | AMPULE | |
| 1348543 | Isoeugenyl Acetate (150 mg) | Reference Standard | 93-29-8 | 150 | mg | VIAL | |
| 1348907 | Isoflupredone Acetate (200 mg) | Reference Standard | 338-98-7 | 200 | mg | VIAL | |
| 1349003 | Isoflurane (1 mL) | Reference Standard | 26675-46-7 | 1 | mL | | |
| 1349014 | Isoflurane Related Compound A (0.1 mL) (1-Chloro-2,2,2-trifluoroethyl chlorodifluoromethyl ether) | Reference Standard | 32778-08-8 | 0.1 | mL | AMPULE | |
| 1349025 | Isoflurane Related Compound B (0.1 mL) (2,2,2-Trifluoroethyl difluoromethyl ether) | Reference Standard | 1885-48-9 | 0.1 | mL | AMPULE | |
| 1349149 | Isoguaifenesin (30 mg) | Reference Standard | 14007-09-1 | 30 | mg | VIAL | |
| 1349604 | Isomalathion (50 mg) | Reference Standard | 3344-12-5 | 50 | mg | | |
| 1349626 | Isomalt (200 mg) | Reference Standard | 64519-82-0 | 200 | mg | VIAL | |
| 1349637 | Isomaltulose (5 g) | Reference Standard | 58024-13-8 | 5 | g | BOTTLE | |
| 1349659 | Isometheptene Mucate (200 mg) | Reference Standard | 7492-31-1 | 200 | mg | VIAL | |
| 1349670 | Isonaringin (30 mg) ((RS)-5-Hydroxy-2-(4-hydroxyphenyl)-4-oxo-3,4-dihydro-2H-chromen-7-yl 6-O-(alpha-L-rhamnopyranosyl)-beta-D-glucopyranoside) | Reference Standard | 14259-46-2 | 30 | mg | VIAL | |
| 1349706 | Isoniazid (200 mg) | Reference Standard | 54-85-3 | 200 | mg | VIAL | |
| 1350002 | Isopropamide Iodide (200 mg) | Reference Standard | 71-81-8 | 200 | mg | VIAL | |
| 1A00290 | Isopropyl 4-acetylbenzoate (COLD SHIPMENT REQUIRED) (25 mg) (Isopropyl 4-acetylbenzoate) | Pharmaceutical Analytical Impurity | 220089-22-5 | 25 | mg | AMPULE | |
| 1350104 | Isopropyl Acetate (1.2 mL/ampule; 3 ampules) | Reference Standard | 108-21-4 | 3.6 | mL | AMPULE | |
| 1350352 | Isopropyl Isostearate (3 x 1 mL) | Reference Standard | 68171-33-5 | 3 | mL | AMPULE | |
| 1350400 | Isopropyl Myristate (5 x 100 mg) | Reference Standard | 110-27-0 | 500 | mg | AMPULE | |
| 1350603 | Isopropyl Palmitate (500 mg) | Reference Standard | 142-91-6 | 500 | mg | AMPULE | |
| 1351005 | Isoproterenol Hydrochloride (125 mg) | Reference Standard | 51-30-9 | 125 | mg | VIAL | |
| 1351107 | Isopteropodine (20 mg) | Reference Standard | 5171-37-9 | 20 | mg | VIAL | |
| 1351800 | Isorhamnetin (30 mg) | Reference Standard | 480-19-3 | 30 | mg | VIAL | |
| 1351818 | Isorhamnetin-3-O-Rutinoside (15 mg) | Reference Standard | 604-80-8 | 15 | mg | VIAL | |
| 1352008 | Isosorbide (75% solution, 1 g) | Reference Standard | 652-67-5 | 1 | g | AMPULE | |
| 1353157 | Isostearyl Isostearate (1 mL) | Reference Standard | 41669-30-1 | 1 | mL | AMPULE | |
| 1353500 | Isotretinoin (200 mg) | Reference Standard | 4759-48-2 | 200 | mg | VIAL | |
| 1354003 | Isoxsuprine Hydrochloride (200 mg) | Reference Standard | 579-56-6 | 200 | mg | VIAL | |
| 1354207 | Isradipine (200 mg) | Reference Standard | 75695-93-1 | 200 | mg | VIAL | |
| 1354218 | Isradipine Related Compound A (15 mg) (Isopropyl methyl 4-(4-benzofurazanyl)-2,6-dimethyl-3,5-pyridinedicarboxylate) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1354251 | Itraconazole (100 mg) | Reference Standard | 84625-61-6 | 100 | mg | VIAL | |
| 1354262 | Itraconazole System Suitability Mixture (25 mg) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1354309 | Ivermectin (200 mg) | Reference Standard | 70288-86-7 | 200 | mg | VIAL | |
| 1354400 | Ixabepilone (100 mg) | Reference Standard | 219989-84-1 | 100 | mg | VIAL | |
| 1354411 | Ixabepilone System Suitability Mixture (10 mg) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1354717 | Jujuboside A (15 mg) | Reference Standard | 55466-04-1 | 15 | mg | VIAL | |
| 1354900 | Kaempferol (15 mg) (3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one) | Reference Standard | 520-18-3 | 15 | mg | VIAL | |
| 1354954 | Kaempferol-3-O-Robinoside-7-O-Glucoside (100 mg) (7-Beta-D-Glucopyranosyloxy-5-hydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-3-yl 6-O-(6-deoxy-alpha-Lmannopyranosyl)-Beta-D-galactopyranoside) | Reference Standard | 114924-89-9 | 100 | mg | | |
| 1355006 | Kanamycin Sulfate (200 mg) | Reference Standard | 5965-95-7 | 200 | mg | VIAL | |
| 1355753 | Kawain (200 mg) | Reference Standard | 500-64-1 | 200 | mg | | |
| 1356009 | Ketamine Hydrochloride CIII (250 mg) | Reference Standard | 1867-66-9 | 250 | mg | VIAL | |
| 1356020 | Ketamine Related Compound A (50 mg) (1-[(2-Chlorophenyl)(methylimino)methyl]cylcopentanol) | Reference Standard | 6740-87-0 | 50 | mg | VIAL | |
| 1356508 | Ketoconazole (200 mg) | Reference Standard | 65277-42-1 | 200 | mg | VIAL | |
| 1356632 | Ketoprofen (200 mg) | Reference Standard | 22071-15-4 | 200 | mg | VIAL | |
| 1356643 | Ketoprofen Related Compound A (25 mg) (alpha-methyl-3-(4-methylbenzoyl) benzeneacetic acid) | Reference Standard | 107257-20-5 | 25 | mg | VIAL | |
| 1356552 | Ketoprofen Related Compound C (20 mg) (2-(3-carboxyphenyl)propionic acid) | Reference Standard | 68432-95-1 | 20 | mg | VIAL | |
| 1356563 | Ketoprofen Related Compound D (20 mg) (3-acetylbenzophenone) | Reference Standard | 66067-44-5 | 20 | mg | VIAL | |
| 1356585 | Ketoprofen Related Compound F (20 mg) (3-(1-Cyanoethyl)benzophenone) | Reference Standard | 42872-30-0 | 20 | mg | VIAL | |
| 1356315 | Ketorolac Related Compound A (20 mg) (5-Benzoyl-N-(1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl)-2,3-dihydro-1H-pyrrolizine-1-carboxamide) | Reference Standard | 167105-80-8 | 20 | mg | VIAL | |
| 1356326 | Ketorolac Related Compound B (20 mg) (5-benzoyl-2,3-dihydro-1H-pyrrolizin-1-ol) | Reference Standard | 154476-25-2 | 20 | mg | VIAL | |
| 1356337 | Ketorolac Related Compound C (20 mg) (5-benzoyl-2,3-dihydro-1H-pyrrolizin-1-one) | Reference Standard | 113502-52-6 | 20 | mg | VIAL | |
| 1356348 | Ketorolac Related Compound D (20 mg) (5-benzoyl-2,3-dihydro-1H-pyrrolizine) | Reference Standard | 113502-55-9 | 20 | mg | VIAL | |
| 1356665 | Ketorolac Tromethamine (200 mg) | Reference Standard | 74103-07-4 | 200 | mg | VIAL | |
| 1356599 | Krill Oil (2 g) | Reference Standard | 8016-13-5 | 2 | g | AMPULE | |
| 1012509 | L-Alanine (200 mg) | Reference Standard | 56-41-7 | 200 | mg | VIAL | |
| 1012531 | L-Alanyl-L-Alanine (200 mg) | Reference Standard | 1948-31-8 | 200 | mg | VIAL | |
| 1012517 | L-Alanyl-L-Glutamine (200 mg) | Reference Standard | 39537-23-0 | 200 | mg | VIAL | |
| 1042102 | L-Arabinitol (250 mg) | Reference Standard | 7643-75-6 | 250 | mg | VIAL | |
| 1042500 | L-Arginine (200 mg) | Reference Standard | 74-79-3 | 200 | mg | VIAL | |
| 1133842 | L-Citrulline (200 mg) | Reference Standard | 372-75-8 | 200 | mg | VIAL | |
| 1161509 | L-Cysteine Hydrochloride (600 mg) | Reference Standard | 7048-04-6 | 600 | mg | VIAL | |
| 1286606 | L-Fucose (200 mg) | Reference Standard | 2438-80-4 | 200 | mg | | |
| 1294987 | L-Glutamic Acid Hydrochloride (100 mg) | Reference Standard | 138-15-8 | 100 | mg | VIAL | |
| 1308505 | L-Histidine (200 mg) | Reference Standard | 71-00-1 | 200 | mg | VIAL | |
| 1308550 | L-Histidine Monohydrochloride Monohydrate (200 mg) | Reference Standard | 5934-29-2 | 200 | mg | VIAL | |
| 1349502 | L-Isoleucine (200 mg) | Reference Standard | 73-32-5 | 200 | mg | VIAL | |
| 1357001 | L-Leucine (200 mg) | Reference Standard | 61-90-5 | 200 | mg | VIAL | |
| 1371501 | L-Lysine Acetate (200 mg) | Reference Standard | 57282-49-2 | 200 | mg | VIAL | |
| 1372005 | L-Lysine Hydrochloride (200 mg) | Reference Standard | 657-27-2 | 200 | mg | VIAL | |
| 1411504 | L-Methionine (200 mg) | Reference Standard | 63-68-3 | 200 | mg | VIAL | |
| 1530503 | L-Phenylalanine (200 mg) | Reference Standard | 63-91-2 | 200 | mg | VIAL | |
| 1568506 | L-Proline (200 mg) | Reference Standard | 147-85-3 | 200 | mg | VIAL | |
| 1612506 | L-Serine (200 mg) | Reference Standard | 56-45-1 | 200 | mg | VIAL | |
| 1652704 | L-Theanine (200 mg) | Reference Standard | 3081-61-6 | 200 | mg | VIAL | |
| 1667202 | L-Threonine (200 mg) | Reference Standard | 72-19-5 | 200 | mg | VIAL | |
| 1700501 | L-Tryptophan (200 mg) | Reference Standard | 73-22-3 | 200 | mg | VIAL | |
| 1705006 | L-Tyrosine (500 mg) | Reference Standard | 60-18-4 | 500 | mg | VIAL | |
| 1708503 | L-Valine (200 mg) | Reference Standard | 72-18-4 | 200 | mg | VIAL | |
| 1295822 | L-alpha-Glycerophosphorylethanolamine (25 mg) | Reference Standard | 33049-08-0 | 25 | mg | VIAL | |
| 1295786 | L-alpha-Glycerylphosphorylcholine (300 mg) | Reference Standard | 28319-77-9 | 300 | mg | VIAL | |
| 1356654 | Labetalol Hydrochloride (200 mg) | Reference Standard | 32780-64-6 | 200 | mg | VIAL | |
| 1356723 | Labetalol Related Compound F (15 mg) (2-Hydroxy-5-[(4-phenylbutan-2-yl)glycyl]benzamide hydrochloride) | Reference Standard | 96441-14-4 | 15 | mg | VIAL | |
| 1357147 | Lacosamide Related Compound D (30 mg) (2-Amino-N-benzyl-3-methoxypropanamide oxalate) | Reference Standard | 1379592-19-4 | 30 | mg | VIAL | |
| 1357103 | Lacosamide CV (250 mg) ((+)-(R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide) | Reference Standard | 175481-36-4 | 250 | mg | VIAL | |
| 1357125 | Lacosamide Related Compound B (30 mg) (2-Acetamido-3-(benzylamino)-3-oxopropyl acetate) | Reference Standard | 1822463-67-1 | 30 | mg | VIAL | |
| 1357170 | Lacosamide Related Compound F (30 mg) (2-Acetamido-N-benzyl-3-hydroxypropanamide) | Reference Standard | 171623-02-2 | 30 | mg | VIAL | |
| 1357158 | Lacosamide S-Enantiomer (30 mg) ((S)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide) | Reference Standard | 175481-37-5 | 30 | mg | VIAL | |
| 1356698 | Lactase (200 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 9031-11-2 | 200 | mg | VIAL | |
| 1356734 | Lactic Acid (1.5 mL/ampule; 3 ampules) | Reference Standard | 50-21-5 | 4.5 | mL | AMPULE | |
| 1356687 | Lactitol (500 mg) | Reference Standard | 81025-04-9 | 500 | mg | VIAL | |
| 1356825 | Lactobionic Acid (200 mg) | Reference Standard | N/A | 200 | mg | VIAL | |
| 1356701 | Lactose Monohydrate (500 mg) | Reference Standard | 64044-51-5 | 500 | mg | VIAL | |
| 1356803 | Lactulose (1 g) | Reference Standard | 4618-18-2 | 1 | g | VIAL | |
| 1048415 | Lagerstroemia speciosa Leaf Dry Extract (1g) | Reference Standard | N/A | 1 | g | VIAL | |
| 1356836 | Lamivudine (200 mg) | Reference Standard | 134678-17-4 | 200 | mg | VIAL | |
| 1356847 | Lamivudine Resolution Mixture A (10 mg) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1356858 | Lamivudine Resolution Mixture B (10 mg) (This is a mixture of lamivudine (about 94%) and lamivudine diastereomer (about 6%)) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1356869 | Lamivudine Resolution Mixture C (0.8 mg) | Reference Standard | N/A | 0.8 | mg | VIAL | |
| 1356756 | Lamotrigine (150 mg) | Reference Standard | 84057-84-1 | 150 | mg | VIAL | |
| 1356778 | Lamotrigine Related Compound B (20 mg) (2,3-dichlorobenzoic acid) | Reference Standard | 50-45-3 | 20 | mg | VIAL | |
| 1356789 | Lamotrigine Related Compound C (10 mg) (3-amino-6-(2,3-dichlorophenyl)-1,2,4-triazin-5(4H)-one) | Reference Standard | 252186-78-0 | 10 | mg | VIAL | |
| 1356790 | Lamotrigine Related Compound D (10 mg) (N-[5-amino-6-(2,3-dichlorophenyl)-1,2,4-triazin-3-yl]-2,3-dichlorobenzamide) | Reference Standard | 252186-79-1 | 10 | mg | VIAL | |
| 1356880 | Lanolin (20 g) | Reference Standard | 8006-54-0 | 20 | g | BOTTLE | |
| 1356905 | Lanolin Alcohols (5 g) | Reference Standard | 8027-33-6 | 5 | g | BOTTLE | |
| 1356916 | Lansoprazole (150 mg) | Reference Standard | 103577-45-3 | 150 | mg | VIAL | |
| 1356927 | Lansoprazole Related Compound A (25 mg) (2-({[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl}sulfonyl)benzimidazole) | Reference Standard | 131926-99-3 | 25 | mg | VIAL | |
| 1356931 | Lansoprazole Related Compound B (25 mg) (2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-pyridin-2-yl]methyl]sulfanyl]-1H-benzimidazole monohydrate) | Reference Standard | 1288338-69-1 | 25 | mg | VIAL | |
| 1357475 | Latanoprost (50 mg) | Reference Standard | 130209-82-4 | 50 | mg | VIAL | |
| 1357486 | Latanoprost Related Compound A (50 mg) (Isopropyl (E)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate) | Reference Standard | 913258-34-1 | 50 | mg | VIAL | |
| 1357497 | Latanoprost Related Compound B (25 mg) (Isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3S)-3-hydroxy-5-phenylpentyl]cyclopentyl]-5-heptenoate) | Reference Standard | 145773-22-4 | 25 | mg | VIAL | |
| 1357522 | Latanoprost Related Compound D (25 mg) (COLD SHIPMENT REQUIRED) (Isopropyl (Z)-7-{(1R,2R,3R,5S)-2-[(R)-5-phenyl-3-(triethylsilyloxy)pentyl]-3,5-bis(triethylsilyloxy)cyclopentyl}hept-5-enoate) | Reference Standard | 477884-78-9 | 25 | mg | VIAL | |
| 1357533 | Latanoprost Related Compound E (25 mg) ((Z)-7-{(1R,2R,3R,5S)-3,5-Dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}-5-heptenoic acid) | Reference Standard | 41639-83-2 | 25 | mg | VIAL | |
| 1356949 | Lauric Acid (500 mg) | Reference Standard | 143-07-7 | 500 | mg | VIAL | |
| 1356945 | Lauroyl Arginine (100 mg) (dodecanoylarginine hydrochloride) | Reference Standard | N/A | 100 | mg | VIAL | |
| 1356950 | Lauroyl Polyoxylglycerides 1500 (500 mg) | Reference Standard | 121548-04-7 | 500 | mg | VIAL | |
| 1356993 | Lauroyl Polyoxylglycerides 300 (500 mg) | Reference Standard | 12737-91-6 | 500 | mg | AMPULE | |
| 1356891 | Lauryl Alcohol (125 mg) | Reference Standard | 112-53-8 | 125 | mg | VIAL | |
| 1356960 | Leflunomide (200 mg) | Reference Standard | 75706-12-6 | 200 | mg | VIAL | |
| 1357045 | Leflunomide Related Compound A (100 mg) (4-(trifluoromethyl)aniline) | Reference Standard | 455-14-1 | 100 | mg | AMPULE | |
| 1357056 | Leflunomide Related Compound B (20 mg) (Z)-2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)but-2-enamide | Reference Standard | 163451-81-8 | 20 | mg | VIAL | |
| 1357067 | Leflunomide Related Compound C (10 mg) (N-(3'-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide) | Reference Standard | 61643-23-0 | 10 | mg | VIAL | |
| 1356971 | Letrozole (200 mg) | Reference Standard | 112809-51-5 | 200 | mg | VIAL | |
| 1356982 | Letrozole Related Compound A (25 mg) (4,4'-(1H-1,3,4-triazol-1-ylmethylene)dibenzonitrile) | Reference Standard | 112809-52-6 | 25 | mg | VIAL | |
| 1358004 | Leucovorin Calcium (500 mg) | Reference Standard | 1492-18-8 | 500 | mg | VIAL | |
| 1358503 | Leuprolide Acetate (1.97 mg) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | 74381-53-6 | 1.97 | mg | VIAL | |
| 1358784 | Levalbuterol Hydrochloride (200 mg) | Reference Standard | 50293-90-8 | 200 | mg | VIAL | |
| 1358795 | Levalbuterol Related Compound A (30 mg) (4-(2-tert-Butylamino-ethyl)-2-hydroxymethyl-phenol) | Reference Standard | 1823256-56-9 | 30 | mg | VIAL | |
| 1358809 | Levalbuterol Related Compound B (20 mg) (alpha-[{(1,1-Dimethylethyl)amino}methyl]-4-hydroxy-3-methyl-benzenemethanol) | Reference Standard | 18910-68-4 | 20 | mg | VIAL | |
| 1358810 | Levalbuterol Related Compound C (30 mg) (alpha-[{(1,1-Dimethylethyl)amino}methyl]-4-hydroxy-3-(methoxymethyl)-benzenemethanol) | Reference Standard | 18910-70-8 | 30 | mg | | |
| 1358820 | Levalbuterol Related Compound D (30 mg) (5-[2-{(1,1-dimethylethyl)amino}-1-hydroxyethyl]-2-hydroxy-benzaldehyde sulfate (2:1)) | Reference Standard | N/A | 30 | mg | | |
| 1358831 | Levalbuterol Related Compound E (30 mg) (alpha-[{(1,1-Dimethylethyl)amino}methyl]-3-(ethoxy-methyl)-4-hydroxy-benzenemethanol) | Reference Standard | 754926-25-5 | 30 | mg | VIAL | |
| 1358842 | Levalbuterol Related Compound F (30 mg) ((R)-1-[4-(Benzyloxy)-3-(hydroxymethyl)phenyl]-2-(tert-butylamino)ethan-1-ol) | Reference Standard | 174607-68-2 | 30 | mg | VIAL | |
| 1358864 | Levalbuterol Related Compound H (10 mg) (4-[2-(tert-Butylamino)-1-methoxyethyl]-2-(hydroxymethyl)phenol acetate) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1359302 | Levamisole Hydrochloride (125 mg) | Reference Standard | 16595-80-5 | 125 | mg | VIAL | |
| 1359404 | Levetiracetam (200 mg) | Reference Standard | 102767-28-2 | 200 | mg | | |
| 1359415 | Levetiracetam Racemic Mixture (15 mg) (1:1 mixture of levetiracetam S-enantiomer-(2S)-2-(2-oxopyrrolidin-1-yl)butanamide and levetiracetam R-enantiomer (2R)-2-(2-oxopyrrolidin-1-yl)butanamide) | Reference Standard | 33996-58-6 | 15 | mg | VIAL | |
| 1359426 | Levetiracetam Related Compound A (20 mg) ((S)-N-(1-amino-1-oxobutan-2-yl)-4-chlorobutanamide) | Reference Standard | 102767-31-7 | 20 | mg | VIAL | |
| 1359437 | Levetiracetam Related Compound B (20 mg) ((S)-2-aminobutanamide hydrochloride) | Reference Standard | 7682-20-4 | 20 | mg | VIAL | |
| 1359506 | Levmetamfetamine CII (75 mg) | Reference Standard | 33817-09-3 | 75 | mg | AMPULE | |
| 1359801 | Levobunolol Hydrochloride (200 mg) | Reference Standard | 27912-14-7 | 200 | mg | VIAL | |
| 1359856 | Levocabastine Hydrochloride (50 mg) | Reference Standard | 79547-78-7 | 50 | mg | VIAL | |
| 1359867 | Levocabastine Related Compound A (50 mg) (1-[cis-4-cyano-4-(4-fluorophenyl)cyclohexyl]-4-phenylpiperidine-4-carboxylic acid hydrochloride) | Reference Standard | 80139-91-9 | 50 | mg | VIAL | |
| 1359903 | Levocarnitine (400 mg) | Reference Standard | 541-15-1 | 400 | mg | VIAL | |
| 1359925 | Levocarnitine Related Compound A (100 mg) (2-propen-1-aminium, 3-carboxy-N,N,N-trimethyl-, chloride) | Reference Standard | 6538-82-5 | 100 | mg | VIAL | |
| 1359958 | Levocetirizine Amide (75 mg) | Reference Standard | 909779-33-5 | 75 | mg | VIAL | |
| 1359969 | Levocetirizine Dihydrochloride (200 mg) | Reference Standard | 130018-87-0 | 200 | mg | VIAL | |
| 1361009 | Levodopa (200 mg) | Reference Standard | 59-92-7 | 200 | mg | VIAL | |
| 1361010 | Levodopa Related Compound A (50 mg) (3-(2,4,5-Trihydroxyphenyl)-L-alanine) (COLD SHIPMENT REQUIRED) | Reference Standard | 27244-64-0 | 50 | mg | VIAL | |
| 1420006 | Levodopa Related Compound B (50 mg) (3-methoxytyrosine) | Reference Standard | 7636-26-2 | 50 | mg | VIAL | |
| 1362103 | Levofloxacin (200 mg) | Reference Standard | 138199-71-0 | 200 | mg | VIAL | |
| 1362114 | Levofloxacin Related Compound A (25 mg) ((S)-9-fluoro-3-methyl-10-(piperazin-1-yl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid) | Reference Standard | 117707-40-1 | 25 | mg | VIAL | |
| 1362125 | Levofloxacin Related Compound B (35 mg) ((S)-9,10,difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid) | Reference Standard | 100986-89-8 | 35 | mg | VIAL | |
| 1362136 | Levofloxacin Related Compound C (25 mg) ((S)-ethyl 9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylate) | Reference Standard | 177472-30-9 | 25 | mg | VIAL | |
| 1362158 | Levofloxacin Related Compound E (25 mg) ((S)-9-Fluoro-2,3-dihydro-3-methyl-10-[2-(methylamino)ethylamino]-7-oxo-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid hydrochloride) | Reference Standard | 1346603-62-0 | 25 | mg | VIAL | |
| 1362169 | Levofloxacin Related Compound F (25 mg) ((S)-2,3-Dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid) | Reference Standard | 117620-85-6 | 25 | mg | VIAL | |
| 1179344 | Levomedetomidine (25 mg) ((R)-4-[1-(2,3-Dimethylphenyl)ethyl]-1H-imidazole hydrochloride) (25 mg) | Reference Standard | 190000-46-5 | 25 | mg | VIAL | |
| 1362307 | Levomenol (100 mg) | Reference Standard | 23089-26-1 | 100 | mg | | |
| 1362359 | Levomethorphan Solution (3 x 1.2 mL) (0.1 mg/mL 3-Methoxy-17-methylmorphinan in methanol) | Reference Standard | 125-70-2 | 3.6 | mL | AMPULE | |
| 1362500 | Levonordefrin (200 mg) | Reference Standard | 829-74-3 | 200 | mg | VIAL | |
| 1362602 | Levonorgestrel (125 mg) | Reference Standard | 797-63-7 | 125 | mg | VIAL | |
| 1364007 | Levorphanol Tartrate CII (500 mg) | Reference Standard | 67227-44-5 | 500 | mg | VIAL | |
| 1365000 | Levothyroxine (500 mg) | Reference Standard | 51-48-9 | 500 | mg | VIAL | |
| 1365043 | Levothyroxine Peak Identification Mixture (3 x 5 mL) (1 mg/mL) (COLD SHIPMENT REQUIRED) | Reference Standard | N/A | 15 | mL | AMPULE | |
| 1365065 | Levothyroxine Sodium (50 mg) | Reference Standard | 25416-65-3 (hydrate) | 50 | mg | VIAL | |
| 1366002 | Lidocaine (250 mg) | Reference Standard | 137-58-6 | 250 | mg | VIAL | |
| 1366013 | Lidocaine Hydrochloride (150 mg) | Reference Standard | 6108-05-0 | 150 | mg | VIAL | |
| 1366080 | Lidocaine Related Compound H (50 mg) (2-Chloro-N-(2,6-dimethylphenyl)acetamide) | Reference Standard | 1131-01-7 | 50 | mg | VIAL | |
| 1366567 | Linalool (0.3 mL) | Reference Standard | 78-70-6 | 0.3 | mL | AMPULE | |
| 1366578 | Linalyl Acetate (0.3 mL) | Reference Standard | 115-95-7 | 0.3 | mL | AMPULE | |
| 1366534 | Linarin (50 mg) | Reference Standard | 480-36-4 | 50 | mg | VIAL | |
| 1367005 | Lincomycin Hydrochloride (200 mg) | Reference Standard | 7179-49-9 | 200 | mg | VIAL | |
| 1367504 | Lindane (200 mg) | Reference Standard | 58-89-9 | 200 | mg | VIAL | |
| 1367515 | Lindane Related Compound A (25 mg) ((1R,2R,3R,4R,5S,6S)-1,2,3,4,5,6-Hexachlorocyclohexane) | Reference Standard | 319-84-6 | 25 | mg | VIAL | |
| 1367561 | Linezolid (200 mg) | Reference Standard | 165800-03-3 | 200 | mg | VIAL | |
| 1367639 | Linezolid R-Isomer (20 mg) (N-{[(R)-3-(3-Fluoro-4-morpholinophenyl)-2-oxo-5-oxazolidinyl]methyl}acetamide) | Reference Standard | 872992-20-6 | 20 | mg | VIAL | |
| 1367570 | Linezolid Related Compound A (20 mg) ((R)-5-(azidomethyl)-3-(3-fluoro-4-morpholinophenyl)oxazolidin-2-one) | Reference Standard | 168828-84-0 | 20 | mg | VIAL | |
| 1367581 | Linezolid Related Compound B (20 mg) ((S)-N-{[3-(3-Fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl]methyl}thioacetamide) | Reference Standard | 216868-57-4 | 20 | mg | VIAL | |
| 1367592 | Linezolid Related Compound C (20 mg) ((S)-5-(aminomethyl)-3-(3-fluoro-4-morpholinophenyl)oxazolidin-2-one) | Reference Standard | 168828-90-8 | 20 | mg | VIAL | |
| 1367606 | Linezolid Related Compound D (20 mg) ((R)-[3-(3-Fluoro-4-morpholinophenyl)-2-oxooxazolidin-5-yl]methyl methanesulfonate) | Reference Standard | 174649-09-3 | 20 | mg | VIAL | |
| 1367699 | Linolenyl Alcohol (5 x 30 mg) | Reference Standard | 506-44-5 | 150 | mg | AMPULE | |
| 1367708 | Linoleoyl Polyoxylglycerides (150 mg) | Reference Standard | N/A | 150 | mg | AMPULE | |
| 1367647 | Linoleyl Alcohol (5 X 30 mg) | Reference Standard | 506-43-4 | 150 | mg | AMPULE | |
| 1368008 | Liothyronine (250 mg) | Reference Standard | 6893-02-3 | 250 | mg | VIAL | |
| 1368019 | Liothyronine Sodium (COLD SHIPMENT REQUIRED) (200 mg) | Reference Standard | 55-06-1 | 200 | mg | VIAL | |
| 1368609 | Lisinopril (300 mg) | Reference Standard | 83915-83-7 | 300 | mg | VIAL | |
| 1368610 | Lisinopril Related Compound A (250 mg) ((S)-2-{(3S,8aS)-3-(4-aminobutyl)-1,4-dioxohexahydropyrrolo[1,2-alpha]pyrazin-2(1H)-yl}-4-phenylbutanoic acid) | Reference Standard | 328385-86-0 | 250 | mg | VIAL | |
| 1369000 | Lithium Carbonate (300 mg) | Reference Standard | 554-13-2 | 300 | mg | VIAL | |
| 1369055 | Lithol Rubine BK (100 mg) (2-Naphthalenecarboxylic acid, 3-hydroxy-4-[(E)-2-(4-methyl-2-sulfophenyl)diazenyl]-, calcium salt (1:1)) | Reference Standard | 5281-04-9 | 100 | mg | VIAL | |
| 1369419 | Lomustine (200 mg) | Reference Standard | 13010-47-4 | 200 | mg | VIAL | |
| 1369431 | Lomustine Related Compound B (25 mg) (1-(2-Chloroethyl)-3-cyclohexylurea) | Reference Standard | 08-11-7 | 25 | mg | VIAL | |
| 1369442 | Lomustine Related Compound C (25 mg) (1,3-Dicyclohexylurea) | Reference Standard | 2387-23-7 | 25 | mg | VIAL | |
| 1369453 | Lomustine Related Compound D (25 mg) (3-(2-Chloroethyl)-1-cyclohexyl-1-nitrosourea) | Reference Standard | 54749-91-6 | 25 | mg | VIAL | |
| 1369689 | Lonicera Japonica Flower Dry Extract (500 mg) | Reference Standard | N/A | 500 | mg | VIAL | |
| 1369703 | Lonicera Macranthoides Flower Dry Extract (500 mg) (Mixture, with identified compendial components Dipsacoside B, Macranthoidin A and Macranthoidin B) | Reference Standard | N/A | 500 | mg | VIAL | |
| 1370000 | Loperamide Hydrochloride (200 mg) | Reference Standard | 34552-83-5 | 200 | mg | VIAL | |
| 1370065 | Loperamide Related Compound F (25 mg) (1r,4s)-4-(4-Chlorophenyl)-1-[4-(dimethylamino)-4-oxo-3,3-diphenylbutyl]-4-hydroxypiperidine 1-oxide hydrate) | Reference Standard | 106900-12-3 | 25 | mg | VIAL | |
| 1370010 | Loperamide System Suitability Mixture (25 mg) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1370101 | Lopinavir (350 mg) | Reference Standard | 192725-17-0 | 350 | mg | VIAL | |
| 1370156 | Lopinavir System Suitability Mixture (10 mg) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1370270 | Loratadine (200 mg) | Reference Standard | 79794-75-5 | 200 | mg | VIAL | |
| 1370280 | Loratadine Related Compound A (15 mg) (8-Chloro-5,6-dihydro-11-(piperidin-4-ylidene)-11H-benzo[5,6]cyclohepta[1,2-b]pyridine) | Reference Standard | 100643-71-8 | 15 | mg | VIAL | |
| 1370291 | Loratadine Related Compound B (15 mg) (8-Chloro-11-(1-methylpiperidin-4-ylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1370269 | Loratadine Related Compound C (15 mg) (8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-one) | Reference Standard | 31251-41-9 | 15 | mg | VIAL | |
| 1370305 | Lorazepam CIV (200 mg) | Reference Standard | 846-49-1 | 200 | mg | VIAL | |
| 1370327 | Lorazepam Related Compound A (25 mg) (7-Chloro-5-(o-chlorophenyl)-1,3-dihydro-3-acetoxy-2H-1,4-benzodiazepin-2-one) | Reference Standard | 2848-96-6 | 25 | mg | VIAL | |
| 1370338 | Lorazepam Related Compound B (25 mg) (2-Amino-2',5-dichlorobenzophenone) | Reference Standard | 2958-36-3 | 25 | mg | VIAL | |
| 1370349 | Lorazepam Related Compound C (25 mg) (6-Chloro-4-(o-chlorophenyl)-2-quinazolinecarboxaldehyde) | Reference Standard | 93955-15-8 | 25 | mg | VIAL | |
| 1370350 | Lorazepam Related Compound D (25 mg) (6-Chloro-4-(o-chlorophenyl)-2-quinazolinecarboxylic Acid) | Reference Standard | 54643-79-7 | 25 | mg | VIAL | |
| 1370360 | Lorazepam Related Compound E (25 mg) (6-Chloro-4-(o-chlorophenyl)-2-quinazoline methanol) | Reference Standard | 773871-49-1 | 25 | mg | VIAL | |
| 1370462 | Losartan Potassium (150 mg) | Reference Standard | 124750-99-8 | 150 | mg | VIAL | |
| 1370473 | Losartan Related Compound A (20 mg) (2-Butyl-4-chloro-1H-imidazole-5-carbaldehyde) | Reference Standard | 83857-96-9 | 20 | mg | VIAL | |
| 1370484 | Losartan Related Compound B (20 mg) (2-Butyl-4-chloro-(1-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1H-imidazol-5-yl)methyl acetate) | Reference Standard | 1006062-27-6 | 20 | mg | VIAL | |
| 1370495 | Losartan Related Compound C (20 mg) (2-Butyl-4-chloro-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-imidazol-5-carbaldehyde) | Reference Standard | 114798-36-6 | 20 | mg | VIAL | |
| 1370509 | Losartan Related Compound D (20 mg) (5-[4'-({2-Butyl-5-[(5-{4'-[(2-butyl-4-chloro-5-hydroxymethyl-1H-imidazol-1-yl)methyl]biphenyl-2-yl}-1H-tetrazol-1-yl)methyl]-4-chloro-1H-imidazol-1-yl}methyl)biphenyl-2-yl]tetrazol, potassium salt) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1370510 | Losartan Related Compound E (20 mg) (5-[4'-({2-Butyl-5-[(5-{4'-[(2-butyl-4-chloro-5-hydroxymethyl-1H-imidazol-1-yl)methyl]biphenyl-2-yl}-2H-tetrazol-2-yl)methyl]-4-chloro-1H-imidazol-1-yl}methyl)biphenyl-2-yl]tetrazol, potassium salt) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1370600 | Lovastatin (125 mg) | Reference Standard | 75330-75-5 | 125 | mg | VIAL | |
| 1236833 | Lovastatin Epimer Mixture (25 mg) (Epilovastatin and Lovastatin 1:1 Mixture) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1370655 | Lovastatin Impurity Identification Mixture (30 mg) | Reference Standard | N/A | 30 | mg | VIAL | |
| 1370611 | Lovastatin Related Compound A (20 mg) (4,4a-Dihydrolovastatin) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1448854 | Low Molecular Weight Heparin Molecular Weight Calibrant (10.6 mg) | Reference Standard | 9041-08-1 | 10.6 | mg | AMPULE | |
| 1304118 | Low Molecular Weight Heparin for Bioassays (5 mg) | Reference Standard | 9041-08-1 | 5 | mg | AMPULE | |
| 1304130 | Low Molecular Weight Heparin for Boron Analysis (300 mg) | Reference Standard | 9041-08-1 | 300 | mg | VIAL | |
| 1546809 | Low-Density Polyethylene (3 strips) | Reference Standard | 9002-88-4 | 1 | EA | OTHER | |
| 1370688 | Low-substituted Carboxymethylcellulose Sodium (100 mg) | Reference Standard | 9004-32-4 | 100 | mg | VIAL | |
| 1329822 | Low-substituted Hydroxypropyl Cellulose (100 mg) | Reference Standard | 9004-64-2 | 100 | mg | VIAL | |
| 1370699 | Loxapine N-Oxide (25 mg) (4-(2-Chlorodibenzo[b,f][1,4]oxazepin-11-yl)-1-methylpiperazine 1-oxide) | Reference Standard | 25967-34-4 | 25 | mg | VIAL | |
| 1370713 | Loxapine Related Compound A (20 mg) (3-Chloro-11-(4-methylpiperazin-1-yl)dibenzo[b,f][1,4]oxazepine) | Reference Standard | 3454-96-4 | 20 | mg | VIAL | |
| 1370702 | Loxapine Succinate (125 mg) | Reference Standard | 27833-64-3 | 125 | mg | VIAL | |
| 1370779 | Lufenuron (200 mg) | Reference Standard | 103055-07-8 | 200 | mg | VIAL | |
| 1370724 | Lufenuron Related Compound B (15 mg) (N-[(2,5-Dichloro-4-hydroxyphenyl)carbamoyl]-2,6-difluorobenzamide) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1370735 | Lufenuron Related Compound C (15 mg) (N-[3-Chloro-4-(1,1,2,3,3,3-hexafluoropropoxy)phenylcarbamoyl]-2,6-difluorobenzamide) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1370780 | Lufenuron Related Compound G (15 mg) (2,5-Dichloro-4-[3-(2,6-difluorobenzoyl)ureido]phenyl phenyl carbonate) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1370746 | Lumefantrine (100 mg) | Reference Standard | 82186-77-4 | 100 | mg | VIAL | |
| 1370757 | Lumefantrine Related Compound A (25 mg) ((RS, Z)-2-(Dibutylamino)-2-(2,7-dichloro-9-(4-chlorobenzylidene)-9H-fluoren-4-yl)ethanol hydrochloride) | Reference Standard | NA | 25 | mg | VIAL | |
| 1370804 | Lutein (3 X 50 mg) | Reference Standard | 127-40-2 | 150 | mg | AMPULE | |
| 1370837 | Luteolin 7-O-Glucoside (30 mg) (2-(3,4-Dihydroxyphenyl)-5-hydroxy-4-oxo-4H-chromen-7-yl beta-D-glucopyranoside) | Reference Standard | 5373-11-5 | 30 | mg | VIAL | |
| 1370881 | Lycopene Preparation (500 mg) | Reference Standard | 502-65-8 | 500 | mg | VIAL | |
| 1370906 | Lynestrenol (20 mg) ((17alpha) -19-Norpregn-4-en-20-yn-17-ol) | Reference Standard | 52-76-6 | 20 | mg | VIAL | |
| 1711133 | Lypressin (2 mg) (8-L-lysine vasopressin) (COLD SHIPMENT REQUIRED) | Reference Standard | 50-57-7 | 2 | mg | VIAL | |
| 1372050 | Lysophosphatidylcholine (250 mg) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | 9008-30-4 | 250 | mg | | |
| 1372061 | Lysophosphatidylcholine (Soy) (40 mg) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | 9008-30-4 | 40 | mg | VIAL | |
| 1373008 | Mafenide Acetate (200 mg) | Reference Standard | 13009-99-9 | 200 | mg | VIAL | |
| 1286209 | Mafenide Related Compound A (50 mg) (4-Formylbenzenesulfonamide) | Reference Standard | 3240-35-5 | 50 | mg | VIAL | |
| 1374000 | Magaldrate (200 mg) | Reference Standard | 74978-16-8 | 200 | mg | VIAL | |
| 1374226 | Magnesium Carbonate (2 g) | Reference Standard | 23389-33-5 | 2 | g | VIAL | |
| 1374248 | Magnesium Chloride (1 g) | Reference Standard | 7791-18-6 | 1 | g | VIAL | |
| 1374259 | Magnesium Citrate (500 mg) | Reference Standard | 3344-18-1 | 500 | mg | VIAL | |
| 1374260 | Magnesium Hydroxide (1 g) | Reference Standard | 1309-42-8 | 1 | g | VIAL | |
| 1374281 | Magnesium Oxide (500 mg) | Reference Standard | 1309-48-4 | 500 | mg | VIAL | |
| 1374292 | Magnesium Phosphate (2 g) (AS) | Reference Standard | 7757-87-1 | 2 | g | VIAL | |
| 1374306 | Magnesium Salicylate (200 mg) | Reference Standard | 18917-95-8 | 200 | mg | VIAL | |
| 1374361 | Magnesium Sulfate (1 g) (Magnesium Sulfate (1:1) heptahydrate) | Reference Standard | 10034-99-8 | 1 | g | | |
| 1374408 | Malathion (500 mg) | Reference Standard | 121-75-5 | 500 | mg | AMPULE | |
| 1374500 | Maleic Acid (300 mg) | Reference Standard | 110-16-7 | 300 | mg | VIAL | |
| 1374601 | Malic Acid (500 mg) | Reference Standard | 6915-15-7 | 500 | mg | VIAL | |
| 1374907 | Maltitol (200 mg) | Reference Standard | 585-88-6 | 200 | mg | VIAL | |
| 1375003 | Maltol (500 mg) | Reference Standard | 118-71-8 | 500 | mg | VIAL | |
| 1375025 | Maltose Monohydrate (500 mg) | Reference Standard | 6363-53-7 | 500 | mg | VIAL | |
| 1375047 | Maltotriose (500 mg) | Reference Standard | 1109-28-0 | 500 | mg | VIAL | |
| 1375058 | Mandelic Acid (500 mg) | Reference Standard | 90-64-2 | 500 | mg | VIAL | |
| 1375149 | Manganese Sulfate (1 g) (AS) | Reference Standard | 10034-96-5 | 1 | g | VIAL | |
| 1375173 | Mangifera Indica Bark Dry Extract (500 mg) | Reference Standard | 4773-96-0 | 500 | mg | VIAL | |
| 1375156 | Mangiferin (15 mg) | Reference Standard | 4773-96-0 | 15 | mg | VIAL | |
| 1375105 | Mannitol (1.5 g) | Reference Standard | 69-65-8 | 1.5 | g | VIAL | |
| 1375182 | Mannose (500 mg) | Reference Standard | 3458-28-4 | 500 | mg | VIAL | |
| 1375207 | Maprotiline Hydrochloride (200 mg) | Reference Standard | 10347-81-6 | 200 | mg | VIAL | |
| 1375241 | Maprotiline Related Compound D (15 mg) (3-(9,10-dihydro-9,10-ethanoanthracen-9-yl)-N-methylprop-2-en-1-amine, hydrochloride) | Reference Standard | 38849-14-8 | 15 | mg | VIAL | |
| 1539803 | Maritime Pine Extract (2 g) | Reference Standard | 90082-75-0 | 2 | g | VIAL | |
| 1375295 | Marmelosin (20 mg) | Reference Standard | 482-44-0 | 20 | mg | VIAL | |
| 1375502 | Mebendazole (200 mg) | Reference Standard | 31431-39-7 | 200 | mg | VIAL | |
| 1375524 | Mebendazole Related Compound D (15 mg) (Methyl 5-benzoyl-1-methylbenzimidazol-2-ylcarbamate) | Reference Standard | 132119-11-0 | 15 | mg | VIAL | |
| 1375706 | Mebrofenin (100 mg) | Reference Standard | 78266-06-5 | 100 | mg | VIAL | |
| 1376006 | Mecamylamine Hydrochloride (200 mg) | Reference Standard | 826-39-1 | 200 | mg | | |
| 1376017 | Mecamylamine Related Compound A (10 mg) (N,1,7,7-tetramethyl bicyclo [2.2.1] heptan-2-amine hydrochloride) | Reference Standard | 91369-45-8 | 10 | mg | VIAL | |
| 1376505 | Mechlorethamine Hydrochloride (100 mg) (International Restricted Sales Item) | Reference Standard | 55-86-7 | 100 | mg | VIAL | |
| 1377009 | Meclizine Hydrochloride (500 mg) | Reference Standard | 31884-77-2 | 500 | mg | VIAL | |
| 1377010 | Meclizine Related Compound A (15 mg) (4-Chlorobenzhydrol) | Reference Standard | 119-56-2 | 15 | mg | VIAL | |
| 1377029 | Meclizine Related Compound B (15 mg) (1-[(4-Chlorophenyl)(phenyl)methyl]-4-(2-methylbenzyl)piperazine dihydrochloride monohydrate) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1377508 | Meclocycline Sulfosalicylate (300 mg) | Reference Standard | 73816-42-9 | 300 | mg | VIAL | |
| 1377803 | Meclofenamate Sodium (500 mg) | Reference Standard | 67254-91-5 | 500 | mg | VIAL | |
| 1378001 | Medroxyprogesterone Acetate (200 mg) | Reference Standard | 71-58-9 | 200 | mg | VIAL | |
| 1378012 | Medroxyprogesterone Acetate Related Compound A (25 mg) (6alpha-Methyl-3,20-dioxopregnan-17-yl acetate) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1378023 | Medroxyprogesterone Acetate Related Compound B (25 mg) (17-Hydroxy-6alpha-methylpregn-4-ene-3,20-dione) | Reference Standard | 520-85-4 | 25 | mg | VIAL | |
| 1379605 | Mefenamic Acid (200 mg) | Reference Standard | 61-68-7 | 200 | mg | VIAL | |
| 1379059 | Mefloquine Hydrochloride (100 mg) | Reference Standard | 51773-92-3 | 100 | mg | VIAL | |
| 1379060 | Mefloquine Related Compound A (20 mg) (threo-mefloquine) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1379106 | Megestrol Acetate (250 mg) | Reference Standard | 595-33-5 | 250 | mg | VIAL | |
| 1379128 | Megestrol Acetate Related Compound C (20 mg) (6,17a-beta-Dimethyl-3,17-dioxo-17a-homoandrosta-4,6-diene-17a-alpha-yl acetate) | Reference Standard | 74910-22-8 | 20 | mg | VIAL | |
| 1379139 | Megestrol Acetate Related Compound D (20 mg) (6-Methylene-3,20-dioxopregn-4-en-17-yl acetate) | Reference Standard | 32634-95-0 | 20 | mg | VIAL | |
| 1379172 | Megestrol Acetate Related Compound H (20 mg) | Reference Standard | 907193-65-1 | 20 | mg | VIAL | |
| 1379140 | Meglumine (500 mg) | Reference Standard | 6284-40-8 | 500 | mg | VIAL | |
| 1379183 | Melamine (250 mg) (2,4,6-Triamino-1,3,5-triazine) | Reference Standard | 108-78-1 | 250 | mg | VIAL | |
| 1380105 | Melatonin (150 mg) | Reference Standard | 73-31-4 | 150 | mg | VIAL | |
| 1380116 | Melatonin Related Compound A (15 mg) (2-(5-methoxy-1H-indol-3-yl)ethanamine) | Reference Standard | 608-07-1 | 15 | mg | VIAL | |
| 1379254 | Melengestrol Acetate (125 mg) | Reference Standard | 2919-66-6 | 125 | mg | VIAL | |
| 1379265 | Melengestrol Acetate Related Compound A (25 mg) (16-Methylene-3,20-dioxopregn-4-en-17-yl acetate) | Reference Standard | 6815-51-6 | 25 | mg | VIAL | |
| 1379276 | Melengestrol Acetate Related Compound B (25 mg) (6,16-Dimethylene-3,20-dioxopregn-4-en-17-yl acetate) | Reference Standard | 80097-73-0 | 25 | mg | VIAL | |
| 1379401 | Meloxicam (400 mg) | Reference Standard | 71125-38-7 | 400 | mg | VIAL | |
| 1379412 | Meloxicam Related Compound A (25 mg) (ethyl-4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylate- 1,1-dioxide) | Reference Standard | 24683-26-9 | 25 | mg | VIAL | |
| 1379423 | Meloxicam Related Compound B (25 mg) (5-Methylthiazol-2-amine) | Reference Standard | 7305-71-7 | 25 | mg | VIAL | |
| 1379434 | Meloxicam Related Compound C (30 mg) (Isopropyl 4-hydroxy-2-methyl-2H-1,2-benzothiazine-3-carboxylate-1,1-dioxide) | Reference Standard | N/A | 30 | mg | VIAL | |
| 1379300 | Melphalan Hydrochloride (200 mg) | Reference Standard | 1465-26-5 | 200 | mg | VIAL | |
| 1380502 | Memantine Hydrochloride (150 mg) | Reference Standard | 41100-52-1 | 150 | mg | BOTTLE | |
| 1380513 | Memantine Related Compound A (50 mg) (1,3-Dimethyladamantane) | Reference Standard | 702-79-4 | 50 | mg | AMPULE | |
| 1380524 | Memantine Related Compound B (15 mg) (3,5-Dimethyladamantane-1-ol) | Reference Standard | 707-37-9 | 15 | mg | VIAL | |
| 1380535 | Memantine Related Compound C (50 mg) (1-Chloro-3,5-dimethyladamantane) | Reference Standard | 707-36-8 | 50 | mg | AMPULE | |
| 1380546 | Memantine Related Compound D (50 mg) (1-Bromo-3,5-dimethyladamantane) | Reference Standard | 941-37-7 | 50 | mg | AMPULE | |
| 1380557 | Memantine Related Compound E (15 mg) (N-3,5-Dimethyladamantan-1-yl formamide) | Reference Standard | 351329-88-9 | 15 | mg | VIAL | |
| 1380568 | Memantine Related Compound F (50 mg) (3-Amino-5,7-dimethyladamantan-1-ol hydrochloride) | Reference Standard | 356572-08-2 | 50 | mg | VIAL | |
| 1380579 | Memantine Related Compound G (30 mg) (3-Methyladamantan-1-amine hydrochloride) | Reference Standard | 33103-93-4 | 30 | mg | VIAL | |
| 1380580 | Memantine Related Compound H (30 mg) (3,5,7-Trimethyladamantan-1-amine hydrochloride) | Reference Standard | 15210-60-3 | 30 | mg | VIAL | |
| 1380591 | Memantine Related Compound I (30 mg) (3-Ethyladamantan-1-amine hydrochloride) | Reference Standard | 80121-67-1 | 30 | mg | VIAL | |
| 1381006 | Menadione (200 mg) | Reference Standard | 58-27-5 | 200 | mg | VIAL | |
| 1381083 | Menaquinone-4 (50 mg) (2-Methyl-3-[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]naphthalene-1,4-dione) (COLD SHIPMENT REQUIRED) | Reference Standard | 863-61-6 | 50 | mg | VIAL | |
| 1381119 | Menaquinone-7 (3 x 50 mg) (Vitamin K2) | Reference Standard | 2124-57-4 | 150 | mg | AMPULE | |
| 1381200 | Menhaden Oil (2 mL) (COLD SHIPMENT REQUIRED) | Reference Standard | 8002-50-4 | 2 | mL | AMPULE | |
| 1381709 | Menthol (250 mg) | Reference Standard | 2216-51-5 | 250 | mg | VIAL | |
| 1383001 | Meperidine Hydrochloride CII (200 mg) | Reference Standard | 50-13-5 | 200 | mg | VIAL | |
| 1386000 | Mephobarbital CIV (250 mg) | Reference Standard | 115-38-8 | 250 | mg | VIAL | |
| 1387002 | Mepivacaine Hydrochloride (200 mg) | Reference Standard | 1722-62-9 | 200 | mg | VIAL | |
| 1389008 | Meprobamate CIV (200 mg) | Reference Standard | 57-53-4 | 200 | mg | VIAL | |
| 1381742 | Meradimate (500 mg/ampule) (Menthyl Anthranilate) (List Chemical) | Reference Standard | 134-09-8 | 500 | mg | AMPULE | |
| 1392002 | Mercaptopurine (500 mg) | Reference Standard | 6112-76-1 | 500 | mg | VIAL | |
| 1392454 | Meropenem (300 mg) | Reference Standard | 119478-56-7 | 300 | mg | VIAL | |
| 1392705 | Mesalamine (200 mg) | Reference Standard | 89-57-6 | 200 | mg | VIAL | |
| 1392807 | Mesna (200 mg) | Reference Standard | 19767-45-4 | 200 | mg | VIAL | |
| 1392818 | Mesna Related Compound A (50 mg) (2-(Acetylthio)ethane-1-sulfonic acid, potassium salt, crystal adduct with potassium chloride) | Reference Standard | N/A | 50 | mg | | |
| 1392829 | Mesna Related Compound B (50 mg) (2,2'-Disulfanediylbis(ethane-1-sulfonic acid), dipotassium salt, crystal adduct with sodium chloride) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1733119 | Meso-Zeaxanthin (5x 30 mg) (Beta-Beta-Carotene-3,3'-diol, (3R ,3' S)-) | Reference Standard | 31272-50-1 | 150 | mg | AMPULE | |
| 1393005 | Mesoridazine Besylate (25 mg) | Reference Standard | 32672-69-8 | 25 | mg | VIAL | |
| 1394008 | Mestranol (200 mg) | Reference Standard | 72-33-3 | 200 | mg | VIAL | |
| 1395204 | Metacresol (1 mL) | Reference Standard | 108-39-4 | 1 | mL | AMPULE | |
| 1395500 | Metaproterenol Sulfate (200 mg) | Reference Standard | 5874-97-5 | 200 | mg | VIAL | |
| 1396003 | Metaraminol Bitartrate (200 mg) | Reference Standard | 33402-03-8 | 200 | mg | VIAL | |
| 1396058 | Metaraminol Enantiomer (25 mg) (3-[(1S,2R)-2-Amino-1-hydroxypropyl]phenol D-tartrate) | Reference Standard | 27303-40-8 | 25 | mg | VIAL | |
| 1396036 | Metaraminol Related Compound A (25 mg) ((E)-1-[3-(benzyloxy)phenyl]-2-(hydroxyimino)propan-1-one) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1396047 | Metaraminol Related Compound B (25 mg) (2-Amino-1-[3-(benzyloxy)phenyl]propan-1-ol) | Reference Standard | 1940-82-5 | 25 | mg | VIAL | |
| 1396149 | Metaxalone (200 mg) | Reference Standard | 1665-48-1 | 200 | mg | VIAL | |
| 1396150 | Metaxalone Related Compound A (10 mg) (4-((3,5-dimethylphenoxy)methyl)imidazolidin-2-one) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1396168 | Metaxalone Related Compound B (25 mg) (1-amino-3-(3,5-dimethylphenoxy)propan-2-ol) | Reference Standard | 66766-07-2 | 25 | mg | VIAL | |
| 1396171 | Metaxalone Related Compound C (25 mg) (Bis[2-hydroxy-3-(3,5-dimethylphenoxy)propyl]amine) | Reference Standard | 805972-34-3 | 25 | mg | VIAL | |
| 1396309 | Metformin Hydrochloride (200 mg) | Reference Standard | 1115-70-4 | 200 | mg | VIAL | |
| 1396310 | Metformin Related Compound A (30 mg) (1-Cyanoguanidine) | Reference Standard | 461-58-5 | 30 | mg | VIAL | |
| 1396331 | Metformin Related Compound B (25 mg) (1-Methylbiguanide hydrochloride) | Reference Standard | 1674-62-0 | 25 | mg | VIAL | |
| 1396342 | Metformin Related Compound C (25 mg) (N,N-Dimethyl-[1,3,5]triazine-2,4,6-triamine) | Reference Standard | 1985-46-2 | 25 | mg | VIAL | |
| 1396364 | Methacholine Chloride (5 x 150 mg) | Reference Standard | 62-51-1 | 750 | mg | VIAL | |
| 1396604 | Methacrylic Acid and Ethyl Acrylate Copolymer (1:1) (Methacrylic Acid Copolymer Type C) (200 mg) | Reference Standard | 25212-88-8 | 200 | mg | VIAL | |
| 1396400 | Methacrylic Acid and Methyl Methacrylate Copolymer (1:1) (200 mg) (Methacrylic Acid Copolymer Type A) | Reference Standard | 25086-15-1 | 200 | mg | VIAL | |
| 1396502 | Methacrylic Acid and Methyl Methacrylate Copolymer (1:2) (200 mg) (Methacrylic Acid Copolymer, Type B) | Reference Standard | 25086-15-1 | 200 | mg | VIAL | |
| 1397006 | Methacycline Hydrochloride (200 mg) | Reference Standard | 3963-95-9 | 200 | mg | VIAL | |
| 1398009 | Methadone Hydrochloride CII (200 mg) | Reference Standard | 1095-90-5 | 200 | mg | VIAL | |
| 1399001 | Methamphetamine Hydrochloride CII (125 mg) | Reference Standard | 51-57-0 | 125 | mg | VIAL | |
| 1406005 | Methazolamide (500 mg) | Reference Standard | 554-57-4 | 500 | mg | VIAL | |
| 1408000 | Methdilazine Hydrochloride (200 mg) | Reference Standard | 1229-35-2 | 200 | mg | VIAL | |
| 1409003 | Methenamine (500 mg) | Reference Standard | 100-97-0 | 500 | mg | VIAL | |
| 1409502 | Methenamine Hippurate (200 mg) | Reference Standard | 5714-73-8 | 200 | mg | VIAL | |
| 1409604 | Methenamine Mandelate (200 mg) | Reference Standard | 587-23-5 | 200 | mg | VIAL | |
| 1411005 | Methimazole (200 mg) | Reference Standard | 60-56-0 | 200 | mg | VIAL | |
| 1411016 | Methimazole Related Compound A (3 x 50 mg) (2,2-Dimethoxy-N-methylethanamine) | Reference Standard | 122-07-6 | 150 | mg | AMPULE | |
| 1411038 | Methimazole Related Compound C (3 x 50 mg) (1-Methyl-2-(methylthio)-1H-imidazole) | Reference Standard | 14486-52-3 | 150 | mg | AMPULE | |
| 1412008 | Methocarbamol (200 mg) | Reference Standard | 532-03-6 | 200 | mg | VIAL | |
| 1413000 | Methohexital CIV (500 mg) | Reference Standard | 151-83-7 | 500 | mg | | |
| 1414003 | Methotrexate (500 mg) | Reference Standard | 59-05-2 | 500 | mg | VIAL | |
| 1414025 | Methotrexate Related Compound B (75 mg) ((S)-2-{4-[(2,4-diaminopteridin-6-yl)methylamino]benzamido}pentanedioic acid) | Reference Standard | 54-62-6 | 75 | mg | VIAL | |
| 1414036 | Methotrexate Related Compound C (50 mg) ((S)-2-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl](methyl)amino}benzamido) pentanedioic acid) | Reference Standard | 2410-93-7 | 50 | mg | VIAL | |
| 1414058 | Methotrexate Related Compound E (50 mg) (4-{[(2,4-Diaminopteridin-6-yl)methyl](methyl)amino}benzoic acid, hemihydrochloride) | Reference Standard | 70844-48-3 | 50 | mg | VIAL | |
| 1413999 | Methotrexate System Suitability Mixture (5 mg) | Reference Standard | NA | 5 | mg | VIAL | |
| 1415006 | Methotrimeprazine (200 mg) | Reference Standard | 60-99-1 | 200 | mg | VIAL | |
| 1417001 | Methoxsalen (200 mg) | Reference Standard | 298-81-7 | 200 | mg | VIAL | |
| 1065345 | Methoxsalen Related Compound A (25 mg) (4-Methoxy-7H-furo[3,2-g]chromen-7-one) | Reference Standard | 484-20-8 | 25 | mg | VIAL | |
| 1349740 | Methoxsalen Related Compound B (25 mg) (4,9-Dimethoxy-7H-furo[3,2-g]chromen-7-one) | Reference Standard | 482-27-9 | 25 | mg | VIAL | |
| 1419109 | Methoxy Polyethylene Glycol Aldehyde, 20kDa (500 mg) | Reference Standard | 125061-88-3 | 500 | mg | VIAL | |
| 1418004 | Methoxyflurane (0.5 mL) | Reference Standard | 76-38-0 | 0.5 | mL | AMPULE | |
| 1418650 | Methoxymethylguanine (20 mg) | Reference Standard | 1202645-50-8 | 20 | mg | VIAL | |
| 1421009 | Methscopolamine Bromide (200 mg) (6Beta,7Beta-Epoxy-3alpha-hydroxy-8-methyl-1alphaH,5alphaH-tropanium bromide (-)-tropate) | Reference Standard | 155-41-9 | 200 | mg | VIAL | |
| 1422001 | Methsuximide (500 mg) | Reference Standard | 77-41-8 | 500 | mg | VIAL | |
| 1424007 | Methyclothiazide (200 mg) | Reference Standard | 135-07-9 | 200 | mg | VIAL | |
| 1424018 | Methyclothiazide Related Compound A (50 mg) (4-Amino-6-chloro-N-3-methyl-m-benzenedisulfonamide) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1430917 | Methyl 12-Hydroxystearate (200 mg) | Reference Standard | 141-23-1 | 200 | mg | VIAL | |
| 1424051 | Methyl Acetate (1.2 mL/ampule; 3 ampules) | Reference Standard | 79-20-9 | 3.6 | mL | AMPULE | |
| 1424062 | Methyl Acrylate, Methyl Methacrylate and Methacrylic Acid (7:3:1) Copolymer 280000 Dispersion (200 mg) | Reference Standard | 26936-24-3 | 200 | mg | AMPULE | |
| 1424109 | Methyl Alcohol (3 x 1.5 mL) | Reference Standard | 67-56-1 | 4.5 | mL | AMPULE | |
| 1424222 | Methyl Benzylidene Camphor (200 mg) (Enzacamene) | Reference Standard | 36861-47-9 | 200 | mg | VIAL | |
| 1424233 | Methyl Caprate (3 x 100 mg) | Reference Standard | 110-42-9 | 300 | mg | AMPULE | |
| 1424244 | Methyl Caproate (3 x 100 mg) | Reference Standard | 106-70-7 | 300 | mg | AMPULE | |
| 1424255 | Methyl Caprylate (300 mg) | Reference Standard | 111-11-5 | 300 | mg | AMPULE | |
| 1430101 | Methyl Ethyl Ketone (1.2 mL/ampule; 3 ampules) | Reference Standard | 78-93-3 | 3.6 | mL | AMPULE | |
| 1430203 | Methyl Isobutyl Ketone (1.2 mL/ampule; 3 ampules) | Reference Standard | 108-10-1 | 3.6 | mL | AMPULE | |
| 1430305 | Methyl Laurate (5 x 100 mg) | Reference Standard | 111-82-0 | 500 | mg | AMPULE | |
| 1430327 | Methyl Linoleate (5 x 50 mg) | Reference Standard | 112-63-0 | 250 | mg | AMPULE | |
| 1430349 | Methyl Linolenate (5 x 50 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 301-00-8 | 250 | mg | AMPULE | |
| 1431501 | Methyl Myristate (3 x 100 mg) | Reference Standard | 124-10-7 | 300 | mg | AMPULE | |
| 1431556 | Methyl Oleate (5 x 100 mg) | Reference Standard | 112-62-9 | 500 | mg | AMPULE | |
| 1431603 | Methyl Palmitate (3 x 100 mg) | Reference Standard | 112-39-0 | 300 | mg | VIAL | |
| 1431625 | Methyl Palmitoleate (3 x 100 mg) | Reference Standard | 1120-25-8 | 300 | mg | AMPULE | |
| 1437392 | Methyl Ricinoleate (100 mg) | Reference Standard | 141-24-2 | 100 | mg | AMPULE | |
| 1437450 | Methyl Salicylate (2 mL) | Reference Standard | 119-36-8 | 2 | mL | AMPULE | |
| 1437461 | Methyl Salicylate Related Compound A (50 mg) (Dimethyl 4-hydroxyisophthalate) | Reference Standard | 5985-24-0 | 50 | mg | VIAL | |
| 1437508 | Methyl Stearate (300 mg) | Reference Standard | 112-61-8 | 300 | mg | VIAL | |
| 1438205 | Methyl Tricosanoate (200 mg) (Tricosanoic acid, methyl ester) | Reference Standard | 2433-97-8 | 200 | mg | VIAL | |
| 1424211 | Methylbenzethonium Chloride (200 mg) | Reference Standard | 25155-18-4 | 200 | mg | | |
| 1424209 | Methylbenzhydrol (50 mg) | Reference Standard | 5472-13-9 | 50 | mg | VIAL | |
| 1424506 | Methylcellulose (1 g) (AS) | Reference Standard | 9004-67-5 | 1 | g | | |
| 1424550 | Methylcobalamin (2 x 150 mg) | Reference Standard | 13422-55-4 | 300 | mg | VIAL | |
| 1426002 | Methyldopa (500 mg) | Reference Standard | 41372-08-1 | 500 | mg | VIAL | |
| 1427027 | Methyldopa Related Compound B (10 mg) ((S)-2-Amino-3-(4-methoxyphenyl)-2-methylpropanoic acid hydrochloride) | Reference Standard | 35026-10-9 | 10 | mg | VIAL | |
| 1427038 | Methyldopa Related Compound C (20 mg) ((S)-2-Amino-3-(3,4-dimethoxyphenyl)-2-methylpropanoic acid hydrochloride monohydrate) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1428008 | Methylene Blue (750 mg) | Reference Standard | 122965-43-9 | 750 | mg | VIAL | |
| 1428229 | Methylene Simvastatin (30 mg) ((1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbut-3-enoate) | Reference Standard | 1449248-72-9 | 30 | mg | VIAL | |
| 1429113 | Methylenediurea (300 mg) (1,1'-Methylenediurea) | Reference Standard | 13547-17-6 | 300 | mg | VIAL | |
| 1430000 | Methylergonovine Maleate (50 mg) | Reference Standard | 57432-61-8 | 50 | mg | VIAL | |
| 1430735 | Methylnaltrexone Bromide (100 mg) | Reference Standard | 73232-52-7 | 100 | mg | VIAL | |
| 1430724 | Methylnaltrexone Peak Identification Mixture CII (10 mg) (Methylnaltrexone Bromide containing about 0.1% methylnaltrexone related compound A) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1432005 | Methylparaben (125 mg) | Reference Standard | 99-76-3 | 125 | mg | VIAL | |
| 1433008 | Methylphenidate Hydrochloride CII (125 mg) | Reference Standard | 23655-65-4 | 125 | mg | VIAL | |
| 1434011 | Methylphenidate Hydrochloride Erythro Isomer Solution CII (0.5 mL) | Reference Standard | N/A | 0.5 | mL | VIAL | |
| 1434022 | Methylphenidate Related Compound A (50 mg) (alpha-Phenyl-2-piperidineacetic Acid Hydrochloride) | Reference Standard | 19395-40-5 | 50 | mg | VIAL | |
| 1435003 | Methylprednisolone (200 mg) | Reference Standard | 83-43-2 | 200 | mg | VIAL | |
| 1436006 | Methylprednisolone Acetate (200 mg) | Reference Standard | 53-36-1 | 200 | mg | VIAL | |
| 1437009 | Methylprednisolone Hemisuccinate (250 mg) | Reference Standard | 2921-57-5 | 250 | mg | VIAL | |
| 1437020 | Methylprednisolone Hemisuccinate Related Compound B (50 mg) (11Beta,21-Dihydroxy-6alpha-methyl-3,20-dioxopregna-1,4-dien-17-yl hydrogen succinate) | Reference Standard | 77074-42-1 | 50 | mg | VIAL | |
| 1437042 | Methylprednisolone Hemisuccinate Related Compound D (50 mg) (11Beta,17-Dihydroxy-6alpha-methyl-3,20-dioxopregna-4-en-21-yl hydrogen succinate) | Reference Standard | 119657-85-1 | 50 | mg | VIAL | |
| 1435014 | Methylprednisolone Related Compound A (25 mg) (17,21-Dihydroxy-6alpha-methylpregna-1,4-diene-3,11,20-trione) | Reference Standard | 91523-05-6 | 25 | mg | VIAL | |
| 1435036 | Methylprednisolone Related Compound C (25 mg) (11beta-Hydroxy-6alpha-methylandrosta-1,4-diene-3,17-dione) | Reference Standard | 61919-52-6 | 25 | mg | VIAL | |
| 1436028 | Methylprednisolone System Suitability Mixture (25 mg) | Reference Standard | NA | 25 | mg | VIAL | |
| 1437202 | Methylpyrrolidone (2 g) | Reference Standard | 872-50-4 | 2 | g | AMPULE | |
| 1437600 | Methylsulfonylmethane (200 mg) | Reference Standard | 67-71-0 | 200 | mg | VIAL | |
| 1438001 | Methyltestosterone CIII (250 mg) | Reference Standard | 58-18-4 | 250 | mg | VIAL | |
| 1440003 | Methysergide Maleate (350 mg) | Reference Standard | 129-49-7 | 350 | mg | VIAL | |
| 1440808 | Metoclopramide Hydrochloride (500 mg) | Reference Standard | 54143-57-6 | 500 | mg | VIAL | |
| 1440819 | Metoclopramide Related Compound A (15 mg) (4-Acetamido-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide) | Reference Standard | 5608-13-9 | 15 | mg | VIAL | |
| 1440820 | Metoclopramide Related Compound B (15 mg) (Methyl 4-acetamido-5-chloro-2-methoxybenzoate) | Reference Standard | 4093-31-6 | 15 | mg | VIAL | |
| 1440841 | Metoclopramide Related Compound D (15 mg) (Methyl 4-acetamido-2-methoxybenzoate) | Reference Standard | 4093-29-2 | 15 | mg | VIAL | |
| 1441200 | Metolazone (200 mg) | Reference Standard | 17560-51-9 | 200 | mg | VIAL | |
| 1268772 | Metomidate Hydrochloride (50 mg) (Methyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate hydrochloride) | Reference Standard | 35944-74-2 | 50 | mg | VIAL | |
| 1441287 | Metoprolol Fumarate (200 mg) | Reference Standard | 119637-66-0 | 200 | mg | VIAL | |
| 1441232 | Metoprolol Related Compound A (20 mg) ((+/-)1-(ethylamino)-3-[4-(2-methoxyethyl)phenoxy]-propan-2-ol) | Reference Standard | 109632-08-8 | 20 | mg | VIAL | |
| 1441243 | Metoprolol Related Compound B (100 mg) ((+/-)1-Chloro-2-hydroxy-3-[4-(2-methoxyethyl)phenoxy]-propane) | Reference Standard | 56718-76-4 | 100 | mg | VIAL | |
| 1441254 | Metoprolol Related Compound C (15 mg) (4-[2-Hydroxy-3-(isopropylamino)propoxy]benzaldehyde hydrochloride) | Reference Standard | 29122-74-5 | 15 | mg | VIAL | |
| 1441265 | Metoprolol Related Compound D (50 mg) ((+/-)N,N-bis-[2-hydroxy-3-[4-(2-methoxyethyl)phenoxy]propyl](1-methylethyl)amine hydrochloride) | Reference Standard | 1486464-40-7 | 50 | mg | VIAL | |
| 1441298 | Metoprolol Succinate (200 mg) | Reference Standard | 98418-47-4 | 200 | mg | VIAL | |
| 1441301 | Metoprolol Tartrate (200 mg) | Reference Standard | 56392-17-7 | 200 | mg | VIAL | |
| 1442009 | Metronidazole (100 mg) | Reference Standard | 443-48-1 | 100 | mg | VIAL | |
| 1442100 | Metronidazole Benzoate (100 mg) | Reference Standard | 13182-89-3 | 100 | mg | VIAL | |
| 1443001 | Metyrapone (200 mg) | Reference Standard | 54-36-4 | 200 | mg | VIAL | |
| 1443205 | Metyrosine (200 mg) | Reference Standard | 672-87-7 | 200 | mg | VIAL | |
| 1443216 | Mevastatin (25 mg) ((1S,7S,8S,8aR)-8-{2-[(2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-7-methyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl (S)-2-methylbutanoate) | Reference Standard | 73573-88-3 | 25 | mg | VIAL | |
| 1443250 | Mexiletine Hydrochloride (200 mg) | Reference Standard | 5370-01-04 | 200 | mg | VIAL | |
| 1443362 | Mibolerone CIII (200 mg) | Reference Standard | 3704-09-4 | 200 | mg | VIAL | |
| 1443384 | Micafungin Sodium (200 mg) (INTERNATIONAL COLD SHIPMENT REQUIRED) | Reference Standard | 208538-73-2 | 200 | mg | VIAL | |
| 1443409 | Miconazole (200 mg) | Reference Standard | 22916-47-8 | 200 | mg | VIAL | |
| 1443500 | Miconazole Nitrate (200 mg) | Reference Standard | 22832-87-7 | 200 | mg | VIAL | |
| 1443431 | Miconazole Related Compound C (50 mg) (2-[(2,4-Dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethan-1-amine hydrochloride) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1443464 | Miconazole Related Compound F (50 mg) (1-{2-[(3,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole) | Reference Standard | 47447-55-2 | 50 | mg | VIAL | |
| 1443497 | Miconazole Related Compound I (50 mg) (1-{2-[(2-Chlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole mononitrate) | Reference Standard | 24169-00-4 | 50 | mg | VIAL | |
| 1098388 | Microcrystalline Cellulose (1 g) | Reference Standard | 9004-34-6 | 1 | g | VIAL | |
| 1719179 | Microcrystalline Wax (30 mg) | Reference Standard | 63231-60-7 | 30 | mg | VIAL | |
| 1443599 | Midazolam CIV (300 mg) | Reference Standard | 59467-70-8 | 300 | mg | VIAL | |
| 1443602 | Midazolam Hydrochloride CIV (200 mg) | Reference Standard | 59467-96-8 | 200 | mg | VIAL | |
| 1443704 | Midodrine Hydrochloride (200 mg) | Reference Standard | 3092-17-9 | 200 | mg | VIAL | |
| 1443715 | Midodrine Related Compound A (40 mg) (1-(2,5 Dimethoxyphenyl)-2-aminoethanol) | Reference Standard | 3600-87-1 | 40 | mg | VIAL | |
| 1443759 | Mifepristone (200 mg) | Reference Standard | 84371-65-3 | 200 | mg | VIAL | |
| 1443806 | Milbemycin Oxime (200 mg) | Reference Standard | 129496-10-2 | 200 | mg | VIAL | |
| 1443657 | Milnacipran Hydrochloride (250 mg) | Reference Standard | 101152-94-7 | 250 | mg | VIAL | |
| 1443668 | Milnacipran Related Compound A (25 mg) (2-(Aminomethyl)-1-phenylcyclopropane-1-carboxylic acid hydrochloride) | Reference Standard | 871100-19-5 (free base) | 25 | mg | VIAL | |
| 1443679 | Milnacipran Related Compound B (25 mg) (1-Phenyl-3-azabicyclo[3.1.0]hexan-2-one) | Reference Standard | 153275-06-0 | 25 | mg | VIAL | |
| 1443680 | Milnacipran Related Compound C (25 mg) ((1RS ,2SR)-2-[(1,3-Dioxoisoindolin-2-yl)methyl]-N,N-diethyl-1-phenylcyclopropane-1-carboxamide) | Reference Standard | 105310-75-6 | 25 | mg | VIAL | |
| 1443908 | Milrinone (500 mg) | Reference Standard | 78415-72-2 | 500 | mg | VIAL | |
| 1443919 | Milrinone Related Compound A (50 mg) (1,6-Dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carboxamide) | Reference Standard | 80047-24-1 | 50 | mg | VIAL | |
| 1443952 | Mineral Oil (1.5 mL) | Reference Standard | 8042-47-5 | 1.5 | mL | AMPULE | |
| 1444004 | Minocycline Hydrochloride (350 mg) | Reference Standard | 13614-98-7 | 350 | mg | VIAL | |
| 1444208 | Minoxidil (125 mg) | Reference Standard | 38304-91-5 | 125 | mg | VIAL | |
| 1444220 | Minoxidil Related Compound E (25 mg) (6-(Piperidin-1-yl)pyrimidine-2,4-diamine) | Reference Standard | 24867-26-3 | 25 | mg | VIAL | |
| 1444279 | Mirtazapine (350 mg) | Reference Standard | 85650-52-8 | 350 | mg | VIAL | |
| 1444285 | Mirtazapine Related Compound A (25 mg) (1,2,3,4,10,14b-hexahydropyrazino[2,1-a]pyrido[2,3-c][2]benzazepine) | Reference Standard | 61337-68-6 | 25 | mg | VIAL | |
| 1444235 | Mirtazapine Related Compound B (25 mg) (1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine 2-oxide monohydrate) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1444241 | Mirtazapine Related Compound C (50 mg) (2-Methyl-3,4,10,14b-tetrahydrobenzo[c]pyrazino[1,2-a]pyrido[3,2-f]azepin-1(2H)-one) | Reference Standard | 191546-96-0 | 50 | mg | VIAL | |
| 1444252 | Mirtazapine Related Compound D (50 mg) (2-Methyl-1,2,3,4-tetrahydrobenzo[c]pyrazino[1,2-a]pyrido[3,2-f]azepin-10(14bH)-one) | Reference Standard | 191546-97-1 | 50 | mg | VIAL | |
| 1444296 | Mirtazapine Resolution Mixture (25 mg) (This mixture contains mirtazapine, impurity A, impurity B, impurity C, impurity D, impurity E and impurity F) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1444300 | Misoprostol (100 mg) | Reference Standard | 59122-46-2 | 100 | mg | VIAL | |
| 1444707 | Mitomycin (50 mg) | Reference Standard | 50-07-7 | 50 | mg | VIAL | |
| 1445007 | Mitotane (500 mg) | Reference Standard | 53-19-0 | 500 | mg | VIAL | |
| 1445018 | Mitotane Related Compound A (25 mg) (2,2-Bis(4-Chlorophenyl)-1,1-dichloroethane) | Reference Standard | 72-54-8 | 25 | mg | VIAL | |
| 1445200 | Mitoxantrone Hydrochloride (400 mg) | Reference Standard | 70476-82-3 | 400 | mg | VIAL | |
| 1445211 | Mitoxantrone System Suitability Mixture (0.3 mg) (Mixture of 0.2 mg 1-Amino-5,8-dihydroxy-4-({2-[(2-hydroxyethyl)amino]ethyl}amino)anthracene-9,10-dione hydrochloride and 0.1 mg Mitoxantrone Hydrochloride) | Reference Standard | N/A | 0.3 | mg | VIAL | |
| 1445404 | Modafinil CIV (200 mg) | Reference Standard | 68693-11-8 | 200 | mg | VIAL | |
| 1445346 | Modafinil Related Compound A (20 mg) (2-[(diphenylmethyl)sulfinyl]acetic acid) | Reference Standard | 63547-24-0 | 20 | mg | VIAL | |
| 1445368 | Modafinil Related Compound C (20 mg) (2-[(diphenylmethyl)sulfenyl]acetamide) | Reference Standard | 68524-30-1 | 20 | mg | VIAL | |
| 1445415 | Modafinil S-enantiomer CIV (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) (30 mg) ((S)-2-(Benzhydrylsulfinyl)acetamide) | Reference Standard | 112111-47-4 | 30 | mg | VIAL | |
| 1445392 | Modafinil Sulfone (30 mg) | Reference Standard | 118779-53-6 | 30 | mg | VIAL | |
| 1445426 | Moexipril Hydrochloride (100 mg) | Reference Standard | 82586-52-5 | 100 | mg | VIAL | |
| 1445608 | Moexipril Related Compound A (20 mg) ((3S)-2-{(2S)-N-[(1S)-1-Carboxy-3-phenylpropyl]alanyl}-1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid) | Reference Standard | 103775-14-0 | 20 | mg | VIAL | |
| 1445619 | Moexipril Related Compound B (20 mg) ((S)-ethyl 2-{(3S,11aS)-8,9-dimethoxy-3-methyl-1,4-dioxo-3,4-dihydro-1H-pyrazino[1,2-b]isoquinolin-2(6H,11H,11aH)-yl}-4-phenylbutanoate) | Reference Standard | 103733-51-3 | 20 | mg | VIAL | |
| 1445620 | Moexipril Related Compound C (20 mg) ((S)-tert-butyl 2-{(S)-2-[(S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino]propanoyl}-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate, maleate) | Reference Standard | 103733-40-0 | 20 | mg | VIAL | |
| 1445631 | Moexipril Related Compound D (20 mg) ((S)-2-{(S)-2-[(S)-4-cyclohexyl-1-ethoxy-1-oxobutan-2-ylamino]propanoyl}-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid hydrochloride) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1445642 | Moexipril Related Compound E (20 mg) ((S)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, hydrochloride) | Reference Standard | 82586-62-7 | 20 | mg | VIAL | |
| 1445653 | Moexipril Related Compound F (20 mg) ((S)-2-[(S)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino]propanoic acid) | Reference Standard | 82717-96-2 | 20 | mg | VIAL | |
| 1445664 | Moexipril Related Compound G (20 mg) ((S)-6,7-dimethoxy-2-{(S)-2-[(S)-1-methoxy-1-oxo-4-phenylbutan-2-ylamino]propanoyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, hydrochloride) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1445448 | Mogroside V (100 mg) | Reference Standard | 88901-36-4 | 100 | mg | VIAL | |
| 1445459 | Molindone Hydrochloride (500 mg) | Reference Standard | 15622-65-8 | 500 | mg | VIAL | |
| 1445437 | Molindone Related Compound A (20 mg) (3-Ethyl-2-methyl-1,5,6,7-tetrahydro-4H-indol-4-one) | Reference Standard | 6116-76-3 | 20 | mg | VIAL | |
| 1445470 | Mometasone Furoate (200 mg) | Reference Standard | 83919-23-7 | 200 | mg | VIAL | |
| 1445481 | Monensin Sodium (200 mg) | Reference Standard | 22373-78-0 | 200 | mg | VIAL | |
| 1445492 | Monk Fruit Extract (500 mg) | Reference Standard | N/A | 500 | mg | VIAL | |
| 1551139 | Monobasic Potassium Phosphate (5 g) | Reference Standard | 7778-77-0 | 5 | g | VIAL | |
| 1445506 | Monobenzone (200 mg) | Reference Standard | 103-16-2 | 200 | mg | VIAL | |
| 1445550 | Monoclonal IgG System Suitability (2 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | N/A | 2 | mg | AMPULE | |
| 1445925 | Monoethanolamine (1 mL) | Reference Standard | 141-43-5 | 1 | mL | AMPULE | |
| 1446000 | Monoglycerides (125 mg) | Reference Standard | 68990-53-4 | 125 | mg | VIAL | |
| 1446600 | Monosodium Glutamate (500 mg) (Monosodium L-glutamate, monohydrate) | Reference Standard | 6106-04-3 | 500 | mg | VIAL | |
| 1446804 | Monostearyl Maleate (100 mg) | Reference Standard | 2424-62-6 | 100 | mg | VIAL | |
| 1446815 | Montelukast Dicyclohexylamine (150 mg) | Reference Standard | 577953-88-9 | 150 | mg | VIAL | |
| 1446848 | Montelukast Racemate (20 mg) | Reference Standard | NA | 20 | mg | VIAL | |
| 1446859 | Montelukast Sodium (50 mg) | Reference Standard | 151767-02-1 | 50 | mg | VIAL | |
| 1446837 | Montelukast for Peak Identification (20 mg) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1446906 | Morantel Tartrate (100 mg) | Reference Standard | 26155-31-7 | 100 | mg | VIAL | |
| 1446950 | Moricizine Hydrochloride (250 mg) | Reference Standard | 29560-58-5 | 250 | mg | VIAL | |
| 1447002 | Morphine Monohydrate CII (50 mg) (AS) | Reference Standard | 6009-81-0 | 50 | mg | VIAL | |
| 1448016 | Morphine Related Compound A CI (20 mg) (7,8-Didehydro-4,5alpha-epoxy-17-methylmorphinan-3,6alpha-diol, N-oxide) | Reference Standard | 639-46-3 | 20 | mg | VIAL | |
| 1448027 | Morphine Related Compound B CII (20 mg) (2,2'-Bimorphine trihydrate) | Reference Standard | 6472-73-7 | 20 | mg | VIAL | |
| 1448005 | Morphine Sulfate CII (500 mg) | Reference Standard | 6211-15-0 | 500 | mg | VIAL | |
| 1448559 | Moxidectin (200 mg) | Reference Standard | 113507-06-5 | 200 | mg | VIAL | |
| 1448560 | Moxidectin System Suitability Mixture (50 mg) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1448606 | Moxifloxacin Hydrochloride (200 mg) | Reference Standard | 192927-63-2 | 200 | mg | VIAL | |
| 1448617 | Moxifloxacin Related Compound A (25 mg) (1-cyclopropyl-6,8-difluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid) | Reference Standard | 151213-15-9 | 25 | mg | VIAL | |
| 1448628 | Moxifloxacin Related Compound B (25 mg) (1-Cyclopropyl-6,8-dimethoxy-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid hydrochloride monohydrate) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1448639 | Moxifloxacin Related Compound C (25 mg) (1-Cyclopropyl-8-ethoxy-6-fluoro-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid hydrochloride monohydrate) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1448640 | Moxifloxacin Related Compound D (15 mg) (1-Cyclopropyl-8-fluoro-6-methoxy-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid) | Reference Standard | 1029364-77-9 | 15 | mg | VIAL | |
| 1448655 | Moxifloxacin Related Compound E (25 mg) (1-Cyclopropyl-6-fluoro-8-hydroxy-1,4-dihydro-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid hydrochloride) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1448661 | Moxifloxacin Related Compound F (25 mg) (1-Cyclopropyl-6-fluoro-8-methoxy-7-(1-methyloctahydro-6H-pyrrolo[3,4-b]pyridin-6-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid) | Reference Standard | 1179992-99-4 | 25 | mg | VIAL | |
| 1448672 | Moxifloxacin Related Compound G (15 mg) (1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[(4aR,7aR)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-3-quinolinecarboxylic acid, monohydrochloride) | Reference Standard | 1394029-14-1 | 15 | mg | VIAL | |
| 1448901 | Mupirocin (50 mg) | Reference Standard | 12650-69-0 | 50 | mg | VIAL | |
| 1448912 | Mupirocin Calcium (200 mg) | Reference Standard | 115074-43-6 | 200 | mg | VIAL | |
| 1448923 | Mupirocin Lithium (100 mg) | Reference Standard | 73346-79-9 | 100 | mg | VIAL | |
| 1448956 | Mycophenolate Mofetil (200 mg) | Reference Standard | 128794-94-5 | 200 | mg | VIAL | |
| 1448967 | Mycophenolate Mofetil Related Compound A (15 mg) (2-Morpholinoethyl (E)-6-(1,3-dihydro-4,6-dihydroxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate) | Reference Standard | 1322681-36-6 | 15 | mg | VIAL | |
| 1448978 | Mycophenolate Mofetil Related Compound B (15 mg) [(RS)-7-hydroxy-5-methoxy-4-methyl-6-[2-(5-methyl-2-oxo-tetrahydrofuran-5-yl)ethyl]-3H-isobenzofuranyl-1-one] | Reference Standard | 26675-76-3 | 15 | mg | VIAL | |
| 1448989 | Mycophenolate Sodium (200 mg) | Reference Standard | 37415-62-6 | 200 | mg | VIAL | |
| 1448990 | Myristic Acid (200 mg) | Reference Standard | 544-63-8 | 200 | mg | VIAL | |
| 1449008 | Myristyl Alcohol (5 x 100 mg) | Reference Standard | 112-72-1 | 500 | mg | VIAL | |
| 1449041 | Myristylpyridinium Chloride (25 mg) (1-Tetradecylpyridinium chloride) | Reference Standard | 2785-54-8 | 25 | mg | VIAL | |
| 1009978 | N-Acetyl-D,L-Methionine (100 mg) (N-Acetylmethionine) | Reference Standard | 1115-47-5 | 100 | mg | VIAL | |
| 1010081 | N-Acetyl-L-Leucine (100 mg) (Acetyl-L-leucine) | Reference Standard | 1188-21-2 | 100 | mg | VIAL | |
| 1010106 | N-Acetyl-L-Tyrosine (100 mg) | Reference Standard | 537-55-3 | 100 | mg | VIAL | |
| 1010022 | N-Acetylglucosamine (200 mg) | Reference Standard | 7512-17-6 | 200 | mg | VIAL | |
| 1612619 | N-Acetylneuraminic Acid (200 mg) | Reference Standard | 131-48-6 | 200 | mg | VIAL | |
| 1010117 | N-Acetylornithine (15 mg) | Reference Standard | 2185-16-2 | 15 | mg | VIAL | |
| 1010015 | N-Acylphosphatidylethanolamine (Soy) Ammonium (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) (20 mg) | Reference Standard | NA | 20 | mg | VIAL | |
| 1064122 | N-Benzyl-N-methyl-ethanolamine (3 x 0.2 mL) (2-[benzyl(methyl)amino]ethanol) | Reference Standard | 101-98-4 | 0.6 | mL | AMPULE | |
| 1046089 | N-Demethylazithromycin (15 mg) | Reference Standard | 172617-84-4 | 15 | mg | VIAL | |
| 1A00180 | N-Ethyl Quetiapine (25 mg) (11-(4-Ethylpiperazin-1-yl)dibenzo[b,f][1,4]thiazepine hydrochloride) | Pharmaceutical Analytical Impurity | 1011758-03-4 (Free base) | 25 | mg | VIAL | |
| 1266802 | N-Ethylpiperazine (0.5 mL) | Reference Standard | 5308-25-8 | 0.5 | mL | AMPULE | |
| 1294284 | N-Glycolylneuraminic Acid (200 mg) | Reference Standard | 1113-83-3 | 200 | mg | VIAL | |
| 1A00230 | N-Isopropyl Carvedilol (25 mg) (1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl](1-methylethyl)amino]-2-propanol) | Pharmaceutical Analytical Impurity | 1246819-01-1 | 25 | mg | VIAL | |
| 1466641 | N-Nitrosodibutylamine (NDBA) (1 mL (1 mg/mL)) (N-Butyl-N-nitroso-1-butanamine) | Reference Standard | 924-16-3 | 1 | mL | AMPULE | |
| 1466652 | N-Nitrosodiethylamine (NDEA) (1 mL (1 mg/mL)) (N-Ethyl-N-nitrosoethanamine) | Reference Standard | 55-18-5 | 1 | mL | AMPULE | |
| 1466663 | N-Nitrosodiisopropylamine (NDIPA) (1 mL (1 mg/mL)) (N-Isopropyl-N-nitrosoisopropylamine) | Reference Standard | 601-77-4 | 1 | mL | AMPULE | |
| 1466674 | N-Nitrosodimethylamine (NDMA) (1 mL (1 mg/mL)) (N-Methyl-N-nitrosomethanamine) | Reference Standard | 62-75-9 | 1 | mL | AMPULE | |
| 1466685 | N-Nitrosoethylisopropylamine (NEIPA) (1 mL (1 mg/mL)) (N-Ethyl-N-nitroso-2-propanamine) | Reference Standard | 16339-04-1 | 1 | mL | AMPULE | |
| 1466696 | N-Nitrosomethylaminobutyric Acid (NMBA) (1 mL (1 mg/mL)) (4-[Methyl(nitroso)amino]butanoic acid) | Reference Standard | 61445-55-4 | 1 | mL | AMPULE | |
| 1466607 | N-Nitrosomethylphenylamine (NMPA) (1 mL (1 mg/mL)) (N-Methyl-N-nitrosophenylamine) | Reference Standard | 614-00-6 | 1 | mL | AMPULE | |
| 1A00530 | N6-(1-Iminoethyl)-D-lysine (10 mg) ((2R)-2-[(2S)-2-Aminobutanamido]butanamide) | Pharmaceutical Analytical Impurity | 1844123-52-9 | 10 | mg | VIAL | |
| 1449518 | Nabumetone (200 mg) | Reference Standard | 42924-53-8 | 200 | mg | VIAL | |
| 1449530 | Nabumetone Related Compound A (15 mg) (1-(6-methoxy-2-naphthyl)-but-1-en-3-one) | Reference Standard | 127053-22-9 | 15 | mg | VIAL | |
| 1449700 | Nadolol (200 mg) | Reference Standard | 42200-33-9 | 200 | mg | VIAL | |
| 1449711 | Nadolol Related Compound A (25 mg) ((2RS,3SR)-5-(2,3-Dihydroxypropoxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1449722 | Nadolol Related Compound B (25 mg) ((2RS,3SR)-5-(2-Hydroxy-3-methoxypropoxy)-1,2,3,4-tetrahydronaphthalene-2,3-diol) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1449733 | Nadolol Related Compound C (25 mg) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1449766 | Nadolol Related Compound F (25 mg) (1-(tert-Butylamino)-3-(naphthalen-1-yloxy)propan-2-ol) | Reference Standard | 2116-22-5 | 25 | mg | VIAL | |
| 1449777 | Nadolol Related Compound G (25 mg) (1-(tert-Butylamino)-3-(5,6,7,8-tetrahydronaphthalen-1-yloxy)propan-2-ol) | Reference Standard | 33841-03-1 | 25 | mg | VIAL | |
| 1450007 | Nafcillin Sodium (200 mg) | Reference Standard | 7177-50-6 | 200 | mg | VIAL | |
| 1450018 | Nafcillin System Suitability Mixture | Reference Standard | N/A | | | | |
| 1450404 | Naftifine Hydrochloride (200 mg) | Reference Standard | 65473-14-5 | 200 | mg | VIAL | |
| 1452002 | Nalorphine Hydrochloride CIII (250 mg) | Reference Standard | 57-29-4 | 250 | mg | VIAL | |
| 1453005 | Naloxone (200 mg) | Reference Standard | 465-65-6 | 200 | mg | VIAL | |
| 1453049 | Naloxone Related Compound D CII (25 mg) (4,5alpha-Epoxy-3,14-dihydroxy-17-(prop-2-enyl)morphinan-7-ene-6-one) | Reference Standard | 26451-92-3 | 25 | mg | VIAL | |
| 1453504 | Naltrexone (200 mg) | Reference Standard | 16590-41-3 | 200 | mg | VIAL | |
| 1453526 | Naltrexone Related Compound A CII (30 mg) (N-(3-butenyl)-noroxymorphone Hydrochloride) | Reference Standard | N/A | 30 | mg | VIAL | |
| 1454008 | Nandrolone CIII (50 mg) | Reference Standard | 434-22-0 | 50 | mg | VIAL | |
| 1455000 | Nandrolone Decanoate CIII (250 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 360-70-3 | 250 | mg | VIAL | |
| 1457006 | Naphazoline Hydrochloride (200 mg) | Reference Standard | 550-99-2 | 200 | mg | VIAL | |
| 1457017 | Naphazoline Related Compound A (30 mg) (N-(2-Aminoethyl)-2-(naphthalen-1-yl)acetamide) | Reference Standard | 36321-43-4 | 30 | mg | VIAL | |
| 1457083 | Naphthalene (200 mg) | Reference Standard | 91-20-3 | 200 | mg | VIAL | |
| 1457301 | Naproxen (200 mg) | Reference Standard | 22204-53-1 | 200 | mg | VIAL | |
| 1457312 | Naproxen Related Compound A (20 mg) (6-methoxy-2-naphthoic acid) | Reference Standard | 2471-70-7 | 20 | mg | VIAL | |
| 1457436 | Naproxen Related Compound G (50 mg) ((R)-2-(6-Methoxynaphthalen-2-yl)propanoic acid) | Reference Standard | 23979-41-1 | 50 | mg | VIAL | |
| 1457414 | Naproxen Related Compound K (50 mg) (1-(6-Methoxynaphthalen-2-yl)ethanol) | Reference Standard | 77301-42-9 | 50 | mg | VIAL | |
| 1457425 | Naproxen Related Compound L (15 mg) (1-(6-methoxynaphthalen-2-yl)ethanone) | Reference Standard | 3900-45-6 | 15 | mg | VIAL | |
| 1457403 | Naproxen Sodium (200 mg) | Reference Standard | 26159-34-2 | 200 | mg | VIAL | |
| 1457458 | Narasin (125 mg) | Reference Standard | 55134-13-9 | 125 | mg | | |
| 1457469 | Naratriptan Hydrochloride (125 mg) | Reference Standard | 143388-64-1 | 125 | mg | VIAL | |
| 1457491 | Naratriptan Resolution Mixture (20 mg) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1457550 | Naringin (200 mg) | Reference Standard | 10236-47-2 | 200 | mg | VIAL | |
| 1457505 | Natamycin (200 mg) | Reference Standard | 7681-93-8 | 200 | mg | VIAL | |
| 1457607 | Nateglinide (200 mg) | Reference Standard | 105816-04-4 | 200 | mg | VIAL | |
| 1457618 | Nateglinide Related Compound A (10 mg) (trans-4-isopropylcyclohexanecarboxylic acid) | Reference Standard | 7077-05-6 | 10 | mg | VIAL | |
| 1457629 | Nateglinide Related Compound B (10 mg) (N-(trans-4-isopropylcyclohexanecarbonyl)-L-phenylalanine) | Reference Standard | 105816-05-5 | 10 | mg | VIAL | |
| 1457630 | Nateglinide Related Compound C (20 mg) (N-(cis-4-isopropylcyclohexanecarbonyl)-D-phenylalanine) | Reference Standard | 105816-06-6 | 20 | mg | VIAL | |
| 1302258 | Native Gymnema Extract (1 g) | Reference Standard | 90045-47-9 | 1 | g | VIAL | |
| 1457844 | Near IR System Suitability (1 unit) (Dysprosium (Dy2O3), Erbium (Er2O3), Holmium (Ho2O3), talc [Mg3Si4O10(OH)2] (1:1:1:1 w/w)) | Reference Standard | N/A | 1 | ea | OTHER | |
| 1457833 | Nebivolol Hydrochloride (150 mg) | Reference Standard | 152520-56-4 | 150 | mg | VIAL | |
| 1457855 | Nebivolol Related Compound A (30 mg) (See USP Certificate for full Chemical Name) | Reference Standard | N/A | 30 | mg | VIAL | |
| 1457866 | Nebivolol Related Compound B (30 mg) (See USP Certificate for full Chemical Name) | Reference Standard | N/A | 30 | mg | VIAL | |
| 1457877 | Nebivolol Related Compound C (100 mg) (COLD SHIPMENT REQUIRED) ((RS)-6-Fluoro-2-[(RS)-oxiran-2-yl]chroman) | Reference Standard | 876514-31-7 | 100 | mg | VIAL | |
| 1457888 | Nebivolol Related Compound D (100 mg) ((RS)-6-Fluoro-2-[(SR)-oxiran-2-yl]chroman) | Reference Standard | 793669-26-8 | 100 | mg | VIAL | |
| 1457899 | Nebivolol Related Compound E (30 mg) (1-(Chroman-2-yl)-2-((2-(6-fluorochroman-2-yl)-2-hydroxyethyl)amino)ethanol hydrochloride) | Reference Standard | N/A | 30 | mg | VIAL | |
| 1A00390 | Nebramine (10 mg) ((1S,2R,3R,4S,6R)-4,6-diamino-3-(((2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxytetrahydro-2H-pyran-2-yl)oxy)cyclohexane-1,2-diol) | Pharmaceutical Analytical Impurity | 34051-04-2 | 10 | mg | VIAL | |
| 1457902 | Nefazodone Hydrochloride (200 mg) | Reference Standard | 82752-99-6 | 200 | mg | VIAL | |
| 1457913 | Nefazodone Related Compound A (25 mg) (1-(3-chlorophenyl)-4-(3-chloropropyl)-piperazine hydrochloride) | Reference Standard | 57059-62-8 | 25 | mg | VIAL | |
| 1457924 | Nefazodone Related Compound B (25 mg) (2-[3-[4-(4-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one hydrochloride) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1457695 | Negundoside (50 mg) ((1S,4aS,7S,7aS)-1,4a,5,6,7,7a-Hexahydro-7-hydroxy-1-{[2-O-(4-hydroxybenzoyl)-beta-D- glucopyranosyl] | Reference Standard | 82451-20-5 | 50 | mg | VIAL | |
| 1458064 | Neodiosmin (30 mg) (5-Hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-oxo-4H-chromen-7-yl 2-O-(alpha-L-rhamnopyranosyl)-beta-Dglucopyranoside) | Reference Standard | 38665-01-9 | 30 | mg | VIAL | |
| 1458042 | Neohesperidin (30 mg) ((S)-5-Hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-oxo-3,4-dihydro-2H-chromen-7-yl 2-O-(alpha-L-rhamnopyranosyl)-beta-D-glucopyranoside) | Reference Standard | 13241-33-3 | 30 | mg | VIAL | |
| 1458086 | Neohesperidin Dihydrochalcone (500 mg) (3,5-Dihydroxy-4-[3-(3-hydroxy-4-methoxyphenyl)propanoyl]phenyl 2-O-(alpha-L-rhamnopyranosyl)-Beta-D-glucopyranoside) | Reference Standard | 20702-77-6 | 500 | mg | VIAL | |
| 1458020 | Neomycin A (2.5 mg) | Reference Standard | 3947-65-7 (free base) | 2.5 | mg | VIAL | |
| 1458019 | Neomycin B (150 mg) | Reference Standard | 28002-70-2 | 150 | mg | VIAL | |
| 1458009 | Neomycin Sulfate (200 mg) | Reference Standard | 1405-10-3 | 200 | mg | VIAL | |
| 1458031 | Neomycin Sulfate System Suitability Mixture (100 mg) | Reference Standard | N/A | 100 | mg | VIAL | |
| 1459001 | Neostigmine Bromide (200 mg) | Reference Standard | 114-80-7 | 200 | mg | VIAL | |
| 1460000 | Neostigmine Methylsulfate (200 mg) | Reference Standard | 51-60-5 | 200 | mg | VIAL | |
| 1460204 | Neotame (200 mg) | Reference Standard | 243116-62-3 | 200 | mg | VIAL | |
| 1460215 | Neotame Related Compound A (15 mg) (N-[N-(3,3-Dimethylbutyl)-L-alpha-aspartyl]-L-phenylalanine) | Reference Standard | 190910-14-6 | 15 | mg | VIAL | |
| 1460317 | Nepafenac (200 mg) | Reference Standard | 78281-72-8 | 200 | mg | VIAL | |
| 1460328 | Nepafenac Related Compound A (25 mg) (2-{2-Amino-3-[hydroxy(phenyl)methyl]phenyl}acetamide) | Reference Standard | 1246956-18-2 | 25 | mg | VIAL | |
| 1460339 | Nepafenac Related Compound B (25 mg) (7-Benzoylindolin-2-one) | Reference Standard | 51135-38-7 | 25 | mg | VIAL | |
| 1460500 | Netilmicin Sulfate (500 mg) | Reference Standard | 56391-57-2 | 500 | mg | VIAL | |
| 1460703 | Nevirapine Anhydrous (100 mg) | Reference Standard | 129618-40-2 | 100 | mg | VIAL | |
| 1460714 | Nevirapine Hemihydrate (100 mg) | Reference Standard | N/A | 100 | mg | VIAL | |
| 1460725 | Nevirapine Related Compound A (15 mg) (5,11-dihydro-6H-11-ethyl-4-methyl-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one) | Reference Standard | 133627-17-5 | 15 | mg | VIAL | |
| 1460736 | Nevirapine Related Compound B (10 mg) (5,11-Dihydro-4-methyl-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepin-6-one) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1460747 | Nevirapine Related Compound C (15 mg) (5,11-Dihydro-6H-11-propyl-4-methyl-dipyrido[3,2-b:2',3'-e] [1,4]diazepin-6-one) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1461003 | Niacin (200 mg) | Reference Standard | 59-67-6 | 200 | mg | VIAL | |
| 1462006 | Niacinamide (500 mg) | Reference Standard | 98-92-0 | 500 | mg | VIAL | |
| 1463224 | Nicardipine Hydrochloride (200 mg) | Reference Standard | 54527-84-3 | 200 | mg | VIAL | |
| 1463246 | Nicardipine Related Compound B (20 mg) (3-{2-[Benzyl(methyl)amino]ethyl}5-methyl 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate oxalate) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1463268 | Nicardipine Related Compound C (10 mg) (Dimethyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate) | Reference Standard | 21881-77-6 | 10 | mg | VIAL | |
| 1463279 | Nicardipine Related Compound D (10 mg) (Bis{2-[benzyl(methyl)amino]ethyl} 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate dihydrochloride) | Reference Standard | 71784-27-5 | 10 | mg | VIAL | |
| 1463304 | Nicotine Bitartrate Dihydrate (400 mg) | Reference Standard | 6019-06-3 | 400 | mg | VIAL | |
| 1463326 | Nicotine Related Compound A (20 mg) (1,2,3,6-tetrahydro-2,3'-bipyridine) | Reference Standard | 2743-90-0 | 20 | mg | AMPULE | |
| 1463337 | Nicotine Related Compound B (20 mg) (3-(1-methyl-1H-pyrrol-2-yl)pyridine) | Reference Standard | 487-19-4 | 20 | mg | AMPULE | |
| 1463348 | Nicotine Related Compound C (20 mg) ((S)-1-methyl-5-(pyridin-3-yl)pyrrolidin-2-one) | Reference Standard | 486-56-6 | 20 | mg | VIAL | |
| 1463359 | Nicotine Related Compound D (20 mg) (3-(4,5-dihydro-3H-pyrrol-2-yl)pyridine fumarate) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1463360 | Nicotine Related Compound E (20 mg) ((1RS,2S)-1-methyl-2-(pyridin-3-yl)pyrrolidine 1-oxide oxalate) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1463371 | Nicotine Related Compound F (20 mg) (3-(pyrrolidin-2-yl)pyridine) | Reference Standard | 5746-86-1 | 20 | mg | AMPULE | |
| 1463382 | Nicotine Related Compound G (20 mg) ((S)-3-(piperidin-2-yl)pyridine) | Reference Standard | 494-52-0 | 20 | mg | AMPULE | |
| 1463508 | Nifedipine (125 mg) | Reference Standard | 21829-25-4 | 125 | mg | VIAL | |
| 1463600 | Nifedipine Nitrophenylpyridine Analog (25 mg) (Dimethyl 4-(2-nitrophenyl)-2,6-dimethylpyridine-3,5-dicarboxylate) | Reference Standard | 67035-22-7 | 25 | mg | VIAL | |
| 1463701 | Nifedipine Nitrosophenylpyridine Analog (25 mg) (Dimethyl 4-(2-nitrosophenyl)-2,6-dimethylpyridine-3,5-dicarboxylate) | Reference Standard | 50428-14-3 | 25 | mg | VIAL | |
| 1463428 | Nilotinib (350 mg) | Reference Standard | 923288-90-8 | 350 | mg | VIAL | |
| 1463439 | Nilotinib Related Compound A (25 mg) (3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)aniline) | Reference Standard | 641571-11-1 | 25 | mg | VIAL | |
| 1463440 | Nilotinib Related Compound B | Reference Standard | 18595-18-1 | | | | |
| 1463457 | Nilotinib Related compound C (25 mg) (3-Amino-4-methylbenzoic acid) | Reference Standard | 2458-12-0 | 25 | mg | VIAL | |
| 1463461 | Nilotinib System Suitability Mixture (10 mg) | Reference Standard | NA | 10 | mg | VIAL | |
| 1463472 | Nilutamide (200 mg) | Reference Standard | 63612-50-0 | 200 | mg | VIAL | |
| 1463858 | Nimodipine (125 mg) | Reference Standard | 66085-59-4 | 125 | mg | VIAL | |
| 1463870 | Nimodipine Related Compound A (50 mg) (2-methoxyethyl-1-methylethyl 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate) | Reference Standard | 85677-93-6 | 50 | mg | VIAL | |
| 1463869 | Nimodipine Related Compound B (50 mg) (bis(2-methoxyethyl) 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate) | Reference Standard | 70172-96-2 | 50 | mg | VIAL | |
| 1463927 | Nisoldipine (250 mg) | Reference Standard | 63675-72-9 | 250 | mg | VIAL | |
| 1463949 | Nisoldipine Related Compound C (30 mg) (Isobutyl (Z)-2-(2-nitrobenzylidene)-3-oxobutanoate) | Reference Standard | N/A | 30 | mg | VIAL | |
| 1464158 | Nisoldipine Related Compound D (30 mg) (3-Isobutyl 5-methyl 2,6-dimethyl-4-(2-nitrophenyl)pyridine-3,5-dicarboxylate) | Reference Standard | 103026-83-1 | 30 | mg | VIAL | |
| 1464169 | Nisoldipine Related Compound E (30 mg) (3-Isobutyl 5-methyl 2,6-dimethyl-4-(2-nitrosophenyl)pyridine-3,5-dicarboxylate) | Reference Standard | 87375-91-5 | 30 | mg | VIAL | |
| 1464183 | Nisoldipine Related Compound G (30 mg) (Diisobutyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate) | Reference Standard | 2226462-71-9 | 30 | mg | VIAL | |
| 1463960 | Nitazoxanide (200 mg) | Reference Standard | 55981-09-4 | 200 | mg | VIAL | |
| 1463971 | Nitazoxanide Related Compound A (25 mg) (5-Nitrothiazole-2-amine) | Reference Standard | 121-66-4 | 25 | mg | VIAL | |
| 1463982 | Nitazoxanide Related Compound B (25 mg) (2-Hydroxy-N-(5-nitrothiazol-2-yl) benzamide) | Reference Standard | 173903-47-4 | 25 | mg | VIAL | |
| 1463950 | Nitrilotriacetic Acid (50 mg) | Reference Standard | 139-13-9 | 50 | mg | VIAL | |
| 1464001 | Nitrofurantoin (500 mg) | Reference Standard | 67-20-9 | 500 | mg | VIAL | |
| 1021703 | Nitrofurantoin Related Compound A (20 mg) (N-(Aminocarbonyl)-N-[([5-nitro-2-furanyl]-methylene)-amino]-glycine) | Reference Standard | 63981-22-6 | 20 | mg | VIAL | |
| 1465004 | Nitrofurazone (200 mg) | Reference Standard | 59-87-0 | 200 | mg | VIAL | |
| 1466007 | Nitrofurazone Related Compound A (50 mg) (1,2-Bis[(5-nitrofuran-2-yl)methylene]hydrazine) | Reference Standard | 112537-96-9 | 50 | mg | VIAL | |
| 1465503 | Nitrofurfural Diacetate (100 mg) | Reference Standard | 92-55-7 | 100 | mg | VIAL | |
| 1467804 | Nizatidine (200 mg) | Reference Standard | 76963-41-2 | 200 | mg | VIAL | |
| 1467848 | Nobiletin (100 mg) (2-(3,4-Dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-chromen-4-one) | Reference Standard | 478-01-3 | 100 | mg | VIAL | |
| 1467950 | Nonoxynol 9 (0.5 mL) | Reference Standard | 68412-54-4 | 0.5 | mL | AMPULE | |
| 1468400 | Nordazepam CIV (50 mg) (7-Chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepin-2-one) | Reference Standard | 1088-11-5 | 50 | mg | VIAL | |
| 1468454 | Norelgestromin (200 mg) | Reference Standard | 53016-31-2 | 200 | mg | VIAL | |
| 1468465 | Norelgestromin Related Compound A (15 mg) (13-Ethyl-17-hydroxy-18,19-dinor-17alpha-pregn-5(6)-en-20-yn-3-one oxime) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1468501 | Norepinephrine Bitartrate (125 mg) | Reference Standard | 108341-18-0 | 125 | mg | VIAL | |
| 1469005 | Norethindrone (200 mg) | Reference Standard | 68-22-4 | 200 | mg | VIAL | |
| 1470004 | Norethindrone Acetate (100 mg) | Reference Standard | 51-98-9 | 100 | mg | VIAL | |
| 1470026 | Norethindrone Related Compound B CIII (30 mg) (Estr-4-ene-3,17-dione) | Reference Standard | 734-32-7 | 30 | mg | VIAL | |
| 1471506 | Norfloxacin (200 mg) | Reference Standard | 70458-96-7 | 200 | mg | VIAL | |
| 1471517 | Norfloxacin Related Compound A (15 mg) (7-Chloro-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid) | Reference Standard | 68077-26-9 | 15 | mg | VIAL | |
| 1471550 | Norfloxacin Related Compound E (15 mg) (7-Chloro-1-ethyl-4-oxo-6-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid) | Reference Standard | 75001-78-4 | 15 | mg | VIAL | |
| 1471583 | Norfloxacin Related Compound H (15 mg) (7-[4-(ethoxycarbonyl)piperazin-1-yl]-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid) | Reference Standard | 105440-01-5 | 15 | mg | VIAL | |
| 1471619 | Norfloxacin Related Compound K (15 mg) (6-Fluoro-1-methyl-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid) | Reference Standard | 70459-07-3 | 15 | mg | VIAL | |
| 1471914 | Norgestimate (200 mg) | Reference Standard | 35189-28-7 | 200 | mg | VIAL | |
| 1471925 | Norgestimate Related Compound A (25 mg) (Levonorgestrel Acetate) | Reference Standard | 13732-69-9 | 25 | mg | VIAL | |
| 1472000 | Norgestrel (125 mg) | Reference Standard | 6533-00-2 | 125 | mg | VIAL | |
| 1472043 | Norgestrel Related Compound L (25 mg) (13-Ethylgon-4-ene-3,17-dione) | Reference Standard | 21800-83-9 | 25 | mg | VIAL | |
| 1473002 | Noroxymorphone Hydrochloride CII (50 mg) (4,5alpha-Epoxy-3,14-dihydroxymorphinan-6-one hydrochloride) | Reference Standard | 52446-24-9 | 50 | mg | VIAL | |
| 1473206 | Norphenylephrine Hydrochloride (25 mg) | Reference Standard | 4779-94-6 | 25 | mg | VIAL | |
| 1473400 | Norscopolamine (20 mg) ((1R ,2R ,4S ,5S ,7s )-3-Oxa-9-azatricyclo[3.3.1.0^2,4]nonan-7-yl (S)-3-hydroxy-2-phenylpropanoate) | Reference Standard | 4684-28-0 | 20 | mg | VIAL | |
| 1474005 | Nortriptyline Hydrochloride (200 mg) | Reference Standard | 894-71-3 | 200 | mg | VIAL | |
| 1474504 | Noscapine (100 mg) | Reference Standard | 128-62-1 | 100 | mg | VIAL | |
| 1475008 | Novobiocin (200 mg) | Reference Standard | 56677-21-5 | 200 | mg | VIAL | |
| 1477003 | Nystatin (200 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 1400-61-9 | 200 | mg | | |
| 1477900 | Octinoxate (500 mg) | Reference Standard | 5466-77-3 | 500 | mg | AMPULE | |
| 1477943 | Octisalate (400 mg) (Octyl Salicylate) | Reference Standard | 118-60-5 | 400 | mg | AMPULE | |
| 1477411 | Octocrylene (500 mg) | Reference Standard | 6197-30-4 | 500 | mg | AMPULE | |
| 1477502 | Octoxynol 9 (200 mg) | Reference Standard | 9002-93-1 | 200 | mg | AMPULE | |
| 1477604 | Octreotide Acetate (4.37 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 79517-01-4 | 4.37 | mg | VIAL | |
| 1477615 | Octreotide Non-Cyclic System Suitability Marker (20 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 774239-80-4 (Free base) | 20 | mg | VIAL | |
| 1477808 | Octyldodecanol (3 x 100 mg) | Reference Standard | 5333-42-6 | 300 | mg | AMPULE | |
| 1478108 | Ofloxacin (200 mg) | Reference Standard | 82419-36-1 | 200 | mg | VIAL | |
| 1478119 | Ofloxacin Related Compound A (25 mg) (9-Fluoro-3-methyl-7-oxo-10-(piperazin-1-yl)-2,3-dihydro-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid) | Reference Standard | 82419-52-1 | 25 | mg | VIAL | |
| 1478301 | Olanzapine (200 mg) | Reference Standard | 132539-06-1 | 200 | mg | VIAL | |
| 1478312 | Olanzapine Related Compound A (15 mg) (5-Methyl-2-((2-nitrophenyl)amino)-3-thiophenecarbonitrile) | Reference Standard | 138564-59-7 | 15 | mg | VIAL | |
| 1478323 | Olanzapine Related Compound B (15 mg) (2-methyl-10H-thieno-[2,3-b][1,5]benzodiazepin-4[5H]-one) | Reference Standard | 221176-49-4 | 15 | mg | VIAL | |
| 1478334 | Olanzapine Related Compound C (5 mg) (2-methyl-4-(4-methylpiperazin-1-yl)-10H-benzo[b]thieno[2,3-e][1,4]diazepine 4'-N-oxide) (COLD SHIPMENT REQUIRED) | Reference Standard | 174794-02-6 | 5 | mg | VIAL | |
| 1478141 | Oleanolic Acid (15 mg) ((3beta)-3-hydroxyolean-12-en-28-oic acid) | Reference Standard | 508-02-1 | 15 | mg | VIAL | |
| 1478130 | Oleic Acid (1 g) | Reference Standard | 112-80-1 | 1 | g | AMPULE | |
| 1478152 | Oleoyl Polyoxylglycerides (100 mg) | Reference Standard | N/A | 100 | mg | AMPULE | |
| 1478163 | Oleuropein (25 mg) | Reference Standard | 32619-42-4 | 25 | mg | VIAL | |
| 1478185 | Oleyl Alcohol (5 x 50 mg) | Reference Standard | 143-28-2 | 250 | mg | AMPULE | |
| 1478200 | Oleyl Oleate (0.5 mL) | Reference Standard | 3687-45-4 | 0.5 | mL | AMPULE | |
| 1478196 | Oleyl Stearate (50 mg) | Reference Standard | 17673-50-6 | 50 | mg | VIAL | |
| 1478210 | Oligosaccharide System Suitability Mixture A (20 ug) | Reference Standard | N/A | 20 | ug | AMPULE | |
| 1478221 | Oligosaccharide System Suitability Mixture B (20 ug) | Reference Standard | N/A | 20 | ug | AMPULE | |
| 1478232 | Oligosaccharide System Suitability Mixture C (20 ug) | Reference Standard | N/A | 20 | ug | AMPULE | |
| 1478243 | Oligosaccharide System Suitability Mixture D (20 ug) | Reference Standard | N/A | 20 | ug | AMPULE | |
| 1478265 | Olive Leaf Dry Extract (500 mg) | Reference Standard | 8001-25-0 | 500 | mg | VIAL | |
| 1478254 | Olive Oil (5 x 200 mg) | Reference Standard | 8001-25-0 | 1000 | mg | AMPULE | |
| 1478367 | Olmesartan Medoxomil (100 mg) | Reference Standard | 144689-63-4 | 100 | mg | VIAL | |
| 1478378 | Olmesartan Medoxomil Related Compound A (20 mg) (1-{[2'-(1H-Tetrazol-5-yl)biphenyl-4-yl]methyl}-4,4-dimethyl-2-propyl-1H-furo[3,4-d]imidazol-6(4H)-one) | Reference Standard | 849206-43-5 | 20 | mg | VIAL | |
| 1478403 | Olopatadine Hydrochloride (150 mg) | Reference Standard | 140462-76-6 | 150 | mg | VIAL | |
| 1478425 | Olopatadine Related Compound B (35 mg) ((Z)-3-{2-(carboxymethyl)dibenzo[b,e]oxepin-11(6H)-ylidene}-N,N-dimethylpropan-1-amine oxide) | Reference Standard | 173174-07-7 | 35 | mg | VIAL | |
| 1478436 | Olopatadine Related Compound C (35 mg) (11-Oxo-6,11-dihydrodibenzo[b,e]oxepin-2-yl acetic acid) | Reference Standard | 55453-87-7 | 35 | mg | VIAL | |
| 1478442 | Omega-3 Free Fatty Acids (750 mg) | Reference Standard | N/A | 750 | mg | AMPULE | |
| 1478505 | Omeprazole (200 mg) | Reference Standard | 73590-58-6 | 200 | mg | VIAL | |
| 1478549 | Omeprazole Magnesium (10 mg) | Reference Standard | 95382-33-5 | 10 | mg | VIAL | |
| 1478516 | Omeprazole Related Compound A (15 mg) (5-methoxy-2-[[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfonyl]-1H-benzimidazole) | Reference Standard | 88546-55-8 | 15 | mg | VIAL | |
| 1478480 | Omeprazole Related Compound B (15 mg) (5-Methoxy-1H-benzimidazol-2-thiol) | Reference Standard | 37052-78-1 | 15 | mg | VIAL | |
| 1478527 | Omeprazole Related Compound E (15 mg) (4-Methoxy-2-[[(RS)-(5-methoxy-1H-benzimidazol-2-yl)sulfinyl]methyl]-3,5-dimethylpyridine 1-oxide) | Reference Standard | 176219-04-8 | 15 | mg | VIAL | |
| 1478491 | Omeprazole Related Compound F and G Mixture (25 mg) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1478561 | Omeprazole Related Compound I (15 mg) (4-Methoxy-2-[[(5-methoxy-1H-benzimidazol-2-yl)sulfonyl]methyl]-3,5-dimethylpyridine 1-oxide) | Reference Standard | 158812-85-2 | 15 | mg | VIAL | |
| 1478571 | Ondansetron (300 mg) | Reference Standard | 99614-02-5 | 300 | mg | VIAL | |
| 1478582 | Ondansetron Hydrochloride (300 mg) | Reference Standard | 103639-04-9 | 300 | mg | VIAL | |
| 1478593 | Ondansetron Related Compound A (50 mg) (3-[(Dimethylamino)methyl]-1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one hydrochloride) | Reference Standard | 119812-29-2 | 50 | mg | VIAL | |
| 1478618 | Ondansetron Related Compound C (30 mg) (1,2,3,9-tetrahydro-9-methyl-4H-carbazol-4-one) | Reference Standard | 27387-31-1 | 30 | mg | VIAL | |
| 1478629 | Ondansetron Related Compound D (30 mg) (1,2,3,9-Tetrahydro-9-methyl-3-methylene-4H-carbazol-4-one) | Reference Standard | 99614-64-9 | 30 | mg | VIAL | |
| 1478630 | Ondansetron Resolution Mixture (50 mg) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1478651 | Ononin (50 mg) (3-(4-Methoxyphenyl)-4-oxo-4H-chromen7-yl beta-D-glucopyranoside) | Reference Standard | 486-62-4 | 50 | mg | VIAL | |
| 1046409 | Open Ring Aztreonam (10 mg) ((2S,3S)-2-{(Z)-2-[2-Aminothiazol-4-yl]-2-[2-carboxypropan-2-yloxyimino]acetamido}-3-(sulfoamino)butanoic acid) | Reference Standard | 87500-74-1 | 10 | mg | VIAL | |
| 1478673 | Orbifloxacin (350 mg) | Reference Standard | 113617-63-3 | 350 | mg | VIAL | |
| 1478800 | Orlistat (200 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 96829-58-2 | 200 | mg | VIAL | |
| 1478811 | Orlistat Related Compound A (25 mg) ((3S,4S)-3-Hexyl-4-[(2R)-2-hydroxytridecyl]-2-oxetanone) | Reference Standard | 104872-06-2 | 25 | mg | VIAL | |
| 1478822 | Orlistat Related Compound B (20 mg) (Diisopropyl hydrazine-1,2-dicarboxylate) | Reference Standard | 19740-72-8 | 20 | mg | VIAL | |
| 1478833 | Orlistat Related Compound C (25 mg) (Triphenylphosphine oxide) | Reference Standard | 791-28-6 | 25 | mg | VIAL | |
| 1478844 | Orlistat Related Compound D (10 mg) (N-formyl-L-leucine (3S,4R,6S)-3-hexyl-2-oxo-6-undecyltetrahydro-2H-pyran-4-yl ester) | Reference Standard | 130793-27-0 | 10 | mg | | |
| 1478877 | Orlistat Related Compound D Solution (2 x 1 mL (5 mg/mL)) ((3S,4R,6S)-3-Hexyl-2-oxo-6-undecyltetrahydro-2H-pyran-4-yl formyl-L-leucinate in acetonitrile) | Reference Standard | 130793-27-0 | 2 | mL | | |
| 1478855 | Orlistat Related Compound E (10 mg) (N-Formyl (S)-isoleucine (S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester) | Reference Standard | 1072902-75-0 | 10 | mg | VIAL | |
| 1479009 | Orphenadrine Citrate (200 mg) | Reference Standard | 4682-36-4 | 200 | mg | VIAL | |
| 1479010 | Orphenadrine Related Compound A (50 mg) ((RS)-N,N-dimethyl-2-[(3-methylphenyl)-phenylmethoxy]ethanamine citrate) (AS) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1479020 | Orphenadrine Related Compound B (20 mg) (N-Ethyl-N,N-dimethyl-2-[phenyl(o-tolyl)methoxy]ethanaminium chloride; also known as N-Ethyl-N,N-dimethyl-2-[phenyl(2-tolyl)methoxy]ethanaminium chloride) | Reference Standard | 93940-17-1 | 20 | mg | VIAL | |
| 1479031 | Orphenadrine Related Compound C (20 mg) (N-methyl-[2-(2-methylbenzhydryloxy)ethyl]amine hydrochloride) | Reference Standard | 10488-36-5 | 20 | mg | VIAL | |
| 1479053 | Orphenadrine Related Compound E (50 mg) (N,N-Dimethyl-2-[phenyl(m-tolyl)methoxy]ethanamine) | Reference Standard | 21945-86-8 | 50 | mg | AMPULE | |
| 1479064 | Orphenadrine Related Compound F (50 mg) (N,N-Dimethyl-2-[phenyl(p-tolyl)methoxy]ethanamine citrate) | Reference Standard | 19804-27-4 | 50 | mg | VIAL | |
| 1479304 | Oseltamivir Phosphate (200 mg) | Reference Standard | 204255-11-8 | 200 | mg | VIAL | |
| 1479315 | Oseltamivir Related Compound A (10 mg) ((3S,4R,5S)-ethyl 4-acetamido-5-amino-2-azido-3-(pentan-3-yloxy)cyclohexanecarboxylate) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1133580 | Oversulfated Chondroitin Sulfate (10 mg) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1481044 | Oxacillin Related Compound C (15 mg) (5-Methyl-3-phenylisoxazole-4-carboxylic acid) | Reference Standard | 1136-45-4 | 15 | mg | VIAL | |
| 1481000 | Oxacillin Sodium (200 mg) | Reference Standard | 7240-38-2 | 200 | mg | VIAL | |
| 1481204 | Oxaliplatin (125 mg) | Reference Standard | 61825-94-3 | 125 | mg | VIAL | |
| 1481215 | Oxaliplatin Related Compound A (100 mg) (Ethanedioic acid, dihydrate) | Reference Standard | 6153-56-6 | 100 | mg | VIAL | |
| 1481226 | Oxaliplatin Related Compound B (15 mg) ([SP-4-2-(1R-trans)]-(1,2-cyclohexanediamine-N,N') dinitratoplatinum(II)) | Reference Standard | 66900-68-3 | 15 | mg | VIAL | |
| 1481237 | Oxaliplatin Related Compound C (20 mg) ([1R-trans-(1,2-cyclohexanediamine-N,N')]-trans-dihydroxido-[oxalato(2-)-O,O']platinum(IV)) | Reference Standard | 111321-67-6 | 20 | mg | VIAL | |
| 1481248 | Oxaliplatin Related Compound D (10 mg) (cis-[(1S,2S)-1,2-cyclohexanediamine-N,N'][oxalato(2-)-O,O']platinum) | Reference Standard | 61758-77-8 | 10 | mg | VIAL | |
| 1481260 | Oxaliplatin Related Compound F (25 mg) ([SP-4-2-(1R-trans)]-(1,2-cyclohexanediamine-N,N') diiodidoplatinum(II)) | Reference Standard | 66845-32-7 | 25 | mg | VIAL | |
| 1481306 | Oxaliplatin System Suitability (25 mg) ([SP-4-2-(1R-trans)]-(1,2-cyclohexanediamine-N,N') dichloridoplatinum(II)) | Reference Standard | 61848-66-6 | 25 | mg | VIAL | |
| 1482003 | Oxandrolone CIII (50 mg) | Reference Standard | 53-39-4 | 50 | mg | VIAL | |
| 1482014 | Oxandrolone Related Compound A CIII (20 mg) (17beta-hydroxy-17alpha-methyl-2-oxa-5alpha-androst-7-en-3-one) | Reference Standard | 1391052-43-9 | 20 | mg | VIAL | |
| 1482025 | Oxandrolone Related Compound B CIII (20 mg) (17 beta-hydroxy-17 alpha-methyl-4-oxa-5 alpha-androsta-3-one) | Reference Standard | 4424-45-7 | 20 | mg | VIAL | |
| 1482036 | Oxandrolone Related Compound C CIII (20 mg) (17,17-dimethyl-18-nor-2-oxa-5alpha-androst-13-en-3-one) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1482207 | Oxaprozin (200 mg) | Reference Standard | 21256-18-8 | 200 | mg | VIAL | |
| 1483006 | Oxazepam CIV (200 mg) | Reference Standard | 604-75-1 | 200 | mg | VIAL | |
| 1483017 | Oxazepam Related Compound A (15 mg) (7-chloro-5-phenyl-4,5-dihydro-1H-benzodiazepine-2,3-dione) | Reference Standard | 19554-95-1 | 15 | mg | VIAL | |
| 1483028 | Oxazepam Related Compound B (15 mg) (7-Chloro-2-oxo-5-phenyl-2,3-dihydro-1H-benzodiazepin-3-yl acetate) | Reference Standard | 1824-74-4 | 15 | mg | VIAL | |
| 1483039 | Oxazepam Related Compound C (15 mg) (6-chloro-4-phenylquinazoline-2-carbaldehyde) | Reference Standard | 5958-05-4 | 15 | mg | VIAL | |
| 1483152 | Oxcarbazepine (100 mg) | Reference Standard | 28721-07-5 | 100 | mg | VIAL | |
| 1483163 | Oxcarbazepine Related Compound A (10 mg) (N-Formyl-10-oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1483174 | Oxcarbazepine Related Compound B (10 mg) (N-Acetyl-10-oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1483185 | Oxcarbazepine Related Compound C (10 mg) (Acridin-9(10H)-one) | Reference Standard | 578-95-0 | 10 | mg | VIAL | |
| 1483196 | Oxcarbazepine Related Compound D (10 mg) (10-(10-Oxo-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamido)-5H-dibenzo[b,f]azepine-5-carboxamide) | Reference Standard | 2642430-32-6 | 10 | mg | VIAL | |
| 1483200 | Oxcarbazepine Related Compound E (10 mg) (10(11H)-Oxo-5H-dibenz[b,f]azepine) | Reference Standard | 21737-58-6 | 10 | mg | VIAL | |
| 1483301 | Oxfendazole (200 mg) | Reference Standard | 53716-50-0 | 200 | mg | VIAL | |
| 1483425 | Oxiconazole Nitrate (200 mg) | Reference Standard | 64211-46-7 | 200 | mg | VIAL | |
| 1483436 | Oxiconazole Related Compound A (20 mg) (2',4'-Dichloro-2-imidazol-1-ylacetophenone (E)-[O-(2,4-dichlorobenzyl)oxime]) | Reference Standard | 76472-50-9 | 20 | mg | VIAL | |
| 1483447 | Oxiconazole Related Compound B (20 mg) ((Z)-1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethanone oxime) | Reference Standard | 64211-06-9 | 20 | mg | VIAL | |
| 1483458 | Oxiconazole Related Compound C (20 mg) (1-(2,4-Dichlorophenyl)-2-(1H -imidazol-1-yl)ethan-1-one hydrochloride) | Reference Standard | 98164-08-0 | 20 | mg | VIAL | |
| 1483469 | Oxiconazole Related Compound D (50 mg) ((2,4-Dichlorophenyl)methanol) | Reference Standard | 1777-82-8 | 50 | mg | VIAL | |
| 1483470 | Oxiconazole Related Compound E (100 mg) (2,4-Dichlorobenzyl chloride) | Reference Standard | 94-99-5 | 100 | mg | VIAL | |
| 1483505 | Oxprenolol Hydrochloride (200 mg) | Reference Standard | 6452-73-9 | 200 | mg | VIAL | |
| 1484009 | Oxtriphylline (500 mg) | Reference Standard | 4499-40-5 | 500 | mg | VIAL | |
| 1485001 | Oxybenzone (150 mg) | Reference Standard | 131-57-7 | 150 | mg | VIAL | |
| 1485103 | Oxybutynin Chloride (200 mg) | Reference Standard | 1508-65-2 | 200 | mg | VIAL | |
| 1485114 | Oxybutynin Related Compound A (100 mg) (Phenylcyclohexylglycolic Acid) | Reference Standard | 4335-77-7 | 100 | mg | VIAL | |
| 1485125 | Oxybutynin Related Compound B (20 mg) (Cyclohexyl Mandelic Acid Methyl Ester) | Reference Standard | 10399-13-0 | 20 | mg | VIAL | |
| 1485136 | Oxybutynin Related Compound C (20 mg) (4-(ethylmethylamino)but-2-ynyl(+/-)-2-cyclohexyl-2-hydroxy-2-phenylacetate hydrochloride) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1485191 | Oxycodone CII (200 mg) | Reference Standard | 76-42-6 | 200 | mg | VIAL | |
| 1485205 | Oxycodone Hydrochloride CII (1 g) | Reference Standard | 124-90-3 | 1 | g | VIAL | |
| 1485216 | Oxycodone Related Compound A CII (10 mg) (14-hydroxycodeinone) (COLD SHIPMENT REQUIRED) | Reference Standard | 508-54-3 | 10 | mg | VIAL | |
| 1485227 | Oxycodone Related Compound B CII (15 mg) (oxycodone N-oxide) | Reference Standard | 71539-52-1 | 15 | mg | VIAL | |
| 1485238 | Oxycodone Related Compound C CII (15 mg) (codeinone) | Reference Standard | 467-13-0 | 15 | mg | VIAL | |
| 1486004 | Oxymetazoline Hydrochloride (200 mg) | Reference Standard | 2315-02-8 | 200 | mg | VIAL | |
| 1486015 | Oxymetazoline Related Compound A (15 mg) (N-(2-Aminoethyl)-2-[4-(tert-butyl)-3-hydroxy-2,6-dimethylphenyl]acetamide hydrochloride) | Reference Standard | 1391053-50-1 | 15 | mg | VIAL | |
| 1487007 | Oxymetholone CIII (200 mg) | Reference Standard | 434-07-1 | 200 | mg | VIAL | |
| 1487029 | Oxymetholone Related Compound B (25 mg) (17Beta-Hydroxy-1-hydroxymethylene-17alpha-methyl-5alpha-androstan-3-one) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1488000 | Oxymorphone CII (300 mg) | Reference Standard | 76-41-5 | 300 | mg | VIAL | |
| 1488019 | Oxymorphone Related Compound A CII (25 mg) (4,5alpha-Epoxy-3,14-dihydroxy-17-methylmorphinan-6-one N-oxide) | Reference Standard | 71360-37-7 | 25 | mg | VIAL | |
| 1490103 | Oxyquinoline Sulfate (200 mg) | Reference Standard | 134-31-6 | 200 | mg | VIAL | |
| 1491004 | Oxytetracycline (200 mg) | Reference Standard | 6153-64-6 | 200 | mg | VIAL | |
| 1491015 | Oxytetracycline Hydrochloride (200 mg) | Reference Standard | 2058-46-0 | 200 | mg | VIAL | |
| 1491300 | Oxytocin (1.81 mg) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | 50-56-6 | 1.81 | mg | VIAL | |
| 1491296 | Oxytocin Identification (15 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 6233-83-6 | 15 | mg | VIAL | |
| 1111908 | P-Chloroaniline (200 mg) | Reference Standard | 106-47-8 | 200 | mg | VIAL | |
| 1467837 | PS NMR System Suitability (1 mg) | Reference Standard | N/A | 1 | mg | AMPULE | |
| 1491332 | Paclitaxel (200 mg) | Reference Standard | 33069-62-4 | 200 | mg | VIAL | |
| 1491365 | Paclitaxel Impurity Mixture (10 mg) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1491343 | Paclitaxel Related Compound A (20 mg) (Cephalomannine) | Reference Standard | 71610-00-9 | 20 | mg | VIAL | |
| 1491354 | Paclitaxel Related Compound B (20 mg) (10-deacetyl-7-epipaclitaxel) | Reference Standard | 78454-17-8 | 20 | mg | VIAL | |
| 1491503 | Padimate O (300 mg) | Reference Standard | 21245-02-3 | 300 | mg | AMPULE | |
| 1491605 | Paeonia Lactiflora Peeled Root Dry Extract (500 mg) | Reference Standard | NA | 500 | mg | VIAL | |
| 1491616 | Paeoniflorin (15 mg) | Reference Standard | 23180-57-6 | 15 | mg | VIAL | |
| 1491809 | Paliperidone (200 mg) | Reference Standard | 144598-75-4 | 200 | mg | VIAL | |
| 1491818 | Paliperidone Related Compound A (20 mg) (3-Ethyl-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-alpha]pyrimidin-4-one) | Reference Standard | 849903-79-3 | 20 | mg | VIAL | |
| 1491820 | Paliperidone Related Compound B (20 mg) (6-fluoro-3-(piperidin-4-yl)benzoisoxazole hydrochloride) | Reference Standard | 84163-13-3 | 20 | mg | VIAL | |
| 1491831 | Paliperidone Related Compound C (20 mg) (3-(2-Chloroethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-alpha]pyrimidin-4-one) | Reference Standard | 130049-82-0 | 20 | mg | VIAL | |
| 1491842 | Paliperidone Related Compound D (20 mg) (3-{2-[4-(6-Fluoro-1,2-benzisoxazol-3-yl) piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one N-oxide) | Reference Standard | 761460-08-6 | 20 | mg | VIAL | |
| 1491795 | Paliperidone Resolution Mixture (20 mg) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1492040 | Palm Oil (1 g) | Reference Standard | 8002-75-3 | 1 | g | AMPULE | |
| 1667869 | Palm Oil Tocotrienols and Tocopherols (150 mg) | Reference Standard | N/A | 150 | mg | AMPULE | |
| 1491900 | Palmatine Chloride (15 mg) | Reference Standard | 10605-02-4 | 15 | mg | VIAL | |
| 1492007 | Palmitic Acid (500 mg) | Reference Standard | 57-10-3 | 500 | mg | VIAL | |
| 1492211 | Palonosetron Enantiomer (15 mg) ((3aR)-2-[(3R)-Quinuclidin-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one hydrochloride) | Reference Standard | 135729-75-8 | 15 | mg | VIAL | |
| 1492200 | Palonosetron Hydrochloride (100 mg) | Reference Standard | 135729-62-3 | 100 | mg | VIAL | |
| 1492222 | Palonosetron Related Compound A (15 mg) ((3aS)-1-Oxo-2-[(3S)-quinuclidin-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinoline 1-oxide) | Reference Standard | 813425-83-1 | 15 | mg | VIAL | |
| 1492233 | Palonosetron Related Compound B (15 mg) ((3S)-3-(1-Oxo-5,6-dihydro-1H-benzo[de]isoquinolin-2(4H)-yl)quinuclidine 1-oxide) | Reference Standard | 1021456-82-5 | 15 | mg | VIAL | |
| 1492244 | Palonosetron Related Compound C (15 mg) ((3aS)-2-[(3R)-Quinuclidin-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one hydrochloride) | Reference Standard | 135729-76-9 | 15 | mg | VIAL | |
| 1492255 | Palonosetron Related Compound D (15 mg) ((3aR)-2-[(3S)-Quinuclidin-3-yl]-2,3,3a,4,5,6-hexahydro-1H-benzo[de]isoquinolin-1-one hydrochloride) | Reference Standard | 135755-51-0 | 15 | mg | VIAL | |
| 1492266 | Palonosetron Related Compound E (15 mg) (2-[(3S)-Quinuclidin-3-yl]-2,4,5,6-tetrahydro-1H-benzo[de]isoquinolin-1-one hydrochloride) | Reference Standard | 135729-55-4 | 15 | mg | VIAL | |
| 1492700 | Pamabrom Related Compound A (30 mg) (8-Chlorotheophylline) | Reference Standard | 85-18-7 | 30 | mg | VIAL | |
| 1492801 | Pamidronate Disodium (100 mg) | Reference Standard | 109552-15-0 | 100 | mg | VIAL | |
| 1493000 | Pamoic Acid (250 mg) | Reference Standard | 130-85-8 | 250 | mg | | |
| 1291719 | Panax Notoginseng Root and Rhizome Dry Extract (1 g) | Reference Standard | N/A | 1 | g | VIAL | |
| 1494057 | Pancreatin Amylase and Protease (2 g) (COLD SHIPMENT REQUIRED) | Reference Standard | 8049-47-6 | 2 | g | VIAL | |
| 1494079 | Pancreatin Lipase (2 g) (COLD SHIPMENT REQUIRED) | Reference Standard | 53608-75-6 | 2 | g | VIAL | |
| 1494217 | Pancuronium Bromide (500 mg) | Reference Standard | 15500-66-0 | 500 | mg | VIAL | |
| 1494228 | Pancuronium Bromide Related Compound A (15 mg) (1,1'-(3alpha,17beta-dihydroxy-5alpha-androstan-2beta,16beta-ylene) bis(1-methylpiperidinium) dibromide) | Reference Standard | 15500-65-9 | 15 | mg | VIAL | |
| 1494239 | Pancuronium Bromide Related Compound B (15 mg) (1,1'-(17beta-Acetoxy-3alpha-hydroxy-5alpha-androstan-2beta,16beta-ylene) bis(1-methylpiperidinium) dibromide) | Reference Standard | 41261-71-6 | 15 | mg | VIAL | |
| 1494240 | Pancuronium Bromide Related Compound C (15 mg) (1,1'-(3alpha-acetoxy-17beta-hydroxy-5alpha-androstan-2beta,16beta-ylene) bis(1-methylpiperidinium) dibromide) | Reference Standard | 27115-86-2 | 15 | mg | VIAL | |
| 1494501 | Panthenol, Racemic (200 mg) | Reference Standard | 16485-10-2 | 200 | mg | VIAL | |
| 1494807 | Pantolactone (500 mg) | Reference Standard | 599-04-2 | 500 | mg | VIAL | |
| 1494909 | Pantoprazole Related Compound A (25 mg) (5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]sulfonyl]-1H-benzimidazole) | Reference Standard | 127780-16-9 | 25 | mg | VIAL | |
| 1494910 | Pantoprazole Related Compound B (25 mg) (5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)methyl]thio]-1H-benzimidazole) | Reference Standard | 102625-64-9 | 25 | mg | VIAL | |
| 1494920 | Pantoprazole Related Compound C (20 mg) (5-(difluoromethoxy)-1H-benzimidazole-2-thiol) | Reference Standard | 97963-62-7 | 20 | mg | VIAL | |
| 1494942 | Pantoprazole Related Compound E (20 mg) (6,6'-Bis(difluoromethoxy)-2,2'-bis[(3,4-dimethoxypyridin-2-yl)methylsulfinyl]-1H,1'H-5,5'-bibenzimidazole) | Reference Standard | 2115779-15-0 | 20 | mg | VIAL | |
| 1494931 | Pantoprazole Related Compounds D and F Mixture (20 mg) | Reference Standard | NA | 20 | mg | VIAL | |
| 1494895 | Pantoprazole Sodium (250 mg) | Reference Standard | 164579-32-2 | 250 | mg | VIAL | |
| 1495005 | Papain (1 g) (COLD SHIPMENT REQUIRED) | Reference Standard | 9001-73-4 | 1 | g | | |
| 1496008 | Papaverine Hydrochloride (200 mg) | Reference Standard | 61-25-6 | 200 | mg | VIAL | |
| 1496802 | Parachlorophenol (500 mg) | Reference Standard | 106-48-9 | 500 | mg | VIAL | |
| 1496904 | Paraffin (1 g) | Reference Standard | 8002-74-2 | 1 | g | VIAL | |
| 1496959 | Paraldehyde CIV (3 x 1.5 mL) | Reference Standard | 123-63-7 | 4.5 | mL | AMPULE | |
| 1498706 | Parbendazole (200 mg) | Reference Standard | 14255-87-9 | 200 | mg | VIAL | |
| 1499403 | Paricalcitol (10 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 131918-61-1 | 10 | mg | VIAL | |
| 1499414 | Paricalcitol Solution (3 mL) (COLD SHIPMENT REQUIRED) | Reference Standard | N/A | 3 | mL | AMPULE | |
| 1500003 | Paromomycin Sulfate (125 mg) | Reference Standard | 1263-89-4 | 125 | mg | VIAL | |
| 1500218 | Paroxetine Hydrochloride (350 mg) | Reference Standard | 110429-35-1 | 350 | mg | VIAL | |
| 1500230 | Paroxetine Related Compound B (15 mg) ((3S,4R)-3-[(Benzodioxol-5-yloxy)methyl]-4-phenylpiperidine hydrochloride) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1500240 | Paroxetine Related Compound C (30 mg) ((3R,4S)-3-[(Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine hydrochloride) OR ((+)-trans-Paroxetine hydrochloride) | Reference Standard | 130855-30-0 | 30 | mg | VIAL | |
| 1500251 | Paroxetine Related Compound D (10 mg) ((3RS,4RS)-3-[(Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine hydrochloride); cis-paroxetine hydrochloride | Reference Standard | N/A | 10 | mg | VIAL | |
| 1500207 | Paroxetine Related Compound E (50 mg) (4-(4-Fluorophenyl)-1-methyl-1,2,3,6-tetrahydropyridine hydrochloride) | Reference Standard | 1012886-75-7 | 50 | mg | VIAL | |
| 1500273 | Paroxetine Related Compound F (25 mg) ((3S,4R)-3-[(Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)-1-methylpiperidine) | Reference Standard | 110429-36-2 | 25 | mg | VIAL | |
| 1500284 | Paroxetine Related Compound G (10 mg) ((+/-)trans-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4''-fluorophenyl-4'-phenyl)piperidine hydrochloride) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1500353 | Paroxetine System Suitability Mixture A (50 mg) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1500400 | Parthenolide (25 mg) | Reference Standard | 20554-84-1 | 25 | mg | VIAL | |
| 1396659 | Partially-Neutralized Methacrylic Acid and Ethyl Acrylate Copolymer (1:1) (1 g) | Reference Standard | 25212-88-8 | 1 | g | VIAL | |
| 1500502 | Particle Count Set (2 blanks and 2 suspensions) | Reference Standard | N/A | 100 | mL | BOTTLE | |
| 1500557 | Peanut Oil (1 g) | Reference Standard | 8002-03-7 | 1 | g | AMPULE | |
| 1500626 | Pegfilgrastim for Bioassay (COLD SHIPMENT REQUIRED) | Reference Standard | 208265-92-3 | 1 | mL | AMPULE | |
| 1A00630 | Pemetrexed Acid N-Hydroxysuccinimide Ester (25 mg) (2,5-dioxopyrrolidin-1-yl 4-(2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzoate) | Pharmaceutical Analytical Impurity | 204257-65-8 | 25 | mg | VIAL | |
| 1A00640 | Pemetrexed Dimethyl Ester (25 mg) (dimethyl (4-(2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzoyl)-L-glutamate) | Pharmaceutical Analytical Impurity | 155405-81-5 | 25 | mg | VIAL | |
| 1500659 | Pemetrexed Disodium (100 mg) (Disodium N-{p-[2-(2-amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-l-glutamate heptahydrate) | Reference Standard | 357166-29-1 | 100 | mg | VIAL | |
| 1A00620 | Pemetrexed Disodium Enantiomer (25 mg) ((2R)-2-[[4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid, sodium salt) | Pharmaceutical Analytical Impurity | 937370-10-0 | 25 | mg | VIAL | |
| 1A00610 | Pemetrexed Glutamide Trisodium Salt (25 mg) (((S)-4-(4-(2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl)benzamido)-4-carboxybutanoyl)-L-glutamic acid, sodium salt) | Pharmaceutical Analytical Impurity | 1265908-59-5 | 25 | mg | VIAL | |
| 1500808 | Penbutolol Sulfate (200 mg) | Reference Standard | 38363-32-5 | 200 | mg | VIAL | |
| 1501006 | Penicillamine (200 mg) | Reference Standard | 52-67-5 | 200 | mg | VIAL | |
| 1501108 | Penicillamine Disulfide (200 mg) (3,3'-Dithiodi-D-valine) | Reference Standard | 20902-45-8 | 200 | mg | VIAL | |
| 1502009 | Penicillin G Benzathine (200 mg) | Reference Standard | 41372-02-5 | 200 | mg | VIAL | |
| 1502508 | Penicillin G Potassium (200 mg) | Reference Standard | 113-98-4 | 200 | mg | VIAL | |
| 1502552 | Penicillin G Procaine (200 mg) | Reference Standard | 6130-64-9 | 200 | mg | VIAL | |
| 1502701 | Penicillin G Sodium (150 mg) | Reference Standard | 69-57-8 | 150 | mg | VIAL | |
| 1504489 | Penicillin V (200 mg) | Reference Standard | 87-08-1 | 200 | mg | VIAL | |
| 1504503 | Penicillin V Potassium (200 mg) | Reference Standard | 132-98-9 | 200 | mg | VIAL | |
| 1504900 | Pentamidine Isethionate (200 mg) | Reference Standard | 140-64-7 | 200 | mg | VIAL | |
| 1504933 | Pentane (1.2 mL/ampule; 3 ampules) | Reference Standard | 109-66-0 | 3.6 | mL | AMPULE | |
| 1505007 | Pentazocine CIV (500 mg) | Reference Standard | 359-83-1 | 500 | mg | VIAL | |
| 1505506 | Pentetic Acid (100 mg) | Reference Standard | 67-43-6 | 100 | mg | VIAL | |
| 1507002 | Pentobarbital CII (200 mg) | Reference Standard | 76-74-4 | 200 | mg | VIAL | |
| 1508901 | Pentoxifylline (200 mg) | Reference Standard | 6493-05-6 | 200 | mg | VIAL | |
| 1510051 | Pepsin for Assay (5 x 1 g) (COLD SHIPMENT REQUIRED) | Reference Standard | 9001-75-6 | 5 | g | VIAL | |
| 1510801 | Perflubron (0.5 mL) | Reference Standard | 423-55-2 | 0.5 | mL | AMPULE | |
| 1510845 | Pergolide Mesylate (200 mg) | Reference Standard | 66104-23-2 | 200 | mg | VIAL | |
| 1510867 | Pergolide Sulfoxide (50 mg) | Reference Standard | 72822-01-6 | 50 | mg | VIAL | |
| 1510889 | Perindopril Erbumine (100 mg) | Reference Standard | 107133-36-8 | 100 | mg | VIAL | |
| 1510890 | Perindopril Related Compound A (20 mg) ((2S,3aS,7aS)-octahydro-1H-indole-2-carboxylic acid) | Reference Standard | 80875-98-5 | 20 | mg | VIAL | |
| 1510903 | Perindopril Related Compound B (10 mg) ((2S,3aS,7aS)-1-{(S)-2-[(S)-1-carboxybutylamino]propanoyl}octahydro-1H-indole-2-carboxylic acid monohydrate) | Reference Standard | 1418095-48-3 | 10 | mg | VIAL | |
| 1510914 | Perindopril Related Compound C (20 mg) ((S)-2-[(3S,5aS,9aS,10aS)-3-methyl-1,4-dioxodecahydropyrazino[1,2-a]indol-2(1H)-yl]pentanoic acid) | Reference Standard | 129970-99-6 | 20 | mg | VIAL | |
| 1510925 | Perindopril Related Compound D (25 mg) ((S)-2-{(3S,5aS,9aS,10aR)-3-methyl-1,4-dioxodecahydropyrazino[1,2-a]indol-2(1H)-yl}pentanoic acid) | Reference Standard | 130061-28-8 | 25 | mg | VIAL | |
| 1510936 | Perindopril Related Compound E (10 mg) ((2S,3aS,7aS)-1-{(S)-2-[(S)-1-isopropoxy-1-oxopentan-2-ylamino]propanoyl}octahydro-1H-indole-2-carboxylic acid, tert-butylamine) | Reference Standard | N/A | 10 | mg | | |
| 1510947 | Perindopril Related Compound F (10 mg) ((S)-ethyl 2-{(3S,5aS,9aS,10aS)-3-methyl-1,4-dioxodecahydropyrazino[1,2-a]indol-2(1H)-yl}pentanoate) | Reference Standard | 129970-98-5 | 10 | mg | VIAL | |
| 1510970 | Perindopril Related Compound I (20 mg) (2-Methylpropan-2-amine (2S,3aS,7aS)-1-{(S)-2-[(R)-1-ethoxy-1-oxopentan-2-ylamino]propanoyl}octahydro-1H-indole-2-carboxylate) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1510999 | Perindopril Related Compound K (10 mg) ((3S,5aS,9aS,10aS)-3-methyldecahydropyrazino[1,2-a]indole-1,4-dione) | Reference Standard | 2012-01-07 | 10 | mg | VIAL | |
| 1511000 | Perphenazine (200 mg) | Reference Standard | 58-39-9 | 200 | mg | VIAL | |
| 1511021 | Perphenazine Related Compound B (15 mg) (2-{4-[3-(10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethanol) | Reference Standard | 3533-97-9 | 15 | mg | VIAL | |
| 1511203 | Perphenazine Sulfoxide (25 mg) | Reference Standard | 10078-25-8 | 25 | mg | VIAL | |
| 1513005 | Phenacetin (500 mg) | Reference Standard | 62-44-2 | 500 | mg | VIAL | |
| 1514008 | Phenacetin Melting Point Standard (1 g) (Approximately 135 degrees) | Reference Standard | 62-44-2 | 1 | g | VIAL | |
| 1515000 | Phenazopyridine Hydrochloride (200 mg) | Reference Standard | 136-40-3 | 200 | mg | VIAL | |
| 1516003 | Phencyclidine Hydrochloride CII (25 mg) (AS) | Reference Standard | 956-90-1 | 25 | mg | VIAL | |
| 1516502 | Phendimetrazine Tartrate CIII (350 mg) | Reference Standard | 50-58-8 | 350 | mg | VIAL | |
| 1517006 | Phenelzine Sulfate (200 mg) | Reference Standard | 156-51-4 | 200 | mg | VIAL | |
| 1522301 | Pheniramine Maleate (150 mg) | Reference Standard | 132-20-7 | 150 | mg | VIAL | |
| 1524001 | Phenobarbital CIV (200 mg) | Reference Standard | 50-06-6 | 200 | mg | VIAL | |
| 1524012 | Phenobarbital Related Compound A (30 mg) (5-Ethyl-2,6-diimino-5-phenyltetrahydropyrimidin-4(1H)-one) | Reference Standard | 69125-70-8 | 30 | mg | VIAL | |
| 1524023 | Phenobarbital Related Compound B (30 mg) (5-Ethyl-6-imino-5-phenyldihydropyrimidine-2,4(1H,3H)-dione) | Reference Standard | 58042-96-9 | 30 | mg | VIAL | |
| 1524806 | Phenol (500 mg) | Reference Standard | 108-95-2 | 500 | mg | VIAL | |
| 1525707 | Phenothiazine (500 mg) | Reference Standard | 92-84-2 | 500 | mg | VIAL | |
| 1525999 | Phenoxybenzamine Alcohol (COLD SHIPMENT REQUIRED) (50 mg) (2-[Benzyl(1-phenoxypropan-2-yl)amino]ethan-1-ol) | Reference Standard | 101-45-1 | 50 | mg | AMPULE | |
| 1526007 | Phenoxybenzamine Hydrochloride (250 mg) | Reference Standard | 63-92-3 | 250 | mg | | |
| 1526030 | Phenoxybenzamine Nitrile (50 mg) (COLD SHIPMENT REQUIRED) (3-[Benzyl(1-phenoxypropan-2-yl)amino]propanenitrile) | Reference Standard | N/A | 50 | mg | AMPULE | |
| 1526200 | Phenoxyethanol (500 mg) (2-Phenoxyethanol) | Reference Standard | 122-99-6 | 500 | mg | AMPULE | |
| 1528501 | Phentermine Hydrochloride CIV (200 mg) | Reference Standard | 1197-21-3 | 200 | mg | VIAL | |
| 1528512 | Phentermine Related Compound A (30 mg) (N-(2-Methyl-1-phenylpropan-2-yl)formamide) | Reference Standard | 52117-13-2 | 30 | mg | VIAL | |
| 1528534 | Phentermine Related Compound C (100 mg) ((2-Methylprop-1-en-1-yl)benzene) | Reference Standard | 768-49-0 | 100 | mg | AMPULE | |
| 1529071 | Phentolamine Keto Analog (25 mg) (N-(3-Hydroxyphenyl)-N-(4-tolyl)-4,5-dihydro-1H-imidazole-2-carboxamide) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1530004 | Phentolamine Mesylate (200 mg) | Reference Standard | 65-28-1 | 200 | mg | VIAL | |
| 1529016 | Phentolamine Related Compound A (25 mg) (N-(2-Aminoethyl)-2-[(3-hydroxyphenyl)(4-tolyl)amino]acetamide) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1534209 | Phenyl Salicylate Melting Point Standard (1 g) (COLD SHIPMENT REQUIRED) (Approximately 41 degrees) | Reference Standard | 118-55-8 | 1 | g | VIAL | |
| 1531007 | Phenylbutazone (250 mg) | Reference Standard | 50-33-9 | 250 | mg | VIAL | |
| 1614523 | Phenylbutyrate Related Compound A (25 mg) (4-oxo-4-phenylbutanoic acid) | Reference Standard | 2051-95-8 | 25 | mg | VIAL | |
| 1614556 | Phenylbutyrate Related Compound B (100 mg) (3,4-dihydronaphthalen-1(2H)-one) | Reference Standard | 529-34-0 | 100 | mg | AMPULE | |
| 1614534 | Phenylbutyrate Related Compound C (25 mg) (4-cyclohexylbutanoic acid) (COLD SHIPMENT REQUIRED) | Reference Standard | 4441-63-8 | 25 | mg | VIAL | |
| 1532950 | Phenylephrine Bitartrate (25 mg) | Reference Standard | 17162-39-9 | 25 | mg | VIAL | |
| 1533002 | Phenylephrine Hydrochloride (200 mg) | Reference Standard | 61-76-7 | 200 | mg | VIAL | |
| 1533024 | Phenylephrine Related Compound C (30 mg) (1-(3-Hydroxyphenyl)-2-(methylamino)ethan-1-one hydrochloride) | Reference Standard | 94240-17-2 | 30 | mg | VIAL | |
| 1533035 | Phenylephrine Related Compound D (30 mg) ((R)-3-{2-[Benzyl(methyl)amino]-1-hydroxyethyl}phenol) | Reference Standard | 1367567-95-0 | 30 | mg | VIAL | |
| 1533046 | Phenylephrine Related Compound E (30 mg) (2-[Benzyl(methyl)amino]-1-(3-hydroxyphenyl)ethan-1-one hydrochloride) | Reference Standard | 71786-67-9 | 30 | mg | VIAL | |
| 1533261 | Phenylephrine Related Compound F (30 mg) ((R)-2-Methyl-1,2,3,4-tetrahydroisoquinoline-4,8-diol hydrochloride monohydrate) | Reference Standard | 1007885-60-0 | 30 | mg | VIAL | |
| 1533272 | Phenylephrine Related Compound G (30 mg) ((R)-N-(2-Hydroxy-2-(3-hydroxyphenyl)ethyl)-N-methylglycine) | Reference Standard | 1094089-46-9 | 30 | mg | VIAL | |
| 1533250 | Phenylethyl Alcohol (1 mL) | Reference Standard | 60-12-8 | 1 | mL | AMPULE | |
| 1534005 | Phenylpropanolamine Hydrochloride (250 mg) (List Chemical) | Reference Standard | 154-41-6 | 250 | mg | VIAL | |
| 1534402 | Phenyltoloxamine Citrate (100 mg) | Reference Standard | 1176-08-5 | 100 | mg | VIAL | |
| 1534413 | Phenyltoloxamine Related Compound A (50 mg) (2-(2-benzylphenoxy)ethylmethylamine hydrochloride) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1535008 | Phenytoin (200 mg) | Reference Standard | 57-41-0 | 200 | mg | VIAL | |
| 1535019 | Phenytoin Related Compound A (50 mg) (2,2-Diphenylglycine) | Reference Standard | 3060-50-2 | 50 | mg | VIAL | |
| 1535020 | Phenytoin Related Compound B (50 mg) (2,2-Diphenyl-2-ureidoacetic acid) | Reference Standard | 6802-95-5 | 50 | mg | VIAL | |
| 1535507 | Phenytoin Sodium (200 mg) | Reference Standard | 630-93-3 | 200 | mg | VIAL | |
| 1535700 | Phosphated Riboflavin (100 mg) | Reference Standard | 6184-17-4 | 100 | mg | VIAL | |
| 1535722 | Phosphatidic Acid (Soy) Monosodium (50 mg) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | N/A | 50 | mg | | |
| 1535733 | Phosphatidylcholine (250 mg) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | 97281-44-2 | 250 | mg | VIAL | |
| 1535755 | Phosphatidylcholine (Soy) (50 mg) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | 97281-47-5 | 50 | mg | VIAL | |
| 1535744 | Phosphatidylethanolamine (100 mg) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | 39382-08-6 | 100 | mg | VIAL | |
| 1535766 | Phosphatidylethanolamine (Soy) (50 mg) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) (1,2-Diacyl-sn-glycero-3-phosphoethanolamine) | Reference Standard | 97281-51-1 | 50 | mg | VIAL | |
| 1535788 | Phosphatidylinositol (Soy) Sodium (20 mg) (Phosphatidylinositol from soybean lecithin) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | 383907-36-6 | 20 | mg | VIAL | |
| 1535802 | Phosphoric Acid (1.5 mL/ampule; 3 ampules) | Reference Standard | 7664-38-2 | 4.5 | mL | AMPULE | |
| 1535959 | Phthalazine (20 mg) | Reference Standard | 253-52-1 | 20 | mg | VIAL | |
| 1535899 | Phthalic Acid (50 mg) | Reference Standard | 88-99-3 | 50 | mg | VIAL | |
| 1536509 | Phyllanthin (15 mg) | Reference Standard | 10351-88-9 | 15 | mg | VIAL | |
| 1537003 | Physostigmine Salicylate (200 mg) | Reference Standard | 57-64-7 | 200 | mg | VIAL | |
| 1537910 | Phytic Acid Solution (5 mL) | Reference Standard | 83-86-3 | 5 | mL | AMPULE | |
| 1538006 | Phytonadione (100 mg x 5 ampules) (Vitamin K1) | Reference Standard | 81818-54-4 | 500 | mg | AMPULE | |
| 1538323 | Picrorhiza kurroa Root and Rhizome Dry Extract | Reference Standard | 91845-42-0 | | | | |
| 1538505 | Pilocarpine (300 mg) | Reference Standard | 92-13-7 | 300 | mg | | |
| 1538902 | Pilocarpine Hydrochloride (200 mg) | Reference Standard | 54-71-7 | 200 | mg | VIAL | |
| 1539009 | Pilocarpine Nitrate (200 mg) | Reference Standard | 148-72-1 | 200 | mg | VIAL | |
| 1569315 | Pimobendan (100 mg) | Reference Standard | 74150-27-9 | 100 | mg | VIAL | |
| 1569326 | Pimobendan Related Compound A (15 mg) (4-[2-(4-Methoxyphenyl)-1H-benzimidazol-5-yl]-3-methyl-4-oxobutanoic acid) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1569337 | Pimobendan Related Compound B (15 mg) (N-[2-Amino-4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl]-4-methoxybenzamide) | Reference Standard | 74149-74-9 | 15 | mg | VIAL | |
| 1539508 | Pimozide (200 mg) | Reference Standard | 2062-78-4 | 200 | mg | VIAL | |
| 1539701 | Pindolol (200 mg) | Reference Standard | 13523-86-9 | 200 | mg | VIAL | |
| 1539814 | Pinitol (30 mg) | Reference Standard | 10284-63-6 | 30 | mg | VIAL | |
| 1539905 | Pioglitazone Hydrochloride (100 mg) | Reference Standard | 112529-15-4 | 100 | mg | VIAL | |
| 1541500 | Piperacillin (350 mg) | Reference Standard | 66258-76-2 | 350 | mg | VIAL | |
| 1541529 | Piperacillin Related Compound E (25 mg) (1-ethylpiperazine-2,3-dione) | Reference Standard | 59702-31-7 | 25 | mg | VIAL | |
| 1541601 | Piperazine (200 mg) | Reference Standard | 110-85-0 | 200 | mg | VIAL | |
| 1541703 | Piperazine Adipate (200 mg) | Reference Standard | 142-88-1 | 200 | mg | VIAL | |
| 1541805 | Piperazine Citrate (200 mg) | Reference Standard | 144-29-6 | 200 | mg | VIAL | |
| 1541907 | Piperazine Dihydrochloride (200 mg) | Reference Standard | 207605-49-0 | 200 | mg | VIAL | |
| 1542003 | Piperazine Phosphate (200 mg) | Reference Standard | 14538-56-8 | 200 | mg | VIAL | |
| 1543200 | Piperine (20 mg) | Reference Standard | 94-62-2 | 20 | mg | | |
| 1544406 | Piroctone Olamine (200 mg) | Reference Standard | 68890-66-4 | 200 | mg | VIAL | |
| 1544417 | Piroctone Related Compound A (15 mg) ((2-[5-methyl-3-(2,4,4-trimethylpentyl)-4,5-dihydroisoxazol-5-yl]acetic acid) 2-aminoethanol salt) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1544428 | Piroctone Related Compound B (25 mg) (4-methyl-6-(2,4,4-trimethylpentyl)-2H-pyran-2-one) | Reference Standard | 50650-75-4 | 25 | mg | AMPULE | |
| 1544508 | Piroxicam (125 mg) | Reference Standard | 36322-90-4 | 125 | mg | VIAL | |
| 1544519 | Piroxicam Related Compound A (50 mg) (Pyridin-2-amine) | Reference Standard | 504-29-0 | 50 | mg | VIAL | |
| 1544520 | Piroxicam Related Compound B (50 mg) (4-Hydroxy-N-(pyridin-2-yl)-2H-benzothiazine-3-carboxamide 1,1-dioxide) | Reference Standard | 65897-46-3 | 50 | mg | VIAL | |
| 1544541 | Piroxicam Related Compound D (50 mg) (Methyl 2-[1,1-dioxido-3-oxobenzoisothiazol-2(3H)-yl]acetate) | Reference Standard | 6639-62-9 | 50 | mg | VIAL | |
| 1544574 | Piroxicam Related Compound G (50 mg) (Methyl 4-hydroxy-2H-benzothiazine-3-carboxylate 1,1-dioxide monohydrate) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1544600 | Piroxicam Related Compound J (50 mg) (Methyl 4-hydroxy-2-methyl-2H-benzothiazine-3-carboxylate 1,1-dioxide) | Reference Standard | 35511-15-0 | 50 | mg | VIAL | |
| 1544858 | Plant Stanol Esters (10 x 100 mg) | Reference Standard | 194673-84-2 | 1000 | mg | VIAL | |
| 1544927 | Plastic Additive 1 (100 mg) (Ethylene bis[3,3-bis[3-(1,1-dimethylethyl)-4-hydroxyphenyl] butanoate]) | Reference Standard | 32509-66-3 | 100 | mg | VIAL | |
| 1545012 | Plastic Additive 10 (100 mg) (dioctadecyl 3,3'-thiodipropionate) | Reference Standard | 693-36-7 | 100 | mg | VIAL | |
| 1545023 | Plastic Additive 11 (100 mg) (Copolymer of Dimethyl Succinate and (4-hydroxy-2,2,6,6-tetramethylpiperidin-1-yl)ethanol)) | Reference Standard | 65447-77-0 | 100 | mg | VIAL | |
| 1545034 | Plastic Additive 12 (100 mg) (Oleamide) | Reference Standard | 301-02-0 | 100 | mg | VIAL | |
| 1545045 | Plastic Additive 13 (100 mg) (Erucamide) | Reference Standard | 112-84-5 | 100 | mg | VIAL | |
| 1545056 | Plastic Additive 14 (100 mg) (Di(2-ethylhexyl) phthalate) | Reference Standard | 117-81-7 | 100 | mg | AMPULE | |
| 1545067 | Plastic Additive 15 (100 mg) (Epoxidized Soya Oil) | Reference Standard | 8013-07-8 | 100 | mg | AMPULE | |
| 1545078 | Plastic Additive 16 (100 mg) (Epoxidized Linseed Oil) | Reference Standard | 8016-11-3 | 100 | mg | AMPULE | |
| 1545090 | Plastic Additive 18 (5 x 25 mg) | Reference Standard | 64685-81-0 | 125 | mg | VIAL | |
| 1544938 | Plastic Additive 2 (200 mg) (pentaerythrityl tetrakis[3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate]) | Reference Standard | 6683-19-8 | 200 | mg | VIAL | |
| 1544949 | Plastic Additive 3 (200 mg) (2,2',2'',6,6',6''-hexa-tert-butyl-4,4',4''-[(2,4,6-trimethyl-1,3,5-benzenetriyl)trismethylene]triphenol) | Reference Standard | 1709-70-2 | 200 | mg | VIAL | |
| 1544950 | Plastic Additive 4 (200 mg) (Octadecyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate) | Reference Standard | 2082-79-3 | 200 | mg | VIAL | |
| 1544964 | Plastic Additive 5 (200 mg) (Tris(2,4-di-tert-butylphenyl) phosphite) | Reference Standard | 31570-04-4 | 200 | mg | VIAL | |
| 1544971 | Plastic Additive 6 (200 mg) (1,3,5-Tris(3,5-di-tert-butyl-4-hydroxybenzyl)-s-triazine-2,4,6(1H,3H,5H)-trione) | Reference Standard | 27676-62-6 | 200 | mg | VIAL | |
| 1544993 | Plastic Additive 8 (100 mg) (Dioctadecyl disulfide) | Reference Standard | 2500-88-1 | 100 | mg | VIAL | |
| 1545001 | Plastic Additive 9 (100 mg) (Didodecyl 3,3'-thiodipropionate) | Reference Standard | 123-28-4 | 100 | mg | VIAL | |
| 1545409 | Polacrilex Resin (100 mg) (Methacrylic acid polymer with divinylbenzene) | Reference Standard | NA | 100 | mg | VIAL | |
| 1545500 | Polacrilin Potassium (200 mg) | Reference Standard | 65405-55-2 | 200 | mg | VIAL | |
| 1546106 | Poloxalene (500 mg) | Reference Standard | 9003-11-6 | 500 | mg | VIAL | |
| 1546150 | Poloxamer Liquid (1 mL) | Reference Standard | 9003-11-6 | 1 | mL | AMPULE | |
| 1546161 | Poloxamer Solid (1 g) | Reference Standard | 9003-11-6 | 1 | g | VIAL | |
| 1548010 | Poly(ethylene-vinyl acetate) (1 g) | Reference Standard | 24937-78-8 | 1 | g | VIAL | |
| 1372333 | Polyallylamine Hydrochloride (200 mg) (2-Propen-1-amine, hydrochloride (1:1), homopolymer) | Reference Standard | 71550-12-4 | 200 | mg | VIAL | |
| 1372344 | Polyamide 6 (1 g) | Reference Standard | 25038-54-4 | 1 | g | VIAL | |
| 1546183 | Polycarbonate (3 Strips, 2'' x 2 1/2'' each) | Reference Standard | 25766-59-0 | 3 | ea | OTHER | |
| 1546194 | Polydatin (20 mg) (3-Hydroxy-5-[(E)-2-(4-hydroxyphenyl)vinyl]phenyl Beta-D-glucopyranoside) | Reference Standard | 27208-80-6 | 20 | mg | VIAL | |
| 1546285 | Polydextrose (200 mg) | Reference Standard | 68424-04-4 | 200 | mg | | |
| 1546300 | Polydimethylsiloxane (500 mg) | Reference Standard | 9016-00-6 | 500 | mg | AMPULE | |
| 1546489 | Polyethylene Glycol 1000 (1 g) | Reference Standard | 25322-68-3 | 1 | g | VIAL | |
| 1546401 | Polyethylene Glycol 200 (1 g) | Reference Standard | 25322-68-3 | 1 | g | AMPULE | |
| 1546423 | Polyethylene Glycol 300 (1 g) | Reference Standard | 25322-68-3 | 1 | g | AMPULE | |
| 1546525 | Polyethylene Glycol 3000 (1 g) | Reference Standard | 25322-68-3 | 1 | g | VIAL | |
| 1546547 | Polyethylene Glycol 3350 (1 g) | Reference Standard | 25322-68-3 | 1 | g | VIAL | |
| 1546445 | Polyethylene Glycol 400 (1 g) | Reference Standard | 25322-68-3 | 1 | g | AMPULE | |
| 1546569 | Polyethylene Glycol 4000 (1 g) (alpha-hydro-omega-hydroxypoly(oxy-1,2-ethanediyl)) | Reference Standard | 25322-68-3 | 1 | g | VIAL | |
| 1546467 | Polyethylene Glycol 600 (1 g) | Reference Standard | 25322-68-3 | 1 | g | AMPULE | |
| 1546580 | Polyethylene Glycol 6000 (1 g) | Reference Standard | 25322-68-3 | 1 | g | VIAL | |
| 1546605 | Polyethylene Glycol 8000 (1 g) | Reference Standard | 25322-68-3 | 1 | g | VIAL | |
| 1546853 | Polyethylene Oxide (100 mg) | Reference Standard | 25322-68-3 | 100 | mg | VIAL | |
| 1546900 | Polyethylene Terephthalate (3 strips (2'' x 2 1/2'' each)) | Reference Standard | 25038-59-9 | 1 | EA | OTHER | |
| 1546922 | Polyethylene Terephthalate G (PETG) (3 Strips) | Reference Standard | 25640-14-6 | 1 | ea | OTHER | |
| 1547110 | Polyglycerol (250 mg) | Reference Standard | 25618-55-7 | 250 | mg | VIAL | |
| 1546944 | Polyglyceryl 3 Diisostearate (1 mL) | Reference Standard | 63705-03-3 | 1 | mL | AMPULE | |
| 1546933 | Polyglyceryl 3 Dioleate (1 g) | Reference Standard | 9007-48-1 | 1 | g | VIAL | |
| 1546955 | Polyglyceryl 6 Dioleate (1 g) | Reference Standard | 76009-37-5 | 1 | g | VIAL | |
| 1547153 | Polygonum multiflorum Root Dry Extract (200 mg) | Reference Standard | N/A | 200 | mg | VIAL | |
| 1546966 | Polyisobutylene (1 g) | Reference Standard | 9003-27-4 | 1 | g | VIAL | |
| 1547007 | Polymyxin B Sulfate (200 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | N/A | 200 | mg | VIAL | |
| 1547302 | Polyoxyl 10 Oleyl Ether (1 mL) | Reference Standard | 9004-98-2 | 1 | mL | AMPULE | |
| 1372606 | Polyoxyl 10 Stearyl Ether (1 g) | Reference Standard | 9005-00-9 | 1 | g | VIAL | |
| 1547550 | Polyoxyl 100 Stearate (200 mg) | Reference Standard | 9004-99-3 | 200 | mg | VIAL | |
| 1547255 | Polyoxyl 15 Hydroxystearate (500 mg) | Reference Standard | 70142-34-6 | 500 | mg | VIAL | |
| 1547346 | Polyoxyl 2 Stearyl Ether (1 g) | Reference Standard | 9005-00-9 | 1 | g | VIAL | |
| 1547801 | Polyoxyl 20 Cetostearyl Ether (100 mg) | Reference Standard | 68439-49-6 | 100 | mg | VIAL | |
| 1547368 | Polyoxyl 20 Stearyl Ether (1 g) | Reference Standard | 9005-00-9 | 1 | g | VIAL | |
| 1372468 | Polyoxyl 23 Lauryl Ether (0.5 g) | Reference Standard | 9002-92-0 | 0.5 | g | VIAL | |
| 1547391 | Polyoxyl 32 Stearate (200 mg) | Reference Standard | N/A | 200 | mg | VIAL | |
| 1547200 | Polyoxyl 35 Castor Oil (1 g) | Reference Standard | 61791-12-6 | 1 | g | AMPULE | |
| 1372424 | Polyoxyl 4 Lauryl Ether (1 mL) | Reference Standard | 5274-68-0 | 1 | mL | AMPULE | |
| 1547903 | Polyoxyl 40 Stearate (200 mg) | Reference Standard | 9004-99-3 | 200 | mg | VIAL | |
| 1547379 | Polyoxyl 6 Stearate (200 mg) | Reference Standard | N/A | 200 | mg | VIAL | |
| 1547459 | Polyoxyl 75 Stearate (200 mg) | Reference Standard | N/A | 200 | mg | VIAL | |
| 1547380 | Polyoxyl 8 Stearate (200 mg) | Reference Standard | 9004-99-3 | 200 | mg | VIAL | |
| 1372435 | Polyoxyl 9 Lauryl Ether (1 g) (Polyethylene glycol monolauryl ether (n=9)) | Reference Standard | 9002-92-0 | 1 | g | VIAL | |
| 1372504 | Polyoxyl Oleate (500 mg) | Reference Standard | 9004-96-0 | 500 | mg | AMPULE | |
| 1547991 | Polypropylene Glycol 11 Stearyl Ether (500 mg) | Reference Standard | 25231-21-4 | 500 | mg | AMPULE | |
| 1547925 | Polysorbate 20 (2 g) | Reference Standard | 9005-64-5 | 2 | g | AMPULE | |
| 1547936 | Polysorbate 40 (2 g) | Reference Standard | 9005-66-7 | 2 | g | VIAL | |
| 1547947 | Polysorbate 60 (2 g) | Reference Standard | 9005-67-8 | 2 | g | VIAL | |
| 1547969 | Polysorbate 80 (4 x 0.5 g) | Reference Standard | 9005-65-6 | 2 | g | AMPULE | |
| 1548032 | Polyvinyl Acetate (1 g) | Reference Standard | 9003-20-7 | 1 | g | VIAL | |
| 1548043 | Polyvinyl Acetate Dispersion (1 g) (Polyvinyl Acetate stabilized with Povidone and Sodium Lauryl Sulfate) | Reference Standard | 9003-20-7 | 1 | g | AMPULE | |
| 1548065 | Polyvinyl Alcohol (100 mg) | Reference Standard | 9002-89-5 | 100 | mg | VIAL | |
| 1548076 | Polyvinyl Chloride (100 mg) | Reference Standard | 9002-86-2 | 100 | mg | VIAL | |
| 1544916 | Polyvinyl Chloride, Plasticized (3 Strips, 2'' x 2 1/2'' each) | Reference Standard | 9002-86-2 | 3 | ea | OTHER | |
| 1548098 | Pomegranate Juice Concentrate (5 x 1 mL) | Reference Standard | N/A | 5 | mL | AMPULE | |
| 1548087 | Ponceau 4R (50 mg) | Reference Standard | 2611-82-7 | 50 | mg | VIAL | |
| 1549807 | Potassium Acetate (500 mg) (AS) | Reference Standard | 127-08-2 | 500 | mg | VIAL | |
| 1548156 | Potassium Alginate (100 mg) | Reference Standard | 9005-36-1 | 100 | mg | VIAL | |
| 1548101 | Potassium Benzoate (1 g) | Reference Standard | 582-25-2 | 1 | g | VIAL | |
| 1548134 | Potassium Bicarbonate (1 g) | Reference Standard | 298-14-6 | 1 | g | VIAL | |
| 1549840 | Potassium Bitartrate (3 g) (AS) | Reference Standard | 868-14-4 | 3 | g | VIAL | |
| 1548167 | Potassium Carbonate (1 g) | Reference Standard | 584-08-7 | 1 | g | VIAL | |
| 1548190 | Potassium Chloride (1 g) | Reference Standard | 7447-40-7 | 1 | g | VIAL | |
| 1548225 | Potassium Citrate (1 g) | Reference Standard | 6100-05-6 | 1 | g | VIAL | |
| 1550001 | Potassium Gluconate (200 mg) | Reference Standard | 299-27-4 | 200 | mg | VIAL | |
| 1551004 | Potassium Guaiacolsulfonate (500 mg) | Reference Standard | 78247-49-1 | 500 | mg | VIAL | |
| 1548280 | Potassium Iodide (1 g) | Reference Standard | 7681-11-0 | 1 | g | VIAL | |
| 1548349 | Potassium Nitrate (100 mg) | Reference Standard | 7757-79-1 | 100 | mg | VIAL | |
| 1548350 | Potassium Nitrate Melting Point Standard (1 g) (Potassium Nitrate) | Reference Standard | 7757-79-1 | 1 | g | VIAL | |
| 1548407 | Potassium Sorbate (1 g) | Reference Standard | 24634-61-5 | 1 | g | VIAL | |
| 1551150 | Potassium Sucrose Octasulfate (300 mg) | Reference Standard | 73264-44-5 | 300 | mg | VIAL | |
| 1551300 | Potassium Trichloroammineplatinate (25 mg) | Reference Standard | 13820-91-2 | 25 | mg | VIAL | |
| 1551503 | Povidone (100 mg) | Reference Standard | 9003-39-8 | 100 | mg | VIAL | |
| 1291683 | Powdered American Ginseng Extract (1.5 g) | Reference Standard | 90045-38-8 | 1.5 | g | VIAL | |
| 1034873 | Powdered Andrographis Extract (500 mg) | Reference Standard | 90244-84-1 | 500 | mg | VIAL | |
| 1043309 | Powdered Ashwagandha Root Extract (1 g) | Reference Standard | 90147-43-6 | 1 | g | | |
| 1291708 | Powdered Asian Ginseng Extract (1.5 g) | Reference Standard | N/A | 1.5 | g | VIAL | |
| 1048244 | Powdered Bacopa Extract (500 mg) | Reference Standard | 93164-89-7 | 500 | mg | VIAL | |
| 1071268 | Powdered Bilberry Extract (500 mg) | Reference Standard | 84082-34-8 | 500 | mg | VIAL | |
| 1076206 | Powdered Black Cohosh Extract (1.5 g) | Reference Standard | 84776-26-1 | 1.5 | g | VIAL | |
| 1509019 | Powdered Black Pepper Extract (1 g) | Reference Standard | 84929-41-9 | 1 | g | VIAL | |
| 1096848 | Powdered Cat's Claw Extract (1 g) | Reference Standard | 289626-41-1 | 1 | g | VIAL | |
| 1297770 | Powdered Centella Asiatica Extract (1 g) | Reference Standard | N/A | 1 | g | VIAL | |
| 1105009 | Powdered Chaste Tree Extract (1.5 g) | Reference Standard | 91722-47-3 | 1.5 | g | VIAL | |
| 1105417 | Powdered Chinese Salvia Extract (1 g) | Reference Standard | 115939-25-8 | 1 | g | VIAL | |
| 1298401 | Powdered Decaffeinated Green Tea Extract (300 mg) | Reference Standard | 84650-60-2 | 300 | mg | VIAL | |
| 1231706 | Powdered Echinacea Angustifolia Extract (1 g) | Reference Standard | 84696-11-7 | 1 | g | VIAL | |
| 1231717 | Powdered Echinacea Pallida Extract (1 g) | Reference Standard | 97281-15-7 | 1 | g | VIAL | |
| 1231728 | Powdered Echinacea Purpurea Extract (1 g) | Reference Standard | 90028-20-9 | 1 | g | VIAL | |
| 1234704 | Powdered Eleuthero Extract (1.5 g) | Reference Standard | 84696-12-5 | 1.5 | g | VIAL | |
| 1283255 | Powdered Forskohlii Extract (500 mg) | Reference Standard | N/A | 500 | mg | VIAL | |
| 1288340 | Powdered Garcinia Hydroxycitrate Extract (500 mg) | Reference Standard | N/A | 500 | mg | VIAL | |
| 1291504 | Powdered Ginger (500 mg) | Reference Standard | NA | 500 | mg | VIAL | |
| 1309911 | Powdered Holy Basil Extract (1 g) | Reference Standard | 91845-35-1 | 1 | g | VIAL | |
| 1355709 | Powdered Kava Extract (1 g) | Reference Standard | N/A | 1 | g | VIAL | |
| 1374383 | Powdered Malabar-Nut-Tree, Leaf Extract (1 g) | Reference Standard | N/A | 1 | g | VIAL | |
| 1443850 | Powdered Milk Thistle Extract (250 mg) | Reference Standard | 84604-20-6 | 250 | mg | VIAL | |
| 1536510 | Powdered Phyllanthus Amarus Extract (1 g) | Reference Standard | N/A | 1 | g | VIAL | |
| 1599500 | Powdered Red Clover Extract (500 mg) | Reference Standard | N/A | 500 | mg | VIAL | |
| 1605668 | Powdered Rosemary Extract (1 g) | Reference Standard | 84604-14-8 | 1 | g | VIAL | |
| 1605680 | Powdered Rosemary Hydrophilic Extract (1 g) | Reference Standard | 84604-14-8 | 1 | g | VIAL | |
| 1607506 | Powdered St. John's Wort Extract (600 mg) | Reference Standard | 84082-80-4 | 600 | mg | VIAL | |
| 1707931 | Powdered Valerian Extract (1 g) | Reference Standard | 8057-49-6 | 1 | g | VIAL | |
| 1553000 | Pralidoxime Chloride (200 mg) | Reference Standard | 14018-50-9 | 200 | mg | VIAL | |
| 1553859 | Pramipexole Dihydrochloride Monohydrate (200 mg) | Reference Standard | 191217-81-9 | 200 | mg | VIAL | |
| 1553768 | Pramipexole Related Compound A (15 mg) ((S)-4,5,6,7-Tetrahydrobenzothiazole-2,6-diamine) | Reference Standard | 106092-09-5 | 15 | mg | VIAL | |
| 1553815 | Pramipexole Related Compound D (25 mg) ((R)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole dihydrochloride) | Reference Standard | 104632-27-1 | 25 | mg | VIAL | |
| 1553837 | Pramipexole Related Compound F (25 mg) ((6S,7R)-2-Amino-6-(propylamino)-4,5,6,7-tetrahydrobenzothiazol-7-ol) | Reference Standard | 2166216-34-6 | 25 | mg | VIAL | |
| 1553848 | Pramipexole Related Compound G (25 mg) ((6S,7S)-2-Amino-6-(propylamino)-4,5,6,7-tetrahydrobenzothiazol-7-ol) | Reference Standard | 1001648-71-0 | 25 | mg | VIAL | |
| 1554002 | Pramoxine Hydrochloride (400 mg) | Reference Standard | 637-58-1 | 400 | mg | VIAL | |
| 1554104 | Prasugrel Hydrochloride (150 mg) (5-[2-Cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetate hydrochloride) | Reference Standard | 389574-19-0 | 150 | mg | VIAL | |
| 1554192 | Pravastatin 1,1,3,3-Tetramethylbutylamine (200 mg) | Reference Standard | 151006-14-3 | 200 | mg | VIAL | |
| 1554217 | Pravastatin Related Compound A (10 mg) (Sodium (3R,5R)-3,5-dihydroxy-7-[(1S,2R,3S,8S,8aR)-3-hydroxy-2-methyl-8-[[(2S)-2-methylbutanoyl]oxy]-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] heptanoate) | Reference Standard | 81093-43-8 | 10 | mg | VIAL | |
| 1554228 | Pravastatin Related Compound B (20 mg) (sodium (3R,5R)-3,5-dihydroxy-7-((1S,2S,6R,8S,8aR)-6-hydroxy-2-methyl-8-((S)-2-methylbutanoyloxy)-1,2,6,7,8,8a-hexahydronaphthalen-1-yl)heptanoate) | Reference Standard | 81176-41-2 | 20 | mg | VIAL | |
| 1554206 | Pravastatin Sodium (50 mg) | Reference Standard | 81131-70-6 | 50 | mg | VIAL | |
| 1554501 | Prazepam CIV (500 mg) | Reference Standard | 2955-38-6 | 500 | mg | VIAL | |
| 1554603 | Praziquantel (200 mg) | Reference Standard | 55268-74-1 | 200 | mg | VIAL | |
| 1554658 | Praziquantel Related Compound A (20 mg) (2-benzoyl-1,2,3,6,7,11b-hexahydro-4H-pyrazino [2,1-a]isoquinolin-4-one) | Reference Standard | 54761-87-4 | 20 | mg | VIAL | |
| 1554669 | Praziquantel Related Compound B (50 mg) (2-(cyclohexylcarbonyl)-2,3,6,7-tetrahydro-4H-pyrazino [2,1-a]isoquinolin-4-one) | Reference Standard | 125273-86-1 | 50 | mg | VIAL | |
| 1554670 | Praziquantel Related Compound C (50 mg) (2-(N-formylhexahydrohippuroyl)-1,2,3,4-tetrahydroisoquinolin-1-one) | Reference Standard | 125273-88-3 | 50 | mg | | |
| 1554705 | Prazosin Hydrochloride (350 mg) | Reference Standard | 19237-84-4 | 350 | mg | VIAL | |
| 1554749 | Prazosin Related Compound D (25 mg) (Furan-2-yl(piperazin-1-yl)methanone) | Reference Standard | 40172-95-0 | 25 | mg | VIAL | |
| 1554909 | Prednicarbate (200 mg) | Reference Standard | 73771-04-7 | 200 | mg | VIAL | |
| 1554910 | Prednicarbate Related Compound A (20 mg) (1,2-dihydroprednicarbate) | Reference Standard | 671225-26-6 | 20 | mg | VIAL | |
| 1554920 | Prednicarbate Related Compound B (20 mg) (prednisolone-17-ethylcarbonate) | Reference Standard | 104286-02-4 | 20 | mg | VIAL | |
| 1554931 | Prednicarbate Related Compound C (20 mg) (prednisolone-21-propionate) | Reference Standard | 5740-62-5 | 20 | mg | VIAL | |
| 1555005 | Prednisolone (200 mg) | Reference Standard | 50-24-8 | 200 | mg | VIAL | |
| 1556008 | Prednisolone Acetate (200 mg) | Reference Standard | 52-21-1 | 200 | mg | VIAL | |
| 1556507 | Prednisolone Hemisuccinate (125 mg) | Reference Standard | 2920-86-7 | 125 | mg | VIAL | |
| 1557000 | Prednisolone Sodium Phosphate (500 mg) | Reference Standard | 125-02-0 | 500 | mg | VIAL | |
| 1558003 | Prednisolone Tebutate (200 mg) | Reference Standard | 7681-14-3 | 200 | mg | VIAL | |
| 1559006 | Prednisone (250 mg) | Reference Standard | 53-03-2 | 250 | mg | VIAL | |
| 1559505 | Prednisone Tablets (30 tablets) | Reference Standard | 53-03-2 | 300 | mg | BLISTER PACK | |
| 1559618 | Pregabalin CV (200 mg) | Reference Standard | 148553-50-8 | 200 | mg | VIAL | |
| 1559629 | Pregabalin Related Compound A (25 mg) ((R)-3-(Aminomethyl)-5-methylhexanoic acid) | Reference Standard | 148553-51-9 | 25 | mg | VIAL | |
| 1559647 | Pregabalin Related Compound C (25 mg) (COLD SHIPMENT REQUIRED) (4-Isobutylpyrrolidin-2-one) | Reference Standard | 61312-87-6 | 25 | mg | VIAL | |
| 1559709 | Prekallikrein Activator (22.5 IU) | Reference Standard | N/A | 22.5 | | AMPULE | |
| 1560990 | Prilocaine (200 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 721-50-6 | 200 | mg | VIAL | |
| 1561008 | Prilocaine Hydrochloride (200 mg) | Reference Standard | 1786-81-8 | 200 | mg | VIAL | |
| 1561019 | Prilocaine Related Compound A (100 mg) (o-toluidine hydrochloride) | Reference Standard | 636-21-5 | 100 | mg | VIAL | |
| 1561020 | Prilocaine Related Compound B (50 mg) ((RS)-N-(4-methylphenyl)-2-(propylamino)propanamide) | Reference Standard | 744961-76-0 | 50 | mg | VIAL | |
| 1561507 | Primaquine Phosphate (200 mg) | Reference Standard | 63-45-6 | 200 | mg | VIAL | |
| 1561518 | Primaquine Related Compound A (15 mg) (8-[(4-Aminopentyl)amino]-6-methoxyquinoline) | Reference Standard | 525-61-1 | 15 | mg | VIAL | |
| 1562000 | Primidone (200 mg) | Reference Standard | 125-33-7 | 200 | mg | VIAL | |
| 1562011 | Primidone Related Compound A (20 mg) (2-Ethyl-2-phenylmalonamide) | Reference Standard | 7206-76-0 | 20 | mg | VIAL | |
| 1562033 | Primidone Related Compound C (20 mg) (2-phenyl butyramide) | Reference Standard | 90-26-6 | 20 | mg | VIAL | |
| 1563003 | Probenecid (200 mg) | Reference Standard | 57-66-9 | 200 | mg | VIAL | |
| 1563309 | Probucol (200 mg) | Reference Standard | 23288-49-5 | 200 | mg | VIAL | |
| 1563320 | Probucol Related Compound A (25 mg) (2,2',6,6'-tetra-tert-butyldiphenoquinone) | Reference Standard | 2455-14-3 | 25 | mg | VIAL | |
| 1563331 | Probucol Related Compound B (25 mg) (4,4'-dithio-bis(2,6-di-tert-butylphenol)) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1563342 | Probucol Related Compound C (25 mg) (4-[(3,5-di-tert-butyl-2-hydroxyphenylthio)isopropylidenethio]-2,6-di-tert-butylphenol) | Reference Standard | 1391054-68-4 | 25 | mg | VIAL | |
| 1563502 | Procainamide Hydrochloride (200 mg) | Reference Standard | 614-39-1 | 200 | mg | VIAL | |
| 1564006 | Procaine Hydrochloride (200 mg) | Reference Standard | 51-05-8 | 200 | mg | VIAL | |
| 1565009 | Procarbazine Hydrochloride (200 mg) | Reference Standard | 366-70-1 | 200 | mg | VIAL | |
| 1565010 | Procarbazine Related Compound A (50 mg) (4-Formyl-N-isopropylbenzamide) | Reference Standard | 13255-50-0 | 50 | mg | VIAL | |
| 1566001 | Prochlorperazine Maleate (200 mg) | Reference Standard | 84-02-6 | 200 | mg | VIAL | |
| 1566045 | Prochlorperazine Related Compound A (10 mg) (4-Chloro-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine dihydrochloride) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1566908 | Procyanidin B2 (20 mg) | Reference Standard | 29106-49-8 | 20 | mg | VIAL | |
| 1567004 | Procyclidine Hydrochloride (200 mg) | Reference Standard | 1508-76-5 | 200 | mg | VIAL | |
| 1568007 | Progesterone (200 mg) | Reference Standard | 57-83-0 | 200 | mg | VIAL | |
| 1568018 | Progesterone Related Compound H (25 mg) (Pregna-4,6-diene-3,20-dione) | Reference Standard | 1162-56-7 | 25 | mg | VIAL | |
| 1567999 | Progesterone System Suitability Mixture (40 mg) (Mixture contains 20-alpha-Progerol, 20-Beta-Progerol, 17alpha-Progesterone, 20-alpha-Progerol acetate, 20-Beta-Progerol acetate and Cyclohexylidene progesterone in Progesterone) | Reference Standard | N/A | 40 | mg | VIAL | |
| 1568040 | Proguanil Hydrochloride (200 mg) | Reference Standard | 637-32-1 | 200 | mg | VIAL | |
| 1568028 | Proguanil Related Compound A (25 mg) (1-cyano-3-isopropylguanidine) | Reference Standard | 44830-55-9 | 25 | mg | VIAL | |
| 1568051 | Proguanil Related Compound C (25 mg) (1,5-bis(4-chlorophenyl)biguanide hydrochloride) | Reference Standard | 13590-98-2 | 25 | mg | VIAL | |
| 1568062 | Proguanil Related Compound D (25 mg) (1,5-bis(1-methylethyl)biguanide hydrochloride) | Reference Standard | 35708-82-8 | 25 | mg | VIAL | |
| 1568073 | Proguanil Related Compound E (25 mg) (1-(4-chlorophenyl)-3-cyanoguanidine) | Reference Standard | 1482-62-8 | 25 | mg | VIAL | |
| 1568084 | Proguanil Related Compound F (25 mg) (1-(3,4-dichlorophenyl)-5-isopropylbiguanide hydrochloride) | Reference Standard | 6001-93-0 | 25 | mg | VIAL | |
| 1568095 | Proguanil Related Compound G (25 mg) (1-(3-chlorophenyl)-5-isopropylbiguanide hydrochloride) | Reference Standard | 1071546-52-5 | 25 | mg | VIAL | |
| 1569000 | Promazine Hydrochloride (200 mg) | Reference Standard | 53-60-1 | 200 | mg | VIAL | |
| 1570009 | Promethazine Hydrochloride (500 mg) | Reference Standard | 58-33-3 | 500 | mg | VIAL | |
| 1570029 | Promethazine Related Compound B (25 mg) (N,N-Dimethyl-2-(10H-phenothiazin-10-yl)propan-1-amine hydrochloride) | Reference Standard | 5568-90-1 | 25 | mg | VIAL | |
| 1570304 | Propafenone Hydrochloride (200 mg) | Reference Standard | 34183-22-7 | 200 | mg | VIAL | |
| 1570315 | Propafenone Related Compound A (20 mg) (N-{2-Hydroxy-3-[2-(3-phenylpropanoyl)phenoxy]propyl}-N-propylformamide) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1570326 | Propafenone Related Compound B (50 mg) (RS,E)-1-[2-[2-Hydroxy-3-(propylamino)propoxy]phenyl]-3-phenylprop-2-en-1-one) | Reference Standard | 88308-22-9 | 50 | mg | VIAL | |
| 1570450 | Propanolamine (100 mg) (3-aminopropan-1-ol) | Reference Standard | 156-87-6 | 100 | mg | AMPULE | |
| 1570508 | Propantheline Bromide (200 mg) | Reference Standard | 50-34-0 | 200 | mg | VIAL | |
| 1329505 | Propantheline Bromide Related Compound A (50 mg) (9-Hydroxypropantheline bromide) | Reference Standard | 93446-02-7 | 50 | mg | | |
| 1571001 | Proparacaine Hydrochloride (200 mg) | Reference Standard | 5875-06-9 | 200 | mg | VIAL | |
| 1572208 | Propionic Acid (1.5 mL/ampule; 3 ampules) | Reference Standard | 79-09-4 | 4.5 | mL | AMPULE | |
| 1572503 | Propofol (500 mg) | Reference Standard | 2078-54-8 | 500 | mg | AMPULE | |
| 1572536 | Propofol Related Compound A (25 mg) (3,3'-5,5'-tetraisopropyldiphenol) | Reference Standard | 2416-95-7 | 25 | mg | VIAL | |
| 1572547 | Propofol Related Compound B (30 mg) (2,6-Diisopropyl-1,4-benzoquinone) | Reference Standard | 1988-11-0 | 30 | mg | AMPULE | |
| 1572558 | Propofol Related Compound C (25 mg) (2,6-diisopropylphenyl isopropyl ether) | Reference Standard | N/A | 25 | mg | AMPULE | |
| 1572525 | Propofol Resolution Mixture (100 mg) (Propofol, 2,6-diisopropylphenyl isopropylether, and 2-isopropyl-6-n-propylphenol) | Reference Standard | N/A | 100 | mg | AMPULE | |
| 1576005 | Propranolol Hydrochloride (200 mg) | Reference Standard | 318-98-9 | 200 | mg | VIAL | |
| 1576016 | Propranolol Related Compound A (25 mg) (3-(Naphthalen-1-yloxy)propane-1,2-diol) | Reference Standard | 36112-95-5 | 25 | mg | VIAL | |
| 1576402 | Propyl Acetate (1.2 mL/ampule; 3 ampules) | Reference Standard | 109-60-4 | 3.6 | mL | AMPULE | |
| 1576800 | Propyl Gallate (200 mg) | Reference Standard | 121-79-9 | 200 | mg | VIAL | |
| 1576504 | Propylene Carbonate (200 mg) | Reference Standard | 108-32-7 | 200 | mg | VIAL | |
| 1576708 | Propylene Glycol (5 x 1 mL) | Reference Standard | 57-55-6 | 5 | mL | AMPULE | |
| 1576720 | Propylene Glycol Diacetate (2 x 1 g) | Reference Standard | 623-84-7 | 2 | g | AMPULE | |
| 1576683 | Propylene Glycol Dicaprylate/Dicaprate (1 mL) | Reference Standard | 68583-51-7 | 1 | mL | AMPULE | |
| 1576763 | Propylene Glycol Dilaurate (500 mg) | Reference Standard | 22788-19-8 | 500 | mg | AMPULE | |
| 1576672 | Propylene Glycol Monocaprylate (1 g) (Propylene Glycol Monocaprylate Type II) | Reference Standard | N/A | 1 | g | AMPULE | |
| 1576661 | Propylene Glycol Monocaprylate Type I (1 g) | Reference Standard | 31565-12-5; 85883-73-4 | 1 | g | | |
| 1576785 | Propylene Glycol Monolaurate Type I (500 mg) | Reference Standard | 27194-74-7; 142-55-2 | 500 | mg | AMPULE | |
| 1576796 | Propylene Glycol Monolaurate Type II (500 mg) | Reference Standard | 37321-62-3 | 500 | mg | AMPULE | |
| 1576945 | Propylene Oxide (5 x 0.1 mL) | Reference Standard | 75-56-9 | 0.5 | mL | | |
| 1577008 | Propylparaben (200 mg) | Reference Standard | 94-13-3 | 200 | mg | VIAL | |
| 1578000 | Propylthiouracil (200 mg) | Reference Standard | 51-52-5 | 200 | mg | VIAL | |
| 1578500 | Prostaglandin A1 (25 mg) | Reference Standard | 14152-28-4 | 25 | mg | VIAL | |
| 1578554 | Prostaglandin B1 (25 mg) ((13E,15S)-15-Hydroxy-9-oxoprosta-8(12),13-dien-1-oic Acid) | Reference Standard | 13345-51-2 | 25 | mg | VIAL | |
| 1578612 | Protamine Sulfate (2.73 mg) | Reference Standard | 9009-65-8 | 2.73 | mg | VIAL | |
| 1580002 | Protriptyline Hydrochloride (200 mg) | Reference Standard | 1225-55-4 | 200 | mg | VIAL | |
| 1581005 | Pseudoephedrine Hydrochloride (125 mg) (List Chemical) | Reference Standard | 345-78-8 | 125 | mg | VIAL | |
| 1581504 | Pseudoephedrine Sulfate (200 mg) (List Chemical) | Reference Standard | 7460-12-0 | 200 | mg | VIAL | |
| 1581617 | Pseudoisoeugenyl 2-Methylbutyrate (4 x 50 mg) ((E)-4-Methoxy-2-(prop-1-en-1-yl)phenyl 2-methylbutanoate) | Reference Standard | 58989-20-1 | 200 | mg | AMPULE | |
| 1581672 | Psoralen (10 mg) | Reference Standard | 66-97-7 | 10 | mg | VIAL | |
| 1298219 | Purified Grape Seeds Oligomeric Proanthocyanidins (500 mg) | Reference Standard | N/A | 500 | mg | VIAL | |
| 1302203 | Purified Guggul Extract (500 mg) | Reference Standard | N/A | 500 | mg | VIAL | |
| 1583805 | Pygeum Extract (150 mg) | Reference Standard | 94279-95-5 | 150 | mg | VIAL | |
| 1584003 | Pyrantel Pamoate (500 mg) | Reference Standard | 22204-24-6 | 500 | mg | VIAL | |
| 1584014 | Pyrantel Related Compound A (25 mg) ((Z)-1-Methyl-2-[2-(2-thiophenyl)vinyl]-1,4,5,6-Tetrahydropyrimidine 4,4'-methylenebis[3-hydroxy-2-naphthoate] (1:1)) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1584105 | Pyrantel Tartrate (200 mg) | Reference Standard | 33401-94-4 | 200 | mg | VIAL | |
| 1585006 | Pyrazinamide (200 mg) | Reference Standard | 98-96-4 | 200 | mg | VIAL | |
| 1585017 | Pyrazinamide Related Compound A (25 mg) (Pyrazinecarboxylic acid) | Reference Standard | 98-97-5 | 25 | mg | VIAL | |
| 1585028 | Pyrazinamide Related Compound B (50 mg) (Pyrazinecarbonitrile) | Reference Standard | 19847-12-2 | 50 | mg | AMPULE | |
| 1A00450 | Pyrazinediethanol (10 mg) (2,2'-(pyrazine-2,5-diyl)bis(ethan-1-ol)) | Pharmaceutical Analytical Impurity | 4744-51-8 | 10 | mg | VIAL | |
| 1A00380 | Pyrazinediethanol Propionic Acid (5 mg) (3-(3,6-bis(2-hydroxyethyl)pyrazin-2-yl)propanoate, sodium salt) | Pharmaceutical Analytical Impurity | 96681-85-5 (free acid) | 5 | mg | VIAL | |
| 1585505 | Pyrethrum Extract (100 mg) | Reference Standard | N/A | 100 | mg | AMPULE | |
| 1586009 | Pyridostigmine Bromide (200 mg) | Reference Standard | 101-26-8 | 200 | mg | VIAL | |
| 1586020 | Pyridostigmine Related Compound A (50 mg) (Pyridin-3-yl dimethylcarbamate) | Reference Standard | 51581-32-9 | 50 | mg | AMPULE | |
| 1586031 | Pyridostigmine Related Compound B (10 mg) (3-Hydroxy-1-methylpyridin-1-ium bromide) | Reference Standard | 31034-86-3 | 10 | mg | VIAL | |
| 1587001 | Pyridoxine Hydrochloride (200 mg) | Reference Standard | 58-56-0 | 200 | mg | VIAL | |
| 1588004 | Pyrilamine Maleate (200 mg) | Reference Standard | 59-33-6 | 200 | mg | VIAL | |
| 1589007 | Pyrimethamine (200 mg) | Reference Standard | 58-14-0 | 200 | mg | VIAL | |
| 1589029 | Pyroglutamic Acid (30 mg) ((S)-5-Oxopyrrolidine-2-carboxylic acid) | Reference Standard | 98-79-3 | 30 | mg | VIAL | |
| 1A00460 | Pyrrolic acid Derivative (10 mg) (4-(2-hydroxyethyl)-1H-pyrrole-3-carboxylic acid) | Pharmaceutical Analytical Impurity | 404839-11-8 | 10 | mg | VIAL | |
| 1589040 | Pyrroloquinoline Quinone Disodium (100 mg) | Reference Standard | 1519046-70-8 | 100 | mg | VIAL | |
| 1592205 | Quazepam CIV (200 mg) | Reference Standard | 36735-22-5 | 200 | mg | VIAL | |
| 1592227 | Quazepam Related Compound A (30 mg) (7-Chloro-1-(2,2,2 trifluoroethyl)-5-(2-Fluorophenyl)-1,3-dihydro-2H-1,4-benzodiazepine-2-one) | Reference Standard | 49606-44-2 | 30 | mg | VIAL | |
| 1592409 | Quercetin (200 mg) | Reference Standard | 6151-25-3 | 200 | mg | VIAL | |
| 1A00190 | Quetiapine Desethoxy (COLD SHIPMENT REQUIRED)(25 mg) (2-[4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl]ethanol) | Pharmaceutical Analytical Impurity | 329216-67-3 | 25 | mg | VIAL | |
| 1592704 | Quetiapine Fumarate (200 mg) | Reference Standard | 111974-72-2 | 200 | mg | VIAL | |
| 1592737 | Quetiapine Related Compound B (15 mg) (11-(Piperazin-1-yl)dibenzo[b,f][1,4]thiazepine dihydrochloride) | Reference Standard | 111974-74-4 | 15 | mg | VIAL | |
| 1592781 | Quetiapine Related Compound G (15 mg) (Dibenzo[b,f][1,4]thiazepin-11(10H)-one) | Reference Standard | 3159-07-7 | 15 | mg | VIAL | |
| 1592792 | Quetiapine Related Compound H (15 mg) (4-(Dibenzo[b,f][1,4]thiazepin-11-yl)-1-[2-(2-hydroxyethoxy)ethyl]piperazine 1-oxide) | Reference Standard | 1076199-40-0 | 15 | mg | VIAL | |
| 1592715 | Quetiapine System Suitability (25 mg) (Mixture contains Quetiapine Fumarate and about 1% each of Quetiapine Related Compound B, Quetiapine Related Compound G and Quetiapine Desethoxy) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1A00130 | Quetiapine Tetraethylene Glycol Fumarate Salt (COLD SHIPMENT REQUIRED) (2-(2-(2-(2-(4-(dibenzo[b,f][1,4]thiazepin-11-yl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethan-1-ol-fumarate) | Pharmaceutical Analytical Impurity | 2470243-24-2 | 25 | mg | VIAL | |
| 1593401 | Quinapril Hydrochloride (400 mg) | Reference Standard | 82586-55-8 | 400 | mg | VIAL | |
| 1593412 | Quinapril Related Compound A (50 mg) (Ethyl [3S-[(2R*), 3a, 11ab]]-1,3,4,6,11,11a-hexahydro-3-methyl-1,4-dioxo-a-(2-phenylethyl)-2H-pyrazino[1,2-b]isoquinoline-2-acetate) | Reference Standard | 103733-49-9 | 50 | mg | VIAL | |
| 1593423 | Quinapril Related Compound B (50 mg) (3-Isoquinolinecarboxylic acid, 2-[2-[(1-carboxy-3-phenylpropyl)amino]-1-oxopropyl]-1,2,3,4-tetrahydro-,[3S-[2[R*(R*)],3R*]]) | Reference Standard | 82768-85-2 | 50 | mg | VIAL | |
| 1594506 | Quinic Acid (200 mg) (Cyclohexanecarboxylic acid, 1,3,4,5-tetrahydroxy-, (-)-) | Reference Standard | 77-95-2 | 200 | mg | VIAL | |
| 1595000 | Quinidine Gluconate (200 mg) | Reference Standard | 7054-25-3 | 200 | mg | VIAL | |
| 1595509 | Quinidine Sulfate (500 mg) | Reference Standard | 6591-63-5 | 500 | mg | | |
| 1596807 | Quinine Hydrochloride Dihydrate (1 g) | Reference Standard | 6119-47-7 | 1 | g | VIAL | |
| 1597005 | Quinine Sulfate (500 mg) | Reference Standard | 207671-44-1 | 500 | mg | VIAL | |
| 1597504 | Quininone (50 mg) | Reference Standard | 84-31-1 | 50 | mg | VIAL | |
| 1597617 | Quinoline Yellow (50 mg) | Reference Standard | 8004-92-0 | 50 | mg | VIAL | |
| 1A00140 | R,R,S-Ezetimibe (25 mg) ((3R,4S)-1-(4-fluorophenyl)-3-((R)-3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one) | Pharmaceutical Analytical Impurity | 163380-16-3 | 25 | mg | VIAL | |
| 1134142 | R-Citalopram Oxalate (10 mg) ((R)-1-[3-(Dimethylamino)propyl]-1-(p-fluorophenyl)-5-phthalancarbonitrile oxalate) | Reference Standard | 219861-53-7 | 10 | mg | VIAL | |
| 1A00370 | R-Levetiracetam Hydroxybutyramide Analog (10 mg) ((R)-N-(1-amino-1-oxobutan-2-yl)-4-hydroxybutanamide) | Pharmaceutical Analytical Impurity | 1847568-87-9 | 10 | mg | VIAL | |
| 1413988 | R-Methotrexate (5 mg) (Sodium (R)-2-(4-{[(2,4-Diaminopteridin-6-yl)methyl](methyl)amino}benzamido)pentanedioate) | Reference Standard | N/A | 5 | mg | VIAL | |
| 1478083 | R-Ofloxacin (25 mg) ((R)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid) | Reference Standard | 100986-86-5 | 25 | mg | VIAL | |
| 1478479 | R-Omeprazole (15 mg) (5-Methoxy-2-[(R)-[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole, sodium salt) | Reference Standard | 161796-77-6 | 15 | mg | VIAL | |
| 1598020 | Rabeprazole Related Compound A (25 mg) (1-(1H-Benzimidazol-2-yl)-3-methyl-4-oxo-1,4-dihydropyridine-2-carboxylate, sodium salt) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1598031 | Rabeprazole Related Compound B (15 mg) (2-{[(1H-benzo[d]imidazol-2-yl)sulfinyl]methyl}-4-(3-methoxypropoxy)-3-methylpyridine 1-oxide) | Reference Standard | 924663-38-7 | 15 | mg | VIAL | |
| 1598042 | Rabeprazole Related Compound C (25 mg) (1H-Benzimidazole-2-thiol) | Reference Standard | 583-39-1 | 25 | mg | VIAL | |
| 1598053 | Rabeprazole Related Compound D (25 mg) (2-[[[4-(3-Methoxypropoxy)-3-methyl-2-pyridyl]methyl]sulfonyl]benzimidazole) | Reference Standard | 117976-47-3 | 25 | mg | VIAL | |
| 1598064 | Rabeprazole Related Compound E (25 mg) (2-{[4-(3-Methoxypropoxy)-3-methyl-2-pyridyl]methylthio}benzimidazole) | Reference Standard | 117977-21-6 | 25 | mg | VIAL | |
| 1598075 | Rabeprazole Related Compound F (15 mg) (2-{[(4-Chloro-3-methyl-2-pyridyl)methyl]sulfinyl}benzimidazole) | Reference Standard | 168167-42-8 | 15 | mg | VIAL | |
| 1598019 | Rabeprazole Sodium (250 mg) (2-({[4-(3-Methoxypropoxy)-3-methylpyridin-2-yl]methyl}sulfinyl)benzimidazole sodium salt hydrate) | Reference Standard | 891191-56-3 | 250 | mg | VIAL | |
| 1643292 | Racemethionine (200 mg) | Reference Standard | 59-51-8 | 200 | mg | VIAL | |
| 1643281 | Racemic Tamsulosin Hydrochloride (50 mg) | Reference Standard | 80223-99-0 | 50 | mg | VIAL | |
| 1667235 | Racemic Tiagabine Hydrochloride Mixture (25 mg) ((S)-(+),(R)-(-)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]nipecotic acid, hydrochloride) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1598097 | Racepinephrine Hydrochloride (30 mg) | Reference Standard | 329-63-5 | 30 | mg | VIAL | |
| 1598100 | Ractopamine Hydrochloride (200 mg) | Reference Standard | 90274-24-1 | 200 | mg | VIAL | |
| 1598201 | Raloxifene Hydrochloride (200 mg) | Reference Standard | 82640-04-8 | 200 | mg | VIAL | |
| 1598234 | Raloxifene Related Compound C (20 mg) (1-(2-{4-[6-hydroxy-2-(4-hydroxyphenyl)benzothiophene-3-carbonyl]phenoxy}ethyl)piperidine 1-oxide monohydrate) | Reference Standard | 195454-31-0 | 20 | mg | VIAL | |
| 1598278 | Raltegravir Potassium (200 mg) | Reference Standard | 871038-72-1 | 200 | mg | VIAL | |
| 1598267 | Raltegravir Related Compound E (20 mg) (N-{2-[4-(Benzylcarbamoyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidin-2-yl]propan-2-yl}-5-methyl-1,3,4-oxadiazole-2-carboxamide) | Reference Standard | 1193687-87-4 | 20 | mg | VIAL | |
| 1598303 | Ramipril (125 mg) | Reference Standard | 87333-19-5 | 125 | mg | VIAL | |
| 1598314 | Ramipril Related Compound A (30 mg) ((2S,3aS,6aS)-1-[(S)2-[[(S)-1-(Methoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]-octahydrocyclopenta[b]pyrrole-2-carboxylic acid) | Reference Standard | 108313-11-7 | 30 | mg | VIAL | |
| 1598323 | Ramipril Related Compound B (20 mg) (Ramipril Isopropylester) | Reference Standard | 295328-72-2 | 20 | mg | VIAL | |
| 1598338 | Ramipril Related Compound C (20 mg) (Hexahydroramipril Hydrochloride) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1598347 | Ramipril Related Compound D (20 mg) (Ramipril Diketopiperazine) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1598405 | Ranitidine Hydrochloride (200 mg) | Reference Standard | 66357-59-3 | 200 | mg | VIAL | |
| 1598507 | Ranitidine Related Compound A (50 mg) (5-[[(2-aminoethyl)thio]methyl]-N,N-dimethyl-2-furanmethanamine, hemifumarate salt) | Reference Standard | 91224-69-0 | 50 | mg | VIAL | |
| 1598609 | Ranitidine Related Compound B (50 mg) (N,N'-bis[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-2-nitro-1,1-ethenediamine) | Reference Standard | 72126-78-4 | 50 | mg | VIAL | |
| 1598700 | Ranitidine Related Compound C (50 mg) (N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]sulfinyl]ethyl]-N-methyl-2-nitro-1,1-ethenediamine) | Reference Standard | 73851-70-4 | 50 | mg | VIAL | |
| 1598450 | Ranitidine Resolution Mixture (20 mg) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1598744 | Ranolazine (100 mg) | Reference Standard | 95635-55-5 | 100 | mg | VIAL | |
| 1598755 | Ranolazine Related Compound A (50 mg) ((+/-)-2-[(2-methoxyphenoxy)methyl]oxirane) | Reference Standard | 2210-74-4 | 50 | mg | VIAL | |
| 1598766 | Ranolazine Related Compound B (50 mg) (N-(2,6-Dimethylphenyl)-2-[4-(2-hydroxy-3-phenoxypropyl)piperazin-1-yl]acetamide dihydrochloride monohydrate) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1598777 | Ranolazine Related Compound C (50 mg) (N-(2,6-Dimethylphenyl)-2-(piperazin-1-yl)acetamide) | Reference Standard | 5294-61-1 | 50 | mg | VIAL | |
| 1598788 | Ranolazine Related Compound D (50 mg) (2,2'-(Piperazine-1,4-diyl)bis[N-(2,6-dimethylphenyl)acetamide]) | Reference Standard | 380204-72-8 | 50 | mg | VIAL | |
| 1598802 | Raspberry Alcohol (50 mg) (4-(3-Hydroxybutyl)phenol) | Reference Standard | 69617-84-1 | 50 | mg | VIAL | |
| 1598813 | Raspberry Ketone (100 mg) (4-(4-Hydroxyphenyl)butan-2-one) | Reference Standard | 5471-51-2 | 100 | mg | VIAL | |
| 1599000 | Rauwolfia Serpentina (15 g) | Reference Standard | 8063-17-0 | 15 | g | VIAL | |
| 1600121 | Rebaudioside A (500 mg) (13-[(2-O-Beta-D-glucopyranosyl-3-O-Beta-D-glucopyranosyl-Beta-D-glucopyranosyl)oxy] kaur-16-en-18-oic acid Beta-Dglucopyranosyl ester) | Reference Standard | 58543-16-1 | 500 | mg | | |
| 1348601 | Red Clover Aerial Parts Isoflavone Aglycones Dry Extract (500 mg) | Reference Standard | N/A | 500 | mg | VIAL | |
| 1600303 | Refined Bleached Shellac (1 g) | Reference Standard | 9000-59-3 | 1 | g | VIAL | |
| 1600201 | Regorafenib (200 mg) | Reference Standard | 1019206-88-2 | 200 | mg | VIAL | |
| 1600212 | Regorafenib Related Compound A (15 mg) (4-(4-Amino-3-fluorophenoxy)-N-methylpicolinamide) | Reference Standard | 757251-39-1 | 15 | mg | VIAL | |
| 1600314 | Regular Bleached Shellac (100 mg) | Reference Standard | 9000-59-3 | 100 | mg | VIAL | |
| 1600813 | Repaglinide (200 mg) | Reference Standard | 135062-02-1 | 200 | mg | VIAL | |
| 1600824 | Repaglinide Related Compound A (10 mg) ((S)-3-Methyl-1-[2-(1-piperidinyl)phenyl]butylamine, N-acetyl-L-glutamate salt) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1600835 | Repaglinide Related Compound B (50 mg) (3-Ethoxy-4-ethoxycarbonylphenylacetic acid) | Reference Standard | 99469-99-5 | 50 | mg | VIAL | |
| 1600846 | Repaglinide Related Compound C (25 mg) ((S)-2-Ethoxy-4-[2-[[2-phenyl-1-[2-(1-piperidinyl)phenyl]ethyl]amino]-2-oxoethyl] benzoic acid) | Reference Standard | 1803084-79-8 | 25 | mg | VIAL | |
| 1600868 | Repaglinide Related Compound E (20 mg) ((R)-2-Ethoxy-4-[2-({3-methyl-1-[2-(piperidin-1-yl)phenyl]butyl}amino)-2-oxoethyl]benzoic acid) | Reference Standard | 147852-26-4 | 20 | mg | VIAL | |
| 1601000 | Reserpine (200 mg) | Reference Standard | 50-55-5 | 200 | mg | VIAL | |
| 1601226 | Residual Solvent Class 1 - 1,1,1-Trichloroethane (1.2 mL/ampule; 3 ampules) (Ozone Depleting Substance) | Reference Standard | N/A | 3.6 | mL | AMPULE | |
| 1601204 | Residual Solvent Class 1 - 1,1-Dichloroethene (1.2 mL/ampule; 3 ampules) | Reference Standard | 75-35-4 | 3.6 | mL | | |
| 1601180 | Residual Solvent Class 1 - 1,2-Dichloroethane (1.2 mL/ampule; 3 ampules) | Reference Standard | 107-06-2 | 3.6 | mL | AMPULE | |
| 1601146 | Residual Solvent Class 1 - Benzene (1.2 mL/ampule; 3 ampules) | Reference Standard | 71-43-2 | 3.6 | mL | AMPULE | |
| 1601168 | Residual Solvent Class 1 - Carbon Tetrachloride (1.2 mL/ampule; 3 ampules) (Ozone Depleting Substance) | Reference Standard | 56-23-5 | 3.6 | mL | AMPULE | |
| 1601420 | Residual Solvent Class 2 - 1,2-Dichloroethene (1.2 mL/ampule; 3 ampules) | Reference Standard | N/A | 3.6 | mL | | |
| 1601463 | Residual Solvent Class 2 - 1,2-Dimethoxyethane (1.2 mL/ampule; 3 ampules) | Reference Standard | N/A | 3.6 | mL | AMPULE | |
| 1601521 | Residual Solvent Class 2 - 1,4-Dioxane (1.2 mL/ampule; 3 ampules) | Reference Standard | 123-91-1 | 3.6 | mL | AMPULE | |
| 1601543 | Residual Solvent Class 2 - 2-Ethoxyethanol (1.2 mL/ampule; 3 ampules) | Reference Standard | N/A | 3.6 | mL | AMPULE | |
| 1601645 | Residual Solvent Class 2 - 2-Methoxyethanol (1.2 mL/ampule; 3 ampules) | Reference Standard | N/A | 3.6 | mL | AMPULE | |
| 1601340 | Residual Solvent Class 2 - Acetonitrile (1.2 mL/ampule; 3 ampules) | Reference Standard | 75-0508 | 3.6 | mL | AMPULE | |
| 1601361 | Residual Solvent Class 2 - Chlorobenzene (1.2 mL/ampule; 3 ampules) | Reference Standard | 108-90-7 | 3.6 | mL | | |
| 1601383 | Residual Solvent Class 2 - Chloroform (1.2 mL/ampule; 3 ampules) | Reference Standard | N/A | 3.6 | mL | AMPULE | |
| 1601394 | Residual Solvent Class 2 - Cumene (1.2 mL/ampule; 3 ampules) | Reference Standard | N/A | 3.6 | mL | AMPULE | |
| 1601408 | Residual Solvent Class 2 - Cyclohexane (1.2 mL/ampule; 3 ampules) | Reference Standard | 110-82-7 | 3.6 | mL | AMPULE | |
| 1601565 | Residual Solvent Class 2 - Ethylene Glycol (1.2 mL/ampule; 3 ampules) | Reference Standard | N/A | 3.6 | mL | AMPULE | |
| 1601587 | Residual Solvent Class 2 - Formamide (1.2 mL/ampule; 3 ampules) | Reference Standard | N/A | 3.6 | mL | AMPULE | |
| 1601601 | Residual Solvent Class 2 - Hexane (1.2 mL/ampule; 3 ampules) | Reference Standard | 110-54-3 | 3.6 | mL | AMPULE | |
| 1601623 | Residual Solvent Class 2 - Methanol (1.2 mL/ampule; 3 ampules) | Reference Standard | N/A | 3.6 | mL | AMPULE | |
| 1601667 | Residual Solvent Class 2 - Methylbutylketone (1.2 mL/ampule; 3 ampules) | Reference Standard | 591-78-6 | 3.6 | mL | AMPULE | |
| 1601689 | Residual Solvent Class 2 - Methylcyclohexane (1.2 mL/ampule; 3 ampules) | Reference Standard | N/A | 3.6 | mL | AMPULE | |
| 1601441 | Residual Solvent Class 2 - Methylene Chloride (1.2 mL/ampule; 3 ampules) | Reference Standard | 75-09-02 | 3.6 | mL | AMPULE | |
| 1601452 | Residual Solvent Class 2 - Methylisobutylketone (3 x 1.2 mL) | Reference Standard | 108-10-1 | 3.6 | mL | AMPULE | |
| 1601306 | Residual Solvent Class 2 - Mixture C (1.2 mL/ampule; 3 ampules) | Reference Standard | N/A | 3.6 | mL | AMPULE | |
| 1601485 | Residual Solvent Class 2 - N,N-Dimethylacetamide (1.2 mL/ampule; 3 ampules) | Reference Standard | N/A | 3.6 | mL | AMPULE | |
| 1601500 | Residual Solvent Class 2 - N,N-Dimethylformamide (1.2 mL/ampule; 3 ampules) | Reference Standard | N/A | 3.6 | mL | AMPULE | |
| 1601703 | Residual Solvent Class 2 - N-Methylpyrrolidone (1.2 mL/ampule; 3 ampules) | Reference Standard | 872-50-4 | 3.6 | mL | AMPULE | |
| 1601725 | Residual Solvent Class 2 - Nitromethane (1.2 mL/ampule; 3 ampules) | Reference Standard | N/A | 3.6 | mL | | |
| 1601747 | Residual Solvent Class 2 - Pyridine (1.2 mL/ampule; 3 ampules) | Reference Standard | 110-86-1 | 3.6 | mL | AMPULE | |
| 1601769 | Residual Solvent Class 2 - Sulfolane (1.2 mL/ampule; 3 ampules) | Reference Standard | 126-33-0 | 3.6 | mL | AMPULE | |
| 1601770 | Residual Solvent Class 2 - Tetrahydrofuran (1.2 mL/ampule; 3 ampules) | Reference Standard | 109-99-9 | 3.6 | mL | AMPULE | |
| 1601780 | Residual Solvent Class 2 - Tetralin (1.2 mL/ampule; 3 ampules) | Reference Standard | 119-64-2 | 3.6 | mL | AMPULE | |
| 1601805 | Residual Solvent Class 2 - Toluene (1.2 mL/ampule; 3 ampules) | Reference Standard | N/A | 3.6 | mL | AMPULE | |
| 1601827 | Residual Solvent Class 2 - Trichloroethylene (1.2 mL/ampule; 3 ampules) | Reference Standard | N/A | 3.6 | mL | AMPULE | |
| 1601849 | Residual Solvent Class 2 - Xylenes (1.2 mL/ampule; 3 ampules) | Reference Standard | N/A | 3.6 | mL | AMPULE | |
| 1601281 | Residual Solvents Class 2 - Mixture A (1.2 mL/ampule; 3 ampules) | Reference Standard | N/A | 3.6 | mL | AMPULE | |
| 1601292 | Residual Solvents Class 2 - Mixture B (1.2 mL/ampule; 3 ampules) | Reference Standard | N/A | 3.6 | mL | AMPULE | |
| 1601102 | Residual Solvents Mixture - Class 1 (1.2 mL/ampule; 3 ampules) (Ozone Depleting Substance) | Reference Standard | N/A | 3.6 | mL | AMPULE | |
| 1602003 | Resorcinol (200 mg) | Reference Standard | 108-46-3 | 200 | mg | VIAL | |
| 1716002 | Retinyl Acetate (Vitamin A) (10 ampules x 0.5 g) | Reference Standard | 127-47-9 | 5 | g | AMPULE | |
| 1602502 | Retinyl Palmitate (4 x 50 mg) | Reference Standard | 79-81-2 | 200 | mg | AMPULE | |
| 1602580 | Rhodiola Rosea Root and Rhizome Dry Extract (1 g) | Reference Standard | N/A | 1 | g | VIAL | |
| 1602599 | Rhoifolin (15 mg) | Reference Standard | 17306-46-6 | 15 | mg | VIAL | |
| 1602706 | Ribavirin (200 mg) | Reference Standard | 36791-04-5 | 200 | mg | VIAL | |
| 1602717 | Ribavirin Related Compound A (15 mg) (1-beta-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxylic acid) | Reference Standard | 39925-19-4 | 15 | mg | VIAL | |
| 1602740 | Ribavirin Related Compound D (15 mg) (1H-1,2,4-triazole-3-carboxamide) | Reference Standard | 3641-08-5 | 15 | mg | VIAL | |
| 1603006 | Riboflavin (500 mg) | Reference Standard | 83-88-5 | 500 | mg | VIAL | |
| 1603108 | Ribose (300 mg) | Reference Standard | 50-69-1 | 300 | mg | VIAL | |
| 1603800 | Rifabutin (50 mg) | Reference Standard | 72559-06-9 | 50 | mg | VIAL | |
| 1604009 | Rifampin (300 mg) | Reference Standard | 13292-46-1 | 300 | mg | VIAL | |
| 1604202 | Rifampin Quinone (25 mg) (1,4-dideoxy-1,4-dihydro-3-[[[4-methyl-1-piperazinyl]imino]methyl]-1,4-dioxo-rifamycin) | Reference Standard | 13983-13-6 | 25 | mg | VIAL | |
| 1604199 | Rifampin-N-Oxide (25 mg) | Reference Standard | 125833-03-6 | 25 | mg | VIAL | |
| 1604337 | Riluzole (200 mg) | Reference Standard | 1744-22-5 | 200 | mg | VIAL | |
| 1604348 | Riluzole Related Compound A (25 mg) (4-trifluoromethoxyaniline) | Reference Standard | 461-82-5 | 25 | mg | AMPULE | |
| 1604508 | Rimantadine Hydrochloride (300 mg) | Reference Standard | 1501-84-4 | 300 | mg | VIAL | |
| 1604600 | Rimexolone (100 mg) | Reference Standard | 49697-38-3 | 100 | mg | VIAL | |
| 1604519 | Riociguat (250 mg) | Reference Standard | 625115-55-1 | 250 | mg | VIAL | |
| 1604527 | Riociguat System Suitability Mixture (25 mg) (This is a mixture containing (approximately 0.2% of related compound B and 0.5% of related compound C) riociguat, riociguat related compound B and riociguat related compound C) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1604494 | Riociguat System Suitability Mixture II (25 mg) (This is a mixture containing riociguat, riociguat related compound A and riociguat related compound C) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1604621 | Risedronate Related Compound A (20 mg) ([1-Hydroxy-2-(2-pyridinyl)ethylidene]bis(phosphonic acid), monohydrate) | Reference Standard | 1220806-40-5 | 20 | mg | VIAL | |
| 1604632 | Risedronate Related Compound B (20 mg) ([3,6-bis[(3-pyridinyl)methyl]-2,5-dihydroxy-2,5-dioxido-1,4,2,5-dioxadiphosphorinane-3,6-diyl]bis[phosphonic acid] disodium tetrahydrate salt) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1604643 | Risedronate Related Compound C (20 mg) ([2-(3-pyridinyl)ethylidene-1,1]bis(phosphonic acid)) | Reference Standard | 75755-10-1 | 20 | mg | VIAL | |
| 1604610 | Risedronate Sodium (350 mg) | Reference Standard | 329003-65-8 | 350 | mg | VIAL | |
| 1604654 | Risperidone (100 mg) | Reference Standard | 106266-06-2 | 100 | mg | VIAL | |
| 1A00600 | Risperidone Difluoroketone (10 mg) (3-(2-(4-(2,4-difluorobenzoyl)piperidin-1-yl)ethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one) | Pharmaceutical Analytical Impurity | 158697-67-7 | 10 | mg | VIAL | |
| 1604756 | Risperidone Related Compound G (25 mg) (3-{2-[4-(4-Fluoro-2-hydroxybenzoyl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one hydrochloride) | Reference Standard | 152542-00-2 | 25 | mg | VIAL | |
| 1604676 | Risperidone Related Compounds Mixture (25 mg) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1604665 | Risperidone System Suitability Mixture (10 mg) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1604701 | Ritodrine Hydrochloride (200 mg) | Reference Standard | 23239-51-2 | 200 | mg | VIAL | |
| 1604803 | Ritonavir (200 mg) | Reference Standard | 155213-67-5 | 200 | mg | VIAL | |
| 1604814 | Ritonavir Related Compounds Mixture (50 mg) | Reference Standard | 155213-67-5 | 50 | mg | VIAL | |
| 1604530 | Rivaroxaban (200 mg) | Reference Standard | 366789-02-8 | 200 | mg | VIAL | |
| 1A00670 | Rivaroxaban Open Ring (10 mg) ((R)-5-chloro-N-(2-hydroxy-3-((4-(3-oxomorpholino)phenyl)amino)propyl)thiophene-2-carboxamide) | Pharmaceutical Analytical Impurity | 721401-53-2 | 10 | mg | VIAL | |
| 1A00650 | Rivaroxaban Open Ring Methylamine (10 mg) ((S)-4-(4-((2-hydroxy-3-(methylamino)propyl)amino)phenyl)morpholin-3-one) | Pharmaceutical Analytical Impurity | 2459303-14-9 | 10 | mg | VIAL | |
| 1A00660 | Rivaroxaban Phthalamide (25 mg) (N1,N2-bis(((S)-2-oxo-3-(4-(3-oxomorpholino)phenyl)oxazolidin-5-yl)methyl)phthalamide) | Pharmaceutical Analytical Impurity | 1365267-36-2 | 25 | mg | VIAL | |
| 1604541 | Rivaroxaban R-enantiomer (20 mg) ((R)-5-Chloro-N-({2-oxo-3-[4-(3-oxomorpholino)phenyl]oxazolidin-5-yl}methyl)thiophene-2-carboxamide) | Reference Standard | 865479-71-6 | 20 | mg | VIAL | |
| 1604552 | Rivaroxaban Related Compound B (20 mg) ((S)-N-({2-Oxo-3-[4-(3-oxomorpholino)phenyl]oxazolidin-5-yl}methyl)acetamide) | Reference Standard | 1429334-00-8 | 20 | mg | VIAL | |
| 1604563 | Rivaroxaban Related Compound D (20 mg) (1,3-Bis({(S)-2-oxo-3-[4-(3-oxomorpholino)phenyl]oxazolidin-5-yl}methyl)urea) | Reference Standard | 1365267-35-1 | 20 | mg | VIAL | |
| 1604596 | Rivaroxaban Related Compound G (20 mg) ((S)-2-({2-oxo-3-[4-(3-oxomorpholino)phenyl]oxazolidin-5-yl}methyl)isoindoline-1,3-dione) | Reference Standard | 446292-08-6 | 20 | mg | VIAL | |
| 1604585 | Rivaroxaban Related Compound H (20 mg) ((S)-4,5-Dichloro-N-({2-oxo-3-[4-(3-oxomorpholino)phenyl]oxazolidin-5-yl}methyl)thiophene-2-carboxamide) | Reference Standard | 1770812-37-7 | 20 | mg | VIAL | |
| 1604574 | Rivaroxaban Related Compound J (20 mg) | Reference Standard | 1632463-24-1 | 20 | mg | VIAL | |
| 1604836 | Rivastigmine (0.1 mL) | Reference Standard | 123441-03-2 | 0.1 | mL | AMPULE | |
| 1604869 | Rivastigmine Related Compound A (15 mg) ((+)-Di-(p-toluoyl)-D-tartaric acid) | Reference Standard | 32634-68-7 | 15 | mg | VIAL | |
| 1604870 | Rivastigmine Related Compound B (15 mg) ((R,S)-3-[1-(Dimethylamino)ethyl]phenyl dimethylcarbamate) | Reference Standard | 25081-93-0 | 15 | mg | AMPULE | |
| 1604811 | Rivastigmine Related Compound C (15 mg) ((S)-3-[1-(Dimethylamino)ethyl]phenol) | Reference Standard | 139306-10-8 | 15 | mg | VIAL | |
| 1604825 | Rivastigmine Related Compound D (50 mg) (3-Acetylphenyl ethyl(methyl)carbamate) | Reference Standard | 855300-09-3 | 50 | mg | VIAL | |
| 1604950 | Rivastigmine Related Compound E (15 mg) ((S)-1-(3-{[Ethyl(methyl)carbamoyl]oxy}phenyl)-N,N,N-trimethylethanaminium chloride) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1604961 | Rivastigmine Related Compound F (25 mg) (3-Vinylphenyl ethyl(methyl)carbamate) | Reference Standard | 1346602-84-3 | 25 | mg | AMPULE | |
| 1604858 | Rivastigmine Tartrate (200 mg) | Reference Standard | 129101-54-8 | 200 | mg | VIAL | |
| 1604847 | Rivastigmine Tartrate R-Isomer (20 mg) ((R)-3-[1-(Dimethylamino)ethyl]phenyl ethyl(methyl)carbamate, hydrogen tartrate) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1604880 | Rizatriptan Benzoate (200 mg) | Reference Standard | 145202-66-0 | 200 | mg | VIAL | |
| 1604891 | Rizatriptan Benzoate System Suitability Mixture (15 mg) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1604905 | Rocuronium Bromide (250 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 119302-91-9 | 250 | mg | VIAL | |
| 1604916 | Rocuronium Peak Identification Mixture (25 mg) (rocuronium bromide spiked with rocuronium related compounds A, B, C, D, E, F, G, and H) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1605012 | Roflumilast (500 mg) | Reference Standard | 162401-32-3 | 500 | mg | VIAL | |
| 1605023 | Roflumilast Related Compound A (30 mg) (3-(Cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-hydroxybenzamide) | Reference Standard | 475271-62-6 | 30 | mg | VIAL | |
| 1605034 | Roflumilast Related Compound B (30 mg) (N-(3,5-Dichloropyridin-4-yl)-4-(difluoromethoxy)-3-hydroxybenzamide) | Reference Standard | 1391052-76-8 | 30 | mg | VIAL | |
| 1605045 | Roflumilast Related Compound C (50 mg) (3,5-Dichloropyridin-4-amine) | Reference Standard | 22889-78-7 | 50 | mg | VIAL | |
| 1605056 | Roflumilast Related Compound D (50 mg) (3-(Cyclopropylmethoxy)-4-(difluoromethoxy)benzoic acid) | Reference Standard | 162401-62-9 | 50 | mg | VIAL | |
| 1605067 | Roflumilast Related Compound E (30 mg) (N-(3-Bromo-5-chloropyridin-4-yl)-3-(cyclopropylmethoxy)-4-(difluoromethoxy)benzamide) | Reference Standard | NA | 30 | mg | VIAL | |
| 1605205 | Ropinirole Hydrochloride (200 mg) | Reference Standard | 91374-20-8 | 200 | mg | VIAL | |
| 1605216 | Ropinirole Related Compound A (50 mg) (4-(2-hydroxyethyl)indolin-2-one) | Reference Standard | 139122-19-3 | 50 | mg | VIAL | |
| 1605227 | Ropinirole Related Compound B (50 mg) (4-[2-(Dipropylamino)ethyl]indoline-2,3-dione hydrochloride) | Reference Standard | 221264-21-7 | 50 | mg | VIAL | |
| 1605497 | Ropivacaine (200 mg) | Reference Standard | 84057-95-4 | 200 | mg | VIAL | |
| 1605500 | Ropivacaine Hydrochloride (200 mg) | Reference Standard | 132112-35-7 | 200 | mg | VIAL | |
| 1605512 | Ropivacaine Related Compound A (25 mg) (2,6-dimethylaniline hydrochloride) | Reference Standard | 21436-98-6 | 25 | mg | VIAL | |
| 1605523 | Ropivacaine Related Compound B (50 mg) ((R)-N-(2,6-Dimethylphenyl)-1-propylpiperidine-2-carboxamide hydrochloride monohydrate) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1605588 | Rosavin (25 mg) ((2E)-3-Phenylprop-2-en-1-yl 6-O-alpha-l-arabinopyranosyl-Beta-D-glucopyranoside) | Reference Standard | 84954-92-7 | 25 | mg | VIAL | |
| 1605817 | Rosiglitazone Maleate (200 mg) | Reference Standard | 122320-73-4 | 200 | mg | VIAL | |
| 1605828 | Rosiglitazone Related Compound A (25 mg) ((5Z)-5-{[4-({2-[methyl(2-pyridinyl)amino]ethyl}oxy)phenyl]methylidene}-1,3-thiazolidine-2,4-dione) | Reference Standard | 160596-25-8 | 25 | mg | VIAL | |
| 1605952 | Rosmarinic Acid (25 mg) | Reference Standard | 20283-92-5 | 25 | mg | VIAL | |
| 1606015 | Rosuvastatin Calcium (300 mg) | Reference Standard | 147098-20-2 | 300 | mg | VIAL | |
| 1606059 | Rosuvastatin Enantiomer (25 mg) (Calcium (3S,5R,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate salt (1:2)) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1A00170 | Rosuvastatin Isoamyl Ester (25 mg) ((3S,5R,6E)-7-[4-(4-flurophenyl)-6-(1-methylethyl)-2-[N-methyl(methylsulphonyl)amino]-5-pyrimidinyI]-3,5-dihydroxy-6-heptanoic acid, methyl butyl ester) | Pharmaceutical Analytical Impurity | 1197348-98-3 | 25 | mg | VIAL | |
| 1A00050 | Rosuvastatin Ketone (25mg) ((R,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3-hydroxy-5-oxohept-6-enoic acid) | Pharmaceutical Analytical Impurity | 1422619-13-3 | 25 | mg | VIAL | |
| 1606026 | Rosuvastatin Related Compound A (25 mg) (Calcium (3R,5S,E)-7-{4-(4-fluorophenyl)-2-[(2-hydroxy-N,2-dimethylpropyl)sulfonamide]-6-isopropylpyrimidin-5-yl}-3,5-dihydroxyhept-6-enoate salt (1:2)) | Reference Standard | 1714147-47-3 | 25 | mg | VIAL | |
| 1606037 | Rosuvastatin Related Compound B (25 mg) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1606048 | Rosuvastatin Related Compound C (25 mg) (tert-Butyl2-[(4R,6S)-6-{(E)-2-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl]vinyl}-2,2-dimethyl-1,3-dioxan-4-yl]acetate) | Reference Standard | 289042-12-2 | 25 | mg | VIAL | |
| 1606060 | Rotigotine (50 mg) ((S)-6-{Propyl[2-(thiophen-2-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-1-ol) | Reference Standard | 99755-59-6 | 50 | mg | VIAL | |
| 1606079 | Rotigotine Hydrochloride (300 mg) ((6S )-6-[Propyl(2-(2-thienyl)ethyl)amino]-5,6,7,8-tetrahydronaphthalen-1-ol hydrochloride) | Reference Standard | 125572-93-2 | 300 | mg | VIAL | |
| 1606081 | Rotigotine Racemate (25 mg) ((RS)-6-{Propyl[2-(thiophen-2-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-1-ol hydrochloride) | Reference Standard | 102120-99-0 | 25 | mg | VIAL | |
| 1606117 | Rotigotine Related Compound C (25 mg) ((S)-6-{[2-(Thiophen-2-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-1-ol hydrochloride) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1606140 | Rotigotine Related Compound G (25 mg) ((S)-6-{Bis[2-(thiophen-2-yl)ethyl]amino}-5,6,7,8-tetrahydronaphthalen-1-ol hydrochloride) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1606156 | Rotigotine Related Compound H (25 mg) ((S)-5-Methoxy-N-propyl-N-[2-(thiophen-2-yl)ethyl]-1,2,3,4-tetrahydronaphthalen-2-amine) | Reference Standard | 1148154-91-9 | 25 | mg | AMPULE | |
| 1202253 | Rotigotine Related Compound K (25 mg) (7,8-Dihydronaphthalen-1-ol) | Reference Standard | 51927-48-1 | 25 | mg | VIAL | |
| 1606208 | Roxarsone (200 mg) | Reference Standard | 121-19-7 | 200 | mg | VIAL | |
| 1606401 | Rufinamide (200 mg) | Reference Standard | 106308-44-5 | 200 | mg | VIAL | |
| 1606412 | Rufinamide Related Compound A (25 mg) (1-(2-Fluorobenzyl)-1H-1,2,3-triazole-4-carboxamide) | Reference Standard | 106308-41-2 | 25 | mg | VIAL | |
| 1606423 | Rufinamide Related Compound B (25 mg) (Methyl 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxylate) | Reference Standard | 217448-86-7 | 25 | mg | VIAL | |
| 1606503 | Rutin (100 mg) | Reference Standard | 250249-75-3 | 100 | mg | VIAL | |
| 1012112 | S-Adenosyl-L-Homocysteine (50 mg) | Reference Standard | 979-92-0 | 50 | mg | | |
| 1012316 | S-Adenosyl-L-Methionine 1,4-Butanedisulfonate (250 mg) | Reference Standard | 101020-79-5 | 250 | mg | VIAL | |
| 1013057 | S-Allyl-L-Cysteine (25 mg) | Reference Standard | 21593-77-1 | 25 | mg | VIAL | |
| 1A00440 | S-Levetiracetam Hydroxybutyramide Analog (10 mg) ((S)-N-(1-amino-1-oxobutan-2-yl)-4-hydroxybutanamide) | Pharmaceutical Analytical Impurity | 1868118-63-1 | 10 | mg | VIAL | |
| 1607007 | Saccharin (200 mg) | Reference Standard | 81-07-2 | 200 | mg | VIAL | |
| 1607029 | Saccharin Calcium (150 mg) | Reference Standard | 6485-34-3 | 150 | mg | VIAL | |
| 1607040 | Saccharin Sodium (200 mg) | Reference Standard | 6155-57-3 | 200 | mg | VIAL | |
| 1607200 | Safflower Oil (1 g) | Reference Standard | 8001-23-8 | 1 | g | AMPULE | |
| 1607299 | Safrole (4 x 50 mg) (List Chemical) (5-allylbenzo-1,3-dioxole) | Reference Standard | 94-59-7 | 50 | mg | AMPULE | |
| 1608000 | Salicylamide (200 mg) | Reference Standard | 65-45-2 | 200 | mg | VIAL | |
| 1609002 | Salicylic Acid (125 mg) | Reference Standard | 69-72-7 | 125 | mg | VIAL | |
| 1609013 | Salicylic Acid Related Compound A (100 mg) (4-hydroxybenzoic acid) | Reference Standard | 99-96-7 | 100 | mg | VIAL | |
| 1609024 | Salicylic Acid Related Compound B (100 mg) (4-hydroxyisophthalic acid) | Reference Standard | 636-46-4 | 100 | mg | VIAL | |
| 1609534 | Salidroside (25 mg) (2-(4-Hydroxyphenyl)ethyl-Beta-D-glucopyranoside) | Reference Standard | 10338-51-9 | 25 | mg | VIAL | |
| 1719339 | Salix Species Bark Dry Extract (1 g) | Reference Standard | N/A | 1 | g | VIAL | |
| 1609614 | Salmeterol Related Compound A (20 mg) (4-[1-Hydroxy-2-(4-phenylbutylamino)ethyl]-2-(hydroxymethyl)phenol) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1609625 | Salmeterol Related Compound B (3 x 1.3 mg) (4-{1-Hydroxy-2-[6-(4-phenylbutan-2-yloxy)hexylamino]ethyl}-2- | Reference Standard | 108928-81-0 | 1.3 | mg | VIAL | |
| 1609680 | Salmeterol Related Compound H (30 mg) (1-Hydroxy-4-[2-hydroxy-5-(1-hydroxy-2-{[6-(4-phenylbutoxy)hexyl]amino}ethyl)benzyl]-2-naphthoic acid, monohydrate) | Reference Standard | N/A | 30 | mg | VIAL | |
| 1609589 | Salmeterol Resolution Check (15 mg) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1609590 | Salmeterol System Suitability (15 mg) (Mixture containing salmeterol xinafoate, salmeterol-N-alkyl and salmeterol related compound H) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1609603 | Salmeterol Xinafoate (150 mg) | Reference Standard | 94749-08-3 | 150 | mg | VIAL | |
| 1609807 | Salsalate (150 mg) | Reference Standard | 552-94-3 | 150 | mg | VIAL | |
| 1609818 | Salvianolic Acid B (25 mg) | Reference Standard | 121521-90-2 | 25 | mg | VIAL | |
| 1609793 | Santalum Album Oil (0.5 mL) | Reference Standard | NA | 0.5 | mL | | |
| 1609829 | Saquinavir Mesylate (200 mg) | Reference Standard | 149845-06-7 | 200 | mg | VIAL | |
| 1609831 | Saquinavir Related Compound A (25 mg) (N-tert-butyl-decahydro-2-[2(R)-hydroxy-4-phenyl-3(S)-[[N-(2-quinolylcarbonyl)-D-asparaginyl]amino]butyl]-(4aS,8aS)-isoquinoline-3(S)-carboxamide) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1535813 | Scaffold Human Dermis Reference Photomicrographs (CD) | Reference Standard | N/A | 1 | ea | OTHER | |
| 1609909 | Schisandra chinensis Fruit Dry Extract (1 g) | Reference Standard | N/A | 1 | g | VIAL | |
| 1609895 | Schisandrin (15 mg) | Reference Standard | 7432-28-2 | 15 | mg | VIAL | |
| 1610001 | Scopolamine Hydrobromide (500 mg) | Reference Standard | N/A | 500 | mg | VIAL | |
| 1610090 | Scopoletin (20 mg) | Reference Standard | 92-61-5 | 20 | mg | VIAL | |
| 1610307 | Scutellaria Baicalensis Root Dry Extract (1 g) | Reference Standard | N/A | 1 | g | VIAL | |
| 1611004 | Secobarbital CII (200 mg) | Reference Standard | 76-73-3 | 200 | mg | VIAL | |
| 1611117 | Secoxyloganin (50 mg) ([(2S,3R,4S)-2-(beta-D-Glucopyranosyloxy)-5-(methoxycarbonyl)-3-vinyl-3,4-dihydro-2H-pyran-4-yl]acetic acid) | Reference Standard | 58822-47-2 | 50 | mg | VIAL | |
| 1611729 | Selamectin (350 mg) | Reference Standard | 220119-17-5 | 350 | mg | VIAL | |
| 1611900 | Selegiline Hydrochloride (200 mg) | Reference Standard | 14611-52-0 | 200 | mg | VIAL | |
| 1611944 | Selegiline Related Compound D (15 mg) (N-(1-Phenylpropan-2-yl)prop-2-yn-1-amine hydrochloride) | Reference Standard | 2588-96-7 | 15 | mg | | |
| 1611966 | Selenium Sulfide (200 mg) | Reference Standard | 7488-56-4 | 200 | mg | VIAL | |
| 1611955 | Selenomethionine (100 mg) | Reference Standard | 3211-76-5 | 100 | mg | VIAL | |
| 1612018 | Sennoside A (20 mg) ((9R,9'R)-5,5'-Bis(beta-d-glucopyranosyloxy)-4,4'-dihydroxy-10,10'-dioxo-9,9',10,10'-tetrahydro-9,9'-bianthracene-2,2'-dicarboxylic acid) | Reference Standard | 81-27-6 | 20 | mg | VIAL | |
| 1612029 | Sennoside B (20 mg) | Reference Standard | 128-57-4 | 20 | mg | VIAL | |
| 1612007 | Sennosides (500 mg) | Reference Standard | N/A | 500 | mg | VIAL | |
| 1612539 | Sertraline Hydrochloride (100 mg) | Reference Standard | 79559-97-0 | 100 | mg | VIAL | |
| 1612517 | Sertraline Hydrochloride Racemic Mixture (30 mg) ((1RS,4RS)-4-(3,4-Dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthylamine hydrochloride) | Reference Standard | 79617-89-3 | 30 | mg | VIAL | |
| 1612528 | Sertraline Hydrochloride Related Compound A (25 mg) ((1RS,4SR)-4-(3,4-Dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthylamine hydrochloride) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1612404 | Sesame Oil (1 g) | Reference Standard | 8008-74-0 | 1 | g | AMPULE | |
| 1612415 | Sesame Oil Related Compound A (12 mg/vial; 2 vials) (1,2-dilinoleoyl-3-oleoyl-rac-glycerol) (OLL) | Reference Standard | 2190-21-8 | 24 | mg | VIAL | |
| 1612426 | Sesame Oil Related Compound B (12 mg x 2 ampules) (1,2-dilinoleoyl-3-palmitoyl-rac-glycerol)(PLL) | Reference Standard | 2190-15-0 | 24 | mg | VIAL | |
| 1612459 | Sevelamer Carbonate (100 mg) | Reference Standard | 845273-93-0 | 100 | mg | VIAL | |
| 1612540 | Sevoflurane (1 mL) | Reference Standard | 28523-86-6 | 1 | mL | AMPULE | |
| 1612550 | Sevoflurane Related Compound A (0.2 mL) (1,1,1,3,3-Pentafluoroisopropenyl fluoromethyl ether) | Reference Standard | 58109-34-5 | 0.2 | mL | AMPULE | |
| 1612572 | Sevoflurane Related Compound B (0.2 mL) (1,1,1,3,3,3-hexafluoro-2-methoxy-propane) | Reference Standard | 13171-18-1 | 0.2 | mL | AMPULE | |
| 1612594 | Sevoflurane Related Compound C (0.2 mL) (1,1,1,3,3,3-hexafluoro-2-propanol) | Reference Standard | 920-66-1 | 0.2 | mL | AMPULE | |
| 1612856 | Sibutramine Related Compound A (20 mg) (N-{1-[1-(2-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine hydrochloride) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1612867 | Sibutramine Related Compound B (20 mg) (N-{1-[1-(3-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine hydrochloride) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1612878 | Sibutramine Related Compound C (20 mg) (N-{1-[1-(4-chlorophenyl)cyclobutyl]pentyl}-N,N-dimethylamine hydrochloride) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1612889 | Sibutramine Related Compound D (20 mg) (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N-methylamine hydrochloride) | Reference Standard | 84467-94-7 | 20 | mg | VIAL | |
| 1612561 | Sildenafil Citrate (100 mg) | Reference Standard | 171599-83-0 | 100 | mg | VIAL | |
| 1612685 | Sildenafil Related Compound A (10 mg) (1-{[3-(6,7-Dihydro-1-methyl-7-oxo-3-isobutyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyl}-4-methylpiperazine) | Reference Standard | 1391053-95-4 | 10 | mg | VIAL | |
| 1098399 | Silicified Microcrystalline Cellulose (1 g) | Reference Standard | N/A | 1 | g | VIAL | |
| 1612608 | Silver Sulfadiazine (200 mg) | Reference Standard | 22199-08-2 | 200 | mg | VIAL | |
| 1612630 | Silybin (50 mg) | Reference Standard | 22888-70-6 | 50 | mg | VIAL | |
| 1612641 | Silydianin (30 mg) | Reference Standard | 29782-68-1 | 30 | mg | VIAL | |
| 1612652 | Simethicone (50 g) | Reference Standard | 8050-81-5 | 50 | g | BOTTLE | |
| 1612700 | Simvastatin (200 mg) | Reference Standard | 79902-63-9 | 200 | mg | VIAL | |
| 1612765 | Sirolimus (50 mg) | Reference Standard | 53123-88-9 | 50 | mg | VIAL | |
| 1612743 | Sirolimus System Suitability Mixture (15 mg) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1612801 | Sisomicin Sulfate (500 mg) | Reference Standard | 53179-09-2 | 500 | mg | VIAL | |
| 1612903 | Sitagliptin Phosphate (200 mg) | Reference Standard | 654671-77-9 | 200 | mg | VIAL | |
| 1612914 | Sitagliptin System Suitability Mixture (20 mg) (Sitagliptin Phosphate containing about 0.2% of S-enantiomer) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1443825 | Skim Milk Powder (20 g) | Reference Standard | N/A | 20 | g | BOTTLE | |
| 1443760 | Skim Milk Powder with Maltodextrin Level A (5 g) | Reference Standard | N/A | 5 | g | VIAL | |
| 1443771 | Skim Milk Powder with Maltodextrin Level B (5 g) | Reference Standard | N/A | 5 | g | VIAL | |
| 1443786 | Skim Milk Powder with Maltodextrin Level C (5 g) | Reference Standard | N/A | 5 | g | VIAL | |
| 1443847 | Skim Milk Powder with Melamine - Level A (20 g) | Reference Standard | N/A | 20 | g | BOTTLE | |
| 1443872 | Skim Milk Powder with Melamine - Level C (20 g) | Reference Standard | N/A | 20 | g | BOTTLE | |
| 1443883 | Skim Milk Powder with Melamine - Level D (20 g) | Reference Standard | N/A | 20 | g | BOTTLE | |
| 1443894 | Skim Milk Powder with Melamine - Level E (20 g) | Reference Standard | N/A | 20 | g | BOTTLE | |
| 1613407 | Sodium Acetate (1 g) | Reference Standard | 127-09-3 | 1 | g | VIAL | |
| 1613429 | Sodium Acetate Trihydrate (1 g) | Reference Standard | 6131-90-4 | 1 | g | VIAL | |
| 1613462 | Sodium Alginate (100 mg) | Reference Standard | 9005-38-3 | 100 | mg | VIAL | |
| 1613509 | Sodium Ascorbate (200 mg) | Reference Standard | 134-03-2 | 200 | mg | VIAL | |
| 1613564 | Sodium Benzoate (1 g) | Reference Standard | 532-32-1 | 1 | g | VIAL | |
| 1613655 | Sodium Bicarbonate (3 g) | Reference Standard | 144-55-8 | 3 | g | VIAL | |
| 1613597 | Sodium Bromide (1 g) | Reference Standard | 7647-15-6 | 1 | g | VIAL | |
| 1613600 | Sodium Butyrate (25 mg) | Reference Standard | 156-54-7 | 25 | mg | VIAL | |
| 1613757 | Sodium Carbonate Anhydrous (1 g) | Reference Standard | 497-19-8 | 1 | g | VIAL | |
| 1613804 | Sodium Chloride (1 g) | Reference Standard | 7647-14-5 | 1 | g | VIAL | |
| 1613859 | Sodium Citrate (1 g) | Reference Standard | 6132-04-3 | 1 | g | VIAL | |
| 1613860 | Sodium Cyclamate (200 mg) | Reference Standard | 139-05-9 | 200 | mg | VIAL | |
| 1613881 | Sodium D,L-Malate (50 mg) | Reference Standard | 63474-37-3 | 50 | mg | VIAL | |
| 1613928 | Sodium D-Pantoate (100 mg) | Reference Standard | 60979-68-2 | 100 | mg | VIAL | |
| 1613688 | Sodium Decanoyl Sarcosinate (30 mg) (Sodium N-decanoyl-N-methylglycinate) | Reference Standard | 30377-07-2 | 30 | mg | VIAL | |
| 1614002 | Sodium Fluoride (1 g) (International Restricted Sales Item) | Reference Standard | 7681-49-4 | 1 | g | VIAL | |
| 1614159 | Sodium Hyaluronate for IR Identification (250 mg) | Reference Standard | 9067-32-7 | 250 | mg | VIAL | |
| 1614239 | Sodium Iron EDTA (200 mg) | Reference Standard | 18154-32-0 | 200 | mg | VIAL | |
| 1614308 | Sodium Lactate (200 mg) | Reference Standard | 867-56-1 | 200 | mg | VIAL | |
| 1614374 | Sodium Lauroyl Sarcosinate (150 mg) | Reference Standard | 137-16-6 | 150 | mg | VIAL | |
| 1614363 | Sodium Lauryl Sulfate (1 g) | Reference Standard | 151-21-3 | 1 | g | VIAL | |
| 1614396 | Sodium Metabisulfite (2 X 500 mg) | Reference Standard | 7681-57-4 | 1 | g | VIAL | |
| 1614421 | Sodium Molybdate Dihydrate (200 mg) | Reference Standard | 10102-40-6 | 200 | mg | VIAL | |
| 1614419 | Sodium MonoFluorophosphate (100 mg) | Reference Standard | 10163-15-2 | 100 | mg | VIAL | |
| 1614385 | Sodium Myristoyl Sarcosinate (30 mg) (Sodium N-methyl-N-tetradecanoylglycinate) | Reference Standard | 30364-51-3 | 30 | mg | VIAL | |
| 1614454 | Sodium Nitrite (1 g) | Reference Standard | 7632-00-0 | 1 | g | VIAL | |
| 1614501 | Sodium Nitroprusside (500 mg) | Reference Standard | 13755-38-9 | 500 | mg | VIAL | |
| 1614512 | Sodium Phenylbutyrate (200 mg) | Reference Standard | 1716-12-7 | 200 | mg | VIAL | |
| 1614578 | Sodium Picosulfate (50 mg) | Reference Standard | 10040-45-6 | 50 | mg | VIAL | |
| 1614589 | Sodium Picosulfate Related Compound A (20 mg) (Sodium 4-((4-hydroxyphenyl)(pyridin-2-yl)methyl)phenyl sulfate) | Reference Standard | 32500-19-9 | 20 | mg | VIAL | |
| 1614603 | Sodium Propionate (200 mg) | Reference Standard | 137-40-6 | 200 | mg | | |
| 1614636 | Sodium Salicylate (500 mg) | Reference Standard | 54-21-7 | 500 | mg | VIAL | |
| 1614669 | Sodium Starch Glycolate Type A (400 mg) | Reference Standard | 9063-38-1 | 400 | mg | VIAL | |
| 1614670 | Sodium Starch Glycolate Type B (400 mg) | Reference Standard | 9063-38-1 | 400 | mg | VIAL | |
| 1614705 | Sodium Stearyl Fumarate (200 mg) | Reference Standard | 4070-80-8 | 200 | mg | VIAL | |
| 1614807 | Sodium Sulfate Anhydrous (1 g) | Reference Standard | 7757-82-6 | 1 | g | VIAL | |
| 1614909 | Sodium Tartrate Dihydrate (500 mg/vial; 4 vials) | Reference Standard | 6106-24-7 | 2000 | mg | VIAL | |
| 1615107 | Sodium Thiosulfate (1 g) | Reference Standard | 10102-17-7 | 1 | g | VIAL | |
| 1615138 | Sodium Trifluoroacetate (500 mg) | Reference Standard | 2923-18-4 | 500 | mg | VIAL | |
| 1615311 | Solifenacin Identification Mixture A (15 mg) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1615322 | Solifenacin Identification Mixture B (20 mg) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1615300 | Solifenacin Succinate (100 mg) | Reference Standard | 242478-38-2 | 100 | mg | VIAL | |
| 1615708 | Somatropin (5.64 USP Somatropin Units/vial) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | 12629-01-5 | 1.88 | mg | VIAL | |
| 1615810 | Sophora Japonica Flower Dry Extract (500 mg) | Reference Standard | N/A | 500 | mg | VIAL | |
| 1615887 | Sorafenib Related Compound H (25 mg) (4-(4-{3-[2-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N-methylpicolinamide) | Reference Standard | 1431697-81-2 | 25 | mg | VIAL | |
| 1615876 | Sorafenib Tosylate (200 mg) | Reference Standard | 475207-59-1 | 200 | mg | VIAL | |
| 1615956 | Sorbic Acid (1 g) | Reference Standard | 110-44-1 | 1 | g | VIAL | |
| 1617000 | Sorbitol (125 mg) | Reference Standard | 50-70-4 | 125 | mg | VIAL | |
| 1617408 | Sotalol Hydrochloride (300 mg) | Reference Standard | 959-24-0 | 300 | mg | VIAL | |
| 1617419 | Sotalol Related Compound A (50 mg) (N-[4-[[(1-Methylethyl)amino]acetyl]phenyl]methanesulfonamide monohydrochloride) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1617420 | Sotalol Related Compound B (50 mg) (N-(4-Formylphenyl)methanesulfonamide) | Reference Standard | 83922-54-7 | 50 | mg | VIAL | |
| 1617430 | Sotalol Related Compound C (50 mg) (N-[4-[2-[(1-Methylethyl)amino]ethyl]phenyl]methanesulfonamide monohydrochloride) | Reference Standard | 16974-42-8 | 50 | mg | VIAL | |
| 1617500 | Soybean Oil (1 g) | Reference Standard | 8001-22-7 | 1 | g | AMPULE | |
| 1618003 | Spectinomycin Hydrochloride (200 mg) | Reference Standard | 22189-32-8 | 200 | mg | VIAL | |
| 1618717 | Spinosin (15 mg) | Reference Standard | 72063-39-9 | 15 | mg | VIAL | |
| 1619006 | Spironolactone (125 mg) | Reference Standard | 52-01-7 | 125 | mg | VIAL | |
| 1619051 | Spironolactone Epimer Mixture (30 mg) (7-Epispironolactone approximately 56% and Spironolactone approximately 39% mixture) | Reference Standard | N/A | 30 | mg | VIAL | |
| 1619017 | Spironolactone Related Compound A (100 mg) ((2'R)-3',4'-Dihydro-5'H-spiro[androst-4,6-diene-17,2'-furan]-3,5'-dione) | Reference Standard | 976-71-6 | 100 | mg | VIAL | |
| 1619028 | Spironolactone Related Compound B (30 mg) ((2'R)-7alpha-(Acetylthio)-5'H-spiro[androst-4-ene-17,2'-furan]-3,5'-dione) | Reference Standard | 132458-33-4 | 30 | mg | VIAL | |
| 1619039 | Spironolactone Related Compound C (30 mg) ((2'R)-3',4'-Dihydro-5'H-spiro[androst-4-ene-17,2'-furan]-3,5'-dione) | Reference Standard | 976-70-5 | 30 | mg | VIAL | |
| 1619040 | Spironolactone Related Compound D (30 mg) ((2'R)-7alpha-(Acetyldisulfanyl)-3',4'-dihydro-5'H-spiro[androst-4-ene-17,2'-furan]-3,5'-dione) | Reference Standard | N/A | 30 | mg | VIAL | |
| 1619094 | Spironolactone Related Compound I (30 mg) (S-[17alpha-(Ethoxymethyl)-17-hydroxy-3-oxoandrost-4-en-7alpha-yl]ethanethioate) | Reference Standard | N/A | 30 | mg | VIAL | |
| 1619185 | Spirulina (2 x 100 mg) | Reference Standard | 724424-92-4 | 200 | mg | AMPULE | |
| 1619505 | Squalane (500 mg) | Reference Standard | 111-01-3 | 500 | mg | AMPULE | |
| 1620005 | Stanozolol CIII (200 mg) | Reference Standard | 10418-03-8 | 200 | mg | VIAL | |
| 1036960 | Star Anise Oil (500 mg) | Reference Standard | 68952-43-2 | 500 | mg | AMPULE | |
| 1620209 | Stavudine (250 mg) | Reference Standard | 3056-17-5 | 250 | mg | VIAL | |
| 1620220 | Stavudine System Suitability Mixture (10 mg) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1621008 | Stearic Acid (500 mg) | Reference Standard | 57-11-4 | 500 | mg | VIAL | |
| 1621507 | Stearoyl Polyoxylglycerides (100 mg) | Reference Standard | 9011-21-6 | 100 | mg | VIAL | |
| 1622000 | Stearyl Alcohol (125 mg) | Reference Standard | 112-92-5 | 125 | mg | VIAL | |
| 1622044 | Stearylpyridinium Chloride (25 mg) (1-Octadecylpyridinium chloride) | Reference Standard | 3165-81-9 | 25 | mg | VIAL | |
| 1622317 | Steviol Glycosides System Suitability (50 mg) | Reference Standard | 91722-21-3 | 50 | mg | VIAL | |
| 1622350 | Steviolbioside (100 mg) | Reference Standard | 41093-60-1 | 100 | mg | VIAL | |
| 1622408 | Stevioside (30 mg) | Reference Standard | 57817-89-7 | 30 | mg | VIAL | |
| 1623003 | Streptomycin Sulfate (200 mg) | Reference Standard | 3810-74-0 | 200 | mg | VIAL | |
| 1623411 | Succinic Acid (300 mg) | Reference Standard | 110-15-6 | 300 | mg | VIAL | |
| 1623422 | Succinic Acid Melting Point Standard (1 g) | Reference Standard | 110-15-6 | 1 | g | VIAL | |
| 1623502 | Succinylcholine Chloride (500 mg) | Reference Standard | 6101-15-1 | 500 | mg | VIAL | |
| 1623604 | Succinylmonocholine Chloride (125 mg) | Reference Standard | 5297-17-6 | 125 | mg | VIAL | |
| 1623626 | Sucralose (400 mg) | Reference Standard | 56038-13-2 | 400 | mg | VIAL | |
| 1623659 | Sucromalt (200 mg) | Reference Standard | 911432-63-8 | 200 | mg | VIAL | |
| 1623637 | Sucrose (100 mg) | Reference Standard | 57-50-1 | 100 | mg | VIAL | |
| 1623580 | Sucrose Diacetate Hexaisobutyrate (1 mL) | Reference Standard | 126-13-6 | 1 | mL | VIAL | |
| 1623615 | Sucrose Octaacetate (500 mg) | Reference Standard | 126-14-7 | 500 | mg | VIAL | |
| 1623648 | Sufentanil Citrate CII (25 mg) | Reference Standard | 60561-17-3 | 25 | mg | VIAL | |
| 1623670 | Sulbactam (250 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 68373-14-8 | 250 | mg | VIAL | |
| 1623749 | Sulbactam Related Compound A (15 mg) ((2S)-2-Amino-3-methyl-3-sulfinobutanoic acid) | Reference Standard | 23315-18-6 | 15 | mg | VIAL | |
| 1623772 | Sulbactam Related Compound D (15 mg) (Potassium (2S,5R,6R)-6-bromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate) | Reference Standard | 4027-64-9 | 15 | mg | VIAL | |
| 1623783 | Sulbactam Related Compound E (15 mg) ((2S,5R)-6,6-Dibromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid 4,4-dioxide) | Reference Standard | 76646-91-8 | 15 | mg | VIAL | |
| 1623794 | Sulbactam Related Compound F (15 mg) ((2S,5R)-6,6-Dibromo-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid) | Reference Standard | 24158-88-1 | 15 | mg | VIAL | |
| 1623681 | Sulconazole Nitrate (200 mg) | Reference Standard | 61318-91-0 | 200 | mg | VIAL | |
| 1623692 | Sulconazole Related Compound A (15 mg) (1-[2-(4-Chlorobenzyl)sulfinyl-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole nitrate) | Reference Standard | 77279-29-9 | 15 | mg | VIAL | |
| 1624006 | Sulfacetamide Sodium (500 mg) | Reference Standard | 6209-17-2 | 500 | mg | VIAL | |
| 1624505 | Sulfachlorpyridazine (200 mg) | Reference Standard | 80-32-0 | 200 | mg | VIAL | |
| 1625009 | Sulfadiazine (200 mg) | Reference Standard | 68-35-9 | 200 | mg | VIAL | |
| 1626001 | Sulfadimethoxine (200 mg) | Reference Standard | 122-11-2 | 200 | mg | VIAL | |
| 1626500 | Sulfadoxine (200 mg) | Reference Standard | 2447-57-6 | 200 | mg | VIAL | |
| 1628007 | Sulfamerazine (500 mg) | Reference Standard | 127-79-7 | 500 | mg | VIAL | |
| 1629000 | Sulfamethazine (1 g) | Reference Standard | 57-68-1 | 1 | g | VIAL | |
| 1629019 | Sulfamethazine Related Compound A (100 mg) (4-Amino-N-carbamimidoylbenzenesulfonamide-, monohydrate) | Reference Standard | 6190-55-2 | 100 | mg | VIAL | |
| 1629021 | Sulfamethazine Related Compound B (50 mg) (Mixture containing about 49% of 4-Amino-2-chloro-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide and about 48% of 4-Amino-3-chloro-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1630009 | Sulfamethizole (200 mg) | Reference Standard | 144-82-1 | 200 | mg | VIAL | |
| 1631001 | Sulfamethoxazole (200 mg) | Reference Standard | 723-46-6 | 200 | mg | VIAL | |
| 1631500 | Sulfamethoxazole N4-Glucoside (25 mg) (4-(beta-D-glucopyranosylamino)-N-(5-methyl-3-isoxazolyl)-benzenesulfonamide) | Reference Standard | 119691-75-7 | 25 | mg | VIAL | |
| 1631511 | Sulfamethoxazole Related Compound A (15 mg) (N-{4-[N-(5-methylisoxazol-3-yl)sulfamoyl]phenyl}acetamide) | Reference Standard | 21312-10-7 | 15 | mg | VIAL | |
| 1631522 | Sulfamethoxazole Related Compound B (15 mg) (4-amino-N-{4-[N-(5-methylisoxazol-3-yl)sulfamoyl]phenyl}benzenesulfonamide) | Reference Standard | 135529-16-7 | 15 | mg | VIAL | |
| 1631533 | Sulfamethoxazole Related Compound C (15 mg) (5-methylisoxazol-3-amine) | Reference Standard | 1072-67-9 | 15 | mg | VIAL | |
| 1631566 | Sulfamethoxazole Related Compound F (15 mg) (4-amino-N-(3-methylisoxazol-5-yl)benzenesulfonamide) | Reference Standard | 17103-52-5 | 15 | mg | VIAL | |
| 1632004 | Sulfanilamide (5 g) | Reference Standard | 63-74-1 | 5 | g | VIAL | |
| 1633007 | Sulfanilamide Melting Point Standard (1 g) (Approximately 165 degrees) | Reference Standard | 63-74-1 | 1 | g | VIAL | |
| 1633506 | Sulfanilic Acid (200 mg) (4-Aminobenzenesulfonic acid) | Reference Standard | 121-57-3 | 200 | mg | VIAL | |
| 1634000 | Sulfapyridine (200 mg) | Reference Standard | 144-83-2 | 200 | mg | VIAL | |
| 1635206 | Sulfaquinoxaline (200 mg) | Reference Standard | 59-40-5 | 200 | mg | VIAL | |
| 1635228 | Sulfaquinoxaline Related Compound A (25 mg) (N1,N2-diquinoxalin-2-ylsulfanilamide) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1636005 | Sulfasalazine (125 mg) | Reference Standard | 599-79-1 | 125 | mg | VIAL | |
| 1636118 | Sulfasalazine Related Compound K (25 mg) (5-{4-[N-(6-Methylpyridin-2-yl)sulfamoyl]phenyldiazenyl}salicylic acid) | Reference Standard | 42753-55-9 | 25 | mg | VIAL | |
| 1636504 | Sulfathiazole (350 mg) | Reference Standard | 72-14-0 | 350 | mg | VIAL | |
| 1638000 | Sulfisoxazole (200 mg) | Reference Standard | 127-69-5 | 200 | mg | VIAL | |
| 1639003 | Sulfisoxazole Acetyl (200 mg) | Reference Standard | 80-74-0 | 200 | mg | VIAL | |
| 1642008 | Sulindac (200 mg) | Reference Standard | 38194-50-2 | 200 | mg | VIAL | |
| 1642019 | Sulindac Related Compound A (20 mg) ((E)-2-{5-Fluoro-2-methyl-1-[4-(methylsulfinyl)benzylidene]-1H-inden-3-yl}acetic acid) | Reference Standard | 53933-60-1 | 20 | mg | VIAL | |
| 1642020 | Sulindac Related Compound B (20 mg) ((Z)-2-{5-fluoro-2-methyl-1-[4-(methylsulfonyl)benzylidene]-1H-inden-3-yl}acetic acid) | Reference Standard | 59973-80-7 | 20 | mg | VIAL | |
| 1642031 | Sulindac Related Compound C (20 mg) ((Z)-2-{5-fluoro-2-methyl-1-[4-(methylthio)benzylidene]-1H-inden-3-yl}acetic acid) | Reference Standard | 49627-27-2 | 20 | mg | VIAL | |
| 1642100 | Sulisobenzone (500 mg) | Reference Standard | 4065-45-6 | 500 | mg | VIAL | |
| 1642154 | Sumatriptan (50 mg) | Reference Standard | 103628-46-2 | 50 | mg | VIAL | |
| 1642201 | Sumatriptan Succinate (200 mg) | Reference Standard | 103628-48-4 | 200 | mg | VIAL | |
| 1642212 | Sumatriptan Succinate Related Compound A (15 mg) ([3-[2-(dimethylamino)ethyl]-2-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1H-indol-5-yl]-N-methylmethanesulfonamide, succinate salt) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1642223 | Sumatriptan Succinate Related Compound C (50 mg) ([3-[2-(dimethylamino)ethyl]-1-(hydroxymethyl)-1H-indol-5-yl]-N-methylmethanesulfonamide succinate salt) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1642256 | Sumatriptan Succinate Related Impurities (25 mg) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1642347 | Sunflower Oil (1 g) | Reference Standard | 8001-21-6 | 1 | g | AMPULE | |
| 1642358 | Sunitinib Malate (200 mg) | Reference Standard | 341031-54-7 | 200 | mg | VIAL | |
| 1642507 | Suprofen (200 mg) | Reference Standard | 40828-46-4 | 200 | mg | VIAL | |
| 1642609 | Synephrine (30 mg) | Reference Standard | 94-07-5 | 30 | mg | VIAL | |
| 1642802 | Tacrolimus (150 mg) | Reference Standard | 109581-93-3 | 150 | mg | VIAL | |
| 1642824 | Tacrolimus 8-epimer (15 mg) (See USP Certificate for full Chemical Name) | Reference Standard | 129212-35-7 | 15 | mg | VIAL | |
| 1642835 | Tacrolimus 8-propyl analog (15 mg) (See USP Certificate for full Chemical Name) | Reference Standard | 104987-30-6 | 15 | mg | VIAL | |
| 1642813 | Tacrolimus Related Compound A (15 mg) (See USP Certificate for full Chemical Name) | Reference Standard | 135635-46-0 | 15 | mg | VIAL | |
| 1642857 | Tacrolimus System Suitability Mixture (10 mg) (A mixture consisting of tacrolimus, ascomycin and tacrolimus 8-propyl analog) | Reference Standard | NA | 10 | mg | VIAL | |
| 1642879 | Tadalafil (200 mg) | Reference Standard | 171596-29-5 | 200 | mg | VIAL | |
| 1642904 | Tagatose (200 mg) | Reference Standard | 87-81-0 | 200 | mg | VIAL | |
| 1643306 | Tamoxifen Citrate (200 mg) | Reference Standard | 54965-24-1 | 200 | mg | VIAL | |
| 1643260 | Tamsulosin Hydrochloride (200 mg) | Reference Standard | 106463-17-6 | 200 | mg | VIAL | |
| 1643328 | Tannic Acid (2 g) (AS) | Reference Standard | 1401-55-4 | 2 | g | VIAL | |
| 1643339 | Tanshinone IIA (20 mg) | Reference Standard | 568-72-9 | 20 | mg | VIAL | |
| 1643340 | Tartaric Acid (1 g) | Reference Standard | 87-69-4 | 1 | g | VIAL | |
| 1643361 | Taurine (100 mg) | Reference Standard | 107-35-7 | 100 | mg | VIAL | |
| 1643383 | Tazobactam (200 mg) | Reference Standard | 89786-04-9 | 200 | mg | VIAL | |
| 1643394 | Tazobactam Related Compound A (20 mg) ((2S,3S)-2-Amino-3-methyl-3-sulfino-4-(1H-1,2,3-triazol-1-yl)butyric acid) | Reference Standard | 118175-11-4 | 20 | mg | VIAL | |
| 1643419 | Telmisartan (200 mg) | Reference Standard | 144701-48-4 | 200 | mg | VIAL | |
| 1643420 | Telmisartan Related Compound A (20 mg) (1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzo[d]imidazole monohydrate) | Reference Standard | 1282554-35-1 | 20 | mg | VIAL | |
| 1643437 | Telmisartan Related Compound B (15 mg) (4'-[(1,7'-dimethyl-2'-propyl-1H,1'H-2,5'-bibenzo[d]imidazol-1'-yl)methyl]biphenyl-2-carboxylic acid) | Reference Standard | 1026353-20-7 | 15 | mg | VIAL | |
| 1643408 | Temazepam CIV (200 mg) | Reference Standard | 846-50-4 | 200 | mg | VIAL | |
| 1644319 | Temazepam Related Compound A (15 mg) (5-chloro-2-methylaminobenzophenone) | Reference Standard | 1022-13-5 | 15 | mg | VIAL | |
| 1644364 | Temazepam Related Compound F (15 mg) (7-chloro-1-methyl-5-phenyl-4,5-dihydro-1H-1,4-benzodiazepine-2,3-dione) | Reference Standard | 3294-96-0 | 15 | mg | VIAL | |
| 1646375 | Temazepam Related Compound G (15 mg) (7-Chloro-1,4-dimethyl-5-phenyl-4,5-dihydro-1H-1,4-benzodiazepine-2,3-dione) | Reference Standard | 93329-92-1 | 15 | mg | VIAL | |
| 1643543 | Temozolomide (200 mg) | Reference Standard | 85622-93-1 | 200 | mg | VIAL | |
| 1643554 | Temozolomide Related Compound A (15 mg) (4-diazo-4H-imidazole-5-carboxamide) | Reference Standard | 7008-85-7 | 15 | mg | VIAL | |
| 1643565 | Temozolomide Related Compound B (15 mg) (3-methyl-1,1-diphenylurea) | Reference Standard | 13114-72-2 | 15 | mg | VIAL | |
| 1643576 | Temozolomide Related Compound C (15 mg) (diphenylcarbamic chloride) | Reference Standard | 83-01-2 | 15 | mg | VIAL | |
| 1643736 | Teniposide (200 mg) | Reference Standard | 29767-20-2 | 200 | mg | VIAL | |
| 1643747 | Teniposide Related Compound A (10 mg) (4'-Demethylepipodophyllotoxin) | Reference Standard | 6559-91-7 | 10 | mg | VIAL | |
| 1612719 | Tenivastatin Calcium (2 x 15 mg) (COLD SHIPMENT REQUIRED) (Calcium (3R,5R)-7-{(1S,2S,6R,8S,8aR)-8-[(2,2-dimethylbutanoyl)oxy]-2,6-dimethyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl}-3,5-dihydroxyheptanoate (1:2) monohydrate) | Reference Standard | 530112-57-3 | 30 | mg | VIAL | |
| 1643601 | Tenofovir (15 mg) | Reference Standard | 206184-49-8 | 15 | mg | VIAL | |
| 1643656 | Tenofovir Disoproxil Fumarate (200 mg) | Reference Standard | 202138-50-9 | 200 | mg | VIAL | |
| 1643612 | Tenofovir Disoproxil Related Compound A (10 mg) (O,O-Bis(isopropoxycarbonyloxymethyl) (S)-[1-(6-amino-9H-purin-9-yl)prop-2-yloxy]methylphosphonate fumarate) | Reference Standard | 1432630-26-6 | 10 | mg | VIAL | |
| 1643623 | Tenofovir Disoproxil Related Compound B (10 mg) ((E)-9-(Prop-1-enyl)-9H-purin-6-amine) | Reference Standard | 1446486-33-4 | 10 | mg | VIAL | |
| 1643678 | Tenofovir Disoproxil Related Compound G (15 mg) (O-(Isopropoxycarbonyloxymethyl)-O-isopropyl-{(R)-[1-(6-amino-9H-purin-9-yl)propan-2-yloxy]}methylphosphonate) fumarate) | Reference Standard | 1422284-15-8 | 15 | mg | VIAL | |
| 1643452 | Terazosin Hydrochloride (200 mg) | Reference Standard | 70024-40-7 | 200 | mg | VIAL | |
| 1643463 | Terazosin Related Compound A (50 mg) (6,7-Dimethoxy-2-(piperazin-1-yl)quinazolin-4-amine dihydrochloride) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1643474 | Terazosin Related Compound B (50 mg) (1-(4-hydroxy-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1643485 | Terazosin Related Compound C (25 mg) (1,4-Bis(4-amino-6,7-dimethoxy-2-quinazolinyl)piperazine, dihydrochloride) | Reference Standard | 1486464-41-8 | 25 | mg | VIAL | |
| 1643496 | Terbinafine Hydrochloride (200 mg) | Reference Standard | 78628-80-5 | 200 | mg | VIAL | |
| 1424608 | Terbinafine Related Compound A (25 mg) (N-methyl-C-(naphthalen-1-yl)methanamine hydrochloride) | Reference Standard | 65473-13-4 | 25 | mg | VIAL | |
| 1643532 | Terbinafine Related Compound B (25 mg) ((2Z)-N,6,6-Trimethyl-N-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine hydrochloride) | Reference Standard | 176168-78-8 | 25 | mg | VIAL | |
| 1353215 | Terbinafine Related Compound C (25 mg) ((2E)-N,6,6-Trimethyl-N-(naphthalen-2-ylmethyl)hept-2-en-4-yn-1-amine hydrochloride) | Reference Standard | 877265-30-0 | 25 | mg | VIAL | |
| 1437701 | Terbinafine Related Compound D (25 mg) ((2E)-N,6,6-trimethyl-N-[(4-methylnaphthalen-1-yl)methyl]-hept-2-en-4-yn-1-amine hydrochloride) | Reference Standard | 877265-33-3 | 25 | mg | VIAL | |
| 1643510 | Terbutaline Related Compound A (50 mg) (2-(tert-Butylamino)-1-(3,5-dihydroxyphenyl)ethan-1-one sulfate) | Reference Standard | N/A | 50 | mg | | |
| 1643521 | Terbutaline Related Compound D (25 mg) (2-[Benzyl(tert-butyl)amino]-1-(3,5-dihydroxyphenyl)ethan-1-one) (COLD SHIPMENT REQUIRED) | Reference Standard | 94109-61-2 | 25 | mg | VIAL | |
| 1643500 | Terbutaline Sulfate (125 mg) | Reference Standard | 23031-32-5 | 125 | mg | VIAL | |
| 1643703 | Terconazole (200 mg) | Reference Standard | 67915-31-5 | 200 | mg | VIAL | |
| 1643962 | Teriparatide (1 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 52232-67-4 | 1 | mg | VIAL | |
| 1643984 | Terminalia chebula Fruit Dry Extract (1 g) | Reference Standard | N/A | 1 | g | VIAL | |
| 1644003 | Terpin Hydrate (750 mg) | Reference Standard | 2451-01-6 | 750 | mg | VIAL | |
| 1645006 | Testolactone CIII (125 mg) | Reference Standard | 968-93-4 | 125 | mg | VIAL | |
| 1646009 | Testosterone CIII (125 mg) | Reference Standard | 58-22-0 | 125 | mg | VIAL | |
| 1647001 | Testosterone Cypionate CIII (200 mg) | Reference Standard | 58-20-8 | 200 | mg | VIAL | |
| 1647012 | Testosterone Cypionate Related Compound A (25 mg) (Androst-4-en-3,6-dione-17Beta-yl 3-cyclopentylpropanoate) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1647023 | Testosterone Cypionate Related Compound B (40 mg) (Androst-4,6-dien-3-one-17 Beta-yl 3-cyclopentylpropanoate) | Reference Standard | N/A | 40 | mg | VIAL | |
| 1648004 | Testosterone Enanthate CIII (200 mg) | Reference Standard | 315-37-7 | 200 | mg | VIAL | |
| 1648026 | Testosterone Enanthate Related Compound B CIII (50 mg) (Androst-4-en-3-one-17beta-yl hexanoate) | Reference Standard | 10312-45-5 | 50 | mg | VIAL | |
| 1646042 | Testosterone Enanthate Related Compound F (50 mg) (Androst-4,6-dien-3-one-17Beta-yl heptanoate) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1646053 | Testosterone Enanthate Related Compound G (50 mg) (Androst-4,9(11)-dien-3-one-17Beta-yl heptanoate) | Reference Standard | 119698-27-0 | 50 | mg | VIAL | |
| 1648081 | Testosterone Enanthate Related Compound H CIII (25 mg) (Androst-5-ene-3Beta,17Beta-diyl diheptanoate) | Reference Standard | 162890-98-4 | 25 | mg | VIAL | |
| 1649007 | Testosterone Propionate CIII (200 mg) | Reference Standard | 57-85-2 | 200 | mg | VIAL | |
| 1646010 | Testosterone Related Compound A CIII (20 mg) (Androst-4-ene-3,17-dione) | Reference Standard | 63-05-8 | 20 | mg | VIAL | |
| 1646031 | Testosterone Related Compound C (15 mg) (17alpha-Hydroxyandrost-4-en-3-one) | Reference Standard | 481-30-1 | 15 | mg | VIAL | |
| 1646097 | Testosterone Related Compound I (15 mg) (17beta-Hydroxyandrosta-4,6-dien-3-one) | Reference Standard | 2484-30-2 | 15 | mg | VIAL | |
| 1649801 | Tetrabenazine (200 mg) ((3RS,11bRS)-3-Isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one) | Reference Standard | 58-46-8 | 200 | mg | VIAL | |
| 1649812 | Tetrabenazine Related Compound C (25 mg) ((3RS,11bRS)-3-Butyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one) | Reference Standard | 86457-13-8 | 25 | mg | VIAL | |
| 1649991 | Tetracaine (50 mg) | Reference Standard | 94-24-6 | 50 | mg | VIAL | |
| 1650006 | Tetracaine Hydrochloride (200 mg) | Reference Standard | 136-47-0 | 200 | mg | VIAL | |
| 1650017 | Tetracaine Related Compound B (25 mg) (4-(Butylamino)benzoic acid) | Reference Standard | 4740-24-3 | 25 | mg | VIAL | |
| 1650028 | Tetracaine Related Compound C (25 mg) (Methyl 4-(butylamino)benzoate) | Reference Standard | 71839-12-8 | 25 | mg | VIAL | |
| 1651009 | Tetracycline Hydrochloride (200 mg) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | 64-75-5 | 200 | mg | VIAL | |
| 1652001 | Tetrahydrozoline Hydrochloride (200 mg) | Reference Standard | 522-48-5 | 200 | mg | VIAL | |
| 1652012 | Tetrahydrozoline Related Compound A (50 mg) (1,2,3,4-Tetrahydronaphthalene-1-carbonitrile) | Reference Standard | 56536-96-0 | 50 | mg | AMPULE | |
| 1652023 | Tetrahydrozoline Related Compound B (25 mg) (2-(1,2,3,4-Tetrahydronaphthalen-1-yl)-1H-imidazole) | Reference Standard | 945389-41-3 | 25 | mg | VIAL | |
| 1652034 | Tetrahydrozoline Related Compound C (25 mg) (1,2,3,4-Tetrahydronaphthalene-1-carboxylic acid) | Reference Standard | 1914-65-4 | 25 | mg | VIAL | |
| 1652045 | Tetrahydrozoline Related Compound D (25 mg) (2-(Naphthalen-1-yl)-4,5-dihydro-1H-imidazole hydrochloride) | Reference Standard | 13623-57-9 (free base) | 25 | mg | VIAL | |
| 1652056 | Tetrahydrozoline Related Compound E (25 mg) (N-(2-Aminoethyl)-1,2,3,4-tetrahydronaphthalene-1-carboxamide) | Reference Standard | 84460-89-9 | 25 | mg | VIAL | |
| 1A00400 | Tetramethyl Ethylene Diamine (25 mg) (N1,N1,N2,N2-tetramethylethane-1,2-diamine) | Pharmaceutical Analytical Impurity | 110-18-9 | 25 | mg | AMPULE | |
| 1652158 | Tetraxetan (50 mg) | Reference Standard | 60239-18-1 | 50 | mg | VIAL | |
| 1652169 | Tetraxetan Related Compound A (25 mg) (2,2',2"-[10-(2-Ethoxy-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl]triacetic acid) | Reference Standard | 2101625-18-5 | 25 | mg | VIAL | |
| 1652500 | Thalidomide (200 mg) | Reference Standard | 50-35-1 | 200 | mg | VIAL | |
| 1653004 | Theophylline (200 mg) | Reference Standard | 58-55-9 | 200 | mg | VIAL | |
| 1653117 | Theophylline Melting Point Standard (2 x 500 mg) (Approximately 271 degrees) | Reference Standard | 58-55-9 | 1000 | mg | VIAL | |
| 1653026 | Theophylline Related Compound B (25 mg) (3-Methyl-1H-purine-2,6-dione) | Reference Standard | 1076-22-8 | 25 | mg | VIAL | |
| 1653037 | Theophylline Related Compound C (25 mg) (N-(6-Amino-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-5-yl)formamide) | Reference Standard | 7597-60-6 | 25 | mg | VIAL | |
| 1653048 | Theophylline Related Compound D (30 mg) (N-Methyl-5-(methylamino)-1H-imidazole-4-carboxamide hydrochloride monohydrate) | Reference Standard | N/A | 30 | mg | VIAL | |
| 1653060 | Theophylline Related Compound F (25 mg) (7-(2-Hydroxyethyl)-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione) | Reference Standard | 519-37-9 | 25 | mg | VIAL | |
| 1655000 | Thiabendazole (100 mg) | Reference Standard | 148-79-8 | 100 | mg | VIAL | |
| 1656002 | Thiamine Hydrochloride (500 mg) (Vitamin B1 Hydrochloride) | Reference Standard | 67-03-8 | 500 | mg | VIAL | |
| 1659000 | Thimerosal (500 mg) | Reference Standard | 54-64-8 | 500 | mg | VIAL | |
| 1659001 | Thimerosal Related Compound A (50 mg) (2,2'-Disulfanediyldibenzoic acid) | Reference Standard | 119-80-2 | 50 | mg | VIAL | |
| 1660000 | Thioguanine (200 mg) | Reference Standard | 154-42-7 | 200 | mg | | |
| 1661002 | Thiopental CIII (250 mg) | Reference Standard | 76-75-5 | 250 | mg | VIAL | |
| 1662504 | Thioridazine (200 mg) | Reference Standard | 50-52-2 | 200 | mg | | |
| 1663008 | Thioridazine Hydrochloride (200 mg) | Reference Standard | 130-61-0 | 200 | mg | VIAL | |
| 1663063 | Thioridazine Related Compound F (20 mg) (2-(Methylthio)-10-[2-(piperidin-2-yl)ethyl]-10H-phenothiazine hydrochloride) | Reference Standard | 13002-81-8 | 20 | mg | VIAL | |
| 1663700 | Thiostrepton (200 mg) | Reference Standard | 1393-48-2 | 200 | mg | VIAL | |
| 1664000 | Thiotepa (500 mg) | Reference Standard | 52-24-4 | 500 | mg | VIAL | |
| 1665003 | Thiothixene (250 mg) | Reference Standard | 3313-26-6 | 250 | mg | VIAL | |
| 1667100 | Thonzonium Bromide (200 mg) | Reference Standard | 553-08-2 | 200 | mg | VIAL | |
| 1667213 | Thymol (500 mg) | Reference Standard | 89-83-8 | 500 | mg | VIAL | |
| 1667280 | Tiagabine Hydrochloride (300 mg) | Reference Standard | 145821-59-6 | 300 | mg | VIAL | |
| 1667122 | Tiagabine Isomer (25 mg) (1-(4,4-Bis(4-methylthiophen-2-yl)but-3-en-1-yl)piperidine-3-carboxylic acid) | Reference Standard | 109857-65-0 | 25 | mg | VIAL | |
| 1667224 | Tiagabine Related Compound A (15 mg) ((R)-ethyl 1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylate, hydrochloride) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1667355 | Tiamulin (100 mg) | Reference Standard | 55297-95-5 | 100 | mg | VIAL | |
| 1667290 | Tiamulin Fumarate (250 mg) | Reference Standard | 55297-96-6 | 250 | mg | VIAL | |
| 1667337 | Tiamulin Related Compound A (50 mg) (Tosyl pleuromutilin) | Reference Standard | 31716-01-5 | 50 | mg | VIAL | |
| 1667177 | Ticagrelor (200 mg) | Reference Standard | 274693-27-5 | 200 | mg | VIAL | |
| 1667188 | Ticagrelor Related Compound A (25 mg) ((1R,2S)-2-(3,4-difluorophenyl)cyclopropan-1-amine (R)-mandelate) | Reference Standard | 376608-71-8 | 25 | mg | VIAL | |
| 1667133 | Ticagrelor Related Compound B (25 mg) | Reference Standard | 1788033-05-5 | 25 | mg | VIAL | |
| 1667304 | Ticarcillin Monosodium Monohydrate (350 mg) | Reference Standard | 74682-62-5 | 350 | mg | VIAL | |
| 1667144 | Ticlopidine Hydrochloride (150 mg) | Reference Standard | 53885-35-1 | 150 | mg | VIAL | |
| 1667155 | Ticlopidine Related Compound A (20 mg) (4-oxo-4,5,6,7-tetrahydrothieno-[3,2-c]pyridine) | Reference Standard | 68559-60-4 | 20 | mg | VIAL | |
| 1667166 | Ticlopidine Related Compound B (20 mg) (5-(2-chlorobenzyl)-4-oxo-4,5,6,7-tetrahydrothieno-[3,2-c]pyridine) | Reference Standard | 68559-55-7 | 20 | mg | VIAL | |
| 1667643 | Tigecycline (300 mg) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | 220620-09-7 | 300 | mg | AMPULE | |
| 1667665 | Tigecycline Related Compound B (25 mg) ((4S,4aS,5aR,12aS)-9-Amino-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2- carboxamide hydrochloride (1:x)) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1667359 | Tiletamine Hydrochloride (200 mg) | Reference Standard | 14176-50-2 | 200 | mg | VIAL | |
| 1667370 | Tilmicosin (250 mg) | Reference Standard | 108050-54-0 | 250 | mg | AMPULE | |
| 1667406 | Timolol Maleate (200 mg) | Reference Standard | 26921-17-5 | 200 | mg | | |
| 1667381 | Timolol Related Compound A (20 mg) ((R)-1-(tert-Butylamino)-3-(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-2-ol maleate) | Reference Standard | 26839-77-0 | 20 | mg | VIAL | |
| 1667315 | Timolol Related Compound B (20 mg) (3-(tert-Butylamino)-2-(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-1-ol) | Reference Standard | 59697-06-2 | 20 | mg | VIAL | |
| 1667326 | Timolol Related Compound C (20 mg) (N-(tert-Butyl)-2,3-bis(4-morpholino-1,2,5-thiadiazol-3-yloxy)propan-1-amine maleate) | Reference Standard | 610271-57-3 | 20 | mg | VIAL | |
| 1667369 | Timolol Related Compound D (20 mg) (4-Morpholino-1,2,5-thiadiazol-3-ol) | Reference Standard | 30165-97-0 | 20 | mg | VIAL | |
| 1667443 | Timolol Related Compound E (20 mg) ((S,Z)-4-({1-(tert-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]propan-2-yl}oxy)-4-oxobut-2-enoic acid maleate salt (1:1)) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1667348 | Timolol Related Compound F (20 mg) (3-Chloro-4-morpholino-1,2,5-thiadiazol) | Reference Standard | 30165-96-9 | 20 | mg | VIAL | |
| 1667520 | Tinidazole (200 mg) | Reference Standard | 19387-91-8 | 200 | mg | VIAL | |
| 1667530 | Tinidazole Related Compound A (100 mg) (2-methyl-5-nitroimidazole) | Reference Standard | 696-23-1 | 100 | mg | VIAL | |
| 1667541 | Tinidazole Related Compound B (20 mg) (1-(2-ethyl-sulfonylethyl)-2-methyl-4-nitroimidazole) | Reference Standard | 25459-12-5 | 20 | mg | VIAL | |
| 1667439 | Tioconazole (200 mg) | Reference Standard | 65899-73-2 | 200 | mg | VIAL | |
| 1667450 | Tioconazole Related Compound A (25 mg) (1-[2,4-Dichloro-beta-[(3-thenyl)-oxy]phenethyl]imidazole hydrochloride) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1667461 | Tioconazole Related Compound B (25 mg) (1-[2,4-Dichloro-beta-[(2,5-dichloro-3-thenyl)oxy]phenethyl]imidazole hydrochloride) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1667472 | Tioconazole Related Compound C (25 mg) (1-[2,4-Dichloro-beta-[(5-bromo-2-chloro-3-thenyl)-oxy]-phenethyl]imidazole hydrochloride) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1667574 | Tiotropium Bromide (100 mg) | Reference Standard | 136310-93-5 | 100 | mg | VIAL | |
| 1667619 | Tiotropium Related Compound C (25 mg) ((1R,3s,5S)-3-[2-Hydroxy-2,2-di(thiophen-2-yl)acetoxy]-8,8-dimethyl-8-azabicyclo[3.2.1]oct-6-en-8-ium bromide) | Reference Standard | 136310-95-7 | 25 | mg | VIAL | |
| 1667621 | Tiotropium Related Compound G (50 mg) ((1R,2R,4S,5S,7s)-7-Hydroxy-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.02,4]nonan-9-ium bromide) | Reference Standard | 1508-46-9 | 50 | mg | VIAL | |
| 1667632 | Tiotropium Related Compound H (50 mg) ((2RS,3aSR,5RS,6RS,6aRS)-6-Hydroxy-4,4-dimethylhexahydro-2H-2,5-methanofuro[3,2-b]pyrrol-4-ium bromide) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1667585 | Titanium Dioxide (2 g) | Reference Standard | 13463-67-7 | 2 | g | VIAL | |
| 1667905 | Tizanidine Hydrochloride (200 mg) | Reference Standard | 64461-82-1 | 200 | mg | VIAL | |
| 1667916 | Tizanidine Related Compound A (50 mg) (4-amino-5-chloro-2,1,3-benzothiadiazole) | Reference Standard | 30536-19-7 | 50 | mg | VIAL | |
| 1667924 | Tizanidine Related Compound B (50 mg) (N-acetyltizanidine) | Reference Standard | 173532-15-5 | 50 | mg | VIAL | |
| 1667938 | Tizanidine Related Compound C (50 mg) (1-acetylimidazolidine-2-thione) | Reference Standard | 5391-52-6 | 50 | mg | VIAL | |
| 1667508 | Tobramycin (350 mg) | Reference Standard | 32986-56-4 | 350 | mg | VIAL | |
| 1668001 | Tolazamide (200 mg) | Reference Standard | 1156-19-0 | 200 | mg | VIAL | |
| 1669004 | Tolazoline Hydrochloride (300 mg) | Reference Standard | 59-97-2 | 300 | mg | VIAL | |
| 1670003 | Tolbutamide (200 mg) | Reference Standard | 64-77-7 | 200 | mg | VIAL | |
| 1670207 | Tolcapone (200 mg) | Reference Standard | 134308-13-7 | 200 | mg | VIAL | |
| 1670218 | Tolcapone Related Compound A (25 mg) (4'-methyl-3,4-dihydroxybenzophenone) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1670229 | Tolcapone Related Compound B (25 mg) (4-hydroxy-3-methoxy-4'-methyl-5-nitrobenzophenone) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1670502 | Tolmetin Sodium (500 mg) | Reference Standard | 64490-92-2 | 500 | mg | | |
| 1671006 | Tolnaftate (200 mg) | Reference Standard | 2398-96-1 | 200 | mg | VIAL | |
| 1671468 | Tolterodine S-Enantiomer (15 mg) ((S)-2-[3-(Diisopropylamino)-1-phenylpropyl]-4-methylphenol tartrate) | Reference Standard | 873551-03-2 | 15 | mg | VIAL | |
| 1671479 | Tolterodine System Suitability Mixture (15 mg) | Reference Standard | NA | 15 | mg | VIAL | |
| 1671480 | Tolterodine Tartrate (200 mg) | Reference Standard | 124937-52-6 | 200 | mg | VIAL | |
| 1A00750 | Tolyloyl Bromopropionamide (25 mg) (3-bromo-N,N-dimethyl-4-oxo-4-(p-tolyl)butanamide) | Pharmaceutical Analytical Impurity | 836627-56-6 | 25 | mg | VIAL | |
| 1672100 | Tomato Extract Containing Lycopene (1 g) | Reference Standard | N/A | 1 | g | VIAL | |
| 1672206 | Topiramate (150 mg) | Reference Standard | 97240-79-4 | 150 | mg | VIAL | |
| 1672210 | Topiramate Related Compound A (25 mg) (2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose) | Reference Standard | 20880-92-6 | 25 | mg | VIAL | |
| 1672257 | Topotecan Hydrochloride (350 mg) | Reference Standard | 1067286-75-2 | 350 | mg | VIAL | |
| 1672268 | Topotecan Related Compound A (25 mg) ((S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-8-methoxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1672280 | Topotecan Related Compound C (25 mg) ((S)-4-Ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione) | Reference Standard | 7689-03-4 | 25 | mg | VIAL | |
| 1672304 | Torsemide (200 mg) | Reference Standard | 56211-40-6 | 200 | mg | VIAL | |
| 1672315 | Torsemide Related Compound A (75 mg) (4-[(3-methylphenyl)amino]-3-pyridinesulfonamide) | Reference Standard | 72811-73-5 | 75 | mg | VIAL | |
| 1672326 | Torsemide Related Compound B (50 mg) (N-[(n-butylamino)carbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulfonamide) | Reference Standard | 160972-33-8 | 50 | mg | VIAL | |
| 1672337 | Torsemide Related Compound C (30 mg) (N-[(ethylamino)carbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulfonamide) | Reference Standard | 58155-35-4 | 30 | mg | VIAL | |
| 1672359 | Torsemide Related Compound E (20 mg) (4-(3-Tolyl)-2H-pyrido[4,3-e][1,2,4]thiadiazin-3(4H)-one 1,1-dioxide) | Reference Standard | 72810-61-8 | 20 | mg | VIAL | |
| 1672450 | Trachyspermum Ammi Fruit Oil (1 g) | Reference Standard | N/A | 1 | g | AMPULE | |
| 1672600 | Tramadol Hydrochloride CIV (100 mg) | Reference Standard | 36282-47-0 | 100 | mg | VIAL | |
| 1672610 | Tramadol Related Compound A CIV (25 mg) ((RS,SR)-1-(3-Methoxyphenyl)-2-(dimethylaminomethyl)cyclohexanol hydrochloride) | Reference Standard | 73806-49-2 | 25 | mg | VIAL | |
| 1672621 | Tramadol Related Compound B (25 mg) (2-(dimethylaminomethyl)-1-cyclohexanone hydrochloride) | Reference Standard | 42036-65-7 | 25 | mg | VIAL | |
| 1672687 | Trandolapril (125 mg) | Reference Standard | 87679-37-6 | 125 | mg | VIAL | |
| 1672698 | Trandolapril Related Compound A (25 mg) ((2S,3aR,7aS)-1-[N-[(S)-1-carboxy-3-phenylpropyl]-L-alanyl]hexahydro-2-indolinecarboxylic acid 1-methyl ester) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1672701 | Trandolapril Related Compound C (25 mg) ((2S, 3aR, 7aS)-1-[N-[(S)-1-Carboxy-3-cyclohexylpropyl]-L-alanyl]hexahydro-2-indolinecarboxylic acid 1-ethyl ester hydrochloride) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1672712 | Trandolapril Related Compound D (25 mg) ((S)-ethyl 2-[(3S, 5aS, 9aR, 10aS)-3-methyl-1,4-dioxodecahydropyrazino[1,2-a]indol-2(1H)-yl]-4-phenylbutanoate) | Reference Standard | 149881-40-3 | 25 | mg | VIAL | |
| 1672723 | Trandolapril Related Compound E (25 mg) ((2S,3aR,7aS)-1-[N-[(S)-1-Carboxy-3-phenylpropyl]-L-alanyl]hexahydro-2-indolinecarboxylic acid) | Reference Standard | 87679-71-8 | 25 | mg | VIAL | |
| 1672745 | Tranexamic Acid (200 mg) | Reference Standard | 1197-18-8 | 200 | mg | VIAL | |
| 1672756 | Tranexamic Acid Related Compound C (15 mg) ((RS)-4-(Aminomethyl)cyclohex-1-enecarboxylic acid hydrochloride) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1672803 | Transplatin (25 mg) | Reference Standard | 14913-33-8 | 25 | mg | VIAL | |
| 1672916 | Tranylcypromine Related Compound A (40 mg) ((+/-)-cis-2-phenylcyclopropanamine hydrochloride; cis-tranylcypromine hydrochloride) | Reference Standard | 54779-58-7 | 40 | mg | VIAL | |
| 1672927 | Tranylcypromine Related Compound B (40 mg) ((E)-3-Phenylallylamine hydrochloride) | Reference Standard | 17480-08-9 | 40 | mg | VIAL | |
| 1672905 | Tranylcypromine Sulfate (125 mg) | Reference Standard | 13492-01-8 | 125 | mg | VIAL | |
| 1673001 | Travoprost (3 mL) (COLD SHIPMENT REQUIRED) | Reference Standard | 157283-68-6 | 3 | mL | AMPULE | |
| 1673012 | Travoprost Related Compound A (1.5 mL) ((Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-{(R,E)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl}cyclopentyl)hept-5-enoic acid) (COLD SHIPMENT REQUIRED) | Reference Standard | 54276-17-4 | 1.5 | mL | | |
| 1673500 | Trazodone Hydrochloride (200 mg) | Reference Standard | 25332-39-2 | 200 | mg | | |
| 1673533 | Trazodone Related Compound C (20 mg) (2-{3-[4-(4-chlorophenyl)piperazin-1-yl]propyl}-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one hydrochloride) | Reference Standard | 1263278-77-8 | 20 | mg | VIAL | |
| 1673544 | Trazodone Related Compound D (20 mg) (2-{3-[4-(3-bromophenyl)piperazin-1-yl]propyl}-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one hydrochloride) | Reference Standard | 1263278-80-3 | 20 | mg | VIAL | |
| 1673566 | Trazodone Related Compound F (25 mg) (1-(3-chlorophenyl)-4-(3-chloropropyl)piperazine hydrochloride) | Reference Standard | 52605-52-4 | 25 | mg | VIAL | |
| 1673715 | Trehalose (400 mg) | Reference Standard | 6138-23-4 | 400 | mg | VIAL | |
| 1673828 | Trenbolone Acetate CIII (200 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 10161-34-9 | 200 | mg | VIAL | |
| 1673839 | Trenbolone Acetate System Suitability Mixture CIII (30 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | N/A | 30 | mg | VIAL | |
| 1674004 | Tretinoin (5 X 30 mg) | Reference Standard | 302-79-4 | 150 | mg | VIAL | |
| 1675007 | Triacetin (1 g) | Reference Standard | 102-76-1 | 1 | g | AMPULE | |
| 1676000 | Triamcinolone (250 mg) | Reference Standard | 124-94-7 | 250 | mg | VIAL | |
| 1677002 | Triamcinolone Acetonide (500 mg) | Reference Standard | 76-25-5 | 500 | mg | VIAL | |
| 1679020 | Triamcinolone Acetonide Related Compound B (15 mg) (9-Fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-(11beta,16alpha)-pregna-1,4,14-triene-3,20-dione) | Reference Standard | 1260149-96-9 | 15 | mg | VIAL | |
| 1679037 | Triamcinolone Acetonide Related Compound C (15 mg) (9-Fluoro-11,21,21-trihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-(11beta,16alpha)-pregna-1,4-diene-3,20-dione) | Reference Standard | 161740-69-8 | 15 | mg | VIAL | |
| 1678005 | Triamcinolone Diacetate (350 mg) | Reference Standard | 67-78-7 | 350 | mg | VIAL | |
| 1679008 | Triamcinolone Hexacetonide (200 mg) | Reference Standard | 5611-51-8 | 200 | mg | VIAL | |
| 1680007 | Triamterene (200 mg) | Reference Standard | 396-01-0 | 200 | mg | VIAL | |
| 1680018 | Triamterene Related Compound A (50 mg) (2,4,6-triamino-5-nitrosopyrimidine) | Reference Standard | 1006-23-1 | 50 | mg | VIAL | |
| 1680029 | Triamterene Related Compound B (50 mg) (2,7-diamino-4-hydroxy-6-phenylpteridine) | Reference Standard | 19375-89-4 | 50 | mg | VIAL | |
| 1680030 | Triamterene Related Compound C (50 mg) (2,4-diamino-7-hydroxy-6-phenylpteridine) | Reference Standard | 19152-93-3 | 50 | mg | VIAL | |
| 1680506 | Triazolam CIV (200 mg) | Reference Standard | 28911-01-5 | 200 | mg | VIAL | |
| 1087031 | Tribasic Calcium Phosphate (1 g) (AS) | Reference Standard | 12167-74-7 | 1 | g | VIAL | |
| 1680608 | Tributyl Citrate (500 mg) | Reference Standard | 77-94-1 | 500 | mg | AMPULE | |
| 1680685 | Tributyl Phosphine Oxide (25 mg) | Reference Standard | 814-29-9 | 25 | mg | VIAL | |
| 1680801 | Trichlorfon (200 mg) | Reference Standard | 52-68-6 | 200 | mg | VIAL | |
| 1681000 | Trichlormethiazide (200 mg) | Reference Standard | 133-67-5 | 200 | mg | VIAL | |
| 1681800 | Triclocarban (200 mg) | Reference Standard | 101-20-2 | 200 | mg | VIAL | |
| 1681815 | Triclocarban Related Compound A (15 mg) (1,3-Bis(4-chlorophenyl)urea) | Reference Standard | 1219-99-4 | 15 | mg | VIAL | |
| 1681845 | Triclocarban Related Compound C (15 mg) (1,3-Bis(3,4-dichlorophenyl)urea) | Reference Standard | 4300-43-0 | 15 | mg | VIAL | |
| 1681856 | Triclocarban Related Compound D Mixture (15 mg) (Mixture of 3,5-Bis(4-chlorophenyl)-1-(3,4-dichlorophenyl)biuret and 1,5-Bis(4-chlorophenyl)-3-(3,4-dichlorophenyl)biuret) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1682206 | Triclosan (200 mg) | Reference Standard | 3380-34-5 | 200 | mg | VIAL | |
| 1682217 | Triclosan Related Compounds Mixture A (1.2 mL/ampule; 3 ampules) | Reference Standard | N/A | 3.6 | mL | AMPULE | |
| 1683504 | Trientine Hydrochloride (200 mg) | Reference Standard | 38260-01-4 | 200 | mg | VIAL | |
| 1683606 | Triethyl Citrate (5 x 100 mg) | Reference Standard | 77-93-0 | 500 | mg | AMPULE | |
| 1683559 | Triethylamine (2 mL/ampule; 4 ampules) (N,N-diethylethanamine) | Reference Standard | 121-44-8 | 8 | mL | AMPULE | |
| 1683708 | Triethylene Glycol (0.5 mL) | Reference Standard | 112-27-6 | 0.5 | mL | AMPULE | |
| 1685000 | Trifluoperazine Hydrochloride (200 mg) | Reference Standard | 440-17-5 | 200 | mg | VIAL | |
| 1686003 | Triflupromazine Hydrochloride (200 mg) | Reference Standard | 1098-60-8 | 200 | mg | VIAL | |
| 1686309 | Trifluridine (100 mg) | Reference Standard | 70-00-8 | 100 | mg | VIAL | |
| 1686310 | Trifluridine Related Compound A (10 mg) (5-Carboxy-2'-deoxyuridine) | Reference Standard | 14599-46-3 | 10 | mg | VIAL | |
| 1686386 | Triglycine (50 mg) (glycylglycylglycine) | Reference Standard | 556-33-2 | 50 | mg | VIAL | |
| 1270231 | Trigonella Foenum-graecum Seed Dry Extract (1 g) | Reference Standard | N/A | 1 | g | VIAL | |
| 1686411 | Trigonelline (20 mg) (1-Methylpyridinium-3-carboxylate monohydrate) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1687006 | Trihexyphenidyl Hydrochloride (200 mg) | Reference Standard | 52-49-3 | 200 | mg | VIAL | |
| 1687017 | Trihexyphenidyl Related Compound A (20 mg) (1-Phenyl-3-(piperidin-1-yl)propan-1-one hydrochloride) | Reference Standard | 886-06-6 | 20 | mg | VIAL | |
| 1689001 | Trimeprazine Tartrate (200 mg) | Reference Standard | 4330-99-8 | 200 | mg | VIAL | |
| 1692006 | Trimethobenzamide Hydrochloride (200 mg) | Reference Standard | 554-92-7 | 200 | mg | VIAL | |
| 1692505 | Trimethoprim (300 mg) | Reference Standard | 738-70-5 | 300 | mg | VIAL | |
| 1692516 | Trimethoprim Related Compound A (25 mg) (4-amino-5-(3,4,5-trimethoxybenzyl)pyrimidin-2-ol) | Reference Standard | 60729-91-1 | 25 | mg | VIAL | |
| 1692527 | Trimethoprim Related Compound B (25 mg) ((2,4-diaminopyrimidin-5-yl)(3,4,5-trimethoxyphenyl)methanone) | Reference Standard | 30806-86-1 | 25 | mg | VIAL | |
| 1692709 | Trimipramine Maleate (100 mg) | Reference Standard | 521-78-8 | 100 | mg | VIAL | |
| 1692710 | Trimipramine Related Compound A (25 mg) (dehydro trimipramine) | Reference Standard | 315-69-5 | 25 | mg | VIAL | |
| 1692913 | Triolein (2 x 50 mg) | Reference Standard | 122-32-7 | 100 | mg | AMPULE | |
| 1695004 | Tripelennamine Hydrochloride (200 mg) | Reference Standard | 154-69-8 | 200 | mg | VIAL | |
| 1695343 | Triphenylmethanol (50 mg) | Reference Standard | 76-84-6 | 50 | mg | VIAL | |
| 1696007 | Triprolidine Hydrochloride (300 mg) | Reference Standard | 6138-79-0 | 300 | mg | VIAL | |
| 1696109 | Triprolidine Hydrochloride Z-Isomer (50 mg) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1696131 | Triptorelin Acetate (1.82 mg) (5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-prolylglycinamide acetate salt) (COLD SHIPMENT REQUIRED) | Reference Standard | 57773-63-4 | 1.82 | mg | VIAL | |
| 1696110 | Triptorelin Related Compound A (1.23 mg) | Reference Standard | 102992-39-2 | 1.23 | mg | VIAL | |
| 1696128 | Triptorelin Related Compound B (1.68 mg) | Reference Standard | 321709-35-7 | 1.68 | mg | VIAL | |
| 1696142 | Triptorelin Related Compound C (1.31 mg) (Triptorelin acid; 5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-tryptophyl-L-leucyl-L-arginyl-L-prolylglycine) | Reference Standard | 129418-54-8 | 1.31 | mg | VIAL | |
| 1696200 | Trisalicylic Acid (100 mg) | Reference Standard | 85531-17-5 | 100 | mg | VIAL | |
| 1696153 | Tritricosanoin (50 mg) | Reference Standard | 86850-72-8 | 50 | mg | VIAL | |
| 1696175 | Triuret (300 mg) (Tricarbonodiimidic diamide) | Reference Standard | 556-99-0 | 300 | mg | VIAL | |
| 1696958 | Trolamine (3 mL) (International Restricted Sales Item) | Reference Standard | 102-71-6 | 3 | mL | VIAL | |
| 1698002 | Tromethamine (125 mg) | Reference Standard | 77-86-1 | 125 | mg | VIAL | |
| 1699005 | Tropicamide (200 mg) | Reference Standard | 1508-75-4 | 200 | mg | VIAL | |
| 1699016 | Tropicamide Related Compound A (100 mg) (N-(pyridin-4-ylmethyl)ethanamine) | Reference Standard | 33403-97-3 | 100 | mg | AMPULE | |
| 1699027 | Tropicamide Related Compound B (50 mg) (N-ethyl-2-phenyl-N-(pyridin-4-ylmethyl)acrylamide) | Reference Standard | 57322-50-6 | 50 | mg | VIAL | |
| 1699038 | Tropicamide Related Compound C (25 mg) (3-hydroxy-2-phenylpropionic acid) | Reference Standard | 552-63-6 | 25 | mg | VIAL | |
| 1699049 | Tropicamide Related Compound D (15 mg) (List Chemical) (2-phenylacetic acid) | Reference Standard | 103-82-2 | 15 | mg | VIAL | |
| 1699300 | Trospium Chloride (100 mg) | Reference Standard | 10405-02-4 | 100 | mg | VIAL | |
| 1699311 | Trospium Chloride Related Compound A (20 mg) (Benzilic Acid) (International Restricted Sales Item) | Reference Standard | 76-93-7 | 20 | mg | VIAL | |
| 1699322 | Trospium Chloride Related Compound B (20 mg) ((1R,3r,5S)-8-azabicyclo[3.2.1]octan-3-yl hydroxydiphenylacetate hydrochloride) | Reference Standard | 63516-30-3 | 20 | mg | VIAL | |
| 1699333 | Trospium Chloride Related Compound C (20 mg) ((1R, 3r, 5S)-3-Hydroxyspiro[8-azoniabicyclo[3.2.1]octane-8, 1'-pyrrolidinium]chloride) | Reference Standard | 3464-71-9 | 20 | mg | VIAL | |
| 1699956 | Trypsin Bovine (300 mg) | Reference Standard | 9002-07-7 | 300 | mg | VIAL | |
| 1700013 | Trypsin Recombinant Porcine (2 x 1 mL) (COLD SHIPMENT REQUIRED) | Reference Standard | 9002-07-7 | 2 | mL | VIAL | |
| 1700512 | Tryptophan Related Compound A (15 mg) ((2S,2'S)-3,3'-[Ethane-1,1-diylbis(1H-indole-1,3-diyl)]bis(2-aminopropanoic acid)) | Reference Standard | 132685-02-0 | 15 | mg | VIAL | |
| 1700523 | Tryptophan Related Compound B (25 mg) (2-Acetamido-3-(1H-indol-3-yl)propanoic acid) | Reference Standard | 1218-34-4 | 25 | mg | VIAL | |
| 1702008 | Tubocurarine Chloride (175 mg) | Reference Standard | 6989-98-6 | 175 | mg | VIAL | |
| 1703805 | Tylosin (250 mg) | Reference Standard | 1401-69-0 | 250 | mg | VIAL | |
| 1703850 | Tylosin Tartrate (100 mg) | Reference Standard | 1405-54-5 | 100 | mg | VIAL | |
| 1704003 | Tyloxapol (3 x 200 mg) | Reference Standard | 25301-02-4 | 600 | mg | VIAL | |
| 1445539 | USP mAb 001, Monoclonal IgG1 (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | 174722-31-7 | 2 | mg | AMPULE | |
| 1445547 | USP mAb 002, Monoclonal IgG1 (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | 216974-75-3 | 2 | mg | AMPULE | |
| 1445595 | USP mAb 003, Monoclonal IgG1 (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | 912628-39-8 | 2 | mg | AMPULE | |
| 1705301 | Ubidecarenone (200 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 303-98-0 | 200 | mg | VIAL | |
| 1705323 | Ubidecarenone Related Compound A (15 mg) (Coenzyme Q9) (COLD SHIPMENT REQUIRED) | Reference Standard | 303-97-9 | 15 | mg | AMPULE | |
| 1705312 | Ubidecarenone for System Suitability (25 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 303-98-0 | 25 | mg | VIAL | |
| 1705334 | Ubiquinol (5 x 50 mg) | Reference Standard | 992-78-9 | 250 | mg | | |
| 1705367 | Ulipristal Acetate (200 mg) | Reference Standard | 126784-99-4 | 200 | mg | VIAL | |
| 1705378 | Ulipristal Acetate Related Compound A (25 mg) (11Beta-[4-(Dimethylamino)phenyl]-5alpha-hydroxy-20-oxospiro{19-norpregna-9-en-3,2'-[1,3]dioxolan}-17-yl acetate) | Reference Standard | 730962-28-4 | 25 | mg | VIAL | |
| 1705505 | Undecylenic Acid (200 mg) | Reference Standard | 112-38-9 | 200 | mg | VIAL | |
| 1705753 | Uracil (15 mg) | Reference Standard | 66-22-8 | 15 | mg | VIAL | |
| 1705800 | Uracil Arabinoside (50 mg) | Reference Standard | 3083-77-0 | 50 | mg | VIAL | |
| 1706698 | Urea (200 mg) | Reference Standard | 57-13-6 | 200 | mg | VIAL | |
| 1706701 | Urea C 13 (150 mg) | Reference Standard | 58069-82-2 | 150 | mg | VIAL | |
| 1706712 | Urea Related Compound A (15 mg) (Dicarbonimidic diamide) | Reference Standard | 108-19-0 | 15 | mg | VIAL | |
| 1707114 | Uridine (30 mg) (1-Beta-D-Ribofuranosylpyrimidine-2,4(1H,3H)-dione) | Reference Standard | 58-96-8 | 30 | mg | VIAL | |
| 1707806 | Ursodiol (125 mg) | Reference Standard | 128-13-2 | 125 | mg | VIAL | |
| 1707792 | Ursodiol Related Compound H (25 mg) (3Beta, 7Beta-Dihydroxy-5Beta-cholan-24-oic acid) | Reference Standard | 78919-26-3 | 25 | mg | VIAL | |
| 1707770 | Ursolic Acid (25 mg) | Reference Standard | 77-52-1 | 25 | mg | VIAL | |
| 1707839 | Valacyclovir Hydrochloride (200 mg) | Reference Standard | 502421-45-6 | 200 | mg | VIAL | |
| 1707855 | Valacyclovir Related Compound C (10 mg) (2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]ethyl N-methyl-L-valinate hydrochloride) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1707861 | Valacyclovir Related Compound D (15 mg) (2-[(2-Amino-6-oxo-1,6-dihydro-9H-purin-9yl)methoxy]ethyl N-ethyl-L-valinate) | Reference Standard | 1346747-69-0 | 15 | mg | VIAL | |
| 1707872 | Valacyclovir Related Compound E (25 mg) (2-[(2-amino-6-oxo-1,6-dihydro-9H-purin-9-yl)methoxy]ethyl N-[(benzyloxy)carbonyl]-L-valinate) | Reference Standard | 124832-31-1 | 25 | mg | VIAL | |
| 1707883 | Valacyclovir Related Compound F (25 mg) (2-hydroxyethyl valinate para-toluenesulfonate salt) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1707894 | Valacyclovir Related Compound G (50 mg) (N,N-dimethylpyridin-4-amine) | Reference Standard | 1122-58-3 | 50 | mg | VIAL | |
| 1707828 | Valacyclovir Related Compound M (15 mg) (9-[(2-Hydroxyethoxy)methyl]guanine N-formyl-l-valinate) | Reference Standard | 847670-62-6 | 15 | mg | VIAL | |
| 1707908 | Valerenic Acid (30 mg) | Reference Standard | 3569-10-6 | 30 | mg | VIAL | |
| 1708004 | Valganciclovir Hydrochloride (500 mg) | Reference Standard | 175865-59-5 | 500 | mg | VIAL | |
| 1708707 | Valproic Acid (500 mg) | Reference Standard | 99-66-1 | 500 | mg | AMPULE | |
| 1708729 | Valproic Acid Related Compound A (0.25 mL) (2-allylpent-4-enoic acid) | Reference Standard | 99-67-2 | 0.25 | mL | AMPULE | |
| 1708718 | Valproic Acid Related Compound B (50 mg) ((2RS)-2-(1-methylethyl)pentanoic acid) | Reference Standard | 62391-99-5 | 50 | mg | AMPULE | |
| 1708650 | Valproic Acid Related Compound K (25 mg) (2-Ethyl-2-methylpentanoic acid) | Reference Standard | 5343-52-2 | 25 | mg | AMPULE | |
| 1708730 | Valrubicin (100 mg) | Reference Standard | 56124-62-0 | 100 | mg | VIAL | |
| 1708751 | Valrubicin Resolution Mixture (25 mg) (valrubicin spiked with seven related substances) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1708762 | Valsartan (350 mg) | Reference Standard | 137862-53-4 | 350 | mg | VIAL | |
| 1708773 | Valsartan Related Compound A (10 mg) (N-Valeryl-N-{[2'-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}D-valine) | Reference Standard | 137862-87-4 | 10 | mg | VIAL | |
| 1708784 | Valsartan Related Compound B (10 mg) (N-butyryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]methyl}-L-valine) | Reference Standard | 952652-79-8 | 10 | mg | VIAL | |
| 1708795 | Valsartan Related Compound C (10 mg) (N-Valeryl-N-{[2'-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine benzyl ester) | Reference Standard | 137863-20-8 | 10 | mg | VIAL | |
| 1708810 | Valsartan Related Compound E (15 mg) (N-valeryl-N-{[2'-(1H-tetrazole-5-yl)biphenyl-4-yl]methyl}-L-valine methyl ester) | Reference Standard | 137863-17-3 | 15 | mg | VIAL | |
| 1709029 | Vancomycin B (350 mg) | Reference Standard | 1404-93-9 | 350 | mg | VIAL | |
| 1709018 | Vancomycin B with Monodechlorovancomycin (300 mg) | Reference Standard | 1404-93-9 | 300 | mg | VIAL | |
| 1709007 | Vancomycin Hydrochloride (500 mg) | Reference Standard | 1404-93-9 | 500 | mg | VIAL | |
| 1710006 | Vanillin (200 mg) | Reference Standard | 121-33-5 | 200 | mg | VIAL | |
| 1711009 | Vanillin Melting Point Standard (1 g) (Approximately 82 degrees) | Reference Standard | 121-33-5 | 1 | g | VIAL | |
| 1711010 | Vardenafil Hydrochloride (200 mg) | Reference Standard | 330808-88-3 | 200 | mg | VIAL | |
| 1711064 | Vardenafil Related Compound D (25 mg) (2-{2-Ethoxy-5-[(4-ethyl-4-oxidopiperazin-1-yl)sulfonyl]phenyl}-5-methyl-7-propyl-imidazo[5,1-f][1,2,4]triazin-4(3H)-one) | Reference Standard | 448184-48-3 | 25 | mg | VIAL | |
| 1711075 | Vardenafil Related Compound E (25 mg) (2-[2-Ethoxy-5-(piperazin-1-ylsulfonyl)phenyl]-5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(3H)-one) | Reference Standard | 448184-46-1 | 25 | mg | VIAL | |
| 1711029 | Vardenafil System Suitability (20 mg) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1711031 | Vasicine (20 mg) | Reference Standard | 6159-56-4 | 20 | mg | VIAL | |
| 1711100 | Vasopressin (1.71 mg) (Vasopressin, 8-L-arginine) (COLD SHIPMENT REQUIRED) | Reference Standard | 113-79-1 | 1.71 | mg | | |
| 1711155 | Vecuronium Bromide (50 mg) | Reference Standard | 50700-72-6 | 50 | mg | VIAL | |
| 1711166 | Vecuronium Bromide Related Compound A (25 mg) (3alpha,17Beta-diacetyl-oxy-2Beta, 16Beta-bispiperidinyl-5alpha-androstan) | Reference Standard | 13529-31-2 | 25 | mg | VIAL | |
| 1711177 | Vecuronium Bromide Related Compound B (15 mg) (Piperidinium, 1-[(2beta, 3alpha, 5alpha, 16beta, 17beta)-3-acetyloxy-17-hydroxy-2-(1-piperidinyl)androstan-16-yl]-1-methyl bromide) | Reference Standard | 50587-95-6 | 15 | mg | VIAL | |
| 1711188 | Vecuronium Bromide Related Compound C (15 mg) (Piperidinium, 1-[(2beta,3alpha,5alpha,16beta,17beta)-3,17-dihydroxy-2-(1-piperidinyl) androstan-16-yl]-1-methyl bromide) | Reference Standard | 73319-30-9 | 15 | mg | VIAL | |
| 1711224 | Vecuronium Bromide Related Compound F (15 mg) (Piperidinium,1-[(2beta,3alpha,5alpha,16beta,17beta)-17-acetyloxy-3-hydroxy-2-(1-piperidinyl)androstan-16-yl]-1-methyl bromide) | Reference Standard | 73319-13-8 | 15 | mg | VIAL | |
| 1711268 | Venlafaxine Hydrochloride (100 mg) | Reference Standard | 99300-78-4 | 100 | mg | VIAL | |
| 1711279 | Venlafaxine Related Compound A (10 mg) (1-(1-(4-Methoxyphenyl)-2-(methylamino)ethyl)cyclohexanol hydrochloride) | Reference Standard | 93413-90-2 | 10 | mg | VIAL | |
| 1711202 | Verapamil Hydrochloride (200 mg) | Reference Standard | 152-11-4 | 200 | mg | VIAL | |
| 1711304 | Verapamil Related Compound A (50 mg) (3,4-Dimethoxy-alpha-[3-(methylamino)propyl]-alpha-(1-methylethyl)-benzeneacetonitrile monohydrochloride) | Reference Standard | 67775-97-7 | 50 | mg | VIAL | |
| 1711406 | Verapamil Related Compound B (50 mg) (4-[(3,4-Dimethoxyphenethyl)(methyl)amino]-2-(3,4-dimethoxyphenyl)-2-isopropylbutanenitrile hydrochloride) | Reference Standard | 1794-55-4 | 50 | mg | VIAL | |
| 1711439 | Verapamil Related Compound E (50 mg) (3,4-dimethoxybenzaldehyde) | Reference Standard | 120-14-9 | 50 | mg | VIAL | |
| 1711440 | Verapamil Related Compound F (150 mg) ((3,4-Dimethoxyphenyl)methanol) | Reference Standard | 93-03-8 | 150 | mg | AMPULE | |
| 1711455 | Verbascoside (15 mg) (2-(3,4-Dihydroxyphenyl)ethyl 3-O-(6-deoxy-alpha-L-mannopyranosyl)-4-O-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]-Beta-D-glucopyranoside) | Reference Standard | 61276-17-3 | 15 | mg | VIAL | |
| 1711461 | Verteporfin (200 mg) | Reference Standard | 129497-78-5 | 200 | mg | VIAL | |
| 1711472 | Verteporfin Related Compound A (50 mg) ((+/-)18-Ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo[b]prophine-9,13-dipropanoic acid) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1712001 | Vigabatrin (200 mg) | Reference Standard | 68506-86-5 | 200 | mg | VIAL | |
| 1712012 | Vigabatrin Related Compound A (50 mg) (5-vinylpyrrolidin-2-one) | Reference Standard | 7529-16-0 | 50 | mg | AMPULE | |
| 1712023 | Vigabatrin Related Compound B (30 mg) ((E)-2-(2-aminoethyl)but-2-enoic acid hydrochloride) | Reference Standard | N/A | 30 | mg | VIAL | |
| 1712045 | Vigabatrin Related Compound E (30 mg) (2-(2-aminobut-3-enyl)malonic acid) | Reference Standard | N/A | 30 | mg | VIAL | |
| 1713004 | Vinblastine Sulfate (50 mg) | Reference Standard | 143-67-9 | 50 | mg | AMPULE | |
| 1714007 | Vincristine Sulfate (50 mg) | Reference Standard | 2068-78-2 | 50 | mg | | |
| 1714528 | Vinorelbine Related Compound A (25 mg) (4-O-Deacetylvinorelbine tartrate) | Reference Standard | N/A | 25 | mg | VIAL | |
| 1714506 | Vinorelbine Tartrate (200 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 125317-39-7 | 200 | mg | VIAL | |
| 1714608 | Vinpocetine (100 mg) | Reference Standard | 42971-09-5 | 100 | mg | VIAL | |
| 1714619 | Vinpocetine Related Compound A (30 mg) (ethyl (12S,13aS,13bS)-13a-ethyl-12-hydroxy-2,3,5,6,12,13,13a,13b-octahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]-naphthyridine-12-carboxylate) | Reference Standard | 40163-56-2 | 30 | mg | VIAL | |
| 1714620 | Vinpocetine Related Compound B (30 mg) (Methyl(13aS,13bS)-13a-ethyl-2,3,5,6,13a,13b-hexahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]-naphthyridine-12-carboxylate) | Reference Standard | 4880-92-6 | 30 | mg | VIAL | |
| 1714641 | Vinpocetine Related Compound C (30 mg) (ethyl (13aS,13bS)-13a-ethyl-10-methoxy-2,3,5,6,13a,13b-hexahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate) | Reference Standard | N/A | 30 | mg | VIAL | |
| 1714652 | Vinpocetine Related Compound D (30 mg) (ethyl(12R,13aS,13bS)-13a-ethyl-2,3,5,6,12,13,13a,13b-octahydro-1H-indolo[3,2,1-de]pyrido[3,2,1-ij][1,5]naphthyridine-12-carboxylate) | Reference Standard | 57327-92-1 | 30 | mg | VIAL | |
| 1717504 | Vitamin D Assay System Suitability (1.5 g) | Reference Standard | N/A | 1.5 | g | AMPULE | |
| 1457709 | Vitex negundo Leaf Dry Extract (3 g) | Reference Standard | NA | 3 | g | VIAL | |
| 1717708 | Vitexin (25 mg) ((1S)-1,5-Anhydro-1-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-8-yl]-D-glucitol) | Reference Standard | 3681-93-4 | 25 | mg | VIAL | |
| 1718008 | Voriconazole (100 mg) | Reference Standard | 137234-62-9 | 100 | mg | VIAL | |
| 1718019 | Voriconazole Related Compound A (10 mg) ((2RS, 3RS)-2-(2,4-Difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol) | Reference Standard | 137330-52-0 | 10 | mg | VIAL | |
| 1718020 | Voriconazole Related Compound B (10 mg) ((2S, 3R)-2-(2,4-Difluorophenyl)-3-(5-fluoropyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol) | Reference Standard | 137234-63-0 | 10 | mg | VIAL | |
| 1718039 | Voriconazole Related Compound C (10 mg) (1-(2,4-Difluorophenyl)-2-(1H-1,2,4-triazol-1-yl)ethanone) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1718041 | Voriconazole Related Compound D (10 mg) ((2RS,3SR)-2-(2,4-difluorophenyl)-3-(pyrimidin-4-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol) | Reference Standard | 182369-73-9 | 10 | mg | VIAL | |
| 1718063 | Voriconazole Related Compound F (50 mg) ({(1RS,4SR)-7,7-Dimethyl-2-oxobicyclo[2.2.1]hept-1-yl}methanesulfonic acid) | Reference Standard | 5872-08-2 | 50 | mg | VIAL | |
| 1719000 | Warfarin (200 mg) | Reference Standard | 81-81-2 | 200 | mg | VIAL | |
| 1719102 | Warfarin Related Compound A (50 mg) (3-(o-hydroxyphenyl)-5-phenyl-2-cyclohexen-1-one) | Reference Standard | 15156-56-6 | 50 | mg | VIAL | |
| 1719218 | White Wax (30 mg) | Reference Standard | 8012-89-3 | 30 | mg | VIAL | |
| 1719500 | Withanolide A (15 mg) | Reference Standard | 32911-62-9 | 15 | mg | VIAL | |
| 1719532 | Withanoside IV (15 mg) | Reference Standard | 362472-81-9 | 15 | mg | VIAL | |
| 1720000 | Xanthanoic Acid (100 mg) | Reference Standard | 82-07-5 | 100 | mg | VIAL | |
| 1720203 | Xanthone (100 mg) | Reference Standard | 90-47-1 | 100 | mg | VIAL | |
| 1720407 | Xylazine (200 mg) | Reference Standard | 7361-61-7 | 200 | mg | VIAL | |
| 1720429 | Xylazine Hydrochloride (200 mg) | Reference Standard | 23076-35-9 | 200 | mg | VIAL | |
| 1720600 | Xylitol (1 g) | Reference Standard | 87-99-0 | 1 | g | VIAL | |
| 1721002 | Xylometazoline Hydrochloride (250 mg) | Reference Standard | 1218-35-5 | 250 | mg | VIAL | |
| 1721013 | Xylometazoline Related Compound A (25 mg) (N-(2-Aminoethyl)-2-[4-(tert-butyl)-2,6-dimethylphenyl]acetamide) | Reference Standard | 94266-17-8 | 25 | mg | VIAL | |
| 1722005 | Xylose (1 g) | Reference Standard | 7261-26-9 | 1 | g | VIAL | |
| 1719229 | Yellow Wax (30 mg) | Reference Standard | 8012-89-3 | 30 | mg | VIAL | |
| 1724000 | Yohimbine Hydrochloride (200 mg) | Reference Standard | 65-19-0 | 200 | mg | VIAL | |
| 1724306 | Zalcitabine (200 mg) | Reference Standard | 7481-89-2 | 200 | mg | VIAL | |
| 1724317 | Zalcitabine Related Compound A (50 mg) (2',3'-Didehydro-2',3'-dideoxycytidine) | Reference Standard | 7481-88-1 | 50 | mg | VIAL | |
| 1724350 | Zaleplon CIV (200 mg) | Reference Standard | 151319-34-5 | 200 | mg | VIAL | |
| 1724361 | Zaleplon Related Compound A (15 mg) ((E)-N-(3-[3-(dimethylamino)acryloyl]phenyl)-N-ethylacetamide) | Reference Standard | 96605-66-2 | 15 | mg | VIAL | |
| 1724372 | Zaleplon Related Compound B (15 mg) (N-[3-(3-Cyanopyrazolo[1,5-alpha]pyrimidin-5-yl)phenyl]-N-ethylacetamide) | Reference Standard | 478081-98-0 | 15 | mg | VIAL | |
| 1724383 | Zaleplon Related Compound C (25 mg) (7-[3-(N-ethylacetamido)phenyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide) | Reference Standard | 940951-54-2 | 25 | mg | VIAL | |
| 1724088 | Zanamivir (200 mg) | Reference Standard | 139110-80-8 | 200 | mg | VIAL | |
| 1724077 | Zanamivir Related Compounds Mixture (2.5 mg) | Reference Standard | N/A | 2.5 | mg | VIAL | |
| 1724066 | Zanamivir Resolution Mixture (0.25 mg) (Mixture of zanamivir and talo-zanamivir) | Reference Standard | N/A | 0.25 | mg | VIAL | |
| 1724500 | Zidovudine (400 mg) | Reference Standard | 30516-87-1 | 400 | mg | VIAL | |
| 1724521 | Zidovudine Related Compound B (25 mg) (3'-chloro-3'-deoxythymidine) | Reference Standard | 25526-94-7 | 25 | mg | VIAL | |
| 1724532 | Zidovudine Related Compound C (100 mg) (thymine) | Reference Standard | 65-71-4 | 100 | mg | VIAL | |
| 1724543 | Zidovudine Related Compound D (50 mg) ([1-(2-Deoxy-beta-D-ribofuranosyl)]thymine) | Reference Standard | 50-89-5 | 50 | mg | VIAL | |
| 1724656 | Zileuton (150 mg) | Reference Standard | 111406-87-2 | 150 | mg | VIAL | |
| 1724667 | Zileuton Related Compound A (50 mg) (N-(1-Benzo[b]thien-2-ylethyl) urea) | Reference Standard | 171370-49-3 | 50 | mg | VIAL | |
| 1724678 | Zileuton Related Compound B (50 mg) (2-(Benzo[b]thien-2-oyl)benzo[b]thiophene) | Reference Standard | 97978-07-9 | 50 | mg | VIAL | |
| 1724689 | Zileuton Related Compound C (50 mg) (1-(Benzo[b]thiophen-2-yl)ethan-1-one) | Reference Standard | 22720-75-8 | 50 | mg | VIAL | |
| 1724703 | Zinc Acetate (50 mg) | Reference Standard | 5970-45-6 | 50 | mg | VIAL | |
| 1724736 | Zinc Chloride (100 mg) | Reference Standard | 7646-85-7 | 100 | mg | VIAL | |
| 1724747 | Zinc Oxide (200 mg) | Reference Standard | 1314-13-2 | 200 | mg | VIAL | |
| 1724758 | Zinc Stearate (200 mg) (Mixture of zinc stearate and zinc palmitate) | Reference Standard | N/A | 200 | mg | VIAL | |
| 1724769 | Zinc Sulfate (1 g) | Reference Standard | 7446-19-7 | 1 | g | VIAL | |
| 1724780 | Zinc Undecylenate (200 mg) | Reference Standard | 557-08-4 | 200 | mg | VIAL | |
| 1724408 | Ziprasidone Hydrochloride (200 mg) | Reference Standard | 138982-67-9 | 200 | mg | VIAL | |
| 1724419 | Ziprasidone Related Compound A (10 mg) (3-(Piperazin-1-yl)benzo[d]isothiazole monohydrochloride) | Reference Standard | 87691-88-1 | 10 | mg | VIAL | |
| 1724420 | Ziprasidone Related Compound B (10 mg) (5-(2-(4-(Benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindoline-2,3-dione) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1724441 | Ziprasidone Related Compound C (10 mg) (5,5'-Bis(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6,6'-dichloro-3-hydroxy-3,3'-biindoline-2,2'-dione) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1724452 | Ziprasidone Related Compound D (10 mg) (3-(Benzo[d]isothiazol-3-yl)-5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one) | Reference Standard | N/A | 10 | mg | VIAL | |
| 1724474 | Ziprasidone Related Compound F (15 mg) (Sodium 2-(2-amino-5-{2-[4-(benzo[d]isothiazol-3-yl)piperazin-1-yl]ethyl}-4-chlorophenyl)acetate monohydrate) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1724772 | Ziziphus Jujuba Spinosa Seed Dry Extract (750 mg) | Reference Standard | N/A | 750 | mg | VIAL | |
| 1724805 | Zolazepam Hydrochloride (500 mg) | Reference Standard | 33754-49-3 | 500 | mg | VIAL | |
| 1724827 | Zoledronic Acid (150 mg) | Reference Standard | 165800-06-6 (Monohydrate) | 150 | mg | VIAL | |
| 1724838 | Zoledronic Acid Related Compound A (30 mg) (2-(1H-Imidazol-1-yl)acetic acid) | Reference Standard | 22884-10-2 | 30 | mg | VIAL | |
| 1724849 | Zoledronic Acid Related Compound B (COLD SHIPMENT REQUIRED) (30 mg) (1-Hydroxy-2-[1-(2-hydroxy-2,2-diphosphonoethyl)-1H-imidazol-3-ium-3-yl]-1-phosphonoethylphosphonate) | Reference Standard | 1627731-61-6 | 30 | mg | VIAL | |
| 1727009 | Zolmitriptan (200 mg) | Reference Standard | 139264-17-8 | 200 | mg | VIAL | |
| 1727018 | Zolmitriptan R-Isomer (20 mg) ((R)-4-({3-[2-(Dimethylamino)ethyl]indol-5-yl}methyl)oxazolidin-2-one) | Reference Standard | 139264-24-7 | 20 | mg | VIAL | |
| 1727020 | Zolmitriptan Related Compound A (20 mg) ((S)-4-({3-[2-(Methylamino)ethyl]-1H-indol-5-yl}methyl)oxazolidin-2-one) | Reference Standard | 139264-35-0 | 20 | mg | VIAL | |
| 1727031 | Zolmitriptan Related Compound B (20 mg) ((S)-2-Amino-3-{3-[2-(dimethylamino)ethyl]-1H-indol-5-yl}propan-1-ol) | Reference Standard | 139264-69-0 | 20 | mg | VIAL | |
| 1727064 | Zolmitriptan Related Compound E (25 mg) ((S)-N,N-dimethyl-2-{5-[(2-oxooxazolidin-4-yl)methyl]-1H-indol-3-yl}ethanamine oxide) | Reference Standard | 251451-30-6 | 25 | mg | VIAL | |
| 1727075 | Zolmitriptan Related Compound F (25 mg) (2,2'-[4-(Dimethylamino)butane-1,1-diyl]bis{5-[(S)-(2-oxooxazolidin-4-yl)methyl]-3-(2-dimethylaminoethyl)indole}) | Reference Standard | 1350928-05-0 | 25 | mg | VIAL | |
| 1727086 | Zolmitriptan Related Compound G (25 mg) ((S)-4-(4-Aminobenzyl)oxazolidin-2-one) | Reference Standard | 152305-23-2 | 25 | mg | VIAL | |
| 1727097 | Zolmitriptan Related Compound H (50 mg) (4,4-Diethoxy-N,N-dimethylbutan-1-amine) | Reference Standard | 1116-77-4 | 50 | mg | AMPULE | |
| 1724893 | Zolpidem CIV (10 mg) | Reference Standard | 82626-48-0 | 10 | mg | VIAL | |
| 1724951 | Zolpidem Impurities Mixture CIV (15 mg) | Reference Standard | N/A | 15 | mg | VIAL | |
| 1724918 | Zolpidem Related Compound A (15 mg) (N,N-Dimethyl-2-[7-methyl-2-p-tolylimidazo[1,2-a]pyridin-3-yl]acetamide) | Reference Standard | 1346600-85-8 | 15 | mg | VIAL | |
| 1724907 | Zolpidem Tartrate CIV (200 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 99294-93-6 | 200 | mg | VIAL | |
| 1725003 | Zonisamide (200 mg) | Reference Standard | 68291-97-4 | 200 | mg | VIAL | |
| 1725014 | Zonisamide Related Compound A (20 mg) (1,2-benzisoxazole-3-methanesulfonic acid sodium salt) | Reference Standard | 73101-64-1 | 20 | mg | VIAL | |
| 1725036 | Zonisamide Related Compound C (20 mg) (N'-(benzisoxazol-3-ylmethylsulfonyl)-N,N-dimethylformimidamide) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1729118 | Zopiclone R-Isomer CIV (10 mg) ((-)-(5R)-6-(5-Chloropyridin-2-yl)-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazin-5-yl 4-methylpiperazine-1-carboxylate) | Reference Standard | 43200-80-2 (racemic mixture) | 10 | mg | VIAL | |
| 1181415 | [D-His1]-Exenatide (10 mg) | Reference Standard | NA | 10 | mg | VIAL | |
| 1296701 | [D-His2]-Gonadorelin (1 mg) (5-Oxo-L-prolyl-D-histidyl-L-tryptophyl-L-seryl-L-tyrosylglycyl-L-leucyl-L-arginyl-L-prolylglycinamide) | Reference Standard | 53634-19-8 | 1 | mg | VIAL | |
| 1296712 | [D-Tyr5]-Gonadorelin (1 mg) (5-Oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-D-tyrosylglycyl-L-leucyl-L-arginyl-L-prolylglycinamide) | Reference Standard | 53634-21-2 | 1 | mg | VIAL | |
| 1268998 | [Glu13]-Exenatide (1 mg) | Reference Standard | N/A | 1 | mg | VIAL | |
| 1269009 | [Met(O)14]-Exenatide (1 mg) | Reference Standard | 1678417-38-3 | 1 | mg | VIAL | |
| 1269045 | [N-Acetyl-His1]-Exenatide (1 mg) | Reference Standard | N/A | 1 | mg | VIAL | |
| 1076035 | [des-Glu13]-Bivalirudin (1 mg) (INTERNATIONAL COLD CHAIN SHIPMENT REQUIRED) | Reference Standard | 1107611-94-8 | 1 | mg | VIAL | |
| 1034498 | alpha-Amylcinnamaldehyde Dimethyl Acetal (500 mg) | Reference Standard | 91-87-2 | 500 | mg | AMPULE | |
| 1034501 | alpha-Amylcinnamyl Acetate (500 mg) | Reference Standard | 7493-78-9 | 500 | mg | AMPULE | |
| 1034512 | alpha-Amylcinnamyl Alcohol (500 mg) | Reference Standard | 101-85-9 | 500 | mg | AMPULE | |
| 1034523 | alpha-Amylcinnamyl Formate (500 mg) | Reference Standard | 7493-79-0 | 500 | mg | AMPULE | |
| 1115556 | beta-Chlorogenin (20 mg) | Reference Standard | N/A | 20 | mg | VIAL | |
| 1295662 | beta-Glycerylphosphorylcholine (25 mg) | Reference Standard | 18418-25-2 | 25 | mg | VIAL | |
| 1026004 | m-Aminophenol (300 mg) | Reference Standard | 591-27-5 | 300 | mg | VIAL | |
| 1036948 | o-Anisaldehyde (3 x 0.5 mL) | Reference Standard | 135-02-4 | 1.5 | mL | AMPULE | |
| 1A00240 | o-Celecoxib (25mg) (4-(5-(o-tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide) | Pharmaceutical Analytical Impurity | 170569-99-0 | 25 | mg | VIAL | |
| 1285862 | o-Flutamide (50 mg) | Reference Standard | N/A | 50 | mg | VIAL | |
| 1344305 | o-Iodohippuric Acid (100 mg) | Reference Standard | 147-58-0 | 100 | mg | VIAL | |
| 1672010 | o-Toluenesulfonamide (200 mg) | Reference Standard | 88-19-7 | 200 | mg | VIAL | |
| 1036937 | p-Anisaldehyde (3 x 500 mg) | Reference Standard | 123-11-5 | 1500 | mg | AMPULE | |
| 1598733 | p-Ranolazine (25 mg) (N-(2,6-Dimethylphenyl)-2-{4-[2-hydroxy-3-(4-methoxyphenoxy)propyl]piperazin-1-yl}acetamide) | Reference Standard | 1393717-45-7 | 25 | mg | VIAL | |
| 1672020 | p-Toluenesulfonamide (200 mg) | Reference Standard | 70-55-3 | 200 | mg | VIAL | |
| 1672053 | p-Toluidine (50 mg) (COLD SHIPMENT REQUIRED) | Reference Standard | 106-49-0 | 50 | mg | VIAL | |
| 1012595 | rAlbumin Human (6 mg) (Recombinant Human Albumin) (COLD SHIPMENT REQUIRED) | Reference Standard | 70024-90-7 | 6 | mg | VIAL | |
| 1294036 | rGlucagon (2 x 2.94 mg) (recombinant Glucagon (Human)) (COLD SHIPMENT REQUIRED) | Reference Standard | 16941-32-5 | 5.88 | mg | | |
| 1311714 | rHuman Interleukin 4 (51 micrograms) (recombinant interleukin 4, human) (COLD SHIPMENT REQUIRED) | Reference Standard | N/A | 51 | ug | VIAL | |
| 1578816 | rProtein A (250 uL/ampule; 2 ampules) (DISCONTINUED) | Reference Standard | N/A | 500 | | | |
| 1083303 | tert-Butylmethyl ether (1.2 mL/ampule; 3 ampules) | Reference Standard | 1634-04-4 | 3.6 | mL | AMPULE | |
| 1602105 | trans-Resveratrol (100 mg) | Reference Standard | 501-36-0 | 100 | mg | VIAL | |